


**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2019**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2019

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**Cumulative Supplement 9
September 2019**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	ix
1.5 Availability of the Edition	x
1.6 Report of Counts for the Prescription Drug Product List.....	xi
1.7 Cumulative Supplement Legend	xii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**CUMULATIVE SUPPLEMENT 9
SEPTEMBER 2019**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 39th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been

discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

G AND W LABORATORIES INC
(G AND W LABS)

ACP NIMBLE BUYER INC
(ACP NIMBLE)

G AND W LABORATORIES INC
(G AND W LABS INC)

ACP NIMBLE BUYER INC
(ACP NIMBLE)

INVATECH PHARMA SOLUTION INC (INVATECH)	ATHEM HOLDINGS LLC (ATHEM)
IVAX PHARMACEUTICALS INC (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
LUITPOLD PHARMACEUTICALS INC (LUITPOLD)	AMERICAN REGENT INC (AM REGENT)
MIKART LLC (MIKART)	ANDA REPOSITORY LLC (ANDA REPOSITORY)
PD PARTNERS IV LLC (PD PARTNERS)	PHARMACEUTICAL ASSOCIATES INC (PHARM ASSOC)
RISING HOLDINGS INC (RISING)	ANDA REPOSITORY LLC (ANDA REPOSITORY)
RISING PHARMACEUTICALS INC (RISING PHARMS)	RISING PHARMA HOLDINGS INC (RISING)
SUN PHARMA GLOBAL FZE (SUN PHARMA GLOBAL)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
SUN PHARMA GLOBAL INC (SUN PHARMA GLOBAL)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
TEVA PHARMACEUTICALS USA (TEVA PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA (TEVA PHARMS USA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA INC (TEVA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	ANI PHARMACEUTICALS INC (ANI PHARMAS INC)
WATSON LABORATORIES INC (WATSON LABS)	DR REDDYS LABORATORIES LTD (DR REDDYS)
WATSON LABORATORIES INC (WATSON LABS INC)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)

WATSON LABORATORIES INC
(WATSON LABS INC)

ANI PHARMACEUTICALS INC
(ANI PHARMS INC)

WATSON LABORATORIES INC AN
INDIRECT WHOLLY OWNED SUB OF
TEVA PHARMACEUTICALS USA INC
(WATSON LABS TEVA)

HERITAGE PHARMA LABS INC
(HERITAGE PHARMA)

WATSON LABORATORIES INC AN
INDIRECT WHOLLY OWNED SUB OF
TEVA PHARMACEUTICALS USA INC
(WATSON LABS TEVA)

ANI PHARMACEUTICALS INC
(ANI PHARMS INC)

WATSON LABORATORIES INC AN
INDIRECT WHOLLY OWNED SUB OF
TEVA PHARMACEUTICALS USA INC
(WATSON LABS TEVA)

DR REDDYS LABORATORIES LTD
(DR REDDYS)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), Levo-T (Cediprof Inc NDA 021342), and Levothyroxine Sodium (Lupin Atlantis ANDA 209713) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Stevens J NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), Unithroid (Stevens J NDA 021210), Thyro-tabs (Alvogen NDA 021116), and Levothyroxine Sodium (Lupin Atlantis ANDA 209713) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Stevens J NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Thyro-tabs (Alvogen NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some

products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB1	209713	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
EUTHYROX	PROVELL PHARMS	0.025MG	AB2	021292	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
THYRO-TABS	ALVOGEN	0.025MG	AB2	021116	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB2	209713	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
THYRO-TABS	ALVOGEN	0.025MG	AB4	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic

Equivalence Evaluations, ADP) from the U.S. Government Printing Office:
<http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at
<http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2018</u>	<u>MAR 2019</u>	<u>JUN 2019</u>	<u>SEP 2019</u>	<u>DEC 2019</u>
DRUG PRODUCTS	20295	20580	20693	20688	
LISTED SINGLE	2724	2713	2729	2713	
SOURCE	(13.4%)	(13.2%)	(13.2%)	(13.1%)	
MULTISOURCE	17571	17867	17964	17975	
	(86.6%)	(86.8%)	(86.8%)	(86.9%)	
THERAPEUTICALLY	17483	17777	17964	17892	
EQUIVALENT	(86.1%)	(86.4%)	(86.8%)	(86.5%)	
NOT THERAPEUTICALLY	88	90	85	83	
EQUIVALENT	(0.4%)	(0.4%)	(0.4%)	(0.4%)	
EXCEPTIONS ¹	58	58	58	54	
	(0.3%)	(0.3%)	(0.3%)	(0.3%)	
NEW MOLECULAR	25	3	16	21	
ENTITIES APPROVED					
NUMBER OF	1133	1129	1132	1140	
APPLICANTS					

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
NFTG	New first time generic approval.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

@ ZYDUS PHARMS EQ 600MG BASE;300MG A208990 001 Nov 15, 2018 Mar DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

>A> AB GLENMARK PHARMS 250MG A209227 001 Oct 16, 2019 Sep NEWA
AB MSN LABS PVT LTD 250MG A210686 001 Jul 10, 2019 Jun NEWA
>A> AB QILU PHARM CO LTD 250MG A212462 001 Sep 27, 2019 Sep NEWA
AB WOCKHARDT BIO AG 250MG A208380 001 Feb 27, 2019 Feb NEWA

ACARBOSE

TABLET;ORAL

ACARBOSE

@ MYLAN 25MG A091053 001 Jan 06, 2011 Jun DISC
@ 50MG A091053 002 Jan 06, 2011 Jun DISC
@ 100MG A091053 003 Jan 06, 2011 Jun DISC

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

@ ANI PHARMS INC EQ 200MG BASE A074007 001 Oct 18, 1995 Jul CAHN
@ EQ 400MG BASE A074007 002 Oct 18, 1995 Jul CAHN

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL

APADAZ

+ KEMPHARM 325MG;EQ 4.08MG BASE N208653 002 Jan 04, 2019 Jan NEWA
+ 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Jan NEWA
+ KVK TECH INC 325MG;EQ 4.08MG BASE N208653 002 Jan 04, 2019 Feb CAHN
+ 325MG;EQ 6.12MG BASE N208653 001 Feb 23, 2018 Feb CAHN
+! 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Aug CHRS
+ 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Feb CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

ALLZITAL

>D> LARKEN LABS INC 325MG;25MG A203484 001 Dec 04, 2015 Sep CHRS
>A> ! 325MG;25MG A203484 001 Dec 04, 2015 Sep CHRS

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ LANNETT CO INC 120MG/5ML;12MG/5ML A091238 001 Nov 10, 2011 Jan DISC

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA ELITE LABS INC 300MG;15MG A212418 001 Sep 10, 2019 Aug NEWA
AA 300MG;30MG A212418 002 Sep 10, 2019 Aug NEWA
AA 300MG;60MG A212418 003 Sep 10, 2019 Aug NEWA
>A> AA EYWA 300MG;15MG A211610 001 Jun 27, 2019 Sep CAHN
>A> AA 300MG;30MG A211610 002 Jun 27, 2019 Sep CAHN
>A> AA 300MG;60MG A211610 003 Jun 27, 2019 Sep CAHN
>D> AA WES PHARMA INC 300MG;15MG A211610 001 Jun 27, 2019 Sep CAHN
AA 300MG;15MG A211610 001 Jun 27, 2019 Jun NEWA
>D> AA 300MG;30MG A211610 002 Jun 27, 2019 Sep CAHN
AA 300MG;30MG A211610 002 Jun 27, 2019 Jun NEWA
>D> AA 300MG;60MG A211610 003 Jun 27, 2019 Sep CAHN
AA 300MG;60MG A211610 003 Jun 27, 2019 Jun NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA WES PHARMA INC 325MG/15ML;7.5MG/15ML A211023 001 Mar 08, 2019 Feb NEWA

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ ALVOGEN PINE BROOK 300MG;5MG A208540 001 Nov 08, 2018 Apr DISC
@ 300MG;7.5MG A208540 002 Nov 08, 2018 Apr DISC
@ 300MG;10MG A208540 003 Nov 08, 2018 Apr DISC

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@		325MG;2.5MG	A209958	001	Oct 24, 2018	Apr	DISC
	@		325MG;5MG	A209958	002	Oct 24, 2018	Apr	DISC
	@		325MG;7.5MG	A209958	003	Oct 24, 2018	Apr	DISC
	@		325MG;10MG	A209958	004	Oct 24, 2018	Apr	DISC
	@	ELITE LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018	May	DISC
	@		325MG;5MG	A209924	002	Nov 16, 2018	May	DISC
	@		325MG;7.5MG	A209924	003	Nov 16, 2018	May	DISC
	@		325MG;10MG	A209924	004	Nov 16, 2018	May	DISC
>D> AA		LANNETT CO INC	300MG;5MG	A207171	001	Jun 20, 2017	Sep	DISC
>A>	@		300MG;5MG	A207171	001	Jun 20, 2017	Sep	DISC
>D> AA			300MG;7.5MG	A207171	002	Jun 20, 2017	Sep	DISC
>A>	@		300MG;7.5MG	A207171	002	Jun 20, 2017	Sep	DISC
>D> AA			300MG;10MG	A207171	003	Jun 20, 2017	Sep	DISC
>A>	@		300MG;10MG	A207171	003	Jun 20, 2017	Sep	DISC
>D> AA			325MG;5MG	A207172	001	Jun 22, 2017	Sep	DISC
>A>	@		325MG;5MG	A207172	001	Jun 22, 2017	Sep	DISC
>D> AA			325MG;7.5MG	A207172	002	Jun 22, 2017	Sep	DISC
>A>	@		325MG;7.5MG	A207172	002	Jun 22, 2017	Sep	DISC
>D> AA			325MG;10MG	A207172	003	Jun 22, 2017	Sep	DISC
>A>	@		325MG;10MG	A207172	003	Jun 22, 2017	Sep	DISC
	@	UPSHER SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017	Jan	DISC
	@		325MG;7.5MG	A206484	002	Mar 24, 2017	Jan	DISC
	@		325MG;10MG	A206484	003	Mar 24, 2017	Jan	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

@ MIKART INC 300MG/5ML;10MG/5ML

A202142 001 Nov 27, 2018 May DISC

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

>A> AA		ANDA REPOSITORY	325MG;5MG	A207834	001	Aug 15, 2019	Sep	CAHN
>A> AA			325MG;7.5MG	A207834	002	Aug 15, 2019	Sep	CAHN
>A> AA			325MG;10MG	A207834	003	Aug 15, 2019	Sep	CAHN
>D> AA		HALO PHARM CANADA	325MG;5MG	A207834	001	Aug 15, 2019	Sep	CAHN
AA			325MG;5MG	A207834	001	Aug 15, 2019	Aug	NEWA
>D> AA			325MG;7.5MG	A207834	002	Aug 15, 2019	Sep	CAHN
AA			325MG;7.5MG	A207834	002	Aug 15, 2019	Aug	NEWA
>D> AA			325MG;10MG	A207834	003	Aug 15, 2019	Sep	CAHN
AA			325MG;10MG	A207834	003	Aug 15, 2019	Aug	NEWA
AA		XIROMED	325MG;5MG	A207574	001	Dec 13, 2016	Aug	CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

	@	ACCORD HLTHCARE	500MG	A207659	001	Oct 18, 2018	Apr	DISC
AB		ALEMBIC PHARMS LTD	500MG	A210423	001	Feb 19, 2019	Feb	NEWA
AB		CADILA	500MG	A205301	001	Jan 16, 2019	Mar	CAHN
AB		HERITAGE PHARMA	500MG	A040904	001	Dec 10, 2008	Jul	CAHN
AB	!	HERITAGE PHARMS INC	500MG	A090779	001	Jul 14, 2011	Jul	CHRS
	@	MYLAN	500MG	A203917	001	Jun 18, 2019	Jul	DISC
AB			500MG	A203917	001	Jun 18, 2019	Jun	NEWA
		DIAMOX						
	+	@ TEVA BRANDED PHARM	500MG	N012945	001		Jul	DISC

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP		ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206533	001	Apr 15, 2019	Apr	NEWA
----	--	--------------	--------------------	---------	-----	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

	@	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	Apr	DISC
AP		ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206533	001	Apr 15, 2019	Jun	CAIN

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

>A> AT		MLV	2%	A040607	001	Feb 24, 2005	Sep	CAHN
>D> AT		SAPTALIS PHARMS	2%	A040607	001	Feb 24, 2005	Sep	CAHN
AT			2%	A040607	001	Feb 24, 2005	May	CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

ACETASOL HC

@ ACTAVIS MID ATLANTIC 2%;1%

A087143 001 Jan 13, 1982 Jun DISC

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

@ MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML)

A203624 001 Jun 19, 2015 Mar DISC

TABLET, EFFERVESCENT;ORAL

CETYLEV

+ @ ARBOR PHARMS LLC 500MG

N207916 001 Jan 29, 2016 Mar DISC

+ @ 2.5GM

N207916 002 Jan 29, 2016 Mar DISC

ACITRETIN

CAPSULE;ORAL

SORIATANE

+ @ STIEFEL LABS INC 17.5MG

N019821 003 Aug 06, 2009 Jan DISC

+ @ 22.5MG

N019821 004 Aug 06, 2009 Jan DISC

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

+! CIRCASSIA 0.4MG/INH

N202450 001 Jul 23, 2012 Jun CAHN

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

ASTRAZENECA PHARMS 0.4MG/INH;0.012MG/INH

N210595 001 Mar 29, 2019 Mar NEWA

CIRCASSIA 0.4MG/INH;0.012MG/INH

N210595 001 Mar 29, 2019 Apr CAHN

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB CADILA 200MG

A204313 001 Mar 25, 2016 Aug CAHN

AB KENTON 200MG

A075090 001 Jan 26, 1999 Mar CAHN

CREAM;TOPICAL

ACYCLOVIR

AB PERRIGO UK FINCO 5%

A208702 001 Feb 04, 2019 Jan NFTG

ZOVIRAX

AB +! BAUSCH 5%

N021478 001 Dec 30, 2002 Feb CAHN

AB +! VIB 5%

N021478 001 Dec 30, 2002 Jan CFTG

OINTMENT;OPHTHALMIC

AVACLYR

+ @ FERA PHARMS LLC 3%

N202408 001 Mar 29, 2019 Aug DISC

+! 3%

N202408 001 Mar 29, 2019 Mar NEWA

OINTMENT;TOPICAL

ACYCLOVIR

AB APOTEX INC 5%

A210774 001 Sep 06, 2019 Aug NEWA

AB CIPLA 5%

A211794 001 Jan 18, 2019 Jan NEWA

AB GLENMARK PHARMS SA 5%

A205510 001 Jul 31, 2017 Jun CAHN

@ PERRIGO UK FINCO 5%

A205659 001 Feb 20, 2019 Aug DISC

AB 5%

A205659 001 Feb 20, 2019 Feb NEWA

AB ZYDUS PHARMS 5%

A205974 001 Mar 15, 2019 Mar NEWA

ZOVIRAX

AB +! BAUSCH 5%

N018604 001 Mar 29, 1982 Feb CAHN

TABLET;ORAL

ACYCLOVIR

>A> AB SQUARE PHARMS LTD 400MG

A209366 001 Oct 07, 2019 Sep NEWA

>A> AB 800MG

A209366 002 Oct 07, 2019 Sep NEWA

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

! ZYDUS PHARMS EQ 500MG BASE/VIAL

A206535 001 Aug 31, 2018 Jan CHRS

! EQ 1GM BASE/VIAL

A206535 002 Aug 31, 2018 Jan CHRS

ACYCLOVIR; HYDROCORTISONECREAM; TOPICAL
XERESE

+! BAUSCH 5%;1%

N022436 001 Jul 31, 2009 Feb CAHN

ADAPALENEGEL; TOPICAL
ADAPALENE

AB P AND L 0.1%

A090962 001 Jun 02, 2010 Jul CAHN

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB PERRIGO UK FINCO 0.1%;2.5%

A205033 001 Jan 23, 2018 May CAHN

@ TARO 0.3%;2.5%

A209148 001 Oct 17, 2018 May DISC

ADENOSINEINJECTABLE; INJECTION
ADENOSINE

@ LUITPOLD 3MG/ML

A090010 001 Apr 28, 2009 Mar DISC

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

AB ACTAVIS ELIZABETH 200MG

A208094 001 May 20, 2019 May NEWA

AB EDENBRIDGE PHARMS 200MG

A211117 001 May 14, 2019 Apr NEWA

AB STRIDES PHARMA 200MG

A210011 001 Dec 07, 2018 Aug CAHN

ALBUTEROL SULFATE

POWDER, METERED; INHALATION

PROAIR DIGIHALER

+ TEVA BRANDED PHARM EQ 0.09MG BASE/INH

N205636 002 Dec 21, 2018 Jan NEWA

PROAIR RESPICLICK

+! TEVA BRANDED PHARM EQ 0.09MG BASE/INH

N205636 001 Mar 31, 2015 Jan CPOT

SYRUP; ORAL

ALBUTEROL SULFATE

AA QUAGEN EQ 2MG BASE/5ML

A212197 001 Sep 06, 2019 Aug NEWA

TABLET; ORAL

ALBUTEROL SULFATE

>D> AB AIZANT EQ 2MG BASE

A210948 001 Mar 15, 2019 Sep CAHN

AB EQ 2MG BASE

A210948 001 Mar 15, 2019 Mar NEWA

>D> AB EQ 4MG BASE

A210948 002 Mar 15, 2019 Sep CAHN

AB EQ 4MG BASE

A210948 002 Mar 15, 2019 Mar NEWA

AB APPCO PHARMA LLC EQ 2MG BASE

A207046 001 Jun 29, 2018 Feb CAHN

AB EQ 4MG BASE

A207046 002 Jun 29, 2018 Feb CAHN

>A> AB ARISE EQ 2MG BASE

A210948 001 Mar 15, 2019 Sep CAHN

>A> AB EQ 4MG BASE

A210948 002 Mar 15, 2019 Sep CAHN

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

@ MYLAN EQ 5MG BASE

A076584 001 Aug 04, 2008 Jul DISC

@ EQ 10MG BASE

A076584 002 Aug 04, 2008 Jul DISC

TABLET, EFFERVESCENT; ORAL

BINOSTO

>A> +! ASCEND THERAPS US EQ 70MG BASE

N202344 001 Mar 12, 2012 Sep CAHN

>D> +! MISSION PHARMA EQ 70MG BASE

N202344 001 Mar 12, 2012 Sep CAHN

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

>D> AB HERITAGE PHARMA 10MG

A079056 001 Jul 18, 2011 Sep DISC

>A> @ 10MG

A079056 001 Jul 18, 2011 Sep DISC

AB 10MG

A079056 001 Jul 18, 2011 May CAHN

ALISKIREN HEMIFUMARATE

TABLET; ORAL

ALISKIREN HEMIFUMARATE

AB	ANCHEN PHARMS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Mar NFTG
AB		EQ 300MG BASE	A206665	002	Mar 22, 2019	Mar NFTG
	TEKTURNA					
AB	+ NODEN PHARMA	EQ 150MG BASE	N021985	001	Mar 05, 2007	Mar CFTG
AB	+!	EQ 300MG BASE	N021985	002	Mar 05, 2007	Mar CFTG

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+	CONCORDIA	EQ 0.1% BASE	N020886	001	Feb 02, 1999	Jul CAHN
---	-----------	--------------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	UNICHEM LABS LTD	100MG	A211820	001	Mar 12, 2019	Feb NEWA
AB		300MG	A211820	002	Mar 12, 2019	Feb NEWA

ALLOPURINOL; LESINURAD

TABLET; ORAL

DUZALLO

+	@ IRONWOOD PHARMS INC	200MG; 200MG	N209203	001	Aug 18, 2017	Apr DISC
+	@	300MG; 200MG	N209203	002	Aug 18, 2017	Apr DISC

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

>D> AB	AJANTA PHARMA LTD	EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Sep CHRS
>A> AB	!	EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Sep CHRS
>D>	AXERT					
>D> AB	+ JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Sep DISC
>A>	+ @	EQ 6.25MG BASE	N021001	001	May 07, 2001	Sep DISC
>D> AB	+!	EQ 12.5MG BASE	N021001	002	May 07, 2001	Sep DISC
>A>	+ @	EQ 12.5MG BASE	N021001	002	May 07, 2001	Sep DISC

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

>A> AB	EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep NEWA
>A> AB		EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep NEWA

ALPELISIB

TABLET; ORAL

PIQRAY

+	NOVARTIS	50MG	N212526	001	May 24, 2019	May NEWA
+		150MG	N212526	002	May 24, 2019	May NEWA
+	!	200MG	N212526	003	May 24, 2019	May NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

INFUVITE ADULT

+	SANDOZ CANADA INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	Jul CAHN
>A>	+	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021163	002	Jun 16, 2003	Sep CMS1

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

+	@ EISAI INC	50MG	N019926	001	Dec 26, 1990	Feb DISC
---	-------------	------	---------	-----	--------------	----------

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

>D>	AB	GRAVITI PHARMS	100MG	A207570	001	Sep 30, 2016	Sep CAHN
>A>	AB	INVAGEN PHARMS	100MG	A207570	001	Sep 30, 2016	Sep CAHN
	AB	UPSHER SMITH LABS	100MG	A070589	001	Aug 05, 1986	Jul CAHN

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

>D>	AB	GRAVITI PHARMS	100MG	A207571	001	Jan 31, 2017	Sep CAHN
>A>	AB	INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017	Sep CAHN
	AB	! UPSHER SMITH LABS	100MG	A076186	001	Dec 16, 2002	Jul CAHN

AMBRISANTAN

TABLET;ORAL

AMBRISANTAN

AB		CIPLA	5MG	A210715	001	Apr 26, 2019	Apr NEWA
AB			10MG	A210715	002	Apr 26, 2019	Apr NEWA
AB		MYLAN	5MG	A208441	001	Mar 28, 2019	Mar NFTG
AB			10MG	A208441	002	Mar 28, 2019	Mar NFTG
AB		PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Mar NEWA
AB			10MG	A209509	002	Apr 10, 2019	Mar NEWA
AB		SIGMAPHARM LABS LLC	5MG	A208354	001	Apr 10, 2019	Mar NEWA
AB			10MG	A208354	002	Apr 10, 2019	Mar NEWA
AB		SUN PHARM	5MG	A210784	001	Mar 28, 2019	Mar NFTG
AB			10MG	A210784	002	Mar 28, 2019	Mar NFTG
AB		WATSON LABS INC	5MG	A208252	001	Mar 28, 2019	Mar NFTG
AB			10MG	A208252	002	Mar 28, 2019	Mar NFTG
AB		ZYDUS PHARMS	5MG	A210058	001	Mar 28, 2019	Mar NFTG
AB			10MG	A210058	002	Mar 28, 2019	Mar NFTG
		LETAIRIS					
AB	+	GILEAD	5MG	N022081	001	Jun 15, 2007	Mar CFTG
AB	+	!	10MG	N022081	002	Jun 15, 2007	Mar CFTG

AMIFAMPRIDINE

TABLET;ORAL

RUZURGI

+	!	JACOBUS PHARM CO INC	10MG	N209321	001	May 06, 2019	May NEWA
---	---	----------------------	------	---------	-----	--------------	----------

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

>D>	AP	TEVA PHARMS USA	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Sep DISC
>A>		@	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Sep DISC

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

AB		WINDLAS HLTHCARE	5MG	A204180	001	Aug 07, 2015	Feb CAHN
----	--	------------------	-----	---------	-----	--------------	----------

AMINO ACIDS

INJECTABLE;INJECTION

AMINOSYN 10%

@	ICU MEDICAL INC	10% (10GM/100ML)	N017673	003		Jul DISC
---	-----------------	------------------	---------	-----	--	----------

AMINOSYN 8.5%

@	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004		Jul DISC
---	-----------------	--------------------	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

@	ICU MEDICAL INC	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N017789	003		Jul DISC
---	-----------------	--	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE;INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

@	ICU MEDICAL INC	8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML	N017673	009	Oct 25, 2002	Jul DISC
---	-----------------	---	---------	-----	--------------	----------

AMINOCAPROIC ACID

SYRUP;ORAL					
AMICAR					
AA	+! CLOVER PHARMS	1.25GM/5ML	N015230	002	Aug CTEC
AMINOCAPROIC ACID					
AA	AMNEAL PHARMS LLC	1.25GM/5ML	A212780	001	Aug 23, 2019 Aug NEWA
TABLET;ORAL					
AMICAR					
AB	+ CLOVER PHARMS	1GM	N015197	002	Jun 24, 2004 Feb CHRS
AMINOCAPROIC ACID					
AB	! SUNNY PHARMTECH INC	1GM	A209060	002	Nov 27, 2018 Feb CHRS

AMINOPHYLLINE

INJECTABLE;INJECTION					
AMINOPHYLLINE					
	! HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983 Feb CTEC
	@ LUITPOLD	25MG/ML	A087600	001	Feb DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION					
AMIODARONE HYDROCHLORIDE					
	@ DR REDDYS	50MG/ML	A076163	001	Sep 05, 2003 May CAHN
TABLET;ORAL					
AMIODARONE HYDROCHLORIDE					
AB	RUBICON	200MG	A078578	001	Nov 06, 2008 Jul CAHN

AMLODIPINE BENZOATE

SOLUTION;ORAL					
KATERZIA					
	+! SILVERGATE PHARMS	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019 Jul NEWA

AMLODIPINE BESYLATE

TABLET;ORAL					
AMLODIPINE BESYLATE					
AB	STRIDES PHARMA	EQ 2.5MG BASE	A077516	001	Jul 11, 2007 Apr CAHN
AB		EQ 5MG BASE	A077516	002	Jul 11, 2007 Apr CAHN
AB		EQ 10MG BASE	A077516	003	Jul 11, 2007 Apr CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL					
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM					
	@ ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019 Jun DISC
	@	EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019 Jun DISC
	@	EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019 Jun DISC
	@	EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019 Jun DISC
	@	EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019 Jun DISC
	@	EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019 Jun DISC
	@	EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019 Jun DISC
	@	EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019 Jun DISC
	@	EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019 Jun DISC
	@	EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019 Jun DISC
	@	EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019 Jun DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL					
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE					
	@ CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018 May DISC
	@	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018 May DISC
	@	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018 May DISC
	@	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018 May DISC
	@ MYLAN	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010 Feb DISC
	@	EQ 5MG BASE;10MG	A077375	002	May 21, 2010 Feb DISC
	@	EQ 5MG BASE;20MG	A077375	003	May 21, 2010 Feb DISC
	@	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011 Feb DISC
	@	EQ 10MG BASE;20MG	A077375	004	May 21, 2010 Feb DISC
	@	EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011 Feb DISC
	@ TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007 Jun DISC
	@	EQ 5MG BASE;10MG	A077179	002	May 18, 2007 Jun DISC
	@	EQ 5MG BASE;20MG	A077179	003	May 18, 2007 Jun DISC
	@	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011 Jun DISC
	@	EQ 10MG BASE;20MG	A077179	004	May 18, 2007 Jun DISC

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011	Jun DISC
---	-------------------	---------	-----	--------------	----------

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

+	COEPTIS	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	Mar CAHN
+		EQ 5MG BASE;200MG	N210045	002	May 31, 2018	Mar CAHN
+	!	EQ 10MG BASE;200MG	N210045	003	May 31, 2018	Mar CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

@	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Jul DISC
@		EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Jul DISC
@		EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Jul DISC
@		EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Jul DISC
@		EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Jul DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

@	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	Jul DISC
@		5MG;25MG;160MG	A200435	002	Sep 25, 2012	Jul DISC
@		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	Jul DISC
@		10MG;25MG;160MG	A200435	003	Sep 25, 2012	Jul DISC
@		10MG;25MG;320MG	A200435	004	Sep 25, 2012	Jul DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

@	ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018	Mar DISC
@		EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018	Mar DISC
@		EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018	Mar DISC
@		EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018	Mar DISC
@	TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Jun DISC
@		EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Jun DISC
@		EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Jun DISC
@		EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Jun DISC

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Apr CAHN
+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Apr CAHN
+	!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Apr CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

@	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Jul DISC
@		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Jul DISC
@		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Jul DISC
@		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Jul DISC

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	DECATUR	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Apr CAHN
----	---------	------------------------------------	---------	-----	--------------	----------

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB	!	PERRIGO ISRAEL	EQ 12% BASE	A075774	001	May 01, 2002	May CAHN
----	---	----------------	-------------	---------	-----	--------------	----------

LOTION;TOPICAL

AMMONIUM LACTATE

AB	!	PERRIGO ISRAEL	EQ 12% BASE	A075570	001	Jun 23, 2004	May CAHN
----	---	----------------	-------------	---------	-----	--------------	----------

AMOXICILLINFOR SUSPENSION; ORAL
AMOXICILLIN

@ TEVA	125MG/5ML	A061931	001		Jun	DISC
--------	-----------	---------	-----	--	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUMFOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	125MG/5ML;EQ 31.25MG BASE/5ML	A209371	001	Apr 19, 2019	Apr	NFTG
AB		250MG/5ML;EQ 62.5MG BASE/5ML	A209371	002	Apr 19, 2019	Apr	NEWA
AUGMENTIN '125'							
AB	+ NEOPHARMA	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Apr	CFTG
TABLET; ORAL							
AUGMENTIN '875'							
AB	+ NEOPHARMA	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Feb	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DETROAMP SULFATE AND AMP SULFATE

AB	PAR PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019	May	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019	May	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019	May	NEWA
AB		5MG;5MG;5MG;5MG	A206159	004	May 31, 2019	May	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019	May	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019	May	NEWA

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	AMERIGEN PHARMS LTD	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan	NEWA
AB		5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan	NEWA
AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210080	001	Jul 17, 2019	Jul	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210080	002	Jul 17, 2019	Jul	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210080	003	Jul 17, 2019	Jul	NEWA
AB		5MG;5MG;5MG;5MG	A210080	004	Jul 17, 2019	Jul	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210080	005	Jul 17, 2019	Jul	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210080	006	Jul 17, 2019	Jul	NEWA
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019	May	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019	May	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019	May	NEWA
AB		5MG;5MG;5MG;5MG	A210651	004	May 17, 2019	May	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019	May	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019	May	NEWA
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019	Apr	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019	Apr	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019	Apr	NEWA
AB		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019	Apr	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019	Apr	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019	Apr	NEWA
AB	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	May	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	May	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	May	NEWA
AB		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	May	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	May	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	May	NEWA

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

AA	AUROLIFE PHARMA LLC	5MG	A211639	001	Apr 17, 2019	Apr	NEWA
AA		10MG	A211639	002	Apr 17, 2019	Apr	NEWA
AA	GRANULES PHARMS	5MG	A212619	001	Aug 05, 2019	Jul	NEWA
AA		10MG	A212619	002	Aug 05, 2019	Jul	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

EVEKEO ODT

+	ARBOR PHARMS LLC	5MG	N209905	001	Jan 30, 2019	Jan	NEWA
+		10MG	N209905	002	Jan 30, 2019	Jan	NEWA
+		15MG	N209905	003	Jan 30, 2019	Jan	NEWA
+		20MG	N209905	004	Jan 30, 2019	Jan	NEWA

AMPICILLIN SODIUMINJECTABLE; INJECTION
AMPICILLIN SODIUM

>D>	AP	HOSPIRA INC	EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015	Sep DISC
>A>	@		EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015	Sep DISC

AMPICILLIN SODIUM; SULBACTAM SODIUMINJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

>D>	AP	HOSPIRA INC	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A090375	001	Dec 21, 2011	Sep DISC
>A>	@		EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A090375	001	Dec 21, 2011	Sep DISC
>D>	AP		EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A090653	001	Dec 21, 2011	Sep DISC
>A>	@		EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A090653	001	Dec 21, 2011	Sep DISC
>D>	AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A090375	002	Dec 21, 2011	Sep DISC
>A>	@		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A090375	002	Dec 21, 2011	Sep DISC
>D>	AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A090653	002	Dec 21, 2011	Sep DISC
>A>	@		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A090653	002	Dec 21, 2011	Sep DISC
>D>	AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A090646	001	Dec 21, 2011	Sep DISC
>A>	@		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A090646	001	Dec 21, 2011	Sep DISC
>D>	AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Sep DISC
>A>	@		EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Sep DISC
>D>	AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Sep DISC
>A>	@		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Sep DISC

AMPICILLIN/AMPICILLIN TRIHYDRATECAPSULE; ORAL
AMPICILLIN TRIHYDRATE

@	HERITAGE PHARMA	EQ 250MG BASE	A061502	001		May CAHN
@		EQ 500MG BASE	A061502	002		May CAHN

ANASTROZOLETABLET; ORAL
ANASTROZOLE

AB	FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010	Feb CAHN
AB	KENTON	1MG	A078944	001	Jun 28, 2010	Mar CAHN

ARIPIRAZOLESOLUTION; ORAL
ARIPIRAZOLE

AA	AUROBINDO PHARMA LTD	1MG/ML	A210479	001	Jan 29, 2019	Jan NEWA
TABLET; ORAL						
ARIPIRAZOLE						
AB	ALKEM LABS LTD	2MG	A207105	001	Feb 21, 2019	Feb NEWA
AB		5MG	A207105	002	Feb 21, 2019	Feb NEWA
AB		10MG	A207105	003	Feb 21, 2019	Feb NEWA
AB		15MG	A207105	004	Feb 21, 2019	Feb NEWA
AB		20MG	A207105	005	Feb 21, 2019	Feb NEWA
AB		30MG	A207105	006	Feb 21, 2019	Feb NEWA
@	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Jun DISC
@		5MG	A078607	002	Apr 28, 2015	Jun DISC
@		10MG	A078608	001	Apr 28, 2015	May DISC
@		15MG	A078708	001	Apr 28, 2015	May DISC
@		20MG	A078708	002	Apr 28, 2015	May DISC
@		30MG	A078708	003	Apr 28, 2015	May DISC
@	ZYDUS PHARMS	2MG	A090472	001	Jan 07, 2019	Jun DISC
@		5MG	A090472	002	Jan 07, 2019	Jun DISC
@		10MG	A090472	003	Jan 07, 2019	Jun DISC
@		15MG	A090472	004	Jan 07, 2019	Jun DISC
@		20MG	A090472	005	Jan 07, 2019	Jun DISC
@		30MG	A090472	006	Jan 07, 2019	Jun DISC

ARMODAFINILTABLET; ORAL
ARMODAFINIL

>D>	AB	APOTEX INC	50MG	A201514	001	Mar 25, 2019	Sep DISC
>A>	@		50MG	A201514	001	Mar 25, 2019	Sep DISC
	AB		50MG	A201514	001	Mar 25, 2019	Mar NEWA

TABLET;ORAL
ARMODAFINIL

>D>	AB	150MG	A201514	002	Mar 25, 2019	Sep	DISC
>A>	@	150MG	A201514	002	Mar 25, 2019	Sep	DISC
	AB	150MG	A201514	002	Mar 25, 2019	Mar	NEWA
>D>	AB	250MG	A201514	003	Mar 25, 2019	Sep	DISC
>A>	@	250MG	A201514	003	Mar 25, 2019	Sep	DISC
	AB	250MG	A201514	003	Mar 25, 2019	Mar	NEWA
	AB	AUROBINDO PHARMA LTD 200MG	A206069	004	Dec 07, 2018	Mar	NEWA
	AB	MYLAN PHARMS INC 100MG	A200043	004	May 09, 2019	Apr	NEWA
	AB	200MG	A200043	005	May 09, 2019	Apr	NEWA
	AB	NATCO PHARMA LTD 100MG	A202768	004	Sep 28, 2017	Apr	CTEC

ARSENIC TRIOXIDE

INJECTABLE;INJECTION
ARSENIC TRIOXIDE

AP	STI PHARMA LLC	1MG/ML	A209873	001	May 06, 2019	Apr	NEWA
AP	ZYDUS PHARMS	2MG/ML	A206228	002	Aug 30, 2019	Aug	NFTG
	TRISENOX						
AP	+! CEPHALON	2MG/ML	N021248	002	Oct 13, 2017	Aug	CFTG

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

>D>	ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE								
>D>	AP	HOSPIRA	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138	001	Jun 18, 2010	Sep	DISC	
>A>	@		4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138	001	Jun 18, 2010	Sep	DISC	

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS
INFUVITE PEDIATRIC

+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001	Jul	CAHN
----	-------------------	--	---------	-----	--------------	-----	------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL HYDROCHLORIDE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

>A>	+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004	Sep	CMS1
-----	----	-------------------	--	---------	-----	--------------	-----	------

ASENAPINE MALEATE

TABLET;SUBLINGUAL
SAPHRIS

+	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CTEC
+!		EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CTEC

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA	BRECKENRIDGE	325MG;50MG;40MG	A204195	001	Sep 22, 2016	Aug	CAHN
----	--------------	-----------------	---------	-----	--------------	-----	------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	! SANDOZ	770MG;60MG;50MG	A074654	002	Dec 31, 1996	May	CTEC
	ORPHENGESIC FORTE						
AB	GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998	May	CMFD

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL
ASPIRIN AND DIPYRIDAMOLE

AB	GLENMARK PHARMS LTD	25MG;200MG	A210318	001	May 24, 2019	May	NEWA
AB	GLENMARK PHARMS SA	25MG;200MG	A210318	001	May 24, 2019	Jun	CAHN
AB	LANNETT CO INC	25MG;200MG	A204552	001	Mar 20, 2019	Mar	NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

>A>	AB	HLTHCARE	25MG	A074052	001	May 01, 1992	Sep CAHN
>A>	AB		50MG	A073025	001	Sep 17, 1991	Sep CAHN
>A>	AB		100MG	A073026	001	Sep 17, 1991	Sep CAHN
>D>	AB	SANDOZ	25MG	A074052	001	May 01, 1992	Sep CAHN
>D>	AB		50MG	A073025	001	Sep 17, 1991	Sep CAHN
>D>	AB		100MG	A073026	001	Sep 17, 1991	Sep CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB		ZYDUS PHARMS	50MG;25MG	A210028	001	Mar 08, 2019	Feb NEWA
AB			100MG;25MG	A210028	002	Mar 08, 2019	Feb NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17, 2010	Mar CMFD
AB			25MG	A079017	002	Sep 17, 2010	Mar CMFD
AB			40MG	A079017	003	Sep 17, 2010	Mar CMFD
AB			60MG	A079017	004	Sep 17, 2010	Mar CMFD
AB			80MG	A079017	005	Sep 17, 2010	Mar CMFD
AB			100MG	A079017	006	Sep 17, 2010	Mar CMFD

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		MSN LABS PVT LTD	EQ 10MG BASE	A211933	001	Feb 08, 2019	Feb NEWA
AB			EQ 20MG BASE	A211933	002	Feb 08, 2019	Feb NEWA
AB			EQ 40MG BASE	A211933	003	Feb 08, 2019	Feb NEWA
AB			EQ 80MG BASE	A211933	004	Feb 08, 2019	Feb NEWA

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB		ABHAI LLC	750MG/5ML	A210510	001	May 31, 2019	May NEWA
----	--	-----------	-----------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP		HONG KONG	10MG/ML	A091489	001	Feb 17, 2012	Feb CAHN
>D>	AP	MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017	Sep DISC
>A>		@	10MG/ML	A206096	001	Jun 22, 2017	Sep DISC
		ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP		HONG KONG	10MG/ML	A091488	001	Feb 17, 2012	Feb CAHN
>D>	AP	MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017	Sep DISC
>A>		@	10MG/ML	A206001	001	Apr 07, 2017	Sep DISC

ATROPINE

SOLUTION;INTRAMUSCULAR

ATROPEN

+	!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	Mar CPOT
+	!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	Mar CPOT
+	!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	Mar CPOT
+	!		EQ 2MG SULFATE/0.7ML	N017106	001		Mar CPOT

ATROPINE

@	ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987	Mar CDFR
---	--------	----------------------	---------	-----	--------------	----------

ATROPINE SULFATE

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+	!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	May CDFR
---	---	--------------------	---------------------	---------	-----	--------------	----------

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

>D>	AP	LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019	Sep DISC
>A>		@	100MG/VIAL	A210748	001	Feb 27, 2019	Sep DISC
	AP		100MG/VIAL	A210748	001	Feb 27, 2019	Feb NEWA

AZELAIC ACID

	CREAM; TOPICAL						
	AZELEX						
	+! ALMIRALL	20%	N020428	001	Sep 13, 1995	Apr	CAHN
	GEL; TOPICAL						
	AZELAIC ACID						
AB	TARO	15%	A210549	001	Aug 23, 2019	Aug	NEWA

AZELASTINE HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC						
	AZELASTINE HYDROCHLORIDE						
AT	ALEMBIC PHARMS LTD	0.05%	A209620	001	Mar 20, 2019	Mar	NEWA
AT	SOMERSET THERAPS LLC	0.05%	A207411	001	Mar 29, 2019	Mar	NEWA
	SPRAY, METERED; NASAL						
	AZELASTINE HYDROCHLORIDE						
AB	HI TECH	EQ 0.125MG BASE/SPRAY	A207610	001	May 17, 2019	May	NEWA
AB		EQ 0.1876MG BASE/SPRAY	A210032	001	Aug 23, 2019	Aug	NEWA

AZITHROMYCIN

	TABLET; ORAL						
	AZITHROMYCIN						
AB	BIONPHARMA INC	EQ 250MG BASE	A210000	001	Feb 26, 2019	Feb	NEWA
AB		EQ 500MG BASE	A210001	001	Feb 26, 2019	Feb	NEWA
AB	CSPC OUYI	EQ 250MG BASE	A208250	001	Apr 17, 2019	Apr	NEWA
AB	! PLIVA	EQ 600MG BASE	A065218	001	Nov 14, 2005	Jul	CHRS
	@ TEVA	EQ 250MG BASE	A065153	001	Nov 14, 2005	Jul	DISC
	@	EQ 600MG BASE	A065150	001	Nov 14, 2005	Jul	DISC
	ZITHROMAX						
	+ @ PFIZER	EQ 600MG BASE	N050730	001	Jun 12, 1996	Jul	DISC

AZTREONAM

	INJECTABLE; INJECTION						
	AZACTAM IN PLASTIC CONTAINER						
	+ @ BRISTOL MYERS SQUIBB	20MG/ML	N050632	002	May 24, 1989	Jul	DISC
	+ @	40MG/ML	N050632	001	May 24, 1989	Jul	DISC

BACLOFEN

	INJECTABLE; INTRATHECAL						
	BACLOFEN						
AP	MAIA PHARMS INC	0.5MG/ML	A210048	001	Sep 11, 2019	Aug	NEWA
AP		1MG/ML	A210315	001	Jul 30, 2019	Jul	NEWA
AP		2MG/ML	A210048	002	Sep 11, 2019	Aug	NEWA
	GABLOFEN						
AP	PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Aug	CAHN
AP		0.5MG/ML	N022462	002	Nov 19, 2010	Aug	CAHN
AP	+!	1MG/ML	N022462	004	Jun 22, 2012	Aug	CAHN
AP		2MG/ML	N022462	003	Nov 19, 2010	Aug	CAHN
>A>	SOLUTION; ORAL						
>A>	OZOBAX						
>A>	+! METACEL PHARMS LLC	5MG/5ML	N208193	001	Sep 18, 2019	Sep	NEWA
	TABLET; ORAL						
	BACLOFEN						
AB	EYWA PHARMA	10MG	A211555	001	Feb 01, 2019	Jan	NEWA
AB		20MG	A211555	002	Feb 01, 2019	Jan	NEWA
AB	UPSHER SMITH LABS	10MG	A074584	001	Aug 19, 1996	Jul	CAHN
AB		20MG	A074584	002	Aug 19, 1996	Jul	CAHN

BALSALAZIDE DISODIUM

	CAPSULE; ORAL						
	BALSALAZIDE DISODIUM						
	@ MYLAN	750MG	A077807	001	Dec 28, 2007	Feb	DISC
	TABLET; ORAL						
	BALSALAZIDE DISODIUM						
	@ PAR PHARM INC	1.1GM	A206336	001	Sep 08, 2015	Apr	DISC
	GIAZO						
	+ @ VALEANT PHARMS INTL	1.1GM	N022205	001	Feb 03, 2012	Apr	DISC

BARIUM SULFATEFOR SUSPENSION; ORAL
VARIBAR THIN LIQUID

	+!	BRACCO	81% (120GM/BOT)	N208036	004	Apr 30, 2019	May NEWA
		SUSPENSION; ORAL					
		READI-CAT 2 SMOOTHIE					
>A>	+!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016	Sep CMS1
		READI-CAT 2 SMOOTHIES					
>D>	+!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016	Sep CMS1

BELINOSTATPOWDER; INTRAVENOUS
BELEODAQ

+!	ACROTECH	500MG/VIAL	N206256	001	Jul 03, 2014	Mar CAHN
----	----------	------------	---------	-----	--------------	----------

BENAZEPRIL HYDROCHLORIDETABLET; ORAL
BENAZEPRIL HYDROCHLORIDE

@	HERITAGE PHARMA	5MG	A076267	001	Feb 11, 2004	Feb CAHN
@		10MG	A076267	002	Feb 11, 2004	Feb CAHN
@		20MG	A076267	003	Feb 11, 2004	Feb CAHN
@		40MG	A076267	004	Feb 11, 2004	Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDETABLET; ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	ANI PHARMS INC	5MG; 6.25MG	A076342	001	Feb 11, 2004	May CAHN
@		10MG; 12.5MG	A076342	002	Feb 11, 2004	May CAHN
@		20MG; 12.5MG	A076342	003	Feb 11, 2004	May CAHN
@		20MG; 25MG	A076342	004	Feb 11, 2004	May CAHN

BENDAMUSTINE HYDROCHLORIDEPOWDER; IV (INFUSION)
TREANDA

+!	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Feb CTEC
+!		100MG/VIAL	N022249	001	Mar 20, 2008	Feb CTEC

BENZONATATECAPSULE; ORAL
BENZONATATE

AA	ASCENT PHARMS INC	100MG	A211518	001	Feb 22, 2019	Feb NEWA
AA		150MG	A211518	002	Feb 22, 2019	Feb NEWA
AA		200MG	A211518	003	Feb 22, 2019	Feb NEWA
AA	CSPC OUYI	100MG	A202765	002	Aug 25, 2017	Feb CAHN
AA		200MG	A202765	001	Jul 31, 2015	Feb CAHN
AA	QINGDAO BAHEAL PHARM	100MG	A210562	001	Nov 09, 2018	May CAHN
AA		150MG	A210562	002	Nov 09, 2018	May CAHN
AA		200MG	A210562	003	Nov 09, 2018	May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEGEL; TOPICAL
ACANYA

AB	+!	BAUSCH	2.5%; EQ 1.2% BASE	N050819	001	Oct 23, 2008	Aug CAHN
		BENZACLIN					
AB	+!	BAUSCH	5%; EQ 1% BASE	N050756	001	Dec 21, 2000	Aug CAHN
	@		5%; EQ 1% BASE	N050756	002	Apr 20, 2007	Aug CAHN
		CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE					
AB		GLENMARK PHARMS	5%; EQ 1% BASE	A209252	001	Mar 14, 2019	Jun CMS1
AB			5%; 1% BASE	A209252	001	Mar 14, 2019	Mar NEWA
AB		PERRIGO ISRAEL	2.5%; EQ 1.2% BASE	A205397	001	Sep 09, 2019	Aug NEWA
AB		PERRIGO UK FINCO	5%; EQ 1% BASE	A202440	001	Sep 21, 2015	May CAHN
AB		TARO	2.5%; EQ 1.2% BASE	A206575	001	Aug 19, 2019	Aug NEWA
	@		3.75%; EQ 1.2% BASE	A208683	001	Jun 05, 2018	May DISC
		ONEXTON					
	+!	BAUSCH	3.75%; EQ 1.2% BASE	N050819	002	Nov 24, 2014	Aug CAHN
	+!	DOW PHARM	3.75%; EQ 1.2% BASE	N050819	002	Nov 24, 2014	May CTEC

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

AKTIPAK

+ @ BIOFRONTERA 5%;3%

N050769 001 Nov 27, 2000 Aug DISC

+! 5%;3%

N050769 001 Nov 27, 2000 May CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

@ LUITPOLD 1MG/ML

A091152 001 Mar 29, 2010 Feb DISC

TABLET; ORAL

BENZTROPINE MESYLATE

AA ! ASPEN GLOBAL INC 0.5MG

A204713 001 Apr 14, 2015 Apr CHRS

AA ! 1MG

A204713 002 Apr 14, 2015 Apr CHRS

AA ! 2MG

A204713 003 Apr 14, 2015 Apr CHRS

@ OXFORD PHARMS 0.5MG

A040706 002 Feb 14, 2008 Mar DISC

@ 1MG

A040706 003 Feb 14, 2008 Mar DISC

@ UPSHER SMITH LABS 0.5MG

A040103 001 Dec 12, 1996 Jul CAHN

@ 1MG

A040103 002 Dec 12, 1996 Jul CAHN

@ 2MG

A040103 003 Dec 12, 1996 Jul CAHN

@ USL PHARMA 0.5MG

A040103 001 Dec 12, 1996 Apr DISC

@ 1MG

A040103 002 Dec 12, 1996 Apr DISC

@ 2MG

A040103 003 Dec 12, 1996 Apr DISC

>D> BENZYL ALCOHOL

>D> LOTION; TOPICAL

>D> ULESFIA

>D> +! SHIONOGI INC 5%

N022129 001 Apr 09, 2009 Sep DISC

>A> + @ 5%

N022129 001 Apr 09, 2009 Sep DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPOTASTINE BESILATE

>D> AT APOTEX INC 1.5%

A206066 001 Mar 05, 2019 Sep DISC

>A> @ 1.5%

A206066 001 Mar 05, 2019 Sep DISC

AT 1.5%

A206066 001 Mar 05, 2019 Feb NFTG

AT MICRO LABS 1.5%

A206220 001 Mar 18, 2019 Mar NEWA

AT MYLAN 1.5%

A206220 001 Mar 18, 2019 Apr CAHN

BEPREVE

AT +! BAUSCH AND LOMB INC 1.5%

N022288 001 Sep 08, 2009 Feb CFTG

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB PERRIGO ISRAEL EQ 0.05% BASE

A076592 001 Dec 09, 2003 May CAHN

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

>A> AB HI TECH EQ 0.05% BASE

A208849 001 Oct 11, 2019 Sep NEWA

SPRAY; TOPICAL

SERNIVO

+! ENCORE DERMAT EQ 0.05% BASE/SPRAY

N208079 001 Feb 05, 2016 Mar CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB PERRIGO ISRAEL 0.064%;0.005%

A200174 001 Dec 12, 2014 Mar CAIN

AB PERRIGO UK FINCO 0.064%;0.005%

A200174 001 Dec 12, 2014 May CAHN

AB TOLMAR 0.064%;0.005%

A201615 001 Jan 14, 2013 Mar CAIN

TACLONEX

AB +! LEO PHARMA AS 0.064%;0.005%

N021852 001 Jan 09, 2006 Mar CAIN

SUSPENSION; TOPICAL

TACLONEX

+! LEO PHARMA AS 0.064%;0.005%

N022185 001 May 09, 2008 Mar CAIN

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

>A> AB ANIMA EQ 0.1% BASE

A070052 001 Jul 31, 1985 Sep CAHN

>D> AB STI PHARMA LLC EQ 0.1% BASE

A070052 001 Jul 31, 1985 Sep CAHN

BETHANECHOL CHLORIDETABLET; ORAL
DUVOID

AA	CHARTWELL RX	10MG	A086262	001		Mar	CAHN
AA		25MG	A086263	001		Mar	CAHN
AA		50MG	A085882	003		Mar	CAHN

BEXAROTENEGEL; TOPICAL
TARGRETIN

+!	BAUSCH	1%	N021056	001	Jun 28, 2000	Jun	CAHN
----	--------	----	---------	-----	--------------	-----	------

BICALUTAMIDETABLET; ORAL
BICALUTAMIDE

AB	KENTON	50MG	A091011	001	Jun 10, 2015	Jun	CAHN
>D> AB	TEVA	50MG	A076932	001	Jul 06, 2009	Sep	DISC
>A>	@	50MG	A076932	001	Jul 06, 2009	Sep	DISC

BIMATOPROSTSOLUTION/DROPS; OPHTHALMIC
BIMATOPROST

AT	ALEMBIC PHARMS LTD	0.03%	A210263	001	Apr 12, 2019	Apr	NEWA
AT	GLAND PHARMA LTD	0.03%	A210126	001	Mar 22, 2019	Mar	NEWA
	@ HI-TECH PHARMA CO	0.03%	A203299	001	Nov 08, 2018	Jul	DISC
AT	SOMERSET THERAPS LLC	0.03%	A207601	001	Jun 19, 2019	Jun	NEWA

BISOPROLOL FUMARATETABLET; ORAL
BISOPROLOL FUMARATE

AB	FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002	Jul	CMFD
	@	5MG	A075474	001	Oct 25, 2002	Jan	CAHN
AB		10MG	A075474	002	Oct 25, 2002	Jul	CMFD
	@	10MG	A075474	002	Oct 25, 2002	Jan	CAHN
AB	MYLAN	10MG	A075831	002	Dec 14, 2005	Jul	CHRS
AB	! UNICHEM PHARMS (USA)	10MG	A078635	002	Aug 18, 2009	Jul	CHRS

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDETABLET; ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

@	MYLAN	2.5MG; 6.25MG	A075768	001	Sep 25, 2000	Jul	DISC
@		5MG; 6.25MG	A075768	002	Sep 25, 2000	Jul	DISC
@		10MG; 6.25MG	A075768	003	Sep 25, 2000	Jul	DISC

BIVALIRUDINSOLUTION; INTRAVENOUS
ANGIOMAX RTU

+!	MAIA PHARMS INC	250MG/50ML (5MG/ML)	N211215	001	Jul 25, 2019	Jul	NEWA
----	-----------------	---------------------	---------	-----	--------------	-----	------

BLEOMYCIN SULFATEINJECTABLE; INJECTION
BLEOMYCIN SULFATE

AP	CIPLA	EQ 15 UNITS BASE/VIAL	A209439	001	Mar 11, 2019	Feb	NEWA
----	-------	-----------------------	---------	-----	--------------	-----	------

BORTEZOMIBPOWDER; INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIB

+	@ HOSPIRA INC	1MG/VIAL	N209191	002	Dec 28, 2018	Mar	DISC
---	---------------	----------	---------	-----	--------------	-----	------

BOSENTANTABLET; ORAL
BOSENTAN

AB	ALVOGEN PINE BROOK	62.5MG	A206002	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A206002	002	Apr 26, 2019	Apr	NFTG
AB	AMNEAL PHARMS CO	62.5MG	A209742	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A209742	002	Apr 26, 2019	Apr	NFTG
AB	NATCO PHARMA LTD	62.5MG	A206987	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A206987	002	Apr 26, 2019	Apr	NFTG
AB	PAR PHARM INC	62.5MG	A205699	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A205699	002	Apr 26, 2019	Apr	NFTG
AB	SUN PHARM	62.5MG	A209324	001	Apr 26, 2019	Apr	NFTG

TABLET;ORAL

BOSENTAN

AB		125MG	A209324	002	Apr 26, 2019	Apr	NFTG
AB	WATSON LABS INC	62.5MG	A207110	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A207110	002	Apr 26, 2019	Apr	NFTG
AB	WEST-WARD PHARMS INT	62.5MG	A208695	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A208695	002	Apr 26, 2019	Apr	NFTG
AB	ZYDUS PHARMS	62.5MG	A207760	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A207760	002	Apr 26, 2019	Apr	NFTG
TRACLEER							
AB	+ ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001	Apr	CFTG
AB	+!	125MG	N021290	002	Nov 20, 2001	Apr	CFTG

BREMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

+!	AMAG PHARMS INC	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Jun	NEWA
----	-----------------	--	---------	-----	--------------	-----	------

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

!	BAS ANDA	50MG/ML	A204386	001	Dec 21, 2018	Jun	CAHN
!	BRECKENRIDGE	50MG/ML	A204386	001	Dec 21, 2018	Aug	CAHN

BREXANOLONE

SOLUTION;INTRAVENOUS

ZULRESSO

+!	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jun	NEWA
----	-------------	---------------------	---------	-----	--------------	-----	------

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AT	SOMERSET THERAPS LLC	0.2%	A208992	001	Mar 11, 2019	Feb	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AT2	ALEMBIC PHARMS LTD	EQ 0.09% ACID	A210560	001	Jun 21, 2019	Jun	NEWA
AT2	! HI TECH	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May	CTEC
AT2	INNOPHARMA LICENSING	EQ 0.09% ACID	A203368	001	Jun 03, 2019	May	NEWA

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

AB	APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Feb	CAHN
CAPSULE, EXTENDED RELEASE;ORAL							
ORTIKOS							
+	SUN PHARMA GLOBAL	6MG	N211929	001	Jun 13, 2019	Jun	NEWA
+!		9MG	N211929	002	Jun 13, 2019	Jun	NEWA

SUSPENSION;INHALATION

BUDESONIDE

>D>	AN	APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Sep	CAHN
>D>	AN		0.5MG/2ML	A078202	002	Mar 30, 2009	Sep	CAHN
>A>	AN	NEPHRON	0.25MG/2ML	A078202	001	Mar 30, 2009	Sep	CAHN
>A>	AN		0.5MG/2ML	A078202	002	Mar 30, 2009	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL

UCERIS

AB	+! SALIX	9MG	N203634	001	Jan 14, 2013	Mar	CAHN
----	----------	-----	---------	-----	--------------	-----	------

BUMETANIDE

TABLET;ORAL

BUMETANIDE

AB	HERITAGE PHARMA	0.5MG	A074225	001	Apr 24, 1995	Feb	CAHN
AB		1MG	A074225	002	Apr 24, 1995	Feb	CAHN
AB		2MG	A074225	003	Apr 24, 1995	Feb	CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

>D>	AP	MYLAN ASI	0.25%	A091503	001	Oct 18, 2011	Sep DISC
>A>		@	0.25%	A091503	001	Oct 18, 2011	Sep DISC
>D>	AP		0.5%	A091503	002	Oct 18, 2011	Sep DISC
>A>		@	0.5%	A091503	002	Oct 18, 2011	Sep DISC
		@ NOVOCOL HEALTHCARE	0.5%	A211096	001	Feb 19, 2019	Jun DISC
	AP		0.5%	A211096	001	Feb 19, 2019	Feb NEWA

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

>D>	AP	MYLAN ASI	0.25%	A091487	002	Oct 18, 2011	Sep DISC
>A>		@	0.25%	A091487	002	Oct 18, 2011	Sep DISC
>D>	AP		0.5%	A091487	001	Oct 18, 2011	Sep DISC
>A>		@	0.5%	A091487	001	Oct 18, 2011	Sep DISC
>D>	AP		0.75%	A091487	003	Oct 18, 2011	Sep DISC
>A>		@	0.75%	A091487	003	Oct 18, 2011	Sep DISC

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

	AP	B BRAUN MEDICAL INC	0.75%	A209087	001	Apr 02, 2019	Mar NEWA
--	----	---------------------	-------	---------	-----	--------------	----------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

>A>	+	@ HOSPIRA	0.5%; 0.0091MG/ML	N022046	001	Jul 13, 1983	Sep CMS1
>D>	AP	SEPTODONT	0.5%; 0.0091MG/ML	A077250	001	Sep 27, 2006	Sep CTEC
>A>		!	0.5%; 0.0091MG/ML	A077250	001	Sep 27, 2006	Sep CHRS
>A>			0.5%; 0.0091MG/ML	A077250	001	Sep 27, 2006	Sep CTEC
		BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE					
>D>	AP	+! HOSPIRA	0.5%; 0.0091MG/ML	N022046	001	Jul 13, 1983	Sep DISC
>A>		+ @	0.5%; 0.0091MG/ML	N022046	001	Jul 13, 1983	Sep DISC

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

		@ BARR	EQ 2MG BASE	A090360	001	May 07, 2010	Jul DISC
		@	EQ 8MG BASE	A090360	002	May 07, 2010	Jul DISC
>D>	AB	MYLAN	EQ 2MG BASE	A201066	001	Mar 06, 2015	Sep DISC
>A>		@	EQ 2MG BASE	A201066	001	Mar 06, 2015	Sep DISC
>D>	AB		EQ 8MG BASE	A201066	002	Mar 06, 2015	Sep DISC
>A>		@	EQ 8MG BASE	A201066	002	Mar 06, 2015	Sep DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ALVOGEN PINE BROOK	EQ 2MG BASE; EQ 0.5MG BASE	A205954	001	Jan 24, 2019	Jan NEWA
AB			EQ 4MG BASE; EQ 1MG BASE	A205954	002	Jan 24, 2019	Jan NEWA
AB			EQ 8MG BASE; EQ 2MG BASE	A205954	003	Jan 24, 2019	Jan NEWA
AB			EQ 12MG BASE; EQ 3MG BASE	A205954	004	Jan 24, 2019	Jan NEWA

FILM; SUBLINGUAL

CASSIPA

	+	@ TEVA PHARMS USA	EQ 16MG BASE; EQ 4MG BASE	N208042	001	Sep 07, 2018	Mar DISC
--	---	-------------------	---------------------------	---------	-----	--------------	----------

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

		@ TEVA PHARMS USA	EQ 2MG BASE; EQ 0.5MG BASE	A091149	001	Sep 08, 2014	Jan DISC
		@	EQ 8MG BASE; EQ 2MG BASE	A091149	002	Sep 08, 2014	Jan DISC

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB		APNAR PHARMA LP	75MG	A075584	001	Feb 07, 2000	Jun CAHN
AB			100MG	A075584	002	Feb 07, 2000	Jun CAHN
		@ HERITAGE PHARMA	75MG	A075310	001	Nov 29, 1999	May CAHN
		@	100MG	A075310	002	Nov 29, 1999	May CAHN

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB2	!	ACTAVIS LABS FL INC	150MG	A079094	001	Mar 24, 2009	Jul CHRS
AB3		GRAVITI PHARMS	150MG	A211020	001	Jan 28, 2019	Jan NEWA
AB3			300MG	A211020	002	Jan 28, 2019	Jan NEWA
		@ MYLAN	150MG	A090942	001	Jul 14, 2010	Jul DISC
>D>	AB3	SUN PHARM	150MG	A200695	001	Dec 18, 2014	Sep DISC
>A>		@	150MG	A200695	001	Dec 18, 2014	Sep DISC

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

	@ YICHANG HUMANWELL	100MG	A211347	001	Oct 16, 2018	Apr	DISC
	@	150MG	A211347	002	Oct 16, 2018	Apr	DISC
	@	200MG	A211347	003	Oct 16, 2018	Apr	DISC
AB3	ZHEJIANG JUTAI PHARM	300MG	A211200	001	Sep 05, 2019	Aug	NEWA
	ZYBAN						
	+ @ GLAXOSMITHKLINE	150MG	N020711	003	May 14, 1997	Jul	DISC

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Apr	NEWA
AB		7.5MG	A208972	002	Apr 16, 2019	Apr	NEWA
AB		10MG	A208972	003	Apr 16, 2019	Apr	NEWA
AB		15MG	A208972	004	Apr 16, 2019	Apr	NEWA
AB		30MG	A208972	005	Apr 16, 2019	Apr	NEWA
	@ RUBICON	5MG	A075521	001	Apr 05, 2002	Aug	CAHN
	@	10MG	A075521	002	Apr 05, 2002	Aug	CAHN
	@	15MG	A075521	003	Apr 05, 2002	Aug	CAHN

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN

AP	ACCORD HLTHCARE INC	6MG/ML	A210148	001	Feb 22, 2019	Feb	NEWA
AP	APOTEX INC	6MG/ML	A210448	001	May 07, 2019	Apr	NEWA
AP	ATHENEX INC	6MG/ML	A205106	001	Sep 21, 2018	Jan	CAHN
>D>	@ HOSPIRA INC	6MG/ML	A205672	001	Jul 31, 2018	Sep	CMFD
>A>	AP	6MG/ML	A205672	001	Jul 31, 2018	Sep	CMFD
	@	6MG/ML	A205672	001	Jul 31, 2018	Feb	DISC
AP	SHILPA MEDICARE LTD	6MG/ML	A210931	001	Apr 18, 2019	Apr	NEWA
	MYLERAN						
AP	MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Jul	CAHN

CABERGOLINE

TABLET;ORAL
CABERGOLINE

	@ ACTAVIS LABS FL INC	0.5MG	A078035	001	Apr 21, 2008	Aug	DISC
--	-----------------------	-------	---------	-----	--------------	-----	------

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS
CAFCIT

AP	+! HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Aug	CAHN
	SOLUTION;ORAL						
	CAFCIT						
AA	+! HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Aug	CAHN
	CAFFEINE CITRATE						
	@ LUITPOLD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009	Mar	DISC

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL
MIGERGOT

!	COSETTE	100MG;2MG	A086557	001	Oct 04, 1983	Jul	CAHN
---	---------	-----------	---------	-----	--------------	-----	------

CALCITONIN SALMON

INJECTABLE;INJECTION
CALCIMAR

>D>	@ SANOFI AVENTIS US	200 IU/ML	N017769	001		Sep	CRLD
>A>	+ @	200 IU/ML	N017769	001		Sep	CRLD
	MIACALCIN						
	+ @ MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug	CRLD

CALCITRIOL

CAPSULE;ORAL
CALCITRIOL

	@ SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Jul	DISC
AB		0.25MCG	A204556	001	Feb 21, 2019	Feb	NEWA
	@	0.5MCG	A204556	002	Feb 21, 2019	Jul	DISC
AB		0.5MCG	A204556	002	Feb 21, 2019	Feb	NEWA

	SOLUTION; ORAL						
	CALCITRIOL						
>A>	AA	ELYSIUM	1MCG/ML	A209798	001	Nov 21, 2018	Sep CAHN
>D>	AA	INVATECH PHARMA	1MCG/ML	A209798	001	Nov 21, 2018	Sep CAHN

CALCIUM ACETATE

	TABLET; ORAL						
	CALCIUM ACETATE						
AB		CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Jan CAHN

CALCIUM CHLORIDE

	INJECTABLE; INJECTION						
	CALCIUM CHLORIDE 10%						
AP		MEDEFIL INC	100MG/ML	A211553	001	May 01, 2019	Apr NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

	SOLUTION; INTRAPERITONEAL						
	DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	001	Dec 04, 1992	Jun CRLD
	DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992	Aug CTEC
	+		18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992	Jun CRLD
>D>	DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
>D>	+	BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992	Sep DISC
>A>	+	@	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992	Sep DISC
	+		18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992	Jun CRLD
	DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992	Aug CTEC
	+		18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992	Jun CRLD
	DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	012	Jan 10, 1989	Aug NEWA
	DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	013	Jul 11, 1990	Aug NEWA
	DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	014	Jul 11, 1990	Aug NEWA
	DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	015	Jul 11, 1990	Aug NEWA
	DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	004		Jun CRLD
AT	+		25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	004		Aug CPOT
AT	+		25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020163	001	Dec 04, 1992	Jun CRLD
	DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	005		Jun CRLD
AT	+		25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020163	002	Dec 04, 1992	Jun CRLD
	DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
	+	@ BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	011	Nov 18, 1985	Jun CRLD
	DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	006		Jun CRLD
AT	+		25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020163	003	Dec 04, 1992	Jun CRLD

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

	INJECTABLE; INJECTION						
	LACTATED RINGER'S IN PLASTIC CONTAINER						
AP		FRESENIUS KABI USA	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	A209338	001	Jan 28, 2019	Jan NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	SUN PHARM	150MG	A204668	001	Jun 21, 2019	Jun NEWA
AB		500MG	A204668	002	Jun 21, 2019	Jun NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	BOSCOGEN	12.5MG	A074677	004	May 30, 1997	Jun CMFD
AB		25MG	A074677	002	May 30, 1997	Jun CMFD
AB		50MG	A074677	001	May 30, 1997	Jun CMFD
AB		100MG	A074677	003	May 30, 1997	Jun CMFD

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

@ MYLAN IRELAND LTD

100MG

A076697 001 May 20, 2011 Jul DISC

@

200MG

A076697 002 May 20, 2011 Jul DISC

@

300MG

A076697 003 May 20, 2011 Jul DISC

CARBATROL

AB	+ SHIRE DEV LLC	100MG	N020712	003	Sep 30, 1997	Jan CAHN
AB	+	200MG	N020712	001	Sep 30, 1997	Jan CAHN
AB	+!	300MG	N020712	002	Sep 30, 1997	Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	ZYDUS PHARMS	100MG	A205571	001	Feb 07, 2019	Jan NEWA
AB		200MG	A205571	002	Feb 07, 2019	Jan NEWA
AB		400MG	A205571	003	Feb 07, 2019	Jan NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

@ WOCKHARDT LTD

12.5MG; 200MG; 50MG

A090786 001 Nov 20, 2012 Aug DISC

@

18.75MG; 200MG; 75MG

A090833 001 Nov 20, 2012 Aug DISC

@

25MG; 200MG; 100MG

A090833 002 Nov 20, 2012 Aug DISC

@

31.25MG; 200MG; 125MG

A090833 003 Nov 20, 2012 Aug DISC

@

37.5MG; 200MG; 150MG

A090833 004 Nov 20, 2012 Aug DISC

@

50MG; 200MG; 200MG

A090833 005 Nov 20, 2012 Aug DISC

STALEVO 125

+ ORION PHARMA

31.25MG; 200MG; 125MG

N021485 006 Aug 29, 2008 Aug CTEC

STALEVO 200

+! ORION PHARMA

50MG; 200MG; 200MG

N021485 004 Aug 02, 2007 Aug CTEC

STALEVO 50

+! ORION PHARMA

12.5MG; 200MG; 50MG

N021485 001 Jun 11, 2003 Aug CTEC

STALEVO 75

+ ORION PHARMA

18.75MG; 200MG; 75MG

N021485 005 Aug 29, 2008 Aug CTEC

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	ALEMBIC PHARMS LTD	25MG; 100MG	A210341	001	Jun 05, 2019	May NEWA
AB		50MG; 200MG	A210341	002	Jun 05, 2019	May NEWA

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

! MIKART

4MG/5ML

A040458 001 Apr 25, 2003 Jun CTEC

@ VINTAGE PHARMS

4MG/5ML

A040814 001 Feb 26, 2008 Jun DISC

TABLET; ORAL

CARBINOXAMINE MALEATE

! MIKART

6MG

A207484 001 May 31, 2016 Mar CHRS

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	May CDFR
AP		150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	May CDFR
AP		450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	May CDFR
AP		600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	May CDFR
	@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Mar CDFR

INJECTABLE; INTRAVENOUS CARBOPLATIN									
	@	150MG/15ML (10MG/ML)	A078732	002	Feb 06,	2012	Mar	CDFR	
	@	450MG/45ML (10MG/ML)	A078732	003	Feb 06,	2012	Mar	CDFR	
	@	600MG/60ML (10MG/ML)	A078732	004	Feb 06,	2012	Mar	CDFR	
AP	AKORN	50MG/5ML (10MG/ML)	A090475	001	Jul 29,	2009	May	CDFR	
AP		150MG/15ML (10MG/ML)	A090475	002	Jul 29,	2009	May	CDFR	
AP		450MG/45ML (10MG/ML)	A090475	003	Jul 29,	2009	May	CDFR	
AP		600MG/60ML (10MG/ML)	A091268	002	Jul 28,	2010	May	CDFR	
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861	001	Jan 18,	2007	May	CDFR	
AP		150MG/15ML (10MG/ML)	A077861	002	Jan 18,	2007	May	CDFR	
AP		450MG/45ML (10MG/ML)	A077861	003	Jan 18,	2007	May	CDFR	
AP		600MG/60ML (10MG/ML)	A077861	004	Jan 18,	2007	May	CDFR	
AP	EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28,	2016	May	CDFR	
AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28,	2016	May	CDFR	
AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28,	2016	May	CDFR	
	@ FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077247	001	Oct 21,	2004	Mar	CDFR	
	@	50MG/5ML (10MG/ML)	A077266	001	Feb 15,	2006	Mar	CDFR	
	@	150MG/15ML (10MG/ML)	A077247	002	Oct 21,	2004	Mar	CDFR	
	@	150MG/15ML (10MG/ML)	A077266	002	Feb 15,	2006	Mar	CDFR	
AP		450MG/45ML (10MG/ML)	A077247	003	Oct 21,	2004	Mar	CDFR	
AP		450MG/45ML (10MG/ML)	A077266	003	Feb 15,	2006	May	CDFR	
AP		600MG/60ML (10MG/ML)	A077266	004	Feb 15,	2006	May	CDFR	
AP	GLAND PHARMA LTD	150MG/15ML (10MG/ML)	A207324	002	Feb 15,	2017	May	CDFR	
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15,	2017	May	CDFR	
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15,	2017	May	CDFR	
AP	HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14,	2005	May	CDFR	
AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14,	2005	May	CDFR	
AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14,	2005	May	CDFR	
AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03,	2013	May	CDFR	
AP	HOSPIRA	50MG/5ML (10MG/ML)	A076517	001	Oct 14,	2004	May	CDFR	
AP		150MG/15ML (10MG/ML)	A076517	002	Oct 14,	2004	May	CDFR	
AP		450MG/45ML (10MG/ML)	A076517	003	Oct 14,	2004	May	CDFR	
AP		600MG/60ML (10MG/ML)	A077059	001	Nov 23,	2004	May	CDFR	
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26,	2017	May	CDFR	
AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26,	2017	May	CDFR	
AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26,	2017	May	CDFR	
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26,	2017	May	CDFR	
	@ MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24,	2007	Apr	CDFR	
	@	150MG/15ML (10MG/ML)	A077998	002	Apr 24,	2007	Apr	CDFR	
	@	450MG/45ML (10MG/ML)	A077998	003	Apr 24,	2007	Apr	CDFR	
	@ MYLAN LABS LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23,	2011	Mar	CDFR	
AP	! PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14,	2004	May	CDFR	
	@	50MG/5ML (10MG/ML)	A077679	001	Feb 25,	2009	Mar	CDFR	
AP	!	150MG/15ML (10MG/ML)	A077269	002	Oct 14,	2004	May	CDFR	
	@	150MG/15ML (10MG/ML)	A077679	002	Feb 25,	2009	Mar	CDFR	
AP	!	450MG/45ML (10MG/ML)	A077269	003	Oct 14,	2004	May	CDFR	
	@	450MG/45ML (10MG/ML)	A077679	003	Feb 25,	2009	Mar	CDFR	
AP	!	600MG/60ML (10MG/ML)	A077269	004	Dec 28,	2007	May	CDFR	
AP	PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02,	2008	May	CDFR	
AP		150MG/15ML (10MG/ML)	A078631	002	Dec 02,	2008	May	CDFR	
AP		450MG/45ML (10MG/ML)	A078631	003	Dec 02,	2008	May	CDFR	
AP		600MG/60ML (10MG/ML)	A078631	004	Dec 02,	2008	May	CDFR	
AP	SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08,	2008	May	CDFR	
AP		150MG/15ML (10MG/ML)	A078280	002	May 08,	2008	May	CDFR	
AP		450MG/45ML (10MG/ML)	A078280	003	May 08,	2008	May	CDFR	
AP	SUN PHARM	50MG/5ML (10MG/ML)	A077926	001	Sep 19,	2008	May	CDFR	
AP		150MG/15ML (10MG/ML)	A077926	002	Sep 19,	2008	May	CDFR	
AP		450MG/45ML (10MG/ML)	A077926	003	Sep 19,	2008	May	CDFR	
	@ TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30,	2007	Mar	CDFR	
	@	150MG/15ML (10MG/ML)	A077389	002	Mar 30,	2007	Mar	CDFR	
	@	450MG/45ML (10MG/ML)	A077389	003	Mar 30,	2007	Mar	CDFR	
AP	! TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21,	2005	May	CDFR	
AP	!	150MG/15ML (10MG/ML)	A077139	002	Sep 21,	2005	May	CDFR	
AP	!	450MG/45ML (10MG/ML)	A077139	003	Sep 21,	2005	May	CDFR	
AP	!	600MG/60ML (10MG/ML)	A077139	004	Sep 21,	2005	May	CDFR	
AP	WEST-WARD PHARMS INT	50MG/5ML (10MG/ML)	A077244	001	Oct 15,	2004	May	CDFR	
AP		150MG/15ML (10MG/ML)	A077244	002	Oct 15,	2004	May	CDFR	
AP		450MG/45ML (10MG/ML)	A077244	003	Oct 15,	2004	May	CDFR	
AP		600MG/60ML (10MG/ML)	A077244	004	Jan 20,	2006	May	CDFR	
PARAPLATIN									
+	@ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14,	2003	Mar	CDFR	
+	@	150MG/15ML (10MG/ML)	N020452	002	Jul 14,	2003	Mar	CDFR	
+	@	450MG/45ML (10MG/ML)	N020452	003	Jul 14,	2003	Mar	CDFR	

INJECTABLE; INTRAVENOUS							
PARAPLATIN							
	+ @	600MG/60ML (10MG/ML)		N020452	004	Jan 15, 2004	Mar CDFR
INJECTABLE; IV (INFUSION)							
CARBOPLATIN							
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)		A207324	001	Feb 15, 2017	May CDFR
AP	HONG KONG	50MG/5ML (10MG/ML)		A077096	001	Jun 14, 2005	Feb CAHN
AP		150MG/15ML (10MG/ML)		A077096	002	Jun 14, 2005	Feb CAHN
AP		450MG/45ML (10MG/ML)		A077096	003	Jun 14, 2005	Feb CAHN
AP		600MG/60ML (10MG/ML)		A077096	004	Jun 03, 2013	Feb CAHN
	@ MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)		A077998	001	Apr 24, 2007	Mar DISC
	@	150MG/15ML (10MG/ML)		A077998	002	Apr 24, 2007	Mar DISC
	@	450MG/45ML (10MG/ML)		A077998	003	Apr 24, 2007	Mar DISC
<u>CARBOPROST TROMETHAMINE</u>							
INJECTABLE; INJECTION							
CARBOPROST TROMETHAMINE							
AP	DR REDDYS LABS LTD	EQ 0.25MG BASE/ML		A211941	001	Jul 02, 2019	Jun NFTG
HEMABATE							
AP	+! PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML		N017989	001		Jun CFTG
<u>CARFILZOMIB</u>							
POWDER; INTRAVENOUS							
CARFILZOMIB							
AP	DR REDDYS	60MG/VIAL		A209422	001	Sep 09, 2019	Aug NFTG
KYPROLIS							
AP	+! ONYX THERAP	60MG/VIAL		N202714	001	Jul 20, 2012	Aug CFTG
<u>CARGLUMIC ACID</u>							
TABLET; ORAL							
CARBAGLU							
	+! RECORDATI RARE	200MG		N022562	001	Mar 18, 2010	May CAHN
<u>CARISOPRODOL</u>							
TABLET; ORAL							
CARISOPRODOL							
AA	ALLIED	350MG		A040245	001	Sep 08, 1997	Aug CMFD
	@	350MG		A040245	001	Sep 08, 1997	Jun CAHN
	@ VINTAGE PHARMS	350MG		A040245	001	Sep 08, 1997	Feb DISC
<u>CARMUSTINE</u>							
INJECTABLE; INJECTION							
CARMUSTINE							
AP	STI PHARMA LLC	100MG/VIAL		A209278	001	Apr 02, 2019	Mar NEWA
<u>CARTEOLOL HYDROCHLORIDE</u>							
SOLUTION/DROPS; OPHTHALMIC							
CARTEOLOL HYDROCHLORIDE							
	@ BAUSCH AND LOMB	1%		A075546	001	Jan 20, 2000	May DISC
	! SANDOZ INC	1%		A075476	001	Jan 03, 2000	May CTEC
<u>CARVEDILOL</u>							
TABLET; ORAL							
CARVEDILOL							
AB	RUBICON	3.125MG		A078165	001	Sep 05, 2007	Aug CAHN
AB		6.25MG		A078165	002	Sep 05, 2007	Aug CAHN
AB		12.5MG		A078165	003	Sep 05, 2007	Aug CAHN
AB		25MG		A078165	004	Sep 05, 2007	Aug CAHN
<u>CASPOFUNGIN ACETATE</u>							
POWDER; INTRAVENOUS							
CASPOFUNGIN ACETATE							
	@ CIPLA	50MG/VIAL		A209489	001	Jul 12, 2018	Jan DISC
	@	70MG/VIAL		A209489	002	Jul 12, 2018	Jan DISC
<u>CEFAZOLIN SODIUM</u>							
INJECTABLE; INJECTION							
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER							
	+ @ BAXTER HLTHCARE	EQ 10MG BASE/ML		N050566	003	Jun 08, 1983	Aug CRLD
	+ @	EQ 20MG BASE/ML		N050566	004	Jun 08, 1983	Aug CRLD

INJECTABLE; INJECTION

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ @ BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	001	Jun 08, 1983	Aug CRLD
+ @	EQ 20MG BASE/ML	N050566	002	Jun 08, 1983	Aug CRLD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

>D> AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007	Sep DISC
>A>	@	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007	Sep DISC
>D> AP		EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007	Sep DISC
>A>	@	EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007	Sep DISC
>D> AP		EQ 1GM BASE/VIAL	A202268	001	Jul 30, 2012	Sep DISC
>A>	@	EQ 1GM BASE/VIAL	A202268	001	Jul 30, 2012	Sep DISC
>D> AP		EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007	Sep DISC
>A>	@	EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007	Sep DISC
>D> AP		EQ 2GM BASE/VIAL	A202268	002	Jul 30, 2012	Sep DISC
>A>	@	EQ 2GM BASE/VIAL	A202268	002	Jul 30, 2012	Sep DISC

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

@ SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017	Feb DISC
@	200MG/5ML	A206144	002	Nov 17, 2017	Feb DISC
SUPRAX					
AB ! LUPIN PHARMS	200MG/5ML	A065355	001	Apr 10, 2007	Apr CHRS

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

>D> AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006	Sep DISC
>A>	@	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006	Sep DISC
>D> AP		EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006	Sep DISC
>A>	@	EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006	Sep DISC
>D> AP		EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006	Sep DISC
>A>	@	EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006	Sep DISC
>D> AP		EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Sep DISC
>A>	@	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Sep DISC
>D> AP		EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Sep DISC
>A>	@	EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Sep DISC
>D> AP		EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Sep DISC
>A>	@	EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Sep DISC
>D> AP		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Sep DISC
>A>	@	EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Sep DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

>D> AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Sep DISC
>A>	@	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Sep DISC
>D> AP		EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Sep DISC
>A>	@	EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Sep DISC
>D> AP		EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Sep DISC
>A>	@	EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Sep DISC

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007	Jan CTEC
!	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CHRS
	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CTEC
@ SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jan DISC
@	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jan DISC

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

>D> AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008	Sep DISC
>A>	@	EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008	Sep DISC
>D> AP		EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008	Sep DISC
>A>	@	EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008	Sep DISC
>D> AP		EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008	Sep DISC
>A>	@	EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008	Sep DISC

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

>D>	AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008	Sep DISC
>A>	@		EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008	Sep DISC

CELECOXIB

CAPSULE; ORAL

CELECOXIB

AB		QINGDAO BAHEAL PHARM	50MG	A208856	001	Aug 07, 2019	Jul NEWA
AB			100MG	A208856	002	Aug 07, 2019	Jul NEWA
AB			200MG	A208856	003	Aug 07, 2019	Jul NEWA
AB			400MG	A208856	004	Aug 07, 2019	Jul NEWA

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

AB		ALKEM LABS LTD	EQ 125MG BASE/5ML	A210221	001	Mar 26, 2019	Mar NEWA
AB			EQ 250MG BASE/5ML	A210221	002	Mar 26, 2019	Mar NEWA

CERITINIB

CAPSULE; ORAL

ZYKADIA

	+	@ NOVARTIS	150MG	N205755	001	Apr 29, 2014	Jun DISC
--	---	------------	-------	---------	-----	--------------	----------

TABLET; ORAL

ZYKADIA

	+	! NOVARTIS	150MG	N211225	001	Mar 18, 2019	Mar NEWA
--	---	------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

		@ LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	May DISC
AA		MLV	5MG/5ML	A090191	001	Nov 12, 2009	Aug CAHN
AA	!	PERRIGO PHARMS CO	5MG/5ML	A078398	001	Jun 17, 2008	May CAHN
AA		TORRENT	5MG/5ML	A078870	001	Apr 27, 2009	Jan CAHN

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

	+	@ PARKE DAVIS	10MG/GM; 666 UNITS/GM; 1 UNITS/GM	N050294	001		Aug CRLD
--	---	---------------	-----------------------------------	---------	-----	--	----------

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION

LIBRIUM

		@ BAUSCH	100MG/AMP	N012301	001		Mar CAHN
--	--	----------	-----------	---------	-----	--	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

		@ ACELLA	4MG/5ML; 5MG/5ML	A206891	001	Jun 09, 2017	Aug DISC
		VITUZ					
	+	@ PERSION	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Aug DISC
AA	+	!	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Apr CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	!	PADDOCK LLC	4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Jun CHRS
		@ TORRENT	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Jan CAHN
		ZUTRIPRO					
	+	@ PERSION	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Jul DISC
AA	+	!	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Apr CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

>D>		@ CYCLE PHARMS LTD	30MG/ML	A088157	001	Apr 27, 1983	Sep CAHN
>D>		@	100MG/ML	A088158	001	Apr 27, 1983	Sep CAHN
>A>		@ HIKMA	30MG/ML	A088157	001	Apr 27, 1983	Sep CAHN
>A>		@	100MG/ML	A088158	001	Apr 27, 1983	Sep CAHN

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		UPSHER SMITH LABS	10MG	A083386	001		Jul CAHN
AB	!		25MG	A084112	001		Jul CAHN
AB			50MG	A084113	001		Jul CAHN
AB	!		100MG	A084114	001		Jul CAHN
AB			200MG	A084115	001		Jul CAHN

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

	@	MYLAN	100MG	A088549	002	Jun 01, 1984	May DISC
	@		250MG	A088549	001	Jun 01, 1984	May DISC

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB		AMNEAL PHARMS CO	25MG	A207204	001	Jul 01, 2019	Jun NEWA
AB			50MG	A207204	002	Jul 01, 2019	Jun NEWA
>D>	AB	APPCO PHARMA LLC	25MG	A210742	001	Oct 12, 2018	Sep CAHN
>D>	AB		50MG	A210742	002	Oct 12, 2018	Sep CAHN
>A>	AB	ARISE	25MG	A210742	001	Oct 12, 2018	Sep CAHN
>A>	AB		50MG	A210742	002	Oct 12, 2018	Sep CAHN
AB		UNICHEM LABS LTD	25MG	A211627	001	Aug 06, 2019	Jul NEWA
AB			50MG	A211627	002	Aug 06, 2019	Jul NEWA
AB		ZYDUS PHARMS	25MG	A207813	001	May 10, 2019	Apr NEWA
AB			50MG	A207813	002	May 10, 2019	Apr NEWA

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

>A>	AA	NOVITIUM PHARMA	500MG	A212254	001	Sep 12, 2019	Sep NEWA
>D>	!	WATSON LABS	500MG	A089859	001	May 04, 1988	Sep CTEC
>A>	AA	!	500MG	A089859	001	May 04, 1988	Sep CTEC

CHOLINE C-11

INJECTABLE;INTRAVENOUS

CHOLINE C-11

AP		DECATUR	4-33.1mCi/ML	A206319	001	Nov 13, 2015	Apr CAHN
----	--	---------	--------------	---------	-----	--------------	----------

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB		AUROBINDO PHARMA LTD	EQ 45MG FENOFIBRIC ACID	A212598	001	Jul 25, 2019	Jul NEWA
AB			EQ 135MG FENOFIBRIC ACID	A212598	002	Jul 25, 2019	Jul NEWA
AB		GRAVITI PHARMS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Jul NEWA
AB			EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Jul NEWA
		@ MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013	May DISC
		@	EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013	May DISC
AB		TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Jun NEWA
AB			EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Jun NEWA

CHROMIC PHOSPHATE P-32

INJECTABLE;INJECTION

PHOSPHOCOL P32

	@	CURIUM	5mCi/ML	N017084	001		Jan CAHN
--	---	--------	---------	---------	-----	--	----------

CICLESONIDE

AEROSOL, METERED;INHALATION

ALVESCO

+	!	COVIS PHARMA BV	0.08MG/INH	N021658	002	Jan 10, 2008	Mar CAHN
+	!		0.16MG/INH	N021658	003	Jan 10, 2008	Mar CAHN

AEROSOL, METERED;NASAL

ZETONNA

+	!	COVIS PHARMA BV	0.037MG/INH	N202129	001	Jan 20, 2012	Mar CAHN
---	---	-----------------	-------------	---------	-----	--------------	----------

SPRAY, METERED;NASAL

OMNARIS

+	!	COVIS PHARMA BV	0.05MG/INH	N022004	001	Oct 20, 2006	Mar CAHN
---	---	-----------------	------------	---------	-----	--------------	----------

CICLOPIROXCREAM; TOPICAL
CICLOPIROX

AB	PERRIGO ISRAEL	0.77%	A077364	001	Mar 03, 2006	May CAHN
	SHAMPOO; TOPICAL					
	LOPROX					

AT	+! BAUSCH	1%	N021159	001	Feb 28, 2003	Apr CAHN
	SOLUTION; TOPICAL					
	CICLOPIROX					

AT	ACELLA	8%	A078172	001	Sep 18, 2007	May CAHN
----	--------	----	---------	-----	--------------	----------

AT	ANDA REPOSITORY	8%	A077687	001	Sep 18, 2007	Aug CAHN
----	-----------------	----	---------	-----	--------------	----------

>D> AT	INGENUS PHARMS LLC	8%	A078124	001	Sep 18, 2007	Sep CAHN
--------	--------------------	----	---------	-----	--------------	----------

>A> AT	NOVAST LABS	8%	A078124	001	Sep 18, 2007	Sep CAHN
--------	-------------	----	---------	-----	--------------	----------

CILASTATIN SODIUM; IMIPENEMPOWDER; INTRAVENOUS
IMIPENEM AND CILASTATIN

>D> AP	HOSPIRA INC	EQ 500MG BASE/VIAL; 500MG/VIAL	A090825	002	Nov 16, 2011	Sep DISC
--------	-------------	--------------------------------	---------	-----	--------------	----------

>A>	@	EQ 500MG BASE/VIAL; 500MG/VIAL	A090825	002	Nov 16, 2011	Sep DISC
-----	---	--------------------------------	---------	-----	--------------	----------

>D> AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A091007	001	Nov 16, 2011	Sep DISC
--------	--	--------------------------------	---------	-----	--------------	----------

>A>	@	EQ 500MG BASE/VIAL; 500MG/VIAL	A091007	001	Nov 16, 2011	Sep DISC
-----	---	--------------------------------	---------	-----	--------------	----------

CILASTATIN SODIUM; IMIPENEM; RELEBACTAMPOWDER; INTRAVENOUS
RECARBRIO

+! MSD MERCK CO	EQ 500MG BASE/VIAL; 500MG/VIAL; 250MG/VIAL	N212819	001	Jul 16, 2019	Jul NEWA
-----------------	---	---------	-----	--------------	----------

CILOSTAZOLTABLET; ORAL
CILOSTAZOL

AB	SLATE	50MG	A077208	002	Mar 29, 2006	Aug CAHN
----	-------	------	---------	-----	--------------	----------

AB		100MG	A077208	001	Mar 29, 2006	Aug CAHN
----	--	-------	---------	-----	--------------	----------

CIMETIDINETABLET; ORAL
CIMETIDINE

AB	HIKMA	200MG	A074890	001	Dec 18, 1998	Jun CAHN
----	-------	-------	---------	-----	--------------	----------

AB		300MG	A074890	002	Dec 18, 1998	Jun CAHN
----	--	-------	---------	-----	--------------	----------

AB		400MG	A074890	003	Dec 18, 1998	Jun CAHN
----	--	-------	---------	-----	--------------	----------

AB		800MG	A074890	004	Dec 18, 1998	Jun CAHN
----	--	-------	---------	-----	--------------	----------

CINACALCET HYDROCHLORIDETABLET; ORAL
CINACALCET HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 30MG BASE	A210570	001	May 17, 2019	May NEWA
----	----------------	--------------	---------	-----	--------------	----------

AB		EQ 60MG BASE	A210570	002	May 17, 2019	May NEWA
----	--	--------------	---------	-----	--------------	----------

AB		EQ 90MG BASE	A210570	003	May 17, 2019	May NEWA
----	--	--------------	---------	-----	--------------	----------

AB	LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jun NEWA
----	-----------	--------------	---------	-----	--------------	----------

AB		EQ 60MG BASE	A210548	002	Jun 28, 2019	Jun NEWA
----	--	--------------	---------	-----	--------------	----------

AB		EQ 90MG BASE	A210548	003	Jun 28, 2019	Jun NEWA
----	--	--------------	---------	-----	--------------	----------

CIPROFLOXACININJECTABLE; INJECTION
CIPROFLOXACIN

@ DR REDDYS	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	May CAHN
-------------	----------------------	---------	-----	--------------	----------

@	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	May CAHN
---	----------------------	---------	-----	--------------	----------

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

@ RUBICON	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Jul CAHN
-----------	--------------	---------	-----	--------------	----------

TABLET; ORAL
CIPROFLOXACIN HYDROCHLORIDE

>A> AB	CHARTWELL	EQ 250MG BASE	A076896	001	Nov 04, 2004	Sep CAHN
--------	-----------	---------------	---------	-----	--------------	----------

>A> AB		EQ 500MG BASE	A076896	002	Nov 04, 2004	Sep CAHN
--------	--	---------------	---------	-----	--------------	----------

>A> AB		EQ 750MG BASE	A076896	003	Nov 04, 2004	Sep CAHN
--------	--	---------------	---------	-----	--------------	----------

>D> AB	CHARTWELL MOLECULES	EQ 250MG BASE	A076896	001	Nov 04, 2004	Sep CAHN
--------	---------------------	---------------	---------	-----	--------------	----------

AB		EQ 250MG BASE	A076896	001	Nov 04, 2004	Jul CAHN
----	--	---------------	---------	-----	--------------	----------

>D> AB		EQ 500MG BASE	A076896	002	Nov 04, 2004	Sep CAHN
--------	--	---------------	---------	-----	--------------	----------

AB		EQ 500MG BASE	A076896	002	Nov 04, 2004	Jul CAHN
----	--	---------------	---------	-----	--------------	----------

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

>D>	AB	EQ 750MG BASE	A076896	003	Nov 04, 2004	Sep CAHN
	AB	EQ 750MG BASE	A076896	003	Nov 04, 2004	Jul CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

	!	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May CTEC
AB	!		212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May CHRS
AB	!		425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	May CHRS
	@	ANI PHARMS INC	212.6MG;EQ 287.5MG BASE	A077417	001	Nov 30, 2010	May CAHN
	@		425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010	May CAHN
	@	MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	May DISC
	@		425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	May DISC

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

	@	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Feb DISC
>A>	AP	ANDA REPOSITORY	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Sep CAHN
	AP	NANJING KING-FRIEND	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr NEWA
	AP		EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr NEWA
	AP		EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr NEWA
>D>	AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Sep CAHN
	AP		EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Apr NEWA
		CISATRACURIUM BESYLATE PRESERVATIVE FREE					
	@	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Feb DISC
	@		EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Feb DISC
AP		SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A206791	001	Feb 20, 2019	Feb NEWA
AP			EQ 10MG BASE/ML	A206791	002	Feb 20, 2019	Feb NEWA
		NIMBEX PRESERVATIVE FREE					
AP	+	ABBVIE	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Feb CTEC

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

	@	HERITAGE PHARMA	EQ 10MG BASE	A077033	001	Oct 28, 2004	May CAHN
	@		EQ 10MG BASE	A077213	001	Mar 31, 2006	May CAHN
AB			EQ 10MG BASE	A077232	001	Oct 31, 2005	May CAHN
	@		EQ 20MG BASE	A077033	002	Oct 28, 2004	May CAHN
	@		EQ 20MG BASE	A077213	002	Mar 31, 2006	May CAHN
AB			EQ 20MG BASE	A077232	002	Oct 31, 2005	May CAHN
	@		EQ 40MG BASE	A077033	003	Oct 28, 2004	May CAHN
	@		EQ 40MG BASE	A077213	003	Mar 31, 2006	May CAHN
AB			EQ 40MG BASE	A077232	003	Oct 31, 2005	May CAHN

>D> CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

>D> FOR SOLUTION;ORAL

>D> PREPOPIK

>D>	+	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACK	N202535	001	Jul 16, 2012	Sep DISC
			ET				
>A>	+	@	12GM/PACKET;3.5GM/PACKET;10MG/PACK	N202535	001	Jul 16, 2012	Sep DISC
			ET				
	+	!	12GM/PACKET;3.5GM/PACKET;10MG/PACK	N202535	001	Jul 16, 2012	Jun CMFD
			ET				
	+	@	12GM/PACKET;3.5GM/PACKET;10MG/PACK	N202535	001	Jul 16, 2012	Apr DISC
			ET				

CLADRIBINE

TABLET;ORAL

MAVENCLAD

+	!	EMD SERONO INC	10MG	N022561	001	Mar 29, 2019	Mar NEWA
---	---	----------------	------	---------	-----	--------------	----------

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

>D>	AB	AJANTA PHARMA LTD	250MG	A206714	001	Apr 25, 2019	Sep DISC
>A>		@	250MG	A206714	001	Apr 25, 2019	Sep DISC
	AB		250MG	A206714	001	Apr 25, 2019	Apr NEWA
>D>	AB		500MG	A206714	002	Apr 25, 2019	Sep DISC
>A>		@	500MG	A206714	002	Apr 25, 2019	Sep DISC
	AB		500MG	A206714	002	Apr 25, 2019	Apr NEWA

TABLET;ORAL							
CLARITHROMYCIN							
AB	CHARTWELL	250MG	A065384	001	Aug 20, 2007	Aug	CAHN
AB		500MG	A065384	002	Aug 20, 2007	Aug	CAHN
AB	STRIDES PHARMA	250MG	A202710	001	Jun 10, 2013	Feb	CAHN
AB		500MG	A202710	002	Jun 10, 2013	Feb	CAHN
TABLET, EXTENDED RELEASE;ORAL							
CLARITHROMYCIN							
AB	NOSTRUM LABS INC	500MG	A203243	001	Feb 29, 2016	Jul	CAHN
<u>CLINDAMYCIN PALMITATE HYDROCHLORIDE</u>							
FOR SOLUTION;ORAL							
CLINDAMYCIN PALMITATE HYDROCHLORIDE							
	@ MYLAN	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Mar	DISC
<u>CLINDAMYCIN PHOSPHATE</u>							
GEL;TOPICAL							
CLINDAGEL							
BT	+! BAUSCH	EQ 1% BASE	N050782	001	Nov 27, 2000	May	CAHN
SOLUTION;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AT	ENCUBE ETHICALS	EQ 1% BASE	A209914	001	Jan 28, 2019	Jan	NEWA
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN</u>							
GEL;TOPICAL							
VELTIN							
BX	+! ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb	CAHN
<u>CLOBAZAM</u>							
SUSPENSION;ORAL							
CLOBAZAM							
>D> AB	TARO	2.5MG/ML	A210978	001	Apr 15, 2019	Sep	DISC
>A>	@	2.5MG/ML	A210978	001	Apr 15, 2019	Sep	DISC
AB		2.5MG/ML	A210978	001	Apr 15, 2019	Apr	NEWA
AB	VISTAPHARM	2.5MG/ML	A210746	001	Jul 10, 2019	Jun	NEWA
TABLET;ORAL							
CLOBAZAM							
AB	ACCORD HLTHCARE	10MG	A212398	001	May 23, 2019	May	NEWA
AB		20MG	A212398	002	May 23, 2019	May	NEWA
AB	ALKEM LABS LTD	10MG	A212714	001	Sep 06, 2019	Aug	NEWA
AB		20MG	A212714	002	Sep 06, 2019	Aug	NEWA
AB	MICRO LABS	10MG	A211711	001	Jan 30, 2019	Jan	NEWA
AB		20MG	A211711	002	Jan 30, 2019	Jan	NEWA
	@ TARO	10MG	A209440	001	Oct 22, 2018	Jul	DISC
	@	20MG	A209440	002	Oct 22, 2018	Jul	DISC
<u>CLOBETASOL PROPIONATE</u>							
AEROSOL, FOAM;TOPICAL							
CLOBETASOL PROPIONATE							
AB1	GLENMARK PHARMS LTD	0.05%	A210809	001	Feb 15, 2019	Feb	NEWA
AB2		0.05%	A211450	001	Sep 09, 2019	Aug	NEWA
AB2	PERRIGO UK FINCO	0.05%	A201402	001	Aug 14, 2012	May	CAHN
CREAM;TOPICAL							
CLOBETASOL PROPIONATE							
>A> AB1	RISING	0.05%	A211401	001	Jan 11, 2019	Sep	CAHN
>D> AB1	SOLARIS PHARMA CORP	0.05%	A211401	001	Jan 11, 2019	Sep	CAHN
AB1	XIROMED	0.05%	A210034	001	Jun 15, 2018	Aug	CAHN
LOTION;TOPICAL							
CLOBETASOL PROPIONATE							
	@ HI TECH	0.05%	A211348	001	Oct 26, 2018	Jul	DISC
>A> AB	ZYDUS PHARMS	0.05%	A205249	001	Sep 24, 2019	Sep	NEWA
OINTMENT;TOPICAL							
CLOBETASOL PROPIONATE							
AB	ALEOR DERMACEUTICALS	0.05%	A211800	001	Mar 04, 2019	Feb	NEWA
	@ AMNEAL PHARMS LLC	0.05%	A210551	001	Aug 21, 2018	Feb	DISC
AB	TELIGENT PHARMA INC	0.05%	A208589	001	Jan 23, 2019	Jan	NEWA
AB	XIROMED	0.05%	A209701	001	Apr 17, 2018	Aug	CAHN
SOLUTION;TOPICAL							
CLOBETASOL PROPIONATE							
>A> AT	SAPTALIS PHARMS	0.05%	A211494	001	Oct 02, 2019	Sep	NEWA

		SPRAY; TOPICAL					
		CLOBETASOL PROPIONATE					
>A>	AT	ALEOR DERMACEUTICALS	0.05%	A211191	001	Oct 02, 2019	Sep NEWA
	AT	GLENMARK PHARMS	0.05%	A209004	001	Mar 26, 2018	Aug CAHN
		<u>CLOFARABINE</u>					
		SOLUTION; INTRAVENOUS					
		CLOFARABINE					
AP		ACCORD HLTHCARE	20MG/20ML (1MG/ML)	A212034	001	Feb 22, 2019	Feb NEWA
		@ HOSPIRA INC	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018	Feb DISC
		<u>CLONAZEPAM</u>					
		TABLET; ORAL					
		CLONAZEPAM					
		@ RUBICON	0.5MG	A075468	001	Oct 06, 2000	Aug CAHN
		@	1MG	A075468	002	Oct 06, 2000	Aug CAHN
		@	2MG	A075468	003	Oct 06, 2000	Aug CAHN
		TABLET, ORALLY DISINTEGRATING; ORAL					
		CLONAZEPAM					
AB		ALEMBIC PHARMS LTD	0.125MG	A211033	001	Jun 28, 2019	Jun NEWA
AB			0.25MG	A211033	002	Jun 28, 2019	Jun NEWA
AB			0.5MG	A211033	003	Jun 28, 2019	Jun NEWA
AB			1MG	A211033	004	Jun 28, 2019	Jun NEWA
AB			2MG	A211033	005	Jun 28, 2019	Jun NEWA
		<u>CLONIDINE HYDROCHLORIDE</u>					
		INJECTABLE; INJECTION					
		CLONIDINE HYDROCHLORIDE					
		@ LUITPOLD	1MG/10ML (0.1MG/ML)	A091104	001	Oct 08, 2009	Feb DISC
		@	5MG/10ML (0.5MG/ML)	A091104	002	Oct 08, 2009	Feb DISC
		TABLET; ORAL					
		CLONIDINE HYDROCHLORIDE					
AB		FRONTIDA BIOPHARM	0.1MG	A070923	003	Sep 04, 1987	Apr CMS1
AB			0.2MG	A070923	002	Sep 04, 1987	Apr CMS1
		TABLET, EXTENDED RELEASE; ORAL					
		CLONIDINE HYDROCHLORIDE					
AB1		NOVAST LABS	0.1MG	A209675	001	Mar 05, 2019	Feb NEWA
		@ UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	May DISC
		<u>CLOPIDOGREL BISULFATE</u>					
		TABLET; ORAL					
		CLOPIDOGREL BISULFATE					
AB		ANI PHARMS INC	EQ 300MG BASE	A091216	001	May 17, 2012	May CAHN
		@ CADILA	EQ 75MG BASE	A201686	001	Oct 10, 2012	Jun DISC
AB			EQ 75MG BASE	A201686	001	Oct 10, 2012	Apr CAHN
AB		CELLTRION	EQ 75MG BASE	A202266	001	Aug 14, 2012	Aug CAHN
AB			EQ 300MG BASE	A202266	002	Nov 20, 2012	Aug CAHN
>D>	AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665	001	May 17, 2012	Sep DISC
>A>		@	EQ 75MG BASE	A077665	001	May 17, 2012	Sep DISC
		@	EQ 300MG BASE	A077665	002	May 17, 2012	Feb DISC
		<u>CLORAZEPATE DIPOTASSIUM</u>					
		TABLET; ORAL					
		CLORAZEPATE DIPOTASSIUM					
		@ AUROLIFE PHARMA LLC	3.75MG	A072514	002	May 11, 1990	Jan CMS1
		@	7.5MG	A072514	003	May 11, 1990	Jan CMS1
		<u>CLOTTRIMAZOLE</u>					
		SOLUTION; TOPICAL					
		CLOTTRIMAZOLE					
AT		NOVITIUM PHARMA	1%	A209815	001	Feb 14, 2019	Feb NEWA
AT		TASMAN PHARMA	1%	A212281	001	Jul 25, 2019	Jul NEWA
		<u>CLOZAPINE</u>					
		TABLET; ORAL					
		CLOZARIL					
AB	+	HERITAGE LIFE	50MG	N019758	003	May 20, 2019	May NEWA
AB	+		200MG	N019758	004	May 20, 2019	May NEWA
		TABLET, ORALLY DISINTEGRATING; ORAL					
		FAZACLO ODT					
AB	+	JAZZ	12.5MG	N021590	004	May 30, 2007	Jun CAHN
AB	+		25MG	N021590	001	Feb 10, 2004	Jun CAHN

TABLET, ORALLY DISINTEGRATING;ORAL									
FAZACLO ODT									
	@	50MG		N021590	003	Jun 03, 2005	Jun	CAHN	
AB	+	100MG		N021590	002	Feb 10, 2004	Jun	CAHN	
AB	+	150MG		N021590	005	Jul 09, 2010	Jun	CAHN	
AB	+	200MG		N021590	006	Jul 09, 2010	Jun	CAHN	
>A> <u>COBICISTAT; DARUNAVIR</u>									
>A> TABLET;ORAL									
>A> PREZCOBIX									
>A> +!		JANSSEN PRODS	150MG;800MG	N205395	001	Jan 29, 2015	Sep	CAIN	
>D> <u>COBICISTAT; DARUNAVIR ETHANOLATE</u>									
>D> TABLET;ORAL									
>D> PREZCOBIX									
>D> +!		JANSSEN PRODS	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Sep	CAIN	
<u>CODEINE SULFATE</u>									
SOLUTION;ORAL									
CODEINE SULFATE									
	@ HIKMA	30MG/5ML		N202245	001	Jun 30, 2011	Mar	CAHN	
TABLET;ORAL									
CODEINE SULFATE									
AB	+	HIKMA	15MG	N022402	001	Jul 16, 2009	Mar	CAHN	
AB	+		30MG	N022402	002	Jul 16, 2009	Mar	CAHN	
AB	+		60MG	N022402	003	Jul 16, 2009	Mar	CAHN	
<u>COLCHICINE</u>									
CAPSULE;ORAL									
COLCHICINE									
	@ PAR PHARM INC	0.6MG		A208678	001	Nov 29, 2018	May	DISC	
MITIGARE									
+!		HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	May	CTEC	
SOLUTION;ORAL									
GLOPERBA									
+!		AVION PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019	Jul	CAHN	
+!		ROMEG THERAPS LLC	0.6MG/5ML	N210942	001	Jan 30, 2019	Jan	NEWA	
TABLET;ORAL									
COLCHICINE									
AB		ALKEM LABS LTD	0.6MG	A211250	001	Feb 08, 2019	Feb	NEWA	
AB		DR REDDYS	0.6MG	A209876	001	Sep 06, 2019	Aug	NEWA	
>A> AB		MYLAN	0.6MG	A209470	001	Sep 16, 2019	Sep	NEWA	
AB		WATSON LABS INC	0.6MG	A204461	001	Jul 31, 2019	Jul	NEWA	
	@ ZYDUS PHARMS	0.6MG		A211519	001	Feb 19, 2019	Jul	DISC	
AB			0.6MG	A211519	001	Feb 19, 2019	Feb	NEWA	
COLCRYST									
AB	+	TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	Jan	CTEC	
<u>COLESEVELAM HYDROCHLORIDE</u>									
BAR, CHEWABLE;ORAL									
WELCHOL									
+!		DAIICHI SANKYO INC	3.75GM	N210895	001	Apr 03, 2019	Apr	NEWA	
FOR SUSPENSION;ORAL									
COLESEVELAM HYDROCHLORIDE									
AB		ALKEM LABS LTD	3.75GM/PACKET	A210316	001	May 06, 2019	Apr	NEWA	
		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Mar	CTEC	
WELCHOL									
+ @		DAIICHI SANKYO	1.875GM/PACKET	N022362	001	Oct 02, 2009	Mar	DISC	
TABLET;ORAL									
COLESEVELAM HYDROCHLORIDE									
>A> AB		BIONPHARMA INC	625MG	A208670	001	Sep 13, 2019	Sep	NEWA	
>A> AB		ZYDUS PHARMS	625MG	A207765	001	Oct 07, 2019	Sep	NEWA	
<u>CROMOLYN SODIUM</u>									
SOLUTION;INHALATION									
CROMOLYN SODIUM									
	@ HIKMA	10MG/ML		A075333	001	Apr 30, 2002	Jun	CAHN	
	@ MYLAN SPECIALITY LP	10MG/ML		A074209	001	Apr 26, 1994	Mar	DISC	

CROTAMITONCREAM; TOPICAL
EURAX

+ @ SUN PHARM INDS INC 10% N006927 001 Aug DISC

CYCLOBENZAPRINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
AMRIX

AB	+	TEVA PHARMS INTL	15MG	N021777	001	Feb 01, 2007	Mar CTEC
	+		15MG	N021777	001	Feb 01, 2007	Jan CTEC
AB	+	!	30MG	N021777	002	Feb 01, 2007	Mar CTEC
	+	!	30MG	N021777	002	Feb 01, 2007	Jan CTEC

CYCLOBENZAPRINE HYDROCHLORIDE

AB		APOTEX INC	15MG	A206703	001	Jul 24, 2018	Feb CMFD
	@		15MG	A206703	001	Jul 24, 2018	Jan DISC
AB			30MG	A206703	002	Jul 24, 2018	Feb CMFD
	@		30MG	A206703	002	Jul 24, 2018	Jan DISC
AB		TWI PHARMS INC	15MG	A091281	001	Jan 31, 2013	Mar CMFD
AB			30MG	A091281	002	Jan 31, 2013	Mar CMFD

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		ANDA REPOSITORY	5MG	A073541	002	Apr 06, 2006	Aug CAHN
AB			10MG	A073541	001	May 23, 1995	Aug CAHN

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

AB		CIPLA	25MG	A211608	001	Jan 18, 2019	Jan NEWA
AB			50MG	A211608	002	Jan 18, 2019	Jan NEWA

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

! PURDUE 250MG A060593 001 Aug CAHN

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1		APOTEX INC	25MG	A210721	001	Jul 10, 2019	Jun NEWA
AB1			50MG	A210721	002	Jul 10, 2019	Jun NEWA
AB1			100MG	A210721	003	Jul 10, 2019	Jun NEWA
AB1		IVAX SUB TEVA PHARMS	50MG	A065110	001	Mar 29, 2005	Jun CTEC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A>	AA	ANDA REPOSITORY	2MG/5ML	A204823	001	Dec 27, 2016	Sep CAHN
>A>	AA	ELYSIUM	2MG/5ML	A209108	001	Oct 16, 2018	Sep CAHN
>D>	AA	INVATECH PHARMA	2MG/5ML	A209108	001	Oct 16, 2018	Sep CAHN
>D>	AA	PATRIN PHARMA INC	2MG/5ML	A204823	001	Dec 27, 2016	Sep CAHN
	AA		2MG/5ML	A204823	001	Dec 27, 2016	Jul CAHN
	AA	QUAGEN	2MG/5ML	A212423	001	May 22, 2019	May NEWA
	AA	TORRENT	2MG/5ML	A204823	001	Dec 27, 2016	Jan CAHN

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>D>	AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Sep CAHN
	AA	BEXIMCO PHARMS USA	4MG	A206676	001	Apr 12, 2019	Apr NEWA
>A>	AA	ELYSIUM	4MG	A207555	001	Jan 31, 2017	Sep CAHN
	AA	! HERITAGE PHARMA	4MG	A087056	001		Feb CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

ELCYS

+! EXELA PHARMA SCS LLC 500MG/10ML (50MG/ML) N210660 001 Apr 16, 2019 Apr NEWA

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

>D>	AP	MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011	Sep DISC
>A>		@	20MG/ML	A200916	001	Dec 13, 2011	Sep DISC

DACLATASVIR DIHYDROCHLORIDETABLET; ORAL
DAKLINZA

+ @	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jun DISC
+ @		EQ 60MG BASE	N206843	002	Jul 24, 2015	Jun DISC
+ @		EQ 90MG BASE	N206843	003	Apr 13, 2016	Feb DISC

DACTINOMYCININJECTABLE; INJECTION
DACTINOMYCIN

AP	HISUN PHARM HANGZHOU	0.5MG/VIAL	A207232	001	Jul 16, 2019	Jul NEWA
AP	X-GEN PHARMS INC	0.5MG/VIAL	A203999	001	May 20, 2019	May NEWA

DALFAMPRIDINETABLET, EXTENDED RELEASE; ORAL
DALFAMPRIDINE

AB	MICRO LABS	10MG	A210158	001	Mar 11, 2019	Feb NEWA
AB	SUN PHARM	10MG	A208292	001	May 21, 2019	May NEWA

DANTROLENE SODIUMINJECTABLE; INJECTION
DANTROLENE SODIUM

@	MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Mar DISC
---	---------------------	-----------	---------	-----	--------------	----------

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
QTERNMET XR

+	ASTRAZENECA AB	2.5MG;1GM;EQ 2.5MG BASE	N210874	001	May 02, 2019	May NEWA
+		5MG;1GM;EQ 2.5MG BASE	N210874	002	May 02, 2019	May NEWA
+		5MG;1GM;EQ 5MG BASE	N210874	003	May 02, 2019	May NEWA
+	!	10MG;1GM;EQ 5MG BASE	N210874	004	May 02, 2019	May NEWA

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDETABLET; ORAL
QTERN

+	ASTRAZENECA AB	5MG;EQ 5MG BASE	N209091	002	May 02, 2019	May NEWA
---	----------------	-----------------	---------	-----	--------------	----------

DAPIPRAZOLE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
DAPIPRAZOLE HYDROCHLORIDE

	BARADAINA LLC	0.5%	A204902	001	May 30, 2019	May NEWA
--	---------------	------	---------	-----	--------------	----------

DAPSONEGEL; TOPICAL
ACZONE

AB	+	ALMIRALL	7.5%	N207154	001	Feb 24, 2016	Jun CFTG
	+		7.5%	N207154	001	Feb 24, 2016	Feb CAHN

DAPSONE

AB		TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Jun NFTG
----	--	-------------	------	---------	-----	--------------	----------

TABLET; ORAL
DAPSONE

AB		SAI LIFE SCIENCES	100MG	A207165	001	May 08, 2019	Apr NEWA
	@	TARO	25MG	A209430	001	Mar 01, 2019	May DISC
	@		100MG	A209430	002	Mar 01, 2019	May DISC
AB		TARO PHARM	25MG	A209430	001	Mar 01, 2019	Feb NEWA
AB			100MG	A209430	002	Mar 01, 2019	Feb NEWA

DAPTOMYCINPOWDER; INTRAVENOUS
DAPTOMYCIN

AP		ACCORD HLTHCARE	500MG/VIAL	A211961	001	Jun 24, 2019	Jun NEWA
AP		BE PHARMS	500MG/VIAL	A212513	001	Jun 26, 2019	Jun NEWA
AP		DR REDDYS	500MG/VIAL	A208375	001	May 01, 2019	Apr NEWA
AP		JIANGSU HENGRUI MED	500MG/VIAL	A212022	001	Aug 22, 2019	Aug NEWA
AP		XELLIA PHARMS APS	500MG/VIAL	A206005	001	Jun 15, 2016	Mar CAHN

POWDER; IV (INFUSION)
DAPTOMYCIN

AP		ACCORD HLTHCARE	350MG/VIAL	A212667	001	Jul 12, 2019	Jul NFTG
AP	+	SAGENT PHARMS INC	350MG/VIAL	N208385	001	Sep 12, 2017	Jul CTEC

DAROLUTAMIDETABLET; ORAL
NUBEQA

+! BAYER HEALTHCARE 300MG N212099 001 Jul 30, 2019 Jul NEWA

>A> DARUNAVIRSUSPENSION; ORAL
PREZISTA

>A> +! JANSSEN PRODS 100MG/ML N202895 001 Dec 16, 2011 Sep CAIN

>A> TABLET; ORAL

>A> DARUNAVIR ETHANOLATE

>A> AB TEVA PHARMS USA 600MG A202118 001 Nov 21, 2017 Sep CAIN

>A> PREZISTA

>A> + JANSSEN PRODS 75MG N021976 004 Dec 18, 2008 Sep CAIN

>A> + 150MG N021976 005 Dec 18, 2008 Sep CAIN

>A> + @ 300MG N021976 001 Jun 23, 2006 Sep CAIN

>A> + @ 400MG N021976 003 Oct 21, 2008 Sep CAIN

>A> AB + 600MG N021976 002 Feb 25, 2008 Sep CAIN

>A> +! 800MG N021976 006 Nov 09, 2012 Sep CAIN

>D> DARUNAVIR ETHANOLATE>D> SUSPENSION; ORAL
PREZISTA

>D> +! JANSSEN PRODS EQ 100MG BASE/ML N202895 001 Dec 16, 2011 Sep CAIN

>D> TABLET; ORAL

>D> DARUNAVIR ETHANOLATE

>D> AB TEVA PHARMS USA EQ 600MG BASE A202118 001 Nov 21, 2017 Sep CAIN

>D> PREZISTA

>D> + JANSSEN PRODS EQ 75MG BASE N021976 004 Dec 18, 2008 Sep CAIN

>D> + EQ 150MG BASE N021976 005 Dec 18, 2008 Sep CAIN

>D> + @ EQ 300MG BASE N021976 001 Jun 23, 2006 Sep CAIN

>D> + @ EQ 400MG BASE N021976 003 Oct 21, 2008 Sep CAIN

>D> AB + EQ 600MG BASE N021976 002 Feb 25, 2008 Sep CAIN

>D> +! EQ 800MG BASE N021976 006 Nov 09, 2012 Sep CAIN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET, EXTENDED RELEASE; ORAL
VIEKIRA XR

+ @ ABBVIE INC EQ 200MG BASE; 8.33MG; 50MG; 33.33MG N208624 001 Jul 22, 2016 Apr DISC

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
DAUNORUBICIN HYDROCHLORIDE

AP HISUN PHARM HANGZHOU EQ 5MG BASE/ML A208759 001 Apr 12, 2019 Apr NEWA

AP EQ 20MG BASE/VIAL A206195 001 Apr 25, 2019 Apr NEWA

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

>A> AP INGENUS PHARMS LLC 50MG/VIAL A210984 001 Sep 16, 2019 Sep NEWA

AP MSN LABS PVT LTD 50MG/VIAL A212265 001 Aug 28, 2019 Aug NEWA

AP WOCKHARDT BIO AG 50MG/VIAL A209056 001 Apr 09, 2019 Mar NEWA

DEFERIPRONETABLET; ORAL
DEFERIPRONE

AB @ TARO PHARM INDS LTD 500MG A208800 001 Feb 08, 2019 May DISC

500MG A208800 001 Feb 08, 2019 Feb NFTG

FERRIPROX

AB +! APOPHARMA INC 500MG N021825 001 Oct 14, 2011 May CTEC

+! 500MG N021825 001 Oct 14, 2011 Feb CFTG

+ 1GM N021825 002 Jul 25, 2019 Jul NEWA

DELAVIRDINE MESYLATETABLET; ORAL
RESCRIPTOR

+ @ VIIV HLTHCARE 100MG N020705 001 Apr 04, 1997 Jun DISC

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

>D>	AB	INGENUS PHARMS LLC	10MG	A204963	001	Dec 26, 2017	Sep CAHN
>D>	AB		25MG	A204963	002	Dec 26, 2017	Sep CAHN
>D>	AB		50MG	A204963	003	Dec 26, 2017	Sep CAHN
>D>	AB		75MG	A204963	004	Dec 26, 2017	Sep CAHN
>D>	AB		100MG	A204963	005	Dec 26, 2017	Sep CAHN
>D>	AB		150MG	A204963	006	Dec 26, 2017	Sep CAHN
>A>	AB	NOVAST LABS	10MG	A204963	001	Dec 26, 2017	Sep CAHN
>A>	AB		25MG	A204963	002	Dec 26, 2017	Sep CAHN
>A>	AB		50MG	A204963	003	Dec 26, 2017	Sep CAHN
>A>	AB		75MG	A204963	004	Dec 26, 2017	Sep CAHN
>A>	AB		100MG	A204963	005	Dec 26, 2017	Sep CAHN
>A>	AB		150MG	A204963	006	Dec 26, 2017	Sep CAHN

DESLORATADINE

TABLET;ORAL

DESLORATADINE

		@ MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012	May DISC
AB		PERRIGO	5MG	A078361	001	Dec 22, 2011	Apr CAHN

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DESMOPRESSIN ACETATE

AP		TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Mar CMFD
		SOLUTION;NASAL					
		DDAVP					
	+	FERRING PHARMS INC	0.01%	N017922	001		Jul CTEC
		DESMOPRESSIN ACETATE					
		@ SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012	Jul DISC
		SPRAY, METERED;NASAL					
		NOCTIVA					
	+	@ ALYVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Jun DISC
	+		0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Apr CAHN
	+	@	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Jun DISC
	+		0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Apr CAHN
		TABLET;ORAL					
		DESMOPRESSIN ACETATE					
AB		ABHAI LLC	0.1MG	A210371	001	Jan 28, 2019	Jan NEWA
AB			0.2MG	A210371	002	Jan 28, 2019	Jan NEWA
AB		NOVAST LABS	0.1MG	A208357	001	Jun 06, 2019	May NEWA
AB			0.2MG	A208357	002	Jun 06, 2019	May NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

		@ ACCORD HLTHCARE	0.15MG;0.03MG	A207067	001	Sep 13, 2018	Mar DISC
		ISIBLOOM					
AB		XIROMED	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Aug CAHN
		VOLNEA					
AB		XIROMED	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Aug CAHN

DESONIDE

AEROSOL, FOAM;TOPICAL

VERDESO

	+	ALMIRALL	0.05%	N021978	001	Sep 19, 2006	Feb CAHN
--	---	----------	-------	---------	-----	--------------	----------

OINTMENT;TOPICAL

DESONIDE

AB		ENCUBE ETHICALS	0.05%	A210998	001	Jan 30, 2019	Jan NEWA
AB		TELIGENT PHARMA INC	0.05%	A212002	001	Mar 12, 2019	Feb NEWA

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

		@ ZYDUS PHARMS	0.25%	A205620	001	Sep 28, 2018	Feb DISC
--	--	----------------	-------	---------	-----	--------------	----------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE

+	!	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	May CTEC
+	!		100MG	N204150	002	Mar 04, 2013	May CTEC
		KHEDEZLA					
	@	OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013	May DISC
	@		100MG	N204683	002	Jul 10, 2013	May DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE SUCCINATE

AB		INTELLIPHARMACEUTICS	EQ 50MG BASE	A204805	001	May 07, 2019	Apr NEWA
AB			EQ 100MG BASE	A204805	002	May 07, 2019	Apr NEWA
AB		MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jul CMFD
	@		EQ 50MG BASE	A204095	001	Jun 29, 2015	May DISC
	@		EQ 100MG BASE	A204095	002	Jun 29, 2015	May DISC
	@	YICHANG HUMANWELL	EQ 50MG BASE	A210014	001	Oct 01, 2018	Mar DISC
	@		EQ 100MG BASE	A210014	002	Oct 01, 2018	Mar DISC

DEXAMETHASONE

ELIXIR;ORAL
DEXAMETHASONE

>A>	AA	!	ANIMA	0.5MG/5ML	A084754	001	Sep CAHN
>D>	AA	!	STI PHARMA LLC	0.5MG/5ML	A084754	001	Sep CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

>A>	AP		ANDA REPOSITORY	EQ 4MG PHOSPHATE/ML	A207521	001	Jun 08, 2018	Sep CAHN
	AP		AUROBINDO PHARMA LTD	EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019	May NEWA
	AP	!	FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001		Feb CHRS
		@	LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982	Feb DISC
>D>	AP		SOMERSET THERAPS LLC	EQ 4MG PHOSPHATE/ML	A207521	001	Jun 08, 2018	Sep CAHN
	AP			EQ 10MG PHOSPHATE/ML	A211036	001	May 10, 2019	Apr NEWA
			SOLUTION/DROPS;OPHTHALMIC, OTIC					
			DEXAMETHASONE SODIUM PHOSPHATE					
		!	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996	May CTEC
		@	SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	May DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

		@	CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jul DISC
AP				EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jan NEWA

SOLUTION;INTRAVENOUS
DEXMEDETOMIDINE HYDROCHLORIDE

+		HQ SPCLT PHARMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Mar CPOT
+			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Mar CPOT

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		ALKEM LABS LTD	2.5MG	A212631	001	Jul 19, 2019	Jul NEWA
AB			5MG	A212631	002	Jul 19, 2019	Jul NEWA
AB			10MG	A212631	003	Jul 19, 2019	Jul NEWA
	@	TEVA PHARMS	2.5MG	A077107	003	Jan 29, 2007	May DISC
	@		5MG	A077107	001	Jan 29, 2007	May DISC
	@		10MG	A077107	002	Jan 29, 2007	May DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

AB		ANDA REPOSITORY	5MG	A205077	001	Jun 21, 2019	Aug CAHN
AB			10MG	A205077	002	Jun 21, 2019	Aug CAHN
AB			15MG	A205077	003	Jun 21, 2019	Aug CAHN
	@	MYLAN	5MG	A206735	001	Jan 27, 2016	Aug DISC
	@		10MG	A206735	002	Jan 27, 2016	Aug DISC

CAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMPHETAMINE SULFATE

	@	15MG	A206735	003	Jan 27, 2016	Aug DISC
AB	PII	5MG	A205077	001	Jun 21, 2019	Jun NEWA
AB		10MG	A205077	002	Jun 21, 2019	Jun NEWA
AB		15MG	A205077	003	Jun 21, 2019	Jun NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDESYRUP; ORAL
PROMETHAZINE DM

@ VINTAGE	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	May DISC
-----------	----------------------	---------	-----	--------------	----------

DEXTROSE

INJECTABLE; INJECTION

>D>		DEXTROSE 70% IN PLASTIC CONTAINER				
>D> AP	+!	BAXTER HLTHCARE	70GM/100ML	N017521	006	Mar 26, 1982
>A>	+	@	70GM/100ML	N017521	006	Mar 26, 1982

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML	N018371	003			Jul DISC
POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML	N018371	002			Jul DISC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
+ @ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983		Jul DISC
+ @	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988		Jul DISC
POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	001	Jan 17, 1986		Jul DISC
@	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	006	Mar 28, 1988		Jul DISC
POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	008	Mar 28, 1988		Jul DISC
POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	007	Mar 28, 1988		Jul DISC
POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
+ @ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988		Jul DISC
POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	008	Mar 28, 1988		Jul DISC
POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	002	Jan 17, 1986		Jul DISC
POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	003	Jul 05, 1983		Jul DISC
POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	003	Jan 17, 1986		Jul DISC
POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	004	Jul 05, 1983		Jul DISC
POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	004	Mar 28, 1988		Jul DISC
POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	005	Mar 28, 1988		Jul DISC
@	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	007	Mar 28, 1988		Jul DISC
POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
@ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	005	Mar 28, 1988		Jul DISC
@	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	009	Mar 28, 1988		Jul DISC

DIAZEPAM

GEL; RECTAL

DIASTAT

+ BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997		Feb CAHN
+ @	5MG/ML (5MG/ML)	N020648	002	Jul 29, 1997		Feb CAHN
+ @	10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997		Feb CAHN
+ @	15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997		Feb CAHN
+ @	20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997		Feb CAHN
	DIASTAT ACUDIAL					
+ BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005		Feb CAHN
+!	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005		Feb CAHN

INJECTABLE; INJECTION

DIAZEPAM

AP	BELOTECA INC	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Mar NEWA
AP	! HOSPIRA	10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Mar CTEC

DICLOFENAC

CAPSULE; ORAL

ZORVOLEX

+	EGALET	18MG	N204592	001	Oct 18, 2013	Feb CAHN
+	!	35MG	N204592	002	Oct 18, 2013	Feb CAHN
+	ZYLA	18MG	N204592	001	Oct 18, 2013	Jul CAHN
+	!	35MG	N204592	002	Oct 18, 2013	Jul CAHN

DICLOFENAC EPOLAMINE

SYSTEM; TOPICAL

LICART

+	@ IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Feb DISC
---	-----------------	------	---------	-----	--------------	----------

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB	AMICI	50MG	A076561	001	Mar 18, 2004	May CAHN
----	-------	------	---------	-----	--------------	----------

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB	MYLAN	1%	A204306	001	May 06, 2019	Apr NEWA
AB	PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	May NEWA

SOLUTION; INTRAVENOUS

DICLOFENAC SODIUM

@	MYLAN LABS LTD	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jul DISC
		37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jun NEWA

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

@	MYLAN	100MG	A076152	001	Dec 13, 2001	Jun DISC
---	-------	-------	---------	-----	--------------	----------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

>D>	AB	EXELA HOLDINGS	50MG; 0.2MG	A200540	001	Mar 14, 2014	Sep DISC
>A>		@	50MG; 0.2MG	A200540	001	Mar 14, 2014	Sep DISC
>D>	AB		75MG; 0.2MG	A200540	002	Mar 14, 2014	Sep DISC
>A>		@	75MG; 0.2MG	A200540	002	Mar 14, 2014	Sep DISC

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

>D>		@ APC PHARMS LLC	10MG/ML	A210979	001	Jul 02, 2018	Sep CAHN
		@	10MG/ML	A210979	001	Jul 02, 2018	Feb DISC
AP		CUSTOPHARM INC	10MG/ML	A210788	001	Feb 11, 2019	Jan NEWA
>A>		@ FOSUN PHARMA	10MG/ML	A210979	001	Jul 02, 2018	Sep CAHN
AP		FRESENIUS KABI USA	10MG/ML	A210257	001	Jan 25, 2019	Jan NEWA
AP		NEXUS PHARMS	10MG/ML	A206468	001	Feb 01, 2019	Jan NEWA
AP		SLATE	10MG/ML	A207076	001	Nov 02, 2018	Feb CAHN
AP		SUNGEN PHARMA	10MG/ML	A212058	001	Apr 26, 2019	Apr NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

AA	!	LANNETT CO INC	25MG	A200177	001	Jul 18, 2011	Jul CHRS
		TENUATE					
	+	@ TEVA BRANDED PHARM	25MG	N011722	002		Jul DISC
		TENUATE					
		TABLET, EXTENDED RELEASE; ORAL					
		DIETHYLPROPION HYDROCHLORIDE					
AB	!	LANNETT CO INC	75MG	A091680	001	Oct 24, 2011	Jul CHRS
		TENUATE DOSPAN					
	+	@ TEVA BRANDED PHARM	75MG	N012546	001		Jul DISC

DIGOXIN

ELIXIR; ORAL

DIGOXIN

>D>	+	HIKMA	0.05MG/ML	N021648	001	Aug 26, 2004	Sep CFTG
>A>	AA	+	0.05MG/ML	N021648	001	Aug 26, 2004	Sep CFTG
		+	0.05MG/ML	N021648	001	Aug 26, 2004	Apr CAHN
>A>	AA	NOVITIUM PHARMA	0.05MG/ML	A213000	001	Oct 04, 2019	Sep NFTG

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

AP	+	BAUSCH	1MG/ML	N005929	001		Apr CAHN
		SPRAY, METERED; NASAL					
		MIGRANAL					
	+	BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Apr CAHN
	+	VALEANT	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Jan CPOT

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

AB3	+	BAUSCH	120MG	N020062	001	Aug 10, 1992	Feb CAHN
AB3	+		180MG	N020062	002	Dec 27, 1991	Feb CAHN
AB3	+		240MG	N020062	003	Dec 27, 1991	Feb CAHN
AB3	+		300MG	N020062	004	Dec 27, 1991	Feb CAHN
AB3	+		360MG	N020062	005	Aug 24, 1999	Feb CAHN

DILTIAZEM HYDROCHLORIDE

APOTEX

			120MG	A074943	003	Dec 19, 2000	Aug CTEC
AB2	!		240MG	A074943	001	Aug 06, 1998	May CHRS
	@	MYLAN	120MG	A075124	002	Mar 18, 1998	Aug DISC
AB2			240MG	A075124	001	Mar 18, 1998	May CHRS
AB3		NOVAST LABS	120MG	A208783	001	Jun 14, 2019	Jun NEWA
AB3			180MG	A208783	002	Jun 14, 2019	Jun NEWA
AB3			240MG	A208783	003	Jun 14, 2019	Jun NEWA
AB3			300MG	A208783	004	Jun 14, 2019	Jun NEWA
AB3			360MG	A208783	005	Jun 14, 2019	Jun NEWA
	@	PAR PHARM	360MG	A209766	001	May 30, 2018	Mar DISC

TIAZAC

AB4	+	BAUSCH	120MG	N020401	001	Sep 11, 1995	Feb CAHN
AB4	+		180MG	N020401	002	Sep 11, 1995	Feb CAHN
AB4	+		240MG	N020401	003	Sep 11, 1995	Feb CAHN
AB4	+		300MG	N020401	004	Sep 11, 1995	Feb CAHN
AB4	+		360MG	N020401	005	Sep 11, 1995	Feb CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb CAHN

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

@ DR REDDYS

TABLET; ORAL

CARDIZEM

AB	+	BAUSCH	30MG	N018602	001	Nov 05, 1982	Mar CAHN
AB	+		60MG	N018602	002	Nov 05, 1982	Mar CAHN
AB	+		90MG	N018602	003	Dec 08, 1986	Mar CAHN
AB	+		120MG	N018602	004	Dec 08, 1986	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

AB	+	BAUSCH	120MG	N021392	001	Feb 06, 2003	Mar CAHN
AB	+		180MG	N021392	002	Feb 06, 2003	Mar CAHN
AB	+		240MG	N021392	003	Feb 06, 2003	Mar CAHN
AB	+		300MG	N021392	004	Feb 06, 2003	Mar CAHN
AB	+		360MG	N021392	005	Feb 06, 2003	Mar CAHN
AB	+		420MG	N021392	006	Feb 06, 2003	Mar CAHN

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

@ MYLAN INSTITUTIONAL

RIMSO-50

	+	MYLAN INSTITUTIONAL	50%	A076185	001	Nov 29, 2002	Mar DISC
--	---	---------------------	-----	---------	-----	--------------	----------

	+	MYLAN INSTITUTIONAL	50%	N017788	001		Mar CTEC
--	---	---------------------	-----	---------	-----	--	----------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! HERITAGE PHARMA 50MG

A080738 001

May CAHN

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ DR REDDYS 10MG/ML

A080873 001

May CAHN

@ 50MG/ML

A080873 002

May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@ DR REDDYS 50MG/ML

A080873 003

May CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

@ DR REDDYS 5MG/ML

A074952 001

Nov 26, 1997

May CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB CELLTRION EQ 125MG VALPROIC ACID

A077296 001

Jul 31, 2008

Aug CAHN

AB EQ 250MG VALPROIC ACID

A077296 002

Jul 31, 2008

Aug CAHN

AB EQ 500MG VALPROIC ACID

A077296 003

Jul 31, 2008

Aug CAHN

>D> AB TEVA EQ 125MG VALPROIC ACID

A076941 001

Jul 29, 2008

Sep DISC

>A> @ EQ 125MG VALPROIC ACID

A076941 001

Jul 29, 2008

Sep DISC

>D> AB EQ 250MG VALPROIC ACID

A076941 002

Jul 29, 2008

Sep DISC

>A> @ EQ 250MG VALPROIC ACID

A076941 002

Jul 29, 2008

Sep DISC

>D> AB EQ 500MG VALPROIC ACID

A076941 003

Jul 29, 2008

Sep DISC

>A> @ EQ 500MG VALPROIC ACID

A076941 003

Jul 29, 2008

Sep DISC

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

>D> AB ANCHEN PHARMS EQ 250MG VALPROIC ACID

A078445 001

Feb 26, 2009

Sep DISC

>A> @ EQ 250MG VALPROIC ACID

A078445 001

Feb 26, 2009

Sep DISC

>D> AB EQ 500MG VALPROIC ACID

A078445 002

Aug 04, 2009

Sep DISC

>A> @ EQ 500MG VALPROIC ACID

A078445 002

Aug 04, 2009

Sep DISC

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP ACTAVIS LLC 160MG/8ML (20MG/ML)

N203551 004

Sep 21, 2015

Jun NEWA

@ CIPLA 20MG/2ML (10MG/ML)

A209634 001

Aug 24, 2018

Mar DISC

@ 80MG/8ML (10MG/ML)

A209634 002

Aug 24, 2018

Mar DISC

@ 160MG/16ML (10MG/ML)

A209634 003

Aug 24, 2018

Mar DISC

AP MYLAN LABS LTD 160MG/8ML (20MG/ML)

A208137 001

Apr 01, 2019

Mar NEWA

AP SHILPA MEDICARE LTD 20MG/ML (20MG/ML)

A210327 001

May 16, 2019

May NEWA

AP 80MG/4ML (20MG/ML)

A210327 002

May 16, 2019

May NEWA

AP 160MG/8ML (20MG/ML)

A210327 003

May 16, 2019

May NEWA

AP TEIKOKU PHARMA 20MG/ML (20MG/ML)

N205934 001

Dec 22, 2015

Mar CAHN

AP 80MG/4ML (20MG/ML)

N205934 002

Dec 22, 2015

Mar CAHN

AP 160MG/8ML (20MG/ML)

N205934 003

Dec 22, 2015

Mar CAHN

SOLUTION; INTRAVENOUS

DOCETAXEL

AP SUN PHARMA GLOBAL 20MG/ML (20MG/ML)

N022534 003

Jan 08, 2019

Jan NEWA

AP 80MG/4ML (20MG/ML)

N022534 004

Jan 08, 2019

Jan NEWA

AP 160MG/8ML (20MG/ML)

N022534 005

Jan 08, 2019

Jan NEWA

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

AB AUROBINDO PHARMA LTD 0.125MG

A210740 001

Jan 22, 2019

Jan NEWA

AB 0.25MG

A210740 002

Jan 22, 2019

Jan NEWA

AB 0.5MG

A210740 003

Jan 22, 2019

Jan NEWA

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET; ORAL

DOVATO

+! VIIV HLTHCARE EQ 50MG BASE; 300MG

N211994 001

Apr 08, 2019

Apr NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE						
AB	CADILA	5MG	A090100	001	Oct 24, 2012	Mar CAHN
AB		10MG	A090100	002	Oct 24, 2012	Mar CAHN
AB	HERITAGE PHARMA	5MG	A077344	001	May 31, 2011	May CAHN
AB		10MG	A077344	002	May 31, 2011	May CAHN
	@ OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Mar DISC
AB	STRIDES PHARMA	5MG	A090551	001	May 31, 2011	Apr CAHN
AB		10MG	A090551	002	May 31, 2011	Apr CAHN
	@ SUN PHARM	23MG	A204293	001	Jun 05, 2015	Jul DISC
	@ WOCKHARDT	5MG	A091267	001	May 31, 2011	Jul DISC
	@	10MG	A091267	002	May 31, 2011	Jul DISC

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

@	HERITAGE PHARMA	5MG	A078388	002	Nov 26, 2010	May CAHN
@		10MG	A078388	001	Nov 26, 2010	May CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 2% BASE	A212639	001	Aug 09, 2019	Jul NEWA
AT	FDC LTD	EQ 2% BASE	A205294	001	Jan 24, 2019	Jan NEWA
	@ LUITPOLD	EQ 2% BASE	A079186	001	Nov 18, 2009	Mar DISC
	@ RUBICON	EQ 2% BASE	A078395	001	Oct 28, 2008	Aug CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>A>	AT	ANDA REPOSITORY	EQ 2% BASE; EQ 0.5% BASE	A207523	001	Jun 25, 2019	Sep CAHN
	AT	FDC LTD	EQ 2% BASE; EQ 0.5% BASE	A205295	001	Jun 13, 2019	Jun NEWA
		@ RUBICON	EQ 2% BASE; EQ 0.5% BASE	A078201	001	Oct 28, 2008	Jul CAHN
>D>	AT	SOMERSET THERAPS LLC	EQ 2% BASE; EQ 0.5% BASE	A207523	001	Jun 25, 2019	Sep CAHN
	AT		EQ 2% BASE; EQ 0.5% BASE	A207523	001	Jun 25, 2019	Jun NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	+!	HIKMA	20MG/ML	N014879	001		Mar CAHN
----	----	-------	---------	---------	-----	--	----------

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

>A>	AB	AJANTA PHARMA LTD	EQ 10MG BASE	A212624	001	Sep 13, 2019	Sep NEWA
>A>	AB		EQ 25MG BASE	A212624	002	Sep 13, 2019	Sep NEWA
>A>	AB		EQ 50MG BASE	A212624	003	Sep 13, 2019	Sep NEWA
>A>	AB		EQ 75MG BASE	A212624	004	Sep 13, 2019	Sep NEWA
>A>	AB		EQ 100MG BASE	A212624	005	Sep 13, 2019	Sep NEWA
	AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A211603	001	Mar 27, 2019	Mar NEWA
	AB		EQ 25MG BASE	A211603	002	Mar 27, 2019	Mar NEWA
	AB		EQ 50MG BASE	A211603	003	Mar 27, 2019	Mar NEWA
	AB		EQ 75MG BASE	A211603	004	Mar 27, 2019	Mar NEWA
	AB		EQ 100MG BASE	A211603	005	Mar 27, 2019	Mar NEWA
	AB	PAR PHARM	EQ 10MG BASE	A071422	002	Nov 09, 1987	Aug CMS1
	AB		EQ 25MG BASE	A071422	003	Nov 09, 1987	Aug CMS1
	AB		EQ 50MG BASE	A071422	004	Nov 09, 1987	Aug CMS1
	AB		EQ 75MG BASE	A071422	005	Nov 09, 1987	Aug CMS1
	AB		EQ 150MG BASE	A071422	006	Nov 09, 1987	Aug CMS1

TABLET; ORAL

SILENOR

+	CURRAX	EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr CAHN
+	!	EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr CAHN
+	PERNIX	EQ 3MG BASE	N022036	001	Mar 17, 2010	Feb CAHN
+	!	EQ 6MG BASE	N022036	002	Mar 17, 2010	Feb CAHN

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

>A>	AP	GLAND PHARMA LTD	4MCG/2ML (2MCG/ML)	A210452	001	Sep 26, 2019	Sep NEWA
		+ @ HOSPIRA INC	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018	Jun DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

AP	HISUN PHARM HANGZHOU	20MG/VIAL	A206062	001	May 13, 2019	Apr NEWA
>A>	@ HLTHCARE	2MG/ML	A200146	001	Jul 18, 2012	Sep CAHN
>D>	AP MYLAN LABS LTD	2MG/ML	A200901	001	Feb 14, 2012	Sep DISC
>A>	@	2MG/ML	A200901	001	Feb 14, 2012	Sep DISC
>D>	@ SANDOZ INC	2MG/ML	A200146	001	Jul 18, 2012	Sep CAHN

INJECTABLE, LIPOSOMAL; INJECTION
DOXIL (LIPOSOMAL)

AB	+	BAXTER HLTHCARE CORP	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Aug CAHN
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Aug CAHN

DOXYCYCLINE

CAPSULE; ORAL
MONODOX

AB	+	ALMIRALL	EQ 50MG BASE	N050641	002	Feb 10, 1992	Feb CAHN
AB	+		EQ 75MG BASE	N050641	003	Oct 18, 2006	Feb CAHN
AB	+	!	EQ 100MG BASE	N050641	001	Dec 29, 1989	Feb CAHN

TABLET; ORAL
DOXYCYCLINE

	@	MYLAN	EQ 50MG BASE	A065377	001	Nov 07, 2006	Apr DISC
	@		EQ 75MG BASE	A065377	002	Nov 07, 2006	Apr DISC
	@		EQ 100MG BASE	A065377	003	Nov 07, 2006	May DISC
	@		EQ 150MG BASE	A065427	001	Jun 07, 2007	May DISC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
ACTICLATE CAP

	+	@ ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016	Feb CAHN
		DOXYCYCLINE HYCLATE					
	@	AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018	Mar DISC
	@		EQ 100MG BASE	A211012	002	Sep 24, 2018	Mar DISC
>A>	AB	CHANGZHOU PHARM	EQ 100MG BASE	A209402	001	Oct 07, 2019	Sep NEWA
	@	MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982	Apr DISC
	@		EQ 100MG BASE	A062337	002	Mar 29, 1982	Apr DISC

TABLET; ORAL
ACTICLATE

AB	+	ALMIRALL	EQ 75MG BASE	N205931	001	Jul 25, 2014	Feb CAHN
AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Feb CAHN
		DOXYCYCLINE HYCLATE					
AB		APOTEX INC	EQ 75MG BASE	A209243	001	Apr 15, 2019	Apr NEWA
AB			EQ 150MG BASE	A209243	002	Apr 15, 2019	Apr NEWA
AB		CADILA	EQ 100MG BASE	A207773	001	Oct 30, 2017	Feb CAHN
>A>	AB	CHANGZHOU PHARM	EQ 100MG BASE	A211343	001	Oct 09, 2019	Sep NEWA
AB		EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005	Aug CMFD
AB		HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005	May CAHN

TABLET, DELAYED RELEASE; ORAL

DOXYCYCLINE HYCLATE

	@	MYLAN	EQ 75MG BASE	A090431	001	Dec 28, 2010	Jul DISC
	@		EQ 100MG BASE	A090431	002	Dec 28, 2010	Jul DISC
	@		EQ 200MG BASE	A090431	005	May 19, 2016	Jul DISC
>D>	AB	MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012	Sep DISC
>A>	@		EQ 150MG BASE	A091052	001	Feb 08, 2012	Sep DISC
	@	ZYDUS PHARMS	EQ 75MG BASE	A206772	001	Dec 21, 2018	May DISC
	@		EQ 100MG BASE	A206772	002	Dec 21, 2018	May DISC
	@		EQ 150MG BASE	A206772	003	Dec 21, 2018	May DISC

DROSPIRENONE

TABLET; ORAL
SLYND

+	!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019	May NEWA
---	---	-----------------	-----	---------	-----	--------------	----------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		ANDA REPOSITORY	3MG;0.02MG	A203291	001	Jul 18, 2017	Aug CAHN
AB		HETERO LABS LTD	3MG;0.02MG	A211944	001	Mar 22, 2019	Mar NEWA
		KYRA					
AB		SUN PHARM	3MG;0.02MG	A202318	001	Jul 23, 2019	Jul NEWA

TABLET;ORAL							
LORYNA							
AB	XIROMED	3MG;0.02MG	A079221	001	Mar 28, 2011	Aug	CAHN
TABLET;ORAL-28							
KEMEYA							
AB	SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019	Feb	NEWA
SYEDA							
AB	XIROMED	3MG;0.03MG	A090114	001	Mar 28, 2011	Aug	CAHN
<u>DULOXETINE HYDROCHLORIDE</u>							
CAPSULE, DELAYED REL PELLETS;ORAL							
DULOXETINE HYDROCHLORIDE							
AB	AJANTA PHARMA LTD	EQ 40MG BASE	A208706	004	Mar 11, 2019	Feb	NEWA
AB	INVENTIA	EQ 20MG BASE	A202336	001	Oct 28, 2015	Aug	CAHN
AB		EQ 30MG BASE	A202336	002	Oct 28, 2015	Aug	CAHN
AB		EQ 60MG BASE	A202336	003	Oct 28, 2015	Aug	CAHN
AB	QINGDAO BAHEAL PHARM	EQ 20MG BASE	A210599	001	Apr 17, 2019	Apr	NEWA
AB		EQ 30MG BASE	A210599	002	Apr 17, 2019	Apr	NEWA
AB		EQ 60MG BASE	A210599	003	Apr 17, 2019	Apr	NEWA
	@ TEVA PHARMS USA	EQ 20MG BASE	A090783	001	Dec 11, 2013	Aug	DISC
	@	EQ 30MG BASE	A090783	002	Dec 11, 2013	Aug	DISC
	@	EQ 60MG BASE	A090783	003	Dec 11, 2013	Aug	DISC
AB	YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019	Aug	NEWA
AB		EQ 30MG BASE	A207219	002	Aug 16, 2019	Aug	NEWA
AB		EQ 60MG BASE	A207219	003	Aug 16, 2019	Aug	NEWA
CAPSULE, DELAYED RELEASE;ORAL							
DRIZALMA SPRINKLE							
+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019	Jul	NEWA
+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Jul	NEWA
+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Jul	NEWA
+	!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Jul	NEWA
<u>DUTASTERIDE</u>							
CAPSULE;ORAL							
DUTASTERIDE							
	@ BRECKENRIDGE	0.5MG	A204705	001	Nov 20, 2015	Jun	DISC
	@	0.5MG	A208227	001	Jun 22, 2018	Jun	DISC
AB	CADILA	0.5MG	A204373	001	Oct 04, 2017	Feb	CAHN
<u>ECONAZOLE NITRATE</u>							
CREAM;TOPICAL							
ECONAZOLE NITRATE							
	@ CASI PHARMS INC	1%	A076075	001	Nov 26, 2002	Jun	DISC
AB	! PERRIGO ISRAEL	1%	A076479	001	Jun 23, 2004	May	CAHN
<u>EFAVIRENZ</u>							
TABLET;ORAL							
EFAVIRENZ							
	@ AUROBINDO PHARMA LTD	600MG	A077673	001	Sep 21, 2018	Feb	DISC
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE</u>							
TABLET;ORAL							
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE							
AB	CIPLA	600MG;200MG;300MG	A206894	001	Jun 03, 2019	May	NEWA
	@ TEVA PHARMS USA	600MG;200MG;300MG	A091215	001	Nov 09, 2018	May	DISC
<u>EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE</u>							
TABLET;ORAL							
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE							
	@ MACLEODS PHARMS LTD	400MG;300MG;300MG	N210649	001	Mar 15, 2019	Jun	DISC
		400MG;300MG;300MG	N210649	001	Mar 15, 2019	Mar	NEWA
<u>EFINACONAZOLE</u>							
SOLUTION;TOPICAL							
JUBLIA							
+	! BAUSCH	10%	N203567	001	Jun 06, 2014	Feb	CAHN

ELTROMBOPAG OLAMINETABLET; ORAL
PROMACTA

+ @ NOVARTIS	EQ 100MG ACID	N022291	005	Nov 16, 2012	Feb DISC
--------------	---------------	---------	-----	--------------	----------

EMEDASTINE DIFUMARATESOLUTION/DROPS; OPHTHALMIC
EMADINE

+ @ NOVARTIS	0.05%	N020706	001	Dec 29, 1997	Jul DISC
--------------	-------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@ AMNEAL PHARMS CO	100MG; 150MG	A209721	001	Aug 22, 2018	Feb DISC
@	133MG; 200MG	A209721	002	Aug 22, 2018	Feb DISC
@	167MG; 250MG	A209721	003	Aug 22, 2018	Feb DISC
@	200MG; 300MG	A209721	004	Aug 22, 2018	Feb DISC
@ LAURUS LABS LTD	200MG; 300MG	A212114	001	Jul 26, 2019	Aug DISC
AB	200MG; 300MG	A212114	001	Jul 26, 2019	Jul NEWA
TRUVADA					
+ GILEAD	100MG; 150MG	N021752	002	Mar 10, 2016	Feb CTEC
+	133MG; 200MG	N021752	003	Mar 10, 2016	Feb CTEC
+	167MG; 250MG	N021752	004	Mar 10, 2016	Feb CTEC

ENALAPRIL MALEATEFOR SOLUTION; ORAL
EPANED KIT

+ @ SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013	Mar DISC
-----------------------	--------	---------	-----	--------------	----------

TABLET; ORAL

ENALAPRIL MALEATE

@ BEXIMCO PHARMS USA	2.5MG	A075621	001	Aug 22, 2000	Feb CAHN
@	5MG	A075621	002	Aug 22, 2000	Feb CAHN
@	10MG	A075621	003	Aug 22, 2000	Feb CAHN
@	20MG	A075621	004	Aug 22, 2000	Feb CAHN
AB	HERITAGE PHARMA	A075479	001	Aug 22, 2000	Feb CAHN
AB		A075479	002	Aug 22, 2000	Feb CAHN
AB		A075479	003	Aug 22, 2000	Feb CAHN
AB		A075479	004	Aug 22, 2000	Feb CAHN
@ MYLAN	5MG	A075480	002	Aug 22, 2000	Jun DISC
@	10MG	A075480	003	Aug 22, 2000	Feb DISC
VASOTEC					
AB + BAUSCH	2.5MG	N018998	005	Jul 26, 1988	Mar CAHN
AB +	5MG	N018998	001	Dec 24, 1985	Mar CAHN
AB +	10MG	N018998	002	Dec 24, 1985	Mar CAHN
AB +!	20MG	N018998	003	Dec 24, 1985	Mar CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

AB + BAUSCH	5MG; 12.5MG	N019221	003	Jul 12, 1995	Mar CAHN
AB +!	10MG; 25MG	N019221	001	Oct 31, 1986	Mar CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	DR REDDYS	1.25MG/ML	A075578	001	Aug 22, 2000	May CAHN
----	-----------	-----------	---------	-----	--------------	----------

ENCORAFENIBCAPSULE; ORAL
BRAFTOVI

+ @ ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018	Jul DISC
-------------------------	------	---------	-----	--------------	----------

ENOXAPARIN SODIUMINJECTABLE; INTRAVENOUS, SUBCUTANEOUS
ENOXAPARIN SODIUM

AB	AMPHASTAR PHARMS INC	300MG/3ML (100MG/ML)	A208600	001	Mar 14, 2019	Mar NEWA
----	----------------------	----------------------	---------	-----	--------------	----------

ENTECAVIRTABLET; ORAL
ENTECAVIR

>A>	AB	BRIGHTGENE	0.5MG	A212126	001	Sep 25, 2019	Sep NEWA
>A>	AB		1MG	A212126	002	Sep 25, 2019	Sep NEWA
	AB	MYLAN	0.5MG	A206226	001	Mar 26, 2019	Mar NEWA
	AB		1MG	A206226	002	Mar 26, 2019	Mar NEWA

ENTRECTINIBCAPSULE; ORAL
ROZLYTREK

+	GENENTECH INC	100MG	N212725	001	Aug 15, 2019	Aug NEWA
+	!	200MG	N212725	002	Aug 15, 2019	Aug NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
EPINASTINE HYDROCHLORIDE

@	CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Jun DISC
@	SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011	Jul DISC

EPINEPHRINEINJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE (AUTOINJECTOR)

AB	TEVA PHARMS USA	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Jul CMFD	
	@	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Mar DISC	
	EPIPEN JR.						
AB	+	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul CTEC
	+		0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Mar CTEC
	SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS						
	ADRENALIN						
	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Aug CTEC
AP	+		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jan CDFR
	+		EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jan CDFR
	SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS						
	EPINEPHRINE						
	@	AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Aug DISC
	SOLUTION; INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS						
	EPINEPHRINE						
	+	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	May CDFR

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

>D>	AP	ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008	Sep DISC	
>A>		@	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008	Sep DISC	
>D>	AP	FRESENIUS KABI USA	10MG/5ML (2MG/ML)	A065408	001	Oct 15, 2007	Sep CTEC	
>A>			10MG/5ML (2MG/ML)	A065408	001	Oct 15, 2007	Sep CTEC	
			150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007	Mar CTEC	
>D>		@	MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Sep CAHN
>D>		@		200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Sep CAHN
>D>	AP	MYLAN LABS LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Sep DISC	
>A>		@		50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Sep DISC
>D>	AP		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Sep DISC	
>A>		@		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Sep DISC
>A>		@	ZENNOVA	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Sep CAHN
>A>		@		200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Sep CAHN

EPTIFIBATIDEINJECTABLE; INJECTION
EPTIFIBATIDE

AP	BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Jan CAHN
AP		75MG/100ML	A208554	002	Nov 23, 2018	Jan CAHN
AP	HAINAN POLY PHARM	2MG/ML	A209864	001	Jan 25, 2019	Jan NEWA
AP		75MG/100ML	A209864	002	Jan 25, 2019	Jan NEWA

ERDAFITINIBTABLET; ORAL
BALVERSA

+	JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019	Apr NEWA
+		4MG	N212018	002	Apr 12, 2019	Apr NEWA
+	!	5MG	N212018	003	Apr 12, 2019	Apr NEWA

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB	MYLAN	EQ 25MG BASE	A091002	001	Jun 11, 2014	Feb CMFD
AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	Feb CMFD
AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	Feb CMFD
AB	TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015	Mar CMFD
AB		EQ 150MG BASE	A091059	003	Aug 28, 2015	Mar CMFD
TARCEVA						
AB	+ OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Mar CAHN
AB	+	EQ 25MG BASE	N021743	001	Nov 18, 2004	Feb CTEC
AB	+	EQ 100MG BASE	N021743	002	Nov 18, 2004	Mar CAHN
AB	+	EQ 100MG BASE	N021743	002	Nov 18, 2004	Feb CTEC
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	Mar CAHN
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	Feb CTEC

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP	SAVIOR LIFETEC CORP	EQ 1GM BASE/VIAL	A207647	001	Mar 19, 2019	Mar NEWA
----	---------------------	------------------	---------	-----	--------------	----------

ERYTHROMYCIN

OINTMENT; TOPICAL

AKNE-MYCIN

+	@ BAUSCH	2%	N050584	001	Jan 10, 1985	Apr CAHN
---	----------	----	---------	-----	--------------	----------

SOLUTION; TOPICAL

ERYTHRA-DERM

@	MLV	2%	A062687	001	Feb 05, 1988	Aug CAHN
@	SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Feb CAHN

TABLET, DELAYED RELEASE; ORAL

ERY-TAB

AB	ARBOR PHARMS LLC	250MG	A062298	001		Jun CTEC
AB		333MG	A062298	003	Mar 29, 1982	Jun CTEC
AB	!	500MG	A062298	002		Jun CTEC
ERYTHROMYCIN						
AB	AMNEAL PHARMS CO	250MG	A210954	001	Jul 02, 2019	Jun NEWA
AB		333MG	A210954	002	Jul 02, 2019	Jun NEWA
AB		500MG	A210954	003	Jul 02, 2019	Jun NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

>D>	AB1	+	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	001	Sep CTEC
>A>	AB	+		EQ 200MG BASE/5ML	N050207	001	Sep CTEC

ERYPED

>D>	AB2	+	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Sep CTEC
>A>	AB	+		EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Sep CTEC

ERYTHROMYCIN ETHYLSUCCINATE

>D>	AB1	ANI PHARMS INC	EQ 200MG BASE/5ML	A062055	001	Sep CTEC
>A>	AB		EQ 200MG BASE/5ML	A062055	001	Sep CTEC
>D>	AB2		EQ 200MG BASE/5ML	A062055	003 Nov 02, 2018	Sep CTEC
>A>	AB		EQ 200MG BASE/5ML	A062055	003 Nov 02, 2018	Sep CTEC

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

>A>	AA		ALLIED	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Sep CAHN
>D>	AA		ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Sep CAHN

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	CADILA	EQ 5MG BASE	A077734	001	Sep 11, 2012	Apr CAHN
AB		EQ 10MG BASE	A077734	002	Sep 11, 2012	Apr CAHN
AB		EQ 20MG BASE	A077734	003	Sep 11, 2012	Apr CAHN

ESKETAMINE HYDROCHLORIDE

SPRAY; NASAL

SPRAVATO

+	!	JANSSEN PHARMS	EQ 28MG BASE	N211243	001	Mar 05, 2019	Mar NEWA
---	---	----------------	--------------	---------	-----	--------------	----------

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION
ESMOLOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	10MG/ML	A208538	001	Aug 14, 2019	Jul NEWA
----	------------------	---------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

	@ AMNEAL PHARMS NY	EQ 20MG BASE	A209647	001	Apr 10, 2019	Jun DISC
AB		EQ 20MG BASE	A209647	001	Apr 10, 2019	Mar NEWA
	@	EQ 40MG BASE	A209647	002	Apr 10, 2019	Jun DISC
AB		EQ 40MG BASE	A209647	002	Apr 10, 2019	Mar NEWA
AB	GLENMARK PHARMS	EQ 20MG BASE	A209495	001	May 10, 2019	Apr NEWA
AB		EQ 40MG BASE	A209495	002	May 10, 2019	Apr NEWA
	@ HEC PHARM	EQ 20MG BASE	A207265	002	May 18, 2018	Mar DISC
	@	EQ 40MG BASE	A207265	001	May 18, 2018	Mar DISC
AB	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Jun CTEC
AB		EQ 40MG BASE	A202784	002	Sep 21, 2015	Jun CTEC
AB	ZYDUS PHARMS	EQ 20MG BASE	A206296	001	May 22, 2019	May NEWA
AB		EQ 40MG BASE	A206296	002	May 22, 2019	May NEWA

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE STRONTIUM

	+ @ R2 PHARMA LLC	49.3MG	N202342	002	Aug 06, 2013	Aug DISC
--	-------------------	--------	---------	-----	--------------	----------

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL
ESTRADIOL

AB1	AMNEAL PHARMS LLC	0.025MG/24HR	A211293	001	Feb 04, 2019	Jan NEWA
AB1		0.0375MG/24HR	A211293	002	Feb 04, 2019	Jan NEWA
AB1		0.05MG/24HR	A211293	003	Feb 04, 2019	Jan NEWA
AB1		0.075MG/24HR	A211293	004	Feb 04, 2019	Jan NEWA
AB1		0.1MG/24HR	A211293	005	Feb 04, 2019	Jan NEWA
	GEL;TRANSDERMAL DIVIGEL					
	+! VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007	Jan CHRS

ESTRADIOL VALERATE

INJECTABLE;INJECTION
ESTRADIOL VALERATE

	@ DR REDDYS	40MG/ML	A083714	001		May CAHN
--	-------------	---------	---------	-----	--	----------

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

	@ ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Mar DISC
AB	NOVAST LABS	0.5MG;0.1MG	A210612	001	Apr 03, 2019	Mar NEWA
AB		1MG;0.5MG	A210612	002	Apr 03, 2019	Mar NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL
CENESTIN

	+ @ ASPEN	0.3MG	N020992	001	Jun 21, 2002	Feb CAHN
	+ @	0.45MG	N020992	005	Feb 05, 2004	Feb CAHN
	+ @	0.625MG	N020992	002	Mar 24, 1999	Feb CAHN
	+ @	0.9MG	N020992	003	Mar 24, 1999	Feb CAHN
	+ @	1.25MG	N020992	004	Mar 13, 2000	Feb CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL
ENJUVIA

	@ ASPEN	0.3MG	N021443	001	Dec 20, 2004	Feb CAHN
	@	0.45MG	N021443	002	Dec 20, 2004	Feb CAHN
	@	0.625MG	N021443	003	May 10, 2004	Feb CAHN
	@	0.9MG	N021443	005	Apr 27, 2007	Feb CAHN
	@	1.25MG	N021443	004	May 10, 2004	Feb CAHN

ESZOPICLONE

TABLET; ORAL						
ESZOPICLONE						
	@ BRECKENRIDGE	1MG	A203087	001	May 08, 2019	May DISC
	@	2MG	A203087	002	May 08, 2019	May DISC
	@	3MG	A203087	003	May 08, 2019	May DISC
AB	BRECKENRIDGE PHARM	1MG	A203087	001	May 08, 2019	Apr NEWA
AB		2MG	A203087	002	May 08, 2019	Apr NEWA
AB		3MG	A203087	003	May 08, 2019	Apr NEWA

ETHACRYNATE SODIUM

INJECTABLE; INJECTION						
EDECIN						
AP	+! BAUSCH	EQ 50MG BASE/VIAL	N016093	001		Mar CAHN
AP	+! VALEANT PHARMS INTL	EQ 50MG BASE/VIAL	N016093	001		Jan CAHN

ETHACRYNIC ACID

TABLET; ORAL						
EDECIN						
AB	+! BAUSCH	25MG	N016092	001		Mar CAHN
	@	50MG	N016092	002		Mar CAHN
AB	+! VALEANT PHARMS INTL	25MG	N016092	001		Jan CAHN
	@	50MG	N016092	002		Jan CAHN
ETHACRYNIC ACID						
AB	AGNITIO	25MG	A211809	001	Jul 12, 2019	Jul NEWA
AB	LUPIN LTD	25MG	A211719	001	Sep 06, 2019	Aug NEWA
AB	SCIEGEN PHARMS INC	25MG	A211232	001	Aug 27, 2019	Aug NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28						
LO-MALMOREDE						
AB	NOVAST LABS	0.035MG; 1MG	A209548	001	Feb 11, 2019	Jan NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL						
INTROVALE						
AB	XIROMED	0.03MG; 0.15MG	A079064	001	Sep 27, 2010	Aug CAHN
JAIMIESS						
AB	XIROMED	0.03MG, 0.01MG; 0.15MG, N/A	A203770	001	Dec 27, 2017	Aug CAHN
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL						
AB	XIROMED	0.02MG, 0.1MG; 0.01MG, N/A	A205131	001	Dec 14, 2017	Aug CAHN
SYLEVIA						
AB	SUN PHARM	0.03MG; 0.15MG	A202988	001	Feb 06, 2019	Jan NEWA
TABLET; ORAL-28						
ALTAVERA						
AB	XIROMED	0.03MG; 0.15MG	A079102	001	Aug 03, 2010	Aug CAHN
ELIFEMME						
AB	XIROMED	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202507	001	Dec 04, 2015	Aug CAHN
LEVONORGESTREL AND ETHINYL ESTRADIOL						
	@ MYLAN LABS LTD	0.02MG; 0.1MG	A202247	001	Dec 08, 2014	Jun DISC
VIENVA						
AB1	XIROMED	0.02MG; 0.1MG	A201088	001	May 21, 2015	Aug CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28						
NORETHINDRONE AND ETHINYL ESTRADIOL						
>D>	! MYLAN LABS LTD	0.05MG; 1MG	A203006	001	Aug 05, 2013	Sep DISC
>A>	@	0.05MG; 1MG	A203006	001	Aug 05, 2013	Sep DISC
NORTREL 1/35-28						
AB	! BARR	0.035MG; 1MG	A072696	001	Feb 28, 1992	Mar CHRS
ORTHO-NOVUM 1/35-28						
	+ @ JANSSEN PHARMS	0.035MG; 1MG	N017919	002		Mar DISC
TABLET, CHEWABLE; ORAL						
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	! MYLAN LABS LTD	0.035MG; 0.4MG	A202086	001	Apr 01, 2015	Mar CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21							
HAILEY 1.5/30							
AB		GLENMARK PHARMS	0.03MG;1.5MG	A209297	001	Jun 05, 2018	Jan CDFR
LOESTRIN 21 1.5/30							
AB	+	APIL	0.03MG;1.5MG	N017875	001		Jan CRLD
LOESTRIN 21 1/20							
AB	+	APIL	0.02MG;1MG	N017876	001		Jan CRLD
TABLET, CHEWABLE; ORAL							
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB		XIROMED	0.02MG;1MG	A209609	001	Jul 16, 2018	Aug CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28							
ESTARYLLA							
AB		XIROMED	0.035MG;0.25MG	A090794	001	Jan 30, 2013	Aug CAHN
NORGESTIMATE AND ETHINYL ESTRADIOL							
@ MYLAN LABS LTD							
			0.025MG,0.025MG;0.025MG;0.18MG,0.2	A202132	001	Sep 09, 2015	Jan DISC
			15MG,0.25MG				
>A>	AB	NAARI PTE LTD	0.035MG;0.035MG;0.035MG;0.18MG;0.2	A200383	001	Apr 07, 2015	Sep CAHN
			15MG;0.25MG				
>A>	AB		0.035MG;0.25MG	A200384	001	Apr 07, 2015	Sep CAHN
>D>	AB	OC PHARMA	0.035MG;0.18MG;0.215MG;0.25MG	A200383	001	Apr 07, 2015	Sep CAHN
>D>	AB		0.035MG;0.25MG	A200384	001	Apr 07, 2015	Sep CAHN
ORTHO CYCLEN-28							
	+	@ JANSSEN PHARMS	0.035MG;0.25MG	N019653	002	Dec 29, 1989	Apr DISC
SPRINTEC							
AB	!	BARR	0.035MG;0.25MG	A075804	001	Sep 25, 2002	Apr CHRS
TRI-ESTARYLLA							
AB		XIROMED	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A090793	001	Jan 30, 2013	Aug CAHN
			15MG,0.25MG				
TRI-LO-ESTARYLLA							
AB		XIROMED	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A091232	001	Jun 29, 2015	Aug CAHN
			15MG,0.25MG				

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING; VAGINAL							
ANNOVERA							
	+	! THERAPEUTICSMD INC	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	May CMFD
	+	@	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	Feb DISC

ETHOSUXIMIDE

CAPSULE; ORAL							
ETHOSUXIMIDE							
AB		STRIDES PHARMA	250MG	A211928	001	Feb 19, 2019	Feb NEWA
SYRUP; ORAL							
ETHOSUXIMIDE							
	@	TEVA PHARMS	250MG/5ML	A081306	001	Jul 30, 1993	May DISC

ETOMIDATE

INJECTABLE; INJECTION							
ETOMIDATE							
	@	LUITPOLD	2MG/ML	A078867	001	Dec 22, 2009	Feb DISC
	@	PAR STERILE PRODUCTS	2MG/ML	A091297	001	Jun 20, 2012	Apr DISC

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION							
ETOPOPHOS PRESERVATIVE FREE							
	+	! CHEPLAPHARM	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996	May CAHN

EVEROLIMUS

TABLET; ORAL							
AFINITOR							
	+	! NOVARTIS	5MG	N022334	001	Mar 30, 2009	Apr CHRS
	+		10MG	N022334	002	Mar 30, 2009	Apr CHRS
ZORTRESS							
	+	NOVARTIS	1MG	N021560	004	Aug 10, 2018	Mar NEWA
TABLET, FOR SUSPENSION; ORAL							
AFINITOR DISPERZ							
	+	NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012	Apr CTEC
AB	+		2MG	N203985	001	Aug 29, 2012	Apr CFTG

TABLET, FOR SUSPENSION;ORAL
AFINITOR DISPERZ

	+	3MG	N203985	002	Aug 29, 2012	Apr CTEC
AB	+	3MG	N203985	002	Aug 29, 2012	Apr CFTG
	+	5MG	N203985	003	Aug 29, 2012	Apr CTEC
AB	+	5MG	N203985	003	Aug 29, 2012	Apr CFTG
	EVEROLIMUS					
	@ MYLAN	2MG	A210130	001	Apr 19, 2019	Apr NFTG
	@	3MG	A210130	002	Apr 19, 2019	Apr NFTG
	@	5MG	A210130	003	Apr 19, 2019	Apr NFTG

EXEMESTANE

TABLET;ORAL
EXEMESTANE

	@ AMNEAL PHARMS	25MG	A206421	001	Dec 28, 2018	Jul DISC
	@ BRECKENRIDGE	25MG	A211031	001	Feb 21, 2019	May DISC
AB	BRECKENRIDGE PHARM	25MG	A211031	001	Feb 21, 2019	Feb NEWA
AB	MAYNE PHARMA INC	25MG	A208764	001	Aug 08, 2019	Jul NEWA

EZETIMIBE

TABLET;ORAL
EZETIMIBE

	@ ACCORD HLTHCARE	10MG	A211550	001	Oct 26, 2018	Apr DISC
AB	MYLAN	10MG	A201790	001	Apr 26, 2019	Apr NEWA

EZETIMIBE; SIMVASTATIN

TABLET;ORAL
EZETIMIBE AND SIMVASTATIN

AB	GLENMARK PHARMS LTD	10MG;10MG	A208699	001	Jun 27, 2019	Jun NEWA
AB		10MG;20MG	A208699	002	Jun 27, 2019	Jun NEWA
AB		10MG;40MG	A208699	003	Jun 27, 2019	Jun NEWA
AB		10MG;80MG	A208699	004	Jun 27, 2019	Jun NEWA

FAMOTIDINE

TABLET;ORAL
FAMOTIDINE

AB	CELLTRION	20MG	A075786	001	Apr 16, 2001	Aug CAHN
AB		40MG	A075786	002	Apr 16, 2001	Aug CAHN
	@ MYLAN	40MG	A075704	002	Apr 16, 2001	Apr DISC

FEBUXOSTAT

TABLET;ORAL
FEBUXOSTAT

AB	ALEMBIC PHARMS LTD	40MG	A205421	001	Jul 01, 2019	Jun NFTG
AB		80MG	A205421	002	Jul 01, 2019	Jun NFTG
AB	MYLAN	40MG	A205385	001	Jul 01, 2019	Jun NFTG
AB		80MG	A205385	002	Jul 01, 2019	Jun NFTG
AB	SUN PHARM	40MG	A205467	001	Jul 01, 2019	Jun NFTG
AB		80MG	A205467	002	Jul 01, 2019	Jun NFTG
>A> AB	WEST-WARD PHARMS INT	40MG	A205414	001	Oct 15, 2019	Sep NEWA
>A> AB		80MG	A205414	002	Oct 15, 2019	Sep NEWA

ULORIC

AB	+ TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009	Jun CFTG
AB	+	80MG	N021856	002	Feb 13, 2009	Jun CFTG

FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL
INREBIC

	+	IMPACT	EQ 100MG BASE	N212327	001	Aug 16, 2019	Aug NEWA
--	---	--------	---------------	---------	-----	--------------	----------

FELBAMATE

SUSPENSION;ORAL
FELBAMATE

AB	VISTAPHARM	600MG/5ML	A211333	001	May 31, 2019	May NEWA
----	------------	-----------	---------	-----	--------------	----------

TABLET;ORAL
FELBAMATE

AB	CADILA	400MG	A208970	001	May 30, 2017	Jul CAHN
AB		600MG	A208970	002	May 30, 2017	Jul CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB	YUNG SHIN PHARM	2.5MG	A204800	001	Apr 29, 2019	Apr NEWA
AB		5MG	A204800	002	Apr 29, 2019	Apr NEWA
AB		10MG	A204800	003	Apr 29, 2019	Apr NEWA

FENOFIBRATE

CAPSULE;ORAL
FENOFIBRATE (MICRONIZED)

AB	AUSTARPHARMA	67MG	A207805	001	Nov 16, 2017	Jan CAHN	
AB		134MG	A207805	002	Nov 16, 2017	Jan CAHN	
AB		200MG	A207805	003	Nov 16, 2017	Jan CAHN	
>D>	AB	INGENUS PHARMS LLC	67MG	A207564	001	Apr 19, 2019	Sep CAHN
	AB		67MG	A207564	001	Apr 19, 2019	Apr NEWA
>D>	AB		134MG	A207564	002	Apr 19, 2019	Sep CAHN
	AB		134MG	A207564	002	Apr 19, 2019	Apr NEWA
>D>	AB		200MG	A207564	003	Apr 19, 2019	Sep CAHN
	AB		200MG	A207564	003	Apr 19, 2019	Apr NEWA
>A>	AB	NOVAST LABS	67MG	A207564	001	Apr 19, 2019	Sep CAHN
>A>	AB		134MG	A207564	002	Apr 19, 2019	Sep CAHN
>A>	AB		200MG	A207564	003	Apr 19, 2019	Sep CAHN

TABLET;ORAL
FENOFIBRATE

AB	ALEMBIC PHARMS LTD	48MG	A210476	001	Aug 09, 2019	Jul NEWA		
AB		145MG	A210476	002	Aug 09, 2019	Jul NEWA		
>D>	AB	APPCO PHARMA LLC	54MG	A210670	001	Sep 06, 2019	Sep CAHN	
	AB		54MG	A210670	001	Sep 06, 2019	Aug NEWA	
>D>	AB		160MG	A210670	002	Sep 06, 2019	Sep CAHN	
	AB		160MG	A210670	002	Sep 06, 2019	Aug NEWA	
	AB	AUSTARPHARMA	54MG	A207803	001	Dec 19, 2017	Jan CAHN	
	AB		160MG	A207803	002	Dec 19, 2017	Jan CAHN	
	@	GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018	Feb DISC	
	@		160MG	A210606	002	Aug 17, 2018	Feb DISC	
>A>	AB	NUVO PHARM	54MG	A210670	001	Sep 06, 2019	Sep CAHN	
>A>	AB		160MG	A210670	002	Sep 06, 2019	Sep CAHN	
	AB	ORIT LABS LLC	54MG	A209660	001	Feb 11, 2019	Jan NEWA	
	AB		160MG	A209660	002	Feb 11, 2019	Jan NEWA	
		FENOGLIDE						
AB	+	SALIX	40MG	N022118	001	Aug 10, 2007	Mar CAHN	
AB	+	!	120MG	N022118	002	Aug 10, 2007	Mar CAHN	
>D>		TRIGLIDE						
>D>	BX	+	SKYEPHARMA AG	160MG	N021350	002	May 07, 2005	Sep DISC
>A>		+	@	160MG	N021350	002	May 07, 2005	Sep DISC

FENOFIBRIC ACID

TABLET;ORAL
FIBRICOR

+	ATHENA	35MG	N022418	001	Aug 14, 2009	Feb CAHN
+	!	105MG	N022418	002	Aug 14, 2009	Feb CAHN

FENOPROFEN CALCIUM

TABLET;ORAL
FENOPROFEN CALCIUM
@ ANI PHARMS INC

EQ 600MG BASE

A072274	001	May 02, 1988	May CAHN
---------	-----	--------------	----------

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

AB	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Aug CMFD
	@	100MCG/HR	A077062	004	Aug 20, 2007	Jul DISC
		FENTANYL-25				
AB	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007	Aug CMFD
	@	25MCG/HR	A077062	001	Aug 20, 2007	Jul DISC
		FENTANYL-50				
AB	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007	Aug CMFD
	@	50MCG/HR	A077062	002	Aug 20, 2007	Jul DISC
		FENTANYL-75				
AB	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Aug CMFD
	@	75MCG/HR	A077062	003	Aug 20, 2007	Jul DISC

SPRAY;SUBLINGUAL
SUBSYS

>A>	+	BTCP PHARMA	0.1MG	N202788	001	Jan 04, 2012	Sep CAHN
>A>	+		0.2MG	N202788	002	Jan 04, 2012	Sep CAHN
>A>	+	!	0.4MG	N202788	003	Jan 04, 2012	Sep CAHN
>A>	+		0.6MG	N202788	004	Jan 04, 2012	Sep CAHN
>A>	+		0.8MG	N202788	005	Jan 04, 2012	Sep CAHN
>A>	+		1.2MG	N202788	006	Aug 30, 2012	Sep CAHN
>A>	+		1.6MG	N202788	007	Aug 30, 2012	Sep CAHN
>D>	+	INSYS DEV CO INC	0.1MG	N202788	001	Jan 04, 2012	Sep CAHN
>D>	+		0.2MG	N202788	002	Jan 04, 2012	Sep CAHN
>D>	+	!	0.4MG	N202788	003	Jan 04, 2012	Sep CAHN
>D>	+		0.6MG	N202788	004	Jan 04, 2012	Sep CAHN
>D>	+		0.8MG	N202788	005	Jan 04, 2012	Sep CAHN
>D>	+		1.2MG	N202788	006	Aug 30, 2012	Sep CAHN
>D>	+		1.6MG	N202788	007	Aug 30, 2012	Sep CAHN

FENTANYL CITRATE

INJECTABLE;INJECTION
FENTANYL CITRATE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A210762	001	May 03, 2019	Apr NEWA
		SPRAY, METERED;NASAL					
		LAZANDA					
>A>	+	BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep CAHN
>A>	+	@	EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Sep DISC
>A>	+	@	EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Sep CAHN
>A>	+	!	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep CAHN
>D>	+	ELEFSEE PHARMS INTL	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep CAHN
>D>	+		EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Sep CAHN
>D>	+	!	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep CAHN

FERRIC CARBOXYMALTOS

INJECTABLE;INTRAVENOUS
INJECTAFER

	+	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013	Jun CAHN
--	---	-----------	--------------------------------	---------	-----	--------------	----------

FERRIC MALTOL

CAPSULE;ORAL
ACCRUFER

	+	SHIELD TX	30MG IRON	N212320	001	Jul 25, 2019	Jul NEWA
--	---	-----------	-----------	---------	-----	--------------	----------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

AB		DR REDDYS LABS LTD	4MG	A204975	001	Aug 13, 2019	Jul NEWA
AB			8MG	A204975	002	Aug 13, 2019	Jul NEWA

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL
FEXOFENADINE HYDROCHLORIDE

	@	P AND L	30MG/5ML	A201311	001	Jul 25, 2012	Aug CAHN
--	---	---------	----------	---------	-----	--------------	----------

TABLET;ORAL
FEXOFENADINE HYDROCHLORIDE

	@	MYLAN	30MG	A077081	002	Apr 11, 2008	Jul DISC
--	---	-------	------	---------	-----	--------------	----------

FINAFLOXACIN

SUSPENSION/DROPS;OTIC
XTORO

	+	@ MERLION PHARMS GMBH	0.3%	N206307	001	Dec 17, 2014	Apr DISC
--	---	-----------------------	------	---------	-----	--------------	----------

FINASTERIDE

TABLET;ORAL
FINASTERIDE

	@	MYLAN	5MG	A077578	001	Dec 18, 2006	Jul DISC
--	---	-------	-----	---------	-----	--------------	----------

FLOXURIDINE

INJECTABLE;INJECTION
FLOXURIDINE

	@	LUITPOLD	500MG/VIAL	A203008	001	Nov 22, 2017	Mar DISC
--	---	----------	------------	---------	-----	--------------	----------

FLUCONAZOLEFOR SUSPENSION; ORAL
FLUCONAZOLE

>D>	AB	IVAX SUB TEVA PHARMS	50MG/5ML	A077523	001	Sep 12, 2007	Sep DISC
>A>		@	50MG/5ML	A077523	001	Sep 12, 2007	Sep DISC
>D>	AB		200MG/5ML	A077523	002	Sep 12, 2007	Sep DISC
>A>		@	200MG/5ML	A077523	002	Sep 12, 2007	Sep DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

@ DR REDDYS 200MG/100ML (2MG/ML)

A076653 001 Jul 29, 2004 May CAHN

@ 400MG/200ML (2MG/ML)

A076653 002 Jul 29, 2004 May CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ DR REDDYS 200MG/100ML (2MG/ML)

A076837 001 Jan 13, 2005 May CAHN

@ 400MG/200ML (2MG/ML)

A076837 002 Jan 13, 2005 May CAHN

TABLET; ORAL

FLUCONAZOLE

AB		CHARTWELL	50MG	A076665	001	Jul 29, 2004	Jun CAHN
AB			100MG	A076665	002	Jul 29, 2004	Jun CAHN
AB			150MG	A076665	003	Jul 29, 2004	Jun CAHN
AB			200MG	A076665	004	Jul 29, 2004	Jun CAHN

FLUCYTOSINECAPSULE; ORAL
ANCOBON

AB	+	BAUSCH	250MG	N017001	001		Feb CAHN
AB	+	!	500MG	N017001	002		Feb CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		DECATUR	20-300mCi/ML	A204463	001	Oct 21, 2014	Apr CAHN
----	--	---------	--------------	---------	-----	--------------	----------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

		@ DR REDDYS	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	May CAHN
		@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	May CAHN
AP	!	HIKMA FARMACEUTICA	1MG/10ML (0.1MG/ML)	A078527	002	Mar 23, 2009	Aug CHRS
		@ MYLAN LABS LTD	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Aug DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+ @ MYLAN SPECIALITY LP 0.078MG/INH

N021247 001 Jan 27, 2006 Jul DISC

SPRAY, METERED; NASAL

FLUNISOLIDE

		APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun CMFD
AB			0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun CMFD

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC

FLAC

>A>	AT	ANDA REPOSITORY	0.01%	A210736	001	Apr 11, 2018	Sep CAHN
>D>	AT	PATRIN PHARMA INC	0.01%	A210736	001	Apr 11, 2018	Sep CAHN

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

		@ ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016	Mar DISC
AT		ENCUBE ETHICALS	0.01%	A209913	001	Feb 13, 2019	Jan NEWA
AT		GLASSHOUSE PHARMS	0.01%	A209596	001	Dec 26, 2017	Jan CMFD
AT		LUPIN	0.01%	A206422	001	Sep 02, 2015	Feb CAHN

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

		@ AMNEAL PHARMS LLC	0.05%	A210554	001	Aug 21, 2018	Feb DISC
AB		TELIGENT PHARMA INC	0.1%	A211758	001	Apr 03, 2019	Mar NEWA

SOLUTION; TOPICAL

FLUOCINONIDE

AT		TELIGENT PHARMA INC	0.05%	A207554	001	Mar 18, 2019	Mar NEWA
----	--	---------------------	-------	---------	-----	--------------	----------

FLUOROMETHOLONESUSPENSION/DROPS;OPHTHALMIC
FML FORTE

+!	ALLERGAN	0.25%	N019216	001	Apr 23, 1986	Jun CHRS
+		0.25%	N019216	001	Apr 23, 1986	Jun CRLD

FLUOROMETHOLONE ACETATESUSPENSION/DROPS;OPHTHALMIC
FLAREX

+!	EYEVANCE	0.1%	N019079	001	Feb 11, 1986	Feb CAHN
----	----------	------	---------	-----	--------------	----------

FLUOROMETHOLONE ACETATE; TOBRAMYCINSUSPENSION/DROPS;OPHTHALMIC
TOBRASONE

@	EYEVANCE	0.1%;0.3%	N050628	001	Jul 21, 1989	May CAHN
---	----------	-----------	---------	-----	--------------	----------

FLUOROURACILCREAM;TOPICAL
EFUDEX

AB	+!	BAUSCH	5%	N016831	003	Aug CAHN
----	----	--------	----	---------	-----	----------

FLUOROPLEX

	+!	ALMIRALL	1%	N016988	001	Feb CAHN
--	----	----------	----	---------	-----	----------

INJECTABLE;INJECTION

FLUOROURACIL

>D>	AP	MYLAN LABS LTD	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Sep DISC
-----	----	----------------	----------------------	---------	-----	--------------	----------

>A>		@	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Sep DISC
-----	--	---	----------------------	---------	-----	--------------	----------

>D>	AP		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Sep DISC
-----	----	--	--------------------	---------	-----	--------------	----------

>A>		@	1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Sep DISC
-----	--	---	--------------------	---------	-----	--------------	----------

SOLUTION;TOPICAL

EFUDEX

AT	+!	BAUSCH	2%	N016831	001	Aug CAHN
----	----	--------	----	---------	-----	----------

AT	+!		5%	N016831	002	Aug CAHN
----	----	--	----	---------	-----	----------

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB1		APNAR PHARMA LP	EQ 10MG BASE	A075049	001	Aug 02, 2001	Jun CAHN
-----	--	-----------------	--------------	---------	-----	--------------	----------

AB1			EQ 20MG BASE	A075049	002	Jan 29, 2002	Jun CAHN
-----	--	--	--------------	---------	-----	--------------	----------

AB			EQ 40MG BASE	A075049	003	Jan 29, 2002	Jun CAHN
----	--	--	--------------	---------	-----	--------------	----------

	@	BEXIMCO PHARMS USA	EQ 10MG BASE	A075807	001	Jan 29, 2002	Feb CAHN
--	---	--------------------	--------------	---------	-----	--------------	----------

	@		EQ 20MG BASE	A075807	002	Jan 29, 2002	Feb CAHN
--	---	--	--------------	---------	-----	--------------	----------

AB1		CADILA PHARMS LTD	EQ 10MG BASE	A206993	001	May 23, 2019	May NEWA
-----	--	-------------------	--------------	---------	-----	--------------	----------

AB1			EQ 20MG BASE	A206993	002	May 23, 2019	May NEWA
-----	--	--	--------------	---------	-----	--------------	----------

AB			EQ 40MG BASE	A206993	003	May 23, 2019	May NEWA
----	--	--	--------------	---------	-----	--------------	----------

	@	CELLTRION	EQ 10MG BASE	A078143	001	Jan 16, 2008	Aug CAHN
--	---	-----------	--------------	---------	-----	--------------	----------

	@		EQ 20MG BASE	A078143	002	Jan 16, 2008	Aug CAHN
--	---	--	--------------	---------	-----	--------------	----------

	@		EQ 40MG BASE	A078143	003	Jan 16, 2008	Aug CAHN
--	---	--	--------------	---------	-----	--------------	----------

	@	PAR PHARM	EQ 40MG BASE	A076922	003	Dec 16, 2004	Mar DISC
--	---	-----------	--------------	---------	-----	--------------	----------

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

	@	BARR	EQ 90MG BASE	A076237	001	Mar 24, 2010	Apr DISC
--	---	------	--------------	---------	-----	--------------	----------

!	DR REDDYS LABS LTD	EQ 90MG BASE	A078572	001	Mar 22, 2010	Apr CTEC
---	--------------------	--------------	---------	-----	--------------	----------

AB	!		EQ 90MG BASE	A078572	001	Mar 22, 2010	Apr CHRS
----	---	--	--------------	---------	-----	--------------	----------

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

	@	NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	May CAHN
--	---	------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB		APPCO PHARMA LLC	EQ 10MG BASE	A211696	001	Jan 30, 2019	Jan NEWA
----	--	------------------	--------------	---------	-----	--------------	----------

AB			EQ 20MG BASE	A211696	002	Jan 30, 2019	Jan NEWA
----	--	--	--------------	---------	-----	--------------	----------

>D>	AB		EQ 60MG BASE	A211477	001	Nov 21, 2018	Sep CAHN
-----	----	--	--------------	---------	-----	--------------	----------

AB		DR REDDYS LABS LTD	EQ 60MG BASE	A211721	001	Jan 25, 2019	Jan NEWA
----	--	--------------------	--------------	---------	-----	--------------	----------

AB		G AND W LABS INC	EQ 60MG BASE	A212191	001	Jul 05, 2019	Jun NEWA
----	--	------------------	--------------	---------	-----	--------------	----------

AB		LUPIN LTD	EQ 10MG BASE	A211653	001	Apr 15, 2019	Apr NEWA
----	--	-----------	--------------	---------	-----	--------------	----------

AB			EQ 20MG BASE	A211653	002	Apr 15, 2019	Apr NEWA
----	--	--	--------------	---------	-----	--------------	----------

AB			EQ 60MG BASE	A211632	001	Feb 08, 2019	Feb NEWA
----	--	--	--------------	---------	-----	--------------	----------

AB		SCIEGEN PHARMS INC	EQ 10MG BASE	A210935	001	Mar 20, 2019	Mar NEWA
----	--	--------------------	--------------	---------	-----	--------------	----------

AB			EQ 20MG BASE	A210935	002	Mar 20, 2019	Mar NEWA
----	--	--	--------------	---------	-----	--------------	----------

>A>	AB	TARO	EQ 60MG BASE	A211477	001	Nov 21, 2018	Sep CAHN
-----	----	------	--------------	---------	-----	--------------	----------

AB		UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	May CAHN
----	--	-------------------	--------------	---------	-----	--------------	----------

AB			EQ 20MG BASE	A211696	002	Jan 30, 2019	May CAHN
----	--	--	--------------	---------	-----	--------------	----------

FLUOXYMESTERONETABLET; ORAL
FLUOXYMESTERONE

! UPSHER SMITH LABS 10MG A088342 001 Oct 21, 1983 Jul CAHN

FLUPHENAZINE HYDROCHLORIDETABLET; ORAL
FLUPHENAZINE HYDROCHLORIDEAB ! LANNETT CO INC 10MG A089743 001 Aug 25, 1988 May CHRS
AB MYLAN 10MG A089804 001 Aug 12, 1988 May CHRSFLURANDRENOLIDECREAM; TOPICAL
CORDRAN SPAT +! ALMIRALL 0.025% N012806 003 Feb CAHN
+! 0.05% N012806 002 Feb CAHNLOTION; TOPICAL
CORDRAN

AT +! ALMIRALL 0.05% N013790 001 Feb CAHN

OINTMENT; TOPICAL
CORDRANAT + @ ALMIRALL 0.025% N012806 004 Feb CAHN
+! 0.05% N012806 001 Feb CAHNTAPE; TOPICAL
CORDRAN

+! ALMIRALL 0.004MG/SQ CM N016455 001 Feb CAHN

FLUTAMIDECAPSULE; ORAL
FLUTAMIDE

@ ACTAVIS LABS FL INC 125MG A075820 001 Sep 18, 2001 Apr DISC

FLUTICASONE PROPIONATECREAM; TOPICAL
FLUTICASONE PROPIONATE

AB ! PERRIGO ISRAEL 0.05% A076793 001 May 14, 2004 May CAHN

POWDER; INHALATION
ARMONAIR RESPICLICK>D> + TEVA PHARM 0.055MG/INH N208798 001 Jan 27, 2017 Sep DISC
>A> + @ 0.055MG/INH N208798 001 Jan 27, 2017 Sep DISC
+ @ 0.113MG/INH N208798 002 Jan 27, 2017 Jul DISC
>D> +! 0.232MG/INH N208798 003 Jan 27, 2017 Sep DISC
>A> + @ 0.232MG/INH N208798 003 Jan 27, 2017 Sep DISCFLUTICASONE PROPIONATE; SALMETEROL XINAFOATEPOWDER; INHALATION
ADVAIR DISKUS 100/50AB +! GLAXO GRP LTD 0.1MG/INH;EQ 0.05MG BASE/INH N021077 001 Aug 24, 2000 Jan CFTG
ADVAIR DISKUS 250/50AB +! GLAXO GRP LTD 0.25MG/INH;EQ 0.05MG BASE/INH N021077 002 Aug 24, 2000 Jan CFTG
ADVAIR DISKUS 500/50AB +! GLAXO GRP LTD 0.5MG/INH;EQ 0.05MG BASE/INH N021077 003 Aug 24, 2000 Jan CFTG
AIRDUO DIGIHALER+ TEVA PHARM 0.055MG/INH;EQ 0.014MG BASE/INH N208799 004 Jul 12, 2019 Jul NEWA
+ 0.113MG/INH;EQ 0.014MG BASE/INH N208799 005 Jul 12, 2019 Jul NEWA
+ 0.232MG/INH;EQ 0.014MG BASE/INH N208799 006 Jul 12, 2019 Jul NEWA

AIRDUO RESPICLICK

+! TEVA PHARM 0.232MG/INH;EQ 0.014MG BASE/INH N208799 003 Jan 27, 2017 Jul CMS1

WIXELA INHUB

AB MYLAN 0.1MG/INH;EQ 0.05MG BASE/INH A208891 001 Jan 30, 2019 Jan NFTG
AB 0.25MG/INH;EQ 0.05MG BASE/INH A208891 002 Jan 30, 2019 Jan NFTG
AB 0.5MG/INH;EQ 0.05MG BASE/INH A208891 003 Jan 30, 2019 Jan NFTGFLUVASTATIN SODIUMTABLET, EXTENDED RELEASE; ORAL
FLUVASTATIN SODIUM

@ MYLAN EQ 80MG BASE A202458 001 Sep 11, 2015 Jun DISC

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ MYLAN 25MG
 @ 50MG
 @ 100MG

A075889 001 Nov 29, 2000 May DISC
 A075889 002 Nov 29, 2000 May DISC
 A075889 003 Nov 29, 2000 May DISC

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA QINGDAO BAHEAL PHARM 1MG

A091145 001 Jul 12, 2013 May CAHN

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

+ @ PAR PHARM INC 1.5GM/1.5ML (1GM/ML)
 FOMEPIZOLE

N020696 001 Dec 04, 1997 Jun DISC

AP ! MYLAN INSTITUTIONAL 1.5GM/1.5ML (1GM/ML)

A078639 001 Mar 03, 2008 Jun CHRS

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+ MERCK SHARP DOHME 0.005MG/INH; 0.05MG/INH

N022518 003 Aug 12, 2019 Aug NEWA

FOSAPREPITANT

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

>A> TEVA PHARMS USA 150MG/VIAL

N210064 001 Sep 05, 2019 Sep NEWA

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

AP APOTEX INC EQ 150MG BASE/VIAL
 AP BAXTER HLTHCARE CORP EQ 150MG BASE/VIAL
 AP BE PHARMS EQ 150MG BASE/VIAL
 AP LUPIN LTD EQ 150MG BASE/VIAL
 AP MSN LABS PVT LTD EQ 150MG BASE/VIAL
 AP MYLAN LABS LTD EQ 115MG BASE/VIAL
 AP EQ 150MG BASE/VIAL
 AP SUNGEN PHARMA EQ 150MG BASE/VIAL

A205020 001 Sep 05, 2019 Aug NEWA
 A211860 001 Sep 05, 2019 Aug NEWA
 A212309 001 Sep 05, 2019 Aug NEWA
 A210689 001 Sep 05, 2019 Aug NEWA
 A209965 001 Sep 05, 2019 Aug NEWA
 A204015 001 Sep 05, 2019 Aug NFTG
 A204015 002 Sep 05, 2019 Aug NEWA
 A211624 001 Sep 05, 2019 Aug NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC 10MG; 12.5MG
 @ 20MG; 12.5MG

A076608 001 Dec 03, 2004 May CAHN
 A076608 002 Dec 03, 2004 May CAHN

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@ DR REDDYS EQ 50MG PHENYTOIN NA/ML
 @ LUITPOLD EQ 50MG PHENYTOIN NA/ML
 @ EQ 50MG PHENYTOIN NA/ML

A076886 001 Aug 06, 2007 May CAHN
 A078277 001 Aug 06, 2007 Feb DISC
 A090099 001 May 13, 2010 Feb DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

AB AMNEAL PHARMS CO EQ 2.5MG BASE
 @ EQ 2.5MG BASE

A211292 001 Nov 06, 2018 Aug CMFD
 A211292 001 Nov 06, 2018 May DISC

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

AO +! ASTRAZENECA 50MG/ML
 AP +! 50MG/ML

N021344 001 Apr 25, 2002 Apr CMS1
 N021344 001 Apr 25, 2002 Feb CFTG

FULVESTRANT

AO AMNEAL PHARMS CO 50MG/ML
 AP 50MG/ML
 AO GLENMARK PHARMS INC 50MG/ML
 AO MYLAN INSTITUTIONAL 50MG/ML
 AO SAGENT PHARMS INC 50MG/ML

A210044 001 Mar 04, 2019 Apr CMS1
 A210044 001 Mar 04, 2019 Feb NFTG
 A207754 001 Aug 22, 2019 Aug NEWA
 A208811 001 Jul 23, 2019 Jul NEWA
 A205871 001 Aug 22, 2019 Aug NEWA

INJECTABLE; INTRAMUSCULAR
FULVESTRANT

AO	SANDOZ INC	50MG/ML	A205935	001	May 14, 2019	Apr NEWA
	SOLUTION; INTRAMUSCULAR					
	FULVESTRANT					
	FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N210326	001	May 20, 2019	May NEWA
	TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Aug NEWA

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

AP	AUROBINDO PHARMA LTD	10MG/ML	A212174	001	May 03, 2019	Apr NEWA
	TABLET; ORAL					
	FUROSEMIDE					
	@ ANI PHARMS INC	20MG	A071379	001	Jan 02, 1987	Jul CAHN
>A>	@	40MG	A070413	001	Feb 26, 1986	Sep CAHN
AB	HERITAGE PHARMA	20MG	N018413	001	Nov 30, 1983	Feb CAHN
AB		40MG	N018413	002	Nov 30, 1983	Feb CAHN
AB	HIKMA	20MG	N018823	001	Nov 10, 1983	Apr CAHN
AB		40MG	N018823	002	Nov 10, 1983	Apr CAHN
>D>	@ WATSON LABS INC	40MG	A070413	001	Feb 26, 1986	Sep CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

AB	GRANULES INDIA LTD	100MG	A075360	001	Apr 06, 2005	Jun CAHN
AB		300MG	A075360	002	Apr 06, 2005	Jun CAHN
AB		400MG	A075360	003	Apr 06, 2005	Jun CAHN

TABLET; ORAL
GABAPENTIN

	@ IVAX SUB TEVA PHARMS	600MG	A076017	004	Apr 29, 2005	Jul DISC
	@	800MG	A076017	005	Apr 29, 2005	Jul DISC
	@ LUPIN LTD	600MG	A209306	001	Aug 24, 2018	Mar DISC
	@	800MG	A209306	002	Aug 24, 2018	Mar DISC
AB	RUBICON	600MG	A077661	004	Sep 13, 2006	Aug CAHN
AB		800MG	A077661	005	Sep 13, 2006	Aug CAHN

GADOPENTETATE DIMEGLUMINEINJECTABLE; INJECTION
MAGNEVIST

>D>	+! BAYER HLTHCARE	469.01MG/ML	N019596	001	Jun 02, 1988	Sep DISC
>A>	+ @	469.01MG/ML	N019596	001	Jun 02, 1988	Sep DISC
>D>	+!	469.01MG/ML	N021037	001	Mar 10, 2000	Sep DISC
>A>	+ @	469.01MG/ML	N021037	001	Mar 10, 2000	Sep DISC

GALANTAMINE HYDROBROMIDETABLET; ORAL
GALANTAMINE HYDROBROMIDE

	@ HERITAGE PHARMA	EQ 4MG BASE	A077585	001	Sep 15, 2009	May CAHN
>D> AB		EQ 4MG BASE	A077587	001	Jul 09, 2009	Sep DISC
>A>	@	EQ 4MG BASE	A077587	001	Jul 09, 2009	Sep DISC
AB		EQ 4MG BASE	A077587	001	Jul 09, 2009	May CAHN
	@	EQ 8MG BASE	A077585	002	Sep 15, 2009	May CAHN
>D> AB		EQ 8MG BASE	A077587	002	Jul 09, 2009	Sep DISC
>A>	@	EQ 8MG BASE	A077587	002	Jul 09, 2009	Sep DISC
AB		EQ 8MG BASE	A077587	002	Jul 09, 2009	May CAHN
	@	EQ 12MG BASE	A077585	003	Sep 15, 2009	May CAHN
>D> AB		EQ 12MG BASE	A077587	003	Jul 09, 2009	Sep DISC
>A>	@	EQ 12MG BASE	A077587	003	Jul 09, 2009	Sep DISC
AB		EQ 12MG BASE	A077587	003	Jul 09, 2009	May CAHN

GALLIUM CITRATE GA-67INJECTABLE; INJECTION
GALLIUM CITRATE GA 67

BS	CURIUM	2mCi/ML	N018058	001		Jan CAHN
----	--------	---------	---------	-----	--	----------

GALLIUM DOTATOC GA-68SOLUTION; INTRAVENOUS
GALLIUM DOTATOC GA 68

	+! UIHC PET IMAGING	0.5-4mCi/ML	N210828	001	Aug 21, 2019	Aug NEWA
--	---------------------	-------------	---------	-----	--------------	----------

GALLIUM NITRATEINJECTABLE; INJECTION
GANITE

@ CHEPLAPHARM	25MG/ML	N019961	002	Jan 17, 1991	Aug CAHN
---------------	---------	---------	-----	--------------	----------

GANCICLOVIR

SOLUTION; INTRAVENOUS

GANCICLOVIR

>D>					
>D>	+!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001 Feb 17, 2017 Sep CTNA
>A>		GANZYK-RTU			
>A>	+!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001 Feb 17, 2017 Sep CTNA

GANCICLOVIR SODIUMINJECTABLE; INJECTION
CYTOVENE

AP	+!	CHEPLAPHARM	EQ 500MG BASE/VIAL	N019661	001 Jun 23, 1989 Aug CAHN
		GANCICLOVIR SODIUM			
AP		CUSTOPHARM INC	EQ 500MG BASE/VIAL	A212001	001 Jun 20, 2019 Jun NEWA
AP		FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A090658	001 Jun 21, 2010 Jul CTNA
AP		HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A204204	001 Nov 08, 2018 Jul CTNA
	@	LUITPOLD	EQ 500MG BASE/VIAL	A202624	001 Sep 18, 2013 Jul CTNA
	@		EQ 500MG BASE/VIAL	A202624	001 Sep 18, 2013 Feb DISC
AP		MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204560	001 Nov 17, 2017 Jul CTNA
AP		PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A204950	001 Dec 06, 2016 Jul CTNA

GANIRELIX ACETATEINJECTABLE; INJECTION
GANIRELIX ACETATE

AP	+!	ORGANON USA INC	250MCG/0.5ML	N021057	001 Jul 29, 1999 Mar CPOT
AP		SUN PHARM	250MCG/0.5ML	A204246	001 Nov 30, 2018 Mar CPOT

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A090799	001 Jul 25, 2011 Jan CAHN
AP			EQ 1GM BASE/VIAL	A090799	002 Jul 25, 2011 Jan CAHN
AP			EQ 2GM BASE/VIAL	A090799	003 May 16, 2011 Jan CAHN
AP		INGENUS PHARMS LLC	200MG/5.26ML (38MG/ML)	A210383	001 Feb 14, 2019 Feb NEWA
AP			1GM/26.3ML (38MG/ML)	A210383	002 Feb 14, 2019 Feb NEWA
AP			2GM/52.6ML (38MG/ML)	A210383	003 Feb 14, 2019 Feb NEWA
	@	LUITPOLD	EQ 200MG BASE/VIAL	A202031	001 May 07, 2013 Feb DISC
	@		EQ 1GM BASE/VIAL	A202031	002 May 07, 2013 Feb DISC
AP		SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001 Feb 22, 2019 Feb NEWA
>A>	AP		200MG/5.26ML (38MG/ML)	A210991	001 Oct 04, 2019 Sep NEWA
	AP		EQ 1GM BASE/VIAL	A207575	002 Feb 22, 2019 Feb NEWA
>A>	AP		1GM/26.3ML (38MG/ML)	A210991	002 Oct 04, 2019 Sep NEWA
>A>	AP		2GM/52.6ML (38MG/ML)	A210991	003 Oct 04, 2019 Sep NEWA

GENTAMICIN SULFATEINJECTABLE; INJECTION
GENTAMICIN SULFATE

AP	!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A062366	002 Feb 06, 1986 Jul CHRS
----	---	--------------------	-----------------	---------	---------------------------

OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

>A>	AT	FERA PHARMS LLC	EQ 0.3% BASE	A065024	001 Jul 30, 2004 Sep CAHN
>D>	AT	PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065024	001 Jul 30, 2004 Sep CAHN

GLASDEGIB MALEATETABLET; ORAL
DAURISMO

+	PFIZER INC	EQ 25MG BASE	N210656	001 Nov 21, 2018 Feb CAIN
+	!	EQ 100MG BASE	N210656	002 Nov 21, 2018 Feb CAIN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB		MICRO LABS	1MG	A091220	001 Jun 29, 2012 Mar CAHN
AB			2MG	A091220	002 Jun 29, 2012 Mar CAHN
			3MG	A091220	003 Jun 29, 2012 Mar CAHN
AB			4MG	A091220	004 Jun 29, 2012 Mar CAHN
			6MG	A091220	005 Jun 29, 2012 Mar CAHN

TABLET;ORAL							
GLIMEPIRIDE							
AB		8MG	A091220	006	Jun 29, 2012	Mar	CAHN
<u>GLIPIZIDE</u>							
TABLET;ORAL							
GLIPIZIDE							
	@ BEXIMCO PHARMS USA	5MG	A074542	001	Jun 20, 1995	Feb	CAHN
	@	10MG	A074542	002	Jun 20, 1995	Feb	CAHN
TABLET, EXTENDED RELEASE;ORAL							
GLIPIZIDE							
	@ MYLAN	2.5MG	A202298	001	May 19, 2015	Feb	DISC
	@	5MG	A202298	002	May 19, 2015	Feb	DISC
	@	10MG	A202298	003	May 19, 2015	Feb	DISC
<u>GLIPIZIDE; METFORMIN HYDROCHLORIDE</u>							
TABLET;ORAL							
GLIPIZIDE AND METFORMIN HYDROCHLORIDE							
	@ MYLAN	2.5MG;250MG	A078083	001	Apr 12, 2007	Apr	DISC
<u>GLUCAGON</u>							
POWDER;NASAL							
BAQSIMI							
	+! ELI LILLY AND CO	3MG	N210134	001	Jul 24, 2019	Jul	NEWA
SOLUTION;SUBCUTANEOUS							
>A>	GVOKE HYPOPEN						
>A>	+! XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	003	Sep 10, 2019	Sep	NEWA
>A>	+!	1MG/0.2ML (1MG/0.2ML)	N212097	004	Sep 10, 2019	Sep	NEWA
>A>	GVOKE PFS						
>A>	+! XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019	Sep	NEWA
>A>	+!	1MG/0.2ML (1MG/0.2ML)	N212097	002	Sep 10, 2019	Sep	NEWA
<u>GLYBURIDE</u>							
TABLET;ORAL							
GLYBURIDE							
	@ ORIENT PHARMA CO LTD	1.25MG	A206483	001	Feb 22, 2019	Jul	DISC
AB1		1.25MG	A206483	001	Feb 22, 2019	Feb	NEWA
	@	2.5MG	A206483	002	Feb 22, 2019	Jul	DISC
AB1		2.5MG	A206483	002	Feb 22, 2019	Feb	NEWA
	@	5MG	A206483	003	Feb 22, 2019	Jul	DISC
AB1		5MG	A206483	003	Feb 22, 2019	Feb	NEWA
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE</u>							
TABLET;ORAL							
GLYBURIDE AND METFORMIN HYDROCHLORIDE							
	@ HERITAGE PHARMS INC	1.25MG;250MG	A079009	001	Jun 03, 2009	Aug	DISC
	@	2.5MG;500MG	A079009	002	Jun 03, 2009	Aug	DISC
	@	5MG;500MG	A079009	003	Jun 03, 2009	Aug	DISC
<u>GLYCEROL PHENYLBUTYRATE</u>							
LIQUID;ORAL							
RAVICTI							
	+! HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013	Feb	CAHN
<u>GLYCOPYRROLATE</u>							
INJECTABLE;INJECTION							
GLYCOPYRROLATE							
AP	CAPLIN	0.2MG/ML	A211705	001	Mar 20, 2019	Mar	NEWA
>A>	GLAND PHARMA LTD	0.2MG/ML	A212612	001	Sep 30, 2019	Sep	NEWA
AP	PIRAMAL CRITICAL	0.2MG/ML	A210842	001	Oct 25, 2018	Jun	CAHN
AP	SANDOZ INC	0.2MG/ML	A211334	001	May 14, 2019	Apr	NEWA
ROBINUL							
	+ @ HIKMA	0.2MG/ML	N017558	001		Aug	CAHN
TABLET;ORAL							
GLYCOPYRROLATE							
AA	AUROLIFE PHARMA LLC	2MG	A202675	002	Oct 30, 2018	May	NEWA
AA	KENTON	1MG	A091182	001	Feb 03, 2014	Mar	CAHN
AA		2MG	A091182	002	Feb 03, 2014	Mar	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Apr CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Apr CAHN
AP	!	DR REDDYS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078392	001	Dec 31, 2007	May CAHN
AP	!		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077297	001	Jun 30, 2008	May CAHN
		@ LUITPOLD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274	001	Sep 22, 2010	Feb DISC
			GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE				
AP		BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Apr CAHN
		@ DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	May CAHN
			TABLET; ORAL				
			GRANISETRON HYDROCHLORIDE				
		@ TEVA PHARMS	EQ 1MG BASE	A078080	001	Dec 31, 2007	Jan DISC
AB	!	WEST-WARD PHARMS INT	EQ 1MG BASE	A077842	001	Dec 31, 2007	Jan CHRS

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

OBREDON

		+ @ SOVEREIGN PHARMS	200MG/5ML; 2.5MG/5ML	N205474	001	Nov 14, 2014	Jun DISC
			TABLET; ORAL				
			XTRELUS				
		+ @ ECI PHARMS LLC	400MG; 5MG	N208085	001	Apr 25, 2018	Jun DISC

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB		EPIC PHARMA LLC	EQ 1MG BASE	A074673	001	Feb 28, 1997	Apr CMFD
AB			EQ 2MG BASE	A074673	002	Feb 28, 1997	Apr CMFD
			TABLET, EXTENDED RELEASE; ORAL				
			GUANFACINE HYDROCHLORIDE				
		@ MYLAN	EQ 1MG BASE	A202578	001	Jun 02, 2015	May DISC
		@	EQ 2MG BASE	A202578	002	Jun 02, 2015	May DISC
		@	EQ 3MG BASE	A202578	003	Jun 02, 2015	May DISC
		@	EQ 4MG BASE	A202578	004	Jun 02, 2015	May DISC

HALCINONIDE

CREAM; TOPICAL

HALCINONIDE

AB		MYLAN	0.1%	A211027	001	Aug 12, 2019	Jul NEWA
		HALOG					
AB	+	SUN PHARM INDS INC	0.1%	N017556	001		Aug CFTG

HALOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

HALOBETASOL PROPIONATE

>D>							
>D>	+	MAYNE PHARMA	0.05%	N210566	001	May 24, 2018	Sep CTNA
>A>		LEXETTE					
>A>	+	MAYNE PHARMA	0.05%	N210566	001	May 24, 2018	Sep CTNA
			LOTION; TOPICAL				
			BRYHALI				
	+	BAUSCH	0.01%	N209355	001	Nov 06, 2018	Apr CAHN
	+	DOW PHARM	0.01%	N209355	001	Nov 06, 2018	Jan CHRS
	+		0.01%	N209355	001	Nov 06, 2018	Jan CRLD

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION; TOPICAL

DUOBRII

	+	BAUSCH	0.01%; 0.045%	N209354	001	Apr 25, 2019	Apr NEWA
--	---	--------	---------------	---------	-----	--------------	----------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

		@ INNOGENIX	0.5MG	A071173	002	Jan 02, 1987	May CMS1
		@	1MG	A071173	003	Jan 02, 1987	May CMS1
		@	2MG	A071173	004	Jan 02, 1987	May CMS1
		@	5MG	A071173	005	Jan 07, 1988	May CMS1
		@	10MG	A071173	001	Jan 07, 1988	Mar CAHN
		@	20MG	A071173	006	Jan 07, 1988	May CMS1

TABLET;ORAL
HALOPERIDOL

	!	MYLAN	2MG	A070278	001	Jun 10, 1986	Jan CTEC
AB	!		2MG	A070278	001	Jun 10, 1986	Jan CHRS
	@	SANDOZ	2MG	A071208	001	Nov 17, 1986	Jan DISC

HALOPERIDOL LACTATE

CONCENTRATE;ORAL
HALOPERIDOL

AA	!	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May CHRS
	@	TEVA PHARMS	EQ 2MG BASE/ML	A071617	001	Dec 01, 1988	May DISC
>D>	@	CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	Sep CAHN
>A>	@	HIKMA	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	Sep CAHN

INJECTABLE;INJECTION
HALOPERIDOL

AP		FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Jun NEWA
----	--	--------------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

		B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Aug CAHN
AP	+	HIKMA	1,000 UNITS/ML	N017037	001		Feb CAHN
AP	+		5,000 UNITS/ML	N017037	002		Feb CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Feb CAHN
AP	+		10,000 UNITS/ML	N017037	003		Feb CAHN
AP		NANJING KING-FRIEND	1,000 UNITS/ML	A211007	001	May 28, 2019	May NEWA
AP			5,000 UNITS/ML	A211007	002	May 28, 2019	May NEWA
AP			10,000 UNITS/ML	A211007	003	May 28, 2019	May NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL
HYCODAN

AA	+	GENUS LIFESCIENCES	1.5MG/5ML;5MG/5ML	N005213	002	Jul 26, 1988	Jun CMFD
		HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE					
	@	BRECKENRIDGE	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Jul DISC
AA		BRECKENRIDGE PHARM	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	May NEWA
AA		TORRENT	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	May CMFD
	@		1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Jan CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

	@	LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb DISC
--	---	----------	---------	---------	-----	--------------	----------

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA		UPSHER SMITH LABS	10MG	A209251	001	Jul 09, 2018	Jun CAHN
AA			25MG	A209251	002	Jul 09, 2018	Jun CAHN
AA			50MG	A209251	003	Jul 09, 2018	Jun CAHN
AA			100MG	A209251	004	Jul 09, 2018	Jun CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

	@	APOTEX INC	12.5MG;150MG	A201505	001	Oct 15, 2012	Jul DISC
	@		12.5MG;300MG	A201505	002	Oct 15, 2012	Jul DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET;ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

	@	HERITAGE PHARMA	12.5MG;10MG	A075776	001	Jul 01, 2002	Aug DISC
AB			12.5MG;10MG	A075776	001	Jul 01, 2002	Feb CAHN
	@		12.5MG;20MG	A075776	002	Jul 01, 2002	Aug DISC
AB			12.5MG;20MG	A075776	002	Jul 01, 2002	Feb CAHN
	@		25MG;20MG	A075776	003	Jul 01, 2002	Aug DISC
AB			25MG;20MG	A075776	003	Jul 01, 2002	Feb CAHN

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

	@ ACCORD HLTHCARE	12.5MG;20MG	A209281	001	Feb 07, 2019	Aug DISC
AB		12.5MG;20MG	A209281	001	Feb 07, 2019	Jan NEWA
	@	12.5MG;40MG	A209281	002	Feb 07, 2019	Aug DISC
AB		12.5MG;40MG	A209281	002	Feb 07, 2019	Jan NEWA
	@	25MG;40MG	A209281	003	Feb 07, 2019	Aug DISC
AB		25MG;40MG	A209281	003	Feb 07, 2019	Jan NEWA
	@ TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Jul DISC
	@	25MG;40MG	A200532	003	Apr 24, 2017	Jul DISC
>A> AB	UMEDICA LABS PVT LTD	12.5MG;20MG	A208847	001	Sep 17, 2019	Sep NEWA
>A> AB		12.5MG;40MG	A208847	003	Sep 17, 2019	Sep NEWA
>A> AB		25MG;40MG	A208847	002	Sep 17, 2019	Sep NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ MYLAN	12.5MG;EQ 10MG BASE	A077093	001	Mar 28, 2005	May DISC
	@	12.5MG;EQ 20MG BASE	A077093	002	Mar 28, 2005	May DISC
	@	25MG;EQ 20MG BASE	A077093	003	Mar 28, 2005	May DISC
	QUINARETIC					
AB	LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Feb CAHN
AB		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Feb CAHN
AB		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Feb CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	GLENMARK PHARMS LTD	12.5MG;40MG	A202544	001	Mar 04, 2019	Feb NEWA
AB		12.5MG;80MG	A202544	002	Mar 04, 2019	Feb NEWA
AB		25MG;80MG	A202544	003	Mar 04, 2019	Feb NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

	@ ANI PHARMS INC	25MG;50MG	A074259	001	Mar 30, 1995	Jun DISC
	@ CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31, 1991	Jun DISC
AB	ZYDUS PHARMS	25MG;37.5MG	A208358	001	Feb 11, 2019	Jan NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

	@ ZYDUS PHARMS	12.5MG;80MG	A203000	001	Mar 15, 2019	Aug DISC
AB		12.5MG;80MG	A203000	001	Mar 15, 2019	Mar NEWA
	@	12.5MG;160MG	A203000	002	Mar 15, 2019	Aug DISC
AB		12.5MG;160MG	A203000	002	Mar 15, 2019	Mar NEWA
	@	12.5MG;320MG	A203000	003	Mar 15, 2019	Aug DISC
AB		12.5MG;320MG	A203000	003	Mar 15, 2019	Mar NEWA
	@	25MG;160MG	A203000	004	Mar 15, 2019	Aug DISC
AB		25MG;160MG	A203000	004	Mar 15, 2019	Mar NEWA
	@	25MG;320MG	A203000	005	Mar 15, 2019	Aug DISC
AB		25MG;320MG	A203000	005	Mar 15, 2019	Mar NEWA

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

+!	PERSION	10MG	N202880	001	Oct 25, 2013	Apr CAHN
+		15MG	N202880	002	Oct 25, 2013	Apr CAHN
+		20MG	N202880	003	Oct 25, 2013	Apr CAHN
+		30MG	N202880	004	Oct 25, 2013	Apr CAHN
+		40MG	N202880	005	Oct 25, 2013	Apr CAHN
+		50MG	N202880	006	Oct 25, 2013	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

HYSINGLA ER

+!	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Jul CMS1
+		30MG	N206627	002	Nov 20, 2014	Jul CMS1
+		40MG	N206627	003	Nov 20, 2014	Jul CMS1
+		60MG	N206627	004	Nov 20, 2014	Jul CMS1
+		80MG	N206627	005	Nov 20, 2014	Jul CMS1
+		100MG	N206627	006	Nov 20, 2014	Jul CMS1
+		120MG	N206627	007	Nov 20, 2014	Jul CMS1

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

@ ANI PHARMS INC

5MG; 200MG

A077454 001 Jun 23, 2010 May CAHN

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ MAYNE PHARMA INC

5MG/5ML; 60MG/5ML

A205658 001 Nov 17, 2015 Jun DISC

@ PADDOCK LLC

5MG/5ML; 60MG/5ML

A204658 001 Apr 29, 2014 Jun DISC

@ TORRENT

5MG/5ML; 60MG/5ML

A206661 001 Jan 23, 2019 Feb DISC

AA 5MG/5ML; 60MG/5ML

A206661 001 Jan 23, 2019 Jan NEWA

REZIRA

+ @ PERSION

5MG/5ML; 60MG/5ML

N022442 001 Jun 08, 2011 Jun DISC

AA +!

5MG/5ML; 60MG/5ML

N022442 001 Jun 08, 2011 Apr CAHN

HYDROCORTISONE

CREAM; TOPICAL

NUTRACORT

@ BAUSCH

0.5%

A080442 002 Feb CAHN

@

1%

A080442 003 Feb CAHN

LOTION; TOPICAL

CETACORT

@ BAUSCH

0.5%

A080426 002 Feb CAHN

@

1%

A080426 001 Feb CAHN

TABLET; ORAL

HYDROCORTISONE

AB BRECKENRIDGE

5MG

A207029 001 Apr 27, 2017 Aug CAHN

AB 10MG

A207029 002 Apr 27, 2017 Aug CAHN

AB 20MG

A207029 003 Apr 27, 2017 Aug CAHN

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

AB1 +! BAUSCH

0.1%

N018514 001 Mar 31, 1982 May CAHN

LOTION; TOPICAL

LOCOID

AB +! BAUSCH

0.1%

N022076 001 May 18, 2007 May CAHN

SOLUTION; TOPICAL

LOCOID

AT +! BAUSCH

0.1%

N019116 001 Feb 25, 1987 May CAHN

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB LUPIN LTD

0.2%

A210307 001 Aug 15, 2019 Aug NEWA

AB PERRIGO ISRAEL

0.2%

A075666 001 May 24, 2000 May CAHN

HYDROGEN PEROXIDE

SOLUTION; TOPICAL

ESKATA

+ @ ACLARIS

40%

N209305 001 Dec 14, 2017 Aug DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

+ @ SPECGX LLC

8MG

N021217 001 Mar 01, 2010 Mar DISC

+ @

12MG

N021217 002 Mar 01, 2010 Mar DISC

+ @

16MG

N021217 003 Mar 01, 2010 Mar DISC

+ @

32MG

N021217 004 Aug 24, 2012 Mar DISC

HYDROMORPHONE HYDROCHLORIDE

AB ! OSMOTICA

32MG

A205629 004 Jul 07, 2016 Mar CHRS

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

>D> AB LAURUS LABS LTD

200MG

A210959 001 Jan 15, 2019 Sep DISC

>A> @

200MG

A210959 001 Jan 15, 2019 Sep DISC

AB 200MG

A210959 001 Jan 15, 2019 Jan CAHN

@ LUPIN LTD

200MG

A210543 001 Jul 06, 2018 Feb DISC

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

HYDROXYPROGESTERON CAPROATE

AP1	AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jul	NEWA
HYDROXYPROGESTERONE CAPROATE							
AP	ASPEN	250MG/ML (250MG/ML)	A211777	001	Aug 08, 2019	Jul	NEWA
AP2	!	ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015	Apr CPOT
AP2	!		250MG/ML (250MG/ML)	A200271	001	Aug 24, 2015	Apr CTEC
AP		EUGIA PHARMA	250MG/ML (250MG/ML)	A211071	001	Apr 16, 2019	Apr NEWA
AP1			1250MG/5ML (250MG/ML)	A211070	001	Apr 16, 2019	Apr NEWA
AP2			1250MG/5ML (250MG/ML)	A211142	001	May 09, 2019	Apr NEWA
AP		SLAYBACK PHARMA LLC	250MG/ML (250MG/ML)	A210877	001	Mar 22, 2019	Mar NEWA
AP1			1250MG/5ML (250MG/ML)	A210618	001	Dec 28, 2018	Apr CTEC
AP1		SUN PHARM	1250MG/5ML (250MG/ML)	A208381	001	Apr 09, 2019	Apr CTEC
AP			1250MG/5ML (250MG/ML)	A208381	001	Apr 09, 2019	Mar NEWA
MAKENA							
AP1	+	AMAG PHARMA USA	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Apr CTEC

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+	!	VALEANT PHARMS INTL	5MG	N018771	001		Jan CAHN
---	---	---------------------	-----	---------	-----	--	----------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

!		LUITPOLD	50MG/ML	A087408	002		Mar CMFD
@			50MG/ML	A087408	002		Feb DISC

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

>A>	@	ANIMA	10MG/5ML	A086880	001		Sep CAHN
>D>	@	STI PHARMA LLC	10MG/5ML	A086880	001		Sep CAHN
AA		TORRENT	10MG/5ML	A210634	001	Feb 26, 2019	Feb NEWA

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB		EPIC PHARMA LLC	10MG	A040604	002	Dec 28, 2004	Jan CAHN
AB			25MG	A040604	003	Dec 28, 2004	Jan CAHN
AB			50MG	A040604	001	Dec 28, 2004	Jan CAHN
AB		KVK TECH	25MG	A040786	002	Mar 20, 2007	Feb CMS1
AB			50MG	A040786	003	Mar 20, 2007	Feb CMS1
	@	MYLAN	10MG	A091176	001	Jun 07, 2010	Aug DISC
	@		25MG	A091176	002	Jun 07, 2010	Aug DISC
	@		50MG	A091176	003	Jun 07, 2010	Aug DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

@		BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991	Feb CAHN
---	--	--------------------	-----------------------	---------	-----	--------------	----------

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

+	!	CUMBERLAND PHARMS	800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019	Jan NEWA
---	---	-------------------	----------------------	---------	-----	--------------	----------

SUSPENSION; ORAL

IBUPROFEN

AB		L PERRIGO CO	100MG/5ML	A076925	001	Sep 23, 2004	May CAHN
TABLET; ORAL							
IBUPROFEN							
	@	HEC PHARM	400MG	A204062	001	Sep 10, 2018	Mar DISC
	@		600MG	A204062	002	Sep 10, 2018	Mar DISC
	@		800MG	A204062	003	Sep 10, 2018	Mar DISC
AB		PERRIGO PHARMS CO	400MG	A077114	001	Jul 18, 2005	May CAHN
AB			600MG	A077114	002	Jul 18, 2005	May CAHN
AB			800MG	A077114	003	Jul 18, 2005	May CAHN

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

IBUTILIDE FUMARATE

@		LUITPOLD	0.1MG/ML	A090240	001	Jan 11, 2010	Feb DISC
---	--	----------	----------	---------	-----	--------------	----------

ICATIBANT ACETATEINJECTABLE;SUBCUTANEOUS
FIRAZYR

AP	+	SHIRE ORPHAN THERAP	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Jul CFTG
AP		ICATIBANT ACETATE					
AP		TEVA PHARMS USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A210118	001	Jul 15, 2019	Jul NFTG

IFOSEFAMIDEINJECTABLE;INJECTION
IFOSEFAMIDE

>D>	AP	MYLAN LABS LTD	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012	Sep DISC
>A>		@	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012	Sep DISC
>D>	AP		3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012	Sep DISC
>A>		@	3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012	Sep DISC

ILOPERIDONETABLET;ORAL
FANAPT

	+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Aug CTEC
	+		2MG	N022192	002	May 06, 2009	Aug CTEC
	+		4MG	N022192	003	May 06, 2009	Aug CTEC
	+		6MG	N022192	004	May 06, 2009	Aug CTEC
	+		8MG	N022192	005	May 06, 2009	Aug CTEC
	+		10MG	N022192	006	May 06, 2009	Aug CTEC
	+		12MG	N022192	007	May 06, 2009	Aug CTEC
		ILOPERIDONE					
	@	INVENTIA	1MG	A207231	001	Nov 28, 2016	Aug CAHN
	@		2MG	A207231	002	Nov 28, 2016	Aug CAHN
	@		4MG	A207231	003	Nov 28, 2016	Aug CAHN
	@		6MG	A207231	004	Nov 28, 2016	Aug CAHN
	@		8MG	A207231	005	Nov 28, 2016	Aug CAHN
	@		10MG	A207231	006	Nov 28, 2016	Aug CAHN
	@		12MG	A207231	007	Nov 28, 2016	Aug CAHN
	@	INVENTIA HLTHCARE	1MG	A207231	001	Nov 28, 2016	Jul DISC
	@		2MG	A207231	002	Nov 28, 2016	Jul DISC
	@		4MG	A207231	003	Nov 28, 2016	Jul DISC
	@		6MG	A207231	004	Nov 28, 2016	Jul DISC
	@		8MG	A207231	005	Nov 28, 2016	Jul DISC
	@		10MG	A207231	006	Nov 28, 2016	Jul DISC
	@		12MG	A207231	007	Nov 28, 2016	Jul DISC
	@	TARO PHARM INDS LTD	1MG	A207098	001	Jul 22, 2019	Aug DISC
AB			1MG	A207098	001	Jul 22, 2019	Jul NEWA
	@		2MG	A207098	002	Jul 22, 2019	Aug DISC
AB			2MG	A207098	002	Jul 22, 2019	Jul NEWA
	@		4MG	A207098	003	Jul 22, 2019	Aug DISC
AB			4MG	A207098	003	Jul 22, 2019	Jul NEWA
	@		6MG	A207098	004	Jul 22, 2019	Aug DISC
AB			6MG	A207098	004	Jul 22, 2019	Jul NEWA
	@		8MG	A207098	005	Jul 22, 2019	Aug DISC
AB			8MG	A207098	005	Jul 22, 2019	Jul NEWA
	@		10MG	A207098	006	Jul 22, 2019	Aug DISC
AB			10MG	A207098	006	Jul 22, 2019	Jul NEWA
	@		12MG	A207098	007	Jul 22, 2019	Aug DISC
AB			12MG	A207098	007	Jul 22, 2019	Jul NEWA

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

	@	AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019	Aug DISC
AB			EQ 100MG BASE	A207495	001	Feb 08, 2019	Feb NEWA
	@		EQ 400MG BASE	A207495	002	Feb 08, 2019	Aug DISC
AB			EQ 400MG BASE	A207495	002	Feb 08, 2019	Feb NEWA
AB		BRECKENRIDGE	EQ 100MG BASE	A205990	001	Feb 08, 2019	Feb NEWA
AB			EQ 400MG BASE	A205990	002	Feb 08, 2019	Feb NEWA
AB		NATCO PHARMA LTD	EQ 100MG BASE	A207818	001	Mar 01, 2019	Feb NEWA
AB			EQ 400MG BASE	A207818	002	Mar 01, 2019	Feb NEWA
AB		SHILPA MEDICARE LTD	EQ 100MG BASE	A208302	001	Jan 17, 2019	Jan NEWA
AB			EQ 400MG BASE	A208302	002	Jan 17, 2019	Jan NEWA
AB		WOCKHARDT BIO AG	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan NEWA
AB			EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@ OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Mar DISC
@	25MG	A040751	002	Feb 28, 2008	Mar DISC

IMIQUIMOD

CREAM; TOPICAL

ALDARA

AB	+!	BAUSCH	5%	N020723	001	Feb 27, 1997	Aug CAHN
		ZYCLARA					
	+!	BAUSCH	2.5%	N022483	002	Jul 15, 2011	Aug CAHN
	+!		3.75%	N022483	001	Mar 25, 2010	Aug CAHN

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+	@	GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992	Jun DISC
		INDIUM IN 111 CHLORIDE					
+	!	CURIUM	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan CAHN

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+	!	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jan CAHN
---	---	--------	---------	---------	-----	--------------	----------

INDOMETHACIN

CAPSULE; ORAL

INDOCIN

+	@	EGALET	25MG	N016059	001		Feb CAHN
+	@		50MG	N016059	002		Feb CAHN

INDOMETHACIN

	@	ANI PHARMS INC	25MG	A071148	001	Mar 18, 1987	May CAHN
	@		50MG	A071149	001	Mar 18, 1987	May CAHN
AB		CADILA	25MG	A090403	001	Nov 15, 2010	May CAHN
AB			50MG	A090403	002	Nov 15, 2010	May CAHN
AB	!	GLENMARK GENERICS	50MG	A091276	002	Dec 22, 2010	Aug CHRS
AB		HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986	Feb CAHN
AB			50MG	A070756	001	Feb 12, 1986	Feb CAHN
	@	MYLAN	25MG	N018858	001	Apr 20, 1984	Aug DISC
	@		50MG	A070624	001	Sep 04, 1985	Aug DISC
		TIVORBEX					
+		EGALET	20MG	N204768	001	Feb 24, 2014	Feb CAHN
+	!		40MG	N204768	002	Feb 24, 2014	Feb CAHN

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

+	@	EGALET	75MG	N018185	001	Feb 23, 1982	Feb CAHN
---	---	--------	------	---------	-----	--------------	----------

SUPPOSITORY; RECTAL

INDOCIN

+	@	EGALET	50MG	N017814	001	Aug 13, 1984	Feb CAHN
---	---	--------	------	---------	-----	--------------	----------

SUSPENSION; ORAL

INDOCIN

+	!	EGALET	25MG/5ML	N018332	001	Oct 10, 1985	Feb CAHN
---	---	--------	----------	---------	-----	--------------	----------

INDOMETHACIN

>D>	@	CYCLE PHARMS LTD	25MG/5ML	A071412	001	Mar 18, 1987	Sep CAHN
>A>	@	HIKMA	25MG/5ML	A071412	001	Mar 18, 1987	Sep CAHN

INSULIN ASPART

SOLUTION; SUBCUTANEOUS

Fiasp Penfill

+	!	NOVO	300 UNITS/3ML (100 UNITS/ML)	N208751	003	Sep 24, 2018	Jun NEWA
---	---	------	------------------------------	---------	-----	--------------	----------

INSULIN ASPART; INSULIN DEGLUDEC

SOLUTION; SUBCUTANEOUS

Ryzodeg 70/30

+	@	NOVO	90 UNITS/3ML; 210 UNITS/3ML (30 UNITS/ML; 70 UNITS/ML)	N203313	001	Sep 25, 2015	Jun DISC
---	---	------	--	---------	-----	--------------	----------

INSULIN DEGLUDEC

SOLUTION; SUBCUTANEOUS
TRESIBA
NOVO

1000 UNITS/10ML (100 UNITS/ML)

N203314 003 Nov 21, 2018 Jun NEWA

INSULIN HUMAN

SOLUTION; INTRAVENOUS
MYXREDLIN

+! BAXTER HLTHCARE CORP 100 UNITS/100ML (1 UNIT/ML)
+! CELERITY PHARMS 100 UNITS/100ML (1 UNIT/ML)

N208157 001 Jun 20, 2019 Jul CAHN
N208157 001 Jun 20, 2019 Jun NEWA

IOPROMIDE

INJECTABLE; INJECTION
ULTRAVIST (PHARMACY BULK)

+ @ BAYER HLTHCARE 49.9%
+! 49.9%
+ @ 49.9%

N021425 003 Mar 12, 2004 Aug DISC
N021425 003 Mar 12, 2004 Apr CMFD
N021425 003 Mar 12, 2004 Feb DISC

ULTRAVIST 240

+ @ BAYER HLTHCARE 49.9%
+! 49.9%
+ @ 49.9%

N020220 003 May 10, 1995 Aug DISC
N020220 003 May 10, 1995 Apr CMFD
N020220 003 May 10, 1995 Feb DISC

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION
CONRAY 43

+ @ LIEBEL-FLARSHEIM 43%

N013295 002 Jun DISC

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL
IPRATROPIUM BROMIDE

@ MYLAN SPECIALITY LP 0.021MG/SPRAY
@ 0.042MG/SPRAY

A075552 001 Mar 31, 2003 Mar DISC
A075553 001 Mar 31, 2003 Mar DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

>D> AP MUSTAFA NEVZAT ILAC 40MG/2ML (20MG/ML)
>D> AP 100MG/5ML (20MG/ML)
>A> AP ZENNOVA 40MG/2ML (20MG/ML)
>A> AP 100MG/5ML (20MG/ML)

A090393 002 May 13, 2011 Sep CAHN
A090393 003 May 13, 2011 Sep CAHN
A090393 002 May 13, 2011 Sep CAHN
A090393 003 May 13, 2011 Sep CAHN

IRON DEXTRAN

INJECTABLE; INJECTION
DEXFERRUM

@ LUITPOLD EQ 50MG IRON/ML
PROFERDEX
@ NEW RIVER EQ 50MG IRON/ML

N040024 001 Feb 23, 1996 Mar DISC
N017807 001 Mar DISC

IRON SUCROSE

INJECTABLE; INTRAVENOUS
VENOFER

+ AM REGENT EQ 50MG BASE/2.5ML (EQ 20MG
BASE/ML)
@ EQ 65MG BASE/3.25ML (EQ 20MG
BASE/ML)
@ EQ 75MG BASE/3.75ML (EQ 20MG
BASE/ML)
+! EQ 100MG BASE/5ML (EQ 20MG
BASE/ML)
+ EQ 200MG BASE/10ML (EQ 20MG
BASE/ML)

N021135 002 Mar 20, 2005 Apr CAHN
N021135 005 Mar 29, 2013 Apr CAHN
N021135 003 Mar 29, 2005 Apr CAHN
N021135 001 Nov 06, 2000 Apr CAHN
N021135 004 Feb 09, 2007 Apr CAHN

ISONIAZID

TABLET; ORAL
ISONIAZID

AA ! BARR 100MG
AA ! 300MG
+ @ SANDOZ 100MG
+ @ 300MG

A080936 001 Aug CHRS
A080937 002 Aug CHRS
N008678 002 Aug DISC
N008678 003 Aug DISC

ISOPROPYL ALCOHOLSOLUTION; TOPICAL
ZURAGARD

+! ZUREX PHARMA 70% (10.5ML) N210872 001 Apr 26, 2019 Apr NEWA

ISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE

AP CIPLA 0.2MG/ML A211738 001 Jun 28, 2019 Jun NEWA

ISUPREL

AP +! BAUSCH 0.2MG/ML N010515 001 Mar CAHN

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB + BAUSCH 5MG N012093 007 Jul 29, 1988 Mar CAHN

+ @ 10MG N012093 002 Jul 29, 1988 Mar CAHN

+ @ 20MG N012093 006 Jul 29, 1988 Mar CAHN

+ @ 30MG N012093 005 Jul 29, 1988 Mar CAHN

+! 40MG N012093 001 Jul 29, 1988 Mar CAHN

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

AB HIKMA INTL PHARMS 30MG A076813 002 Mar 30, 2006 Mar CAHN

AB 60MG A076813 001 Jan 07, 2005 Mar CAHN

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

>A> AP ANDA REPOSITORY 1% A210558 001 Jul 12, 2019 Sep CAHN

@ BELOTECA INC 1% A210714 001 Jan 16, 2019 Jul DISC

>D> AP SOMERSET THERAPS LLC 1% A210558 001 Jul 12, 2019 Sep CAHN

AP 1% A210558 001 Jul 12, 2019 Jul NEWA

ISTRADEFYLLINE

TABLET; ORAL

NOURIANZ

+ KYOWA KIRIN 20MG N022075 001 Aug 27, 2019 Aug NEWA

+! 40MG N022075 002 Aug 27, 2019 Aug NEWA

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

AB ANDA REPOSITORY 100MG A206410 001 Jul 02, 2019 Aug CAHN

AB PII 100MG A206410 001 Jul 02, 2019 Jun NEWA

SOLUTION; ORAL

ITRACONAZOLE

AA APOTEX INC 10MG/ML A208481 001 Aug 02, 2019 Jul NEWA

IVABRADINE

SOLUTION; ORAL

CORLANOR

+! AMGEN INC 5MG/5ML (1MG/ML) N209964 001 Apr 22, 2019 Apr NEWA

IVACAFTOR

GRANULE; ORAL

KALYDECO

+ VERTEX PHARMS INC 25MG/PACKET N207925 003 Apr 29, 2019 May NEWA

TABLET; ORAL

KALYDECO

+ VERTEX PHARMS 75MG N203188 002 May 20, 2019 May NEWA

IVACAFTOR; IVACAFTOR, TEZACAFTORTABLET, TABLET; ORAL
SYMDEKO (COPACKAGED)

+! VERTEX PHARMS INC 75MG, N/A; 75MG, 50MG N210491 002 Jun 21, 2019 Jul NEWA

IVERMECTIN

CREAM; TOPICAL							
>A>	IVERMECTIN						
>A> AB	TEVA PHARMS USA	1%	A210019	001	Sep 13, 2019	Sep	NFTG
SOOLANTRA							
>D>	+! GALDERMA LABS LP	1%	N206255	001	Dec 19, 2014	Sep	CFTG
>A> AB	+!	1%	N206255	001	Dec 19, 2014	Sep	CFTG

KETOCONAZOLE

GEL; TOPICAL							
XOLEGEL							
	+! ALMIRALL	2%	N021946	001	Jul 28, 2006	Feb	CAHN
SHAMPOO; TOPICAL							
KETOCONAZOLE							
AB	PERRIGO ISRAEL	2%	A076419	001	Jan 07, 2004	May	CAHN
TABLET; ORAL							
KETOCONAZOLE							
	@ HERITAGE PHARMA	200MG	A074971	001	Jun 15, 1999	May	CAHN
	@	200MG	A075362	001	Jun 15, 1999	May	CAHN
AB	! TARO	200MG	A075319	001	Jun 15, 1999	Apr	CHRS
	@ TEVA	200MG	A075273	001	Jun 15, 1999	Apr	DISC

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION							
KETOROLAC TROMETHAMINE							
AP	WEST-WARD PHARMS INT	15MG/ML	A075772	001	Jul 21, 2004	Feb	CMFD
AP		30MG/ML	A075772	002	Jul 21, 2004	Feb	CMFD
SOLUTION/DROPS; OPHTHALMIC							
KETOROLAC TROMETHAMINE							
	@ AUROBINDO PHARMA LTD	0.4%	A205191	001	Nov 15, 2018	May	DISC
AT	MICRO LABS LTD INDIA	0.5%	A203410	001	Apr 05, 2019	Mar	NEWA
	@ SANDOZ INC	0.4%	A078721	001	Nov 05, 2009	May	DISC
SPRAY, METERED; NASAL							
SPRIX							
	+! ZYLA	15.75MG/SPRAY	N022382	001	May 14, 2010	Jul	CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION							
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE							
AT	LUPIN LTD	EQ 0.3% BASE; EQ 1% BASE	A210183	001	Jul 01, 2019	Jun	NFTG
OMIDRIA							
AT	+! OMEROS	EQ 0.3% BASE; EQ 1% BASE	N205388	001	May 30, 2014	Jun	CFTG

L-GLUTAMINE

FOR SOLUTION; ORAL							
NUTRESTORE							
	+ @ EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	Jun	DISC

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION							
LABETALOL HYDROCHLORIDE							
>D> AP	MYLAN ASI	5MG/ML	A079134	001	Feb 03, 2010	Sep	DISC
>A>	@	5MG/ML	A079134	001	Feb 03, 2010	Sep	DISC
TABLET; ORAL							
LABETALOL HYDROCHLORIDE							
AB	CADILA PHARMS LTD	100MG	A211325	001	May 13, 2019	Apr	NEWA
AB		200MG	A211325	002	May 13, 2019	Apr	NEWA
AB		300MG	A211325	003	May 13, 2019	Apr	NEWA
TRANDATE							
AB	+ CNTY LINE PHARMS	100MG	N018716	001	May 24, 1985	Jan	CRLD
AB	+	200MG	N018716	002	Aug 01, 1984	Jan	CRLD
AB	+	300MG	N018716	003	Aug 01, 1984	Jan	CRLD

LACTULOSE

SOLUTION; ORAL							
LACTULOSE							
	@ BAJAJ	10GM/15ML	A075911	001	Feb 21, 2002	Jan	CAHN
AA	TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Jan	CAHN
AA	XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Aug	CMFD
	@	10GM/15ML	A075911	001	Feb 21, 2002	Mar	CAHN

SOLUTION;ORAL, RECTAL
LACTULOSE

	@ BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Jan CAHN
AA	TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Jan CAHN

LAMIVUDINETABLET;ORAL
LAMIVUDINE

AB	ANNORA	100MG	A211306	001	Mar 21, 2019	Mar NEWA
AB	MACLEODS PHARMS LTD	150MG	A090198	001	May 01, 2019	Apr NEWA
AB		300MG	A090198	002	May 01, 2019	Apr NEWA
	@ MYLAN	150MG	A204528	001	Mar 04, 2016	Apr DISC
	@	300MG	A204528	002	Mar 04, 2016	Apr DISC
AB	MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Feb NEWA
AB		300MG	A078545	002	Mar 05, 2019	Feb NEWA

LAMIVUDINE; ZIDOVUDINETABLET;ORAL
LAMIVUDINE AND ZIDOVUDINE

>A>	AB	ANDA REPOSITORY	150MG;300MG	A206375	001	Apr 10, 2018	Sep CAHN
		@ MYLAN	150MG;300MG	A079079	001	Aug 12, 2019	Aug DISC
	AB		150MG;300MG	A079079	001	Aug 12, 2019	Jul NEWA
		@	150MG;300MG	A204005	001	Aug 28, 2014	Jan DISC
>D>	AB	SHANGHAI DESANO	150MG;300MG	A206375	001	Apr 10, 2018	Sep CAHN

LAMOTRIGINETABLET;ORAL
LAMOTRIGINE

	@ CELLTRION	25MG	A078982	001	Jan 27, 2009	Aug CAHN
	@	100MG	A078982	002	Jan 27, 2009	Aug CAHN
	@	150MG	A078982	003	Jan 27, 2009	Aug CAHN
	@	200MG	A078982	004	Jan 27, 2009	Aug CAHN
AB	RUBICON	25MG	A078625	001	Jan 27, 2009	Jul CAHN
AB		100MG	A078625	002	Jan 27, 2009	Jul CAHN
AB		150MG	A078625	003	Jan 27, 2009	Jul CAHN
AB		200MG	A078625	004	Jan 27, 2009	Jul CAHN

TABLET, CHEWABLE;ORAL
LAMOTRIGINE

	@ TEVA	5MG	A076420	001	Jun 21, 2006	Jul DISC
	@	25MG	A076420	002	Jun 21, 2006	Jul DISC

TABLET, EXTENDED RELEASE;ORAL
LAMOTRIGINE

	@ RUBICON	25MG	A202887	001	Jun 17, 2013	Mar CAHN
	@	50MG	A202887	002	Jun 17, 2013	Mar CAHN
AB		100MG	A202887	003	Jun 17, 2013	Mar CAHN
AB		200MG	A202887	004	Jun 17, 2013	Mar CAHN

LANSOPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

>D>	AB	AJANTA PHARMA LTD	15MG	A203957	001	Oct 14, 2016	Sep DISC
>A>		@	15MG	A203957	001	Oct 14, 2016	Sep DISC
>D>	AB		30MG	A203957	002	Oct 14, 2016	Sep DISC
>A>		@	30MG	A203957	002	Oct 14, 2016	Sep DISC
	AB	ALKEM LABS LTD	15MG	A207394	001	Jan 18, 2019	Jan NEWA
	AB		30MG	A207394	002	Jan 18, 2019	Jan NEWA
		@ BRECKENRIDGE	15MG	A203964	001	Oct 17, 2018	May DISC
		@	30MG	A203964	002	Oct 17, 2018	May DISC
	AB	INVENTIA	15MG	A205868	001	Aug 30, 2017	Aug CAHN
	AB		30MG	A205868	002	Aug 30, 2017	Aug CAHN
		@ KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Feb DISC
		@	30MG	A091212	002	Sep 16, 2013	Feb DISC
	AB	XIROMED	15MG	A203203	001	Jul 25, 2016	Aug CAHN
	AB		30MG	A203203	002	Jul 25, 2016	Aug CAHN

LAROTRECTINIBCAPSULE;ORAL
VITRAKVI

+	BAYER HLTHCARE	25MG	N210861	001	Nov 26, 2018	Feb CAHN
+	!	100MG	N210861	002	Nov 26, 2018	Feb CAHN

SOLUTION;ORAL

VITRAKVI

+!	BAYER HEALTHCARE	20MG/ML	N211710	001	Nov 26, 2018	Feb CAHN
----	------------------	---------	---------	-----	--------------	----------

LAROTRECTINIB SULFATE

CAPSULE;ORAL

VITRAKVI

+	BAYER HLTHCARE	EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CAIN
+		EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CPOT
+		EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CAIN
+		EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CPOT

SOLUTION;ORAL

VITRAKVI

+	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CAIN
+		EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CPOT

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

AT	AUROBINDO PHARMA LTD	0.005%	A206519	001	Sep 03, 2019	Aug NEWA
----	----------------------	--------	---------	-----	--------------	----------

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC

ROCKLATAN

+	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	Mar NEWA
---	------------------	----------------------	---------	-----	--------------	----------

LEDIPASVIR; SOFOSBUVIR

PELLETS;ORAL

HARVONI

+	GILEAD SCIENCES INC	33.75MG;150MG/PACKET	N212477	001	Aug 28, 2019	Aug NEWA
+		45MG;200MG/PACKET	N212477	002	Aug 28, 2019	Aug NEWA

TABLET;ORAL

HARVONI

+	GILEAD SCIENCES INC	45MG;200MG	N205834	002	Aug 28, 2019	Aug NEWA
---	---------------------	------------	---------	-----	--------------	----------

LEFAMULIN ACETATE

SOLUTION;INTRAVENOUS

XENLETA

+	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Aug NEWA
---	---------	--------------------------------------	---------	-----	--------------	----------

TABLET;ORAL

XENLETA

+	NABRIVA	EQ 600MG BASE	N211672	001	Aug 19, 2019	Aug NEWA
---	---------	---------------	---------	-----	--------------	----------

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

AB	ABHAI LLC	10MG	A212453	001	Jun 03, 2019	May NEWA
AB		20MG	A212453	002	Jun 03, 2019	May NEWA
AB	ZYDUS	10MG	A212308	001	Apr 24, 2019	Apr NEWA
AB		20MG	A212308	002	Apr 24, 2019	Apr NEWA

LESINURAD

TABLET;ORAL

ZURAMPIC

+	@ IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015	Apr DISC
---	-----------------------	-------	---------	-----	--------------	----------

LETROZOLE

TABLET;ORAL

LETROZOLE

>D>	@ EUGIA PHARMA	2.5MG	A211717	001	Jan 11, 2019	Sep CMFD
>A>	AB	2.5MG	A211717	001	Jan 11, 2019	Sep CMFD
	@	2.5MG	A211717	001	Jan 11, 2019	Jul DISC
AB	FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011	Feb CAHN

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

AP	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Feb CPOT
----	--------------------	-----------------	---------	-----	--------------	----------

LEUPROLIDE ACETATEFOR SUSPENSION; INTRAMUSCULAR
LUTRATE DEPOT KIT

+ @ GP-PHARM SA 22.5MG/VIAL N205054 001 Aug 28, 2018 Jun DISC

LEVETIRACETAMINJECTABLE; INTRAVENOUS
KEPPRA

AP +! UCB INC 500MG/5ML (100MG/ML) N021872 001 Jul 31, 2006 Jun CDFR

LEVETIRACETAM

@ AKORN 500MG/5ML (100MG/ML) A209934 001 May 04, 2018 Aug DISC

AP 500MG/5ML (100MG/ML) A209934 001 May 04, 2018 Jun CDFR

AP AUROBINDO PHARMA LTD 500MG/5ML (100MG/ML) A204312 001 Feb 01, 2016 Jun CDFR

AP FRESENIUS KABI USA 500MG/5ML (100MG/ML) A090813 001 May 26, 2010 Jun CDFR

AP 500MG/5ML (100MG/ML) A090876 001 Aug 13, 2015 Jun CDFR

AP HAINAN POLY PHARM 500MG/5ML (100MG/ML) A209781 001 Mar 20, 2018 Jun CDFR

AP HIKMA FARMACEUTICA 500MG/5ML (100MG/ML) A090981 001 Oct 13, 2011 Jun CDFR

AP HOSPIRA INC 500MG/5ML (100MG/ML) A202869 001 Apr 06, 2012 Jun CDFR

AP JUBILANT GENERICS 500MG/5ML (100MG/ML) A206838 001 Jun 02, 2016 Jun CDFR

AP MICRO LABS 500MG/5ML (100MG/ML) A211954 001 Aug 09, 2019 Jul NEWA

AP MYLAN LABS LTD 500MG/5ML (100MG/ML) A203308 001 Sep 16, 2016 Jun CDFR

AP SAGENT PHARMS 500MG/5ML (100MG/ML) A091627 001 Jun 26, 2013 Jun CDFR

AP SUN PHARM INDS LTD 500MG/5ML (100MG/ML) A090754 001 Jun 16, 2010 Jun CDFR

AP X GEN PHARMS 500MG/5ML (100MG/ML) A091485 001 Aug 05, 2011 Jun CDFR

LEVETIRACETAM IN SODIUM CHLORIDE

AP AUROBINDO PHARMA LTD 500MG/100ML (5MG/ML) A207160 001 Jan 04, 2017 Jun CDFR

AP 1000MG/100ML (10MG/ML) A207160 002 Jan 04, 2017 Jun CDFR

AP 1500MG/100ML (15MG/ML) A207160 003 Jan 04, 2017 Jun CDFR

AP GLAND PHARMA LTD 500MG/100ML (5MG/ML) A206880 001 Oct 25, 2017 Jun CDFR

AP 1000MG/100ML (10MG/ML) A206880 002 Oct 25, 2017 Jun CDFR

AP 1500MG/100ML (15MG/ML) A206880 003 Oct 25, 2017 Jun CDFR

AP +! HQ SPECIALITY PHARMA 500MG/100ML (5MG/ML) N202543 001 Nov 09, 2011 Jun CDFR

AP +! 1000MG/100ML (10MG/ML) N202543 002 Nov 09, 2011 Jun CDFR

AP +! 1500MG/100ML (15MG/ML) N202543 003 Nov 09, 2011 Jun CDFR

SOLUTION; ORAL

LEVETIRACETAM

AA ANDA REPOSITORY 100MG/ML A079107 001 Jan 15, 2009 Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

>A> AB ANDA REPOSITORY 500MG A204511 001 Feb 23, 2016 Sep CAHN

>A> AB 750MG A204511 002 Feb 23, 2016 Sep CAHN

>A> AB HISUN PHARM HANGZHOU 500MG A207175 001 Sep 28, 2017 Sep CAHN

>A> AB 750MG A207175 002 Sep 28, 2017 Sep CAHN

>D> AB INTELLIPHARMACEUTICS 500MG A204511 001 Feb 23, 2016 Sep CAHN

>D> AB 750MG A204511 002 Feb 23, 2016 Sep CAHN

>D> AB PHARMTAK INC 500MG A207175 001 Sep 28, 2017 Sep CAHN

>D> AB 750MG A207175 002 Sep 28, 2017 Sep CAHN

LEVOBUNOLOL HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE

@ SANDOZ INC 0.5% A074850 001 Oct 28, 1996 May DISC

LEVOCARNITINESOLUTION; ORAL
LEVOCARNITINE

AA NOVITIUM PHARMA 1GM/10ML A211676 001 Aug 14, 2019 Jul NEWA

LEVOCARNITINE SF

AA NOVITIUM PHARMA 1GM/10ML A211676 002 Aug 14, 2019 Jul NEWA

LEVOCETIRIZINE DIHYDROCHLORIDESOLUTION; ORAL
LEVOCETIRIZINE HYDROCHLORIDE

AA HETERO LABS LTD III 2.5MG/5ML A210914 001 Apr 01, 2019 Mar NEWA

LEVOFLOXACINSOLUTION/DROPS; OPHTHALMIC
LEVOFLOXACIN

MICRO LABS LTD INDIA 1.5% A205600 001 Feb 27, 2019 Feb NEWA

TABLET;ORAL								
LEVOFLOXACIN								
AB	CELLTRION	250MG	A090367	001	Jun 20, 2011	Aug	CAHN	
AB		500MG	A090367	002	Jun 20, 2011	Aug	CAHN	
AB		750MG	A090367	003	Jun 20, 2011	Aug	CAHN	
AB	HEC PHARM	250MG	A204968	001	Feb 05, 2019	Jan	NEWA	
AB		500MG	A204968	002	Feb 05, 2019	Jan	NEWA	
AB		750MG	A204968	003	Feb 05, 2019	Jan	NEWA	
<u>LEVOLEUCOVORIN</u>								
POWDER; INTRAVENOUS								
KHAPZORY								
	+	ACROTECH	175MG/VIAL	N211226	001	Oct 19, 2018	Mar	CAHN
	+		300MG/VIAL	N211226	002	Oct 19, 2018	Mar	CAHN
<u>LEVOLEUCOVORIN CALCIUM</u>								
POWDER; INTRAVENOUS								
FUSILEV								
AP	+	ACROTECH	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar	CAHN
LEVOLEUCOVORIN CALCIUM								
	+	@ ACTAVIS LLC	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	Jun	DISC
AP		NANJING KING-FRIEND	EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Aug	NEWA
SOLUTION; INTRAVENOUS								
FUSILEV								
	+	@ ACROTECH	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	Mar	CAHN
	+	@	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	Mar	CAHN
LEVOLEUCOVORIN CALCIUM								
	@	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	Aug	DISC
	@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	Aug	DISC
AP		NANJING KING-FRIEND	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A211002	001	Aug 16, 2019	Aug	NEWA
AP			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A211002	002	Aug 16, 2019	Aug	NEWA
<u>LEVOMILNACIPRAN HYDROCHLORIDE</u>								
CAPSULE, EXTENDED RELEASE;ORAL								
FETZIMA								
	+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jun	CTEC
AB	+		EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan	CFTG
	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jun	CTEC
AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan	CFTG
	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jun	CTEC
AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan	CFTG
	+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jun	CTEC
AB	+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan	CFTG
LEVOMILNACIPRAN HYDROCHLORIDE								
	@	AMNEAL PHARMS CO	EQ 20MG BASE	A210790	001	Feb 04, 2019	Jun	DISC
AB			EQ 20MG BASE	A210790	001	Feb 04, 2019	Jan	NFTG
	@		EQ 40MG BASE	A210790	002	Feb 04, 2019	Jun	DISC
AB			EQ 40MG BASE	A210790	002	Feb 04, 2019	Jan	NFTG
	@		EQ 80MG BASE	A210790	003	Feb 04, 2019	Jun	DISC
AB			EQ 80MG BASE	A210790	003	Feb 04, 2019	Jan	NFTG
	@		EQ 120MG BASE	A210790	004	Feb 04, 2019	Jun	DISC
AB			EQ 120MG BASE	A210790	004	Feb 04, 2019	Jan	NFTG
<u>LEVONORGESTREL</u>								
TABLET;ORAL								
LEVONORGESTREL								
AB	!	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May	CAHN
<u>LEVORPHANOL TARTRATE</u>								
TABLET;ORAL								
LEVORPHANOL TARTRATE								
	@	SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018	Feb	DISC
	!		3MG	A074278	003	Jun 18, 2018	May	CMFD
	@		3MG	A074278	003	Jun 18, 2018	Feb	DISC

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

@ PAR STERILE PRODUCTS 200MCG/VIAL

A205366 001 Dec 07, 2015 Apr DISC

SOLUTION; INTRAVENOUS

LEVOTHYROXINE SODIUM

+! FRESENIUS KABI USA 100MCG/5ML (20MCG/ML)

N210632 001 Apr 11, 2019 Apr NEWA

+! 200MCG/5ML (40MCG/ML)

N210632 002 Apr 11, 2019 Apr NEWA

+! 500MCG/5ML (100MCG/ML)

N210632 003 Apr 11, 2019 Apr NEWA

SOLUTION; ORAL

TIROSINT-SOL

+ INSTITUT BIOCHIMIQUE 13MCG/ML

N206977 001 Dec 15, 2016 Jan CMFD

+ 25MCG/ML

N206977 002 Dec 15, 2016 Jan CMFD

+ 50MCG/ML

N206977 003 Dec 15, 2016 Jan CMFD

+ 75MCG/ML

N206977 004 Dec 15, 2016 Jan CMFD

+ 88MCG/ML

N206977 005 Dec 15, 2016 Jan CMFD

+ 100MCG/ML

N206977 006 Dec 15, 2016 Jan CMFD

+ 112MCG/ML

N206977 007 Dec 15, 2016 Jan CMFD

+ 125MCG/ML

N206977 008 Dec 15, 2016 Jan CMFD

+ 137MCG/ML

N206977 009 Dec 15, 2016 Jan CMFD

+ 150MCG/ML

N206977 010 Dec 15, 2016 Jan CMFD

+ 175MCG/ML

N206977 011 Dec 15, 2016 Jan CMFD

+! 200MCG/ML

N206977 012 Dec 15, 2016 Jan CMFD

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB2 @ AMNEAL PHARMS LLC

0.025MG

A210831 001 Feb 19, 2019 Jun DISC

AB1, 0.025MG

A210831 001 Feb 19, 2019 May CTEC

AB2 0.025MG

A210831 001 Feb 19, 2019 Feb NEWA

@

0.05MG

A210831 002 Feb 19, 2019 Jun DISC

AB2 0.05MG

A210831 002 Feb 19, 2019 May CTEC

AB1, 0.05MG

A210831 002 Feb 19, 2019 Feb NEWA

AB2

@

0.075MG

A210831 003 Feb 19, 2019 Jun DISC

AB2 0.075MG

A210831 003 Feb 19, 2019 May CTEC

AB1, 0.075MG

A210831 003 Feb 19, 2019 Feb NEWA

AB2

@

0.088MG

A210831 004 Feb 19, 2019 Jun DISC

AB2 0.088MG

A210831 004 Feb 19, 2019 May CTEC

AB1, 0.088MG

A210831 004 Feb 19, 2019 Feb NEWA

AB2

@

0.1MG

A210831 005 Feb 19, 2019 Jun DISC

AB2 0.1MG

A210831 005 Feb 19, 2019 May CTEC

AB1, 0.1MG

A210831 005 Feb 19, 2019 Feb NEWA

AB2

@

0.112MG

A210831 006 Feb 19, 2019 Jun DISC

AB2 0.112MG

A210831 006 Feb 19, 2019 May CTEC

AB1, 0.112MG

A210831 006 Feb 19, 2019 Feb NEWA

AB2

@

0.125MG

A210831 007 Feb 19, 2019 Jun DISC

AB2 0.125MG

A210831 007 Feb 19, 2019 May CTEC

AB1, 0.125MG

A210831 007 Feb 19, 2019 Feb NEWA

AB2

@

0.137MG

A210831 008 Feb 19, 2019 Jun DISC

AB2 0.137MG

A210831 008 Feb 19, 2019 May CTEC

AB1, 0.137MG

A210831 008 Feb 19, 2019 Feb NEWA

AB2

@

0.15MG

A210831 009 Feb 19, 2019 Jun DISC

AB2 0.15MG

A210831 009 Feb 19, 2019 May CTEC

AB1, 0.15MG

A210831 009 Feb 19, 2019 Feb NEWA

AB2

@

0.175MG

A210831 010 Feb 19, 2019 Jun DISC

AB2 0.175MG

A210831 010 Feb 19, 2019 May CTEC

AB1, 0.175MG

A210831 010 Feb 19, 2019 Feb NEWA

AB2

@

0.2MG

A210831 011 Feb 19, 2019 Jun DISC

AB2 0.2MG

A210831 011 Feb 19, 2019 May CTEC

AB1, 0.2MG

A210831 011 Feb 19, 2019 Feb NEWA

AB2

@

0.3MG

A210831 012 Feb 19, 2019 Jun DISC

AB2 0.3MG

A210831 012 Feb 19, 2019 May CTEC

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB1,		0.3MG	A210831	012	Feb 19, 2019	Feb NEWA
AB2						
>D> AB2	LUPIN ATLANTIS	0.025MG	A209713	001	Jan 18, 2019	Sep CTEC
>A> AB1,		0.025MG	A209713	001	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.025MG	A209713	001	Jan 18, 2019	Jan NEWA
>D> AB2		0.05MG	A209713	002	Jan 18, 2019	Sep CTEC
>A> AB1,		0.05MG	A209713	002	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.05MG	A209713	002	Jan 18, 2019	Jan NEWA
>D> AB2		0.075MG	A209713	003	Jan 18, 2019	Sep CTEC
>A> AB1,		0.075MG	A209713	003	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.075MG	A209713	003	Jan 18, 2019	Jan NEWA
>D> AB2		0.088MG	A209713	004	Jan 18, 2019	Sep CTEC
>A> AB1,		0.088MG	A209713	004	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.088MG	A209713	004	Jan 18, 2019	Jan NEWA
>D> AB2		0.1MG	A209713	005	Jan 18, 2019	Sep CTEC
>A> AB1,		0.1MG	A209713	005	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.1MG	A209713	005	Jan 18, 2019	Jan NEWA
>D> AB2		0.112MG	A209713	006	Jan 18, 2019	Sep CTEC
>A> AB1,		0.112MG	A209713	006	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.112MG	A209713	006	Jan 18, 2019	Jan NEWA
>D> AB2		0.125MG	A209713	007	Jan 18, 2019	Sep CTEC
>A> AB1,		0.125MG	A209713	007	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.125MG	A209713	007	Jan 18, 2019	Jan NEWA
>D> AB2		0.137MG	A209713	008	Jan 18, 2019	Sep CTEC
>A> AB1,		0.137MG	A209713	008	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.137MG	A209713	008	Jan 18, 2019	Jan NEWA
>D> AB2		0.15MG	A209713	009	Jan 18, 2019	Sep CTEC
>A> AB1,		0.15MG	A209713	009	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.15MG	A209713	009	Jan 18, 2019	Jan NEWA
>D> AB2		0.175MG	A209713	010	Jan 18, 2019	Sep CTEC
>A> AB1,		0.175MG	A209713	010	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.175MG	A209713	010	Jan 18, 2019	Jan NEWA
>D> AB2		0.2MG	A209713	011	Jan 18, 2019	Sep CTEC
>A> AB1,		0.2MG	A209713	011	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.2MG	A209713	011	Jan 18, 2019	Jan NEWA
>D> AB2		0.3MG	A209713	012	Jan 18, 2019	Sep CTEC
>A> AB1,		0.3MG	A209713	012	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.3MG	A209713	012	Jan 18, 2019	Jan NEWA
THYRO-TABS						
AB2, +	ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.05MG	N021116	002	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.075MG	N021116	003	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.088MG	N021116	010	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.1MG	N021116	004	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.112MG	N021116	011	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.125MG	N021116	005	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.137MG	N021116	012	Dec 07, 2004	Mar CAHN
AB4						
AB2, +		0.15MG	N021116	006	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.175MG	N021116	007	Oct 24, 2002	Mar CAHN
AB4						
AB2, +		0.2MG	N021116	008	Oct 24, 2002	Mar CAHN
AB4						
AB2, +!		0.3MG	N021116	009	Oct 24, 2002	Mar CAHN
AB4						
AB2, +	LLOYD	0.025MG	N021116	001	Oct 24, 2002	Feb CMFD
AB4						

TABLET;ORAL
THYRO-TABS

AB2, +	0.05MG	N021116	002	Oct 24, 2002	Feb CMFD
AB4					
AB2, +	0.075MG	N021116	003	Oct 24, 2002	Feb CMFD
AB4					
AB2, +	0.088MG	N021116	010	Oct 24, 2002	Feb CMFD
AB4					
AB2, +	0.1MG	N021116	004	Oct 24, 2002	Feb CMFD
AB4					
AB2, +	0.112MG	N021116	011	Oct 24, 2002	Feb CMFD
AB4					
AB2, +	0.125MG	N021116	005	Oct 24, 2002	Feb CMFD
AB4					
AB2, +	0.137MG	N021116	012	Dec 07, 2004	Feb CMFD
AB4					
AB2, +	0.15MG	N021116	006	Oct 24, 2002	Feb CMFD
AB4					
AB2, +	0.175MG	N021116	007	Oct 24, 2002	Feb CMFD
AB4					
AB2, +	0.2MG	N021116	008	Oct 24, 2002	Feb CMFD
AB4					
AB2, +!	0.3MG	N021116	009	Oct 24, 2002	Feb CMFD
AB4					

LIDOCAINE

OINTMENT;TOPICAL
LIDOCAINE

>A> AT	NOVAST LABS	5%	A208604	001	Sep 20, 2017	Sep CAHN
>D> AT	RICONPHARMA LLC	5%	A208604	001	Sep 20, 2017	Sep CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	1%	A080404	002		Jun CTNA
AP		2%	A080404	003		Jun CTNA
>D> AP	HOSPIRA	1%	A083158	001		Sep CHRS
>A> AP	!	1%	A083158	001		Sep CHRS
>D> AP		2%	A083158	002		Sep CHRS
>A> AP	!	2%	A083158	002		Sep CHRS
>D> AP		20%	A083158	003		Sep DISC
>A>	@	20%	A083158	003		Sep DISC
	@ LUITPOLD	1%	A080850	001		Mar DISC
	@	1%	A091564	001	Aug 14, 2015	Feb DISC
>D>	XYLOCAINE PRESERVATIVE FREE					
>D> AP	+! FRESENIUS KABI USA	1%	N016801	005	Jan 19, 1988	Sep DISC
>A>	+ @	1%	N016801	005	Jan 19, 1988	Sep DISC
>D> AP	+!	2%	N016801	001		Sep DISC
>A>	+ @	2%	N016801	001		Sep DISC
>D> AP	+!	4%	N016801	002		Sep DISC
>A>	+ @	4%	N016801	002		Sep DISC
>D> AP	+!	20%	N016801	004		Sep DISC
>A>	+ @	20%	N016801	004		Sep DISC

JELLY;TOPICAL
ANESTACON

@ BIONPHARMA INC

2%

A080429 001

Apr CAHN

SOLUTION;ORAL

XYLOCAINE VISCOUS

+ @ FRESENIUS KABI USA

2%

N009470 001

Aug CRLD

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

>D> @ LANNETT CO INC

4%

A040710 001

Feb 27, 2007

Sep CMFD

>A> AT

4%

A040710 001

Feb 27, 2007

Sep CMFD

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL
EMLA

AB +! TEVA BRANDED PHARM 2.5%;2.5%

N019941 001

Dec 30, 1992

Apr CAHN

LIFITEGRASTSOLUTION/DROPS;OPHTHALMIC
XIIDRA

>A>	+	NOVARTIS	5%	N208073	001	Jul 11, 2016	Sep CAHN
>D>	+	SHIRE DEV LLC	5%	N208073	001	Jul 11, 2016	Sep CAHN

LINEZOLIDTABLET;ORAL
LINEZOLID

AB		CELLTRION	600MG	A210702	001	Apr 25, 2019	Apr NEWA
	@	MYLAN	600MG	A078845	001	Dec 21, 2015	Jun DISC

LIOETHYRONINE SODIUMTABLET;ORAL
CYTOMEL

AB	+	KING PHARMS	EQ 0.05MG BASE	N010379	003		Jun CHRS
		LIOETHYRONINE SODIUM					
	@	MYLAN	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Mar DISC
	@		EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Mar DISC
	@		EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Mar DISC
AB	!	SIGMAPHARM LABS LLC	EQ 0.05MG BASE	A200295	003	Nov 29, 2012	Jun CHRS
	@	SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jun DISC
	@		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jun DISC
	@		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jun DISC
	@	TEVA PHARMS USA	EQ 0.005MG BASE	A211510	001	Oct 26, 2018	Apr DISC
	@		EQ 0.025MG BASE	A211510	002	Oct 26, 2018	Apr DISC
	@		EQ 0.05MG BASE	A211510	003	Oct 26, 2018	Apr DISC

LISINOPRILTABLET;ORAL
LISINOPRIL

	@	HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Aug DISC
AB			2.5MG	A075752	001	Jul 01, 2002	Feb CAHN
	@		5MG	A075752	002	Jul 01, 2002	Aug DISC
AB			5MG	A075752	002	Jul 01, 2002	Feb CAHN
	@		10MG	A075752	003	Jul 01, 2002	Aug DISC
AB			10MG	A075752	003	Jul 01, 2002	Feb CAHN
	@		20MG	A075752	004	Jul 01, 2002	Aug DISC
AB			20MG	A075752	004	Jul 01, 2002	Feb CAHN
	@		30MG	A075752	005	Jul 01, 2002	Aug DISC
AB			30MG	A075752	005	Jul 01, 2002	Feb CAHN
	@		40MG	A075752	006	Jul 01, 2002	Aug DISC
AB			40MG	A075752	006	Jul 01, 2002	Feb CAHN
	@	MYLAN	2.5MG	A076071	001	Jul 01, 2002	Aug DISC
	@		5MG	A076071	002	Jul 01, 2002	Aug DISC
	@		10MG	A076071	003	Jul 01, 2002	Aug DISC
	@		20MG	A076071	004	Jul 01, 2002	Aug DISC
	@		30MG	A076071	005	Jul 01, 2002	Aug DISC
	@		40MG	A076071	006	Jul 01, 2002	Aug DISC

LITHIUM CARBONATECAPSULE;ORAL
LITHIUM CARBONATE

AB	+	HIKMA	150MG	N017812	002	Jan 28, 1987	Apr CAHN
AB	+		300MG	N017812	001		Apr CAHN
AB	+		600MG	N017812	003	Jan 28, 1987	Apr CAHN
	@	MYLAN	600MG	A078763	001	Apr 15, 2008	Jun DISC

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

@	HERITAGE PHARMA	300MG
@		450MG

A076170	001	Jun 10, 2002	May CAHN
A076366	001	Aug 21, 2003	May CAHN

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	+	HIKMA	EQ 300MG CARBONATE/5ML	N018421	001		Apr CAHN
----	---	-------	------------------------	---------	-----	--	----------

LORAZEPAMCONCENTRATE; ORAL
LORAZEPAM

AA	LANNETT CO INC	2MG/ML	A 079244	001	Apr 28, 2009	Jul CAHN
AA	SAPTALIS PHARMS	2MG/ML	A 079244	001	Apr 28, 2009	Feb CAHN

INJECTABLE; INJECTION
ATIVAN

AP	+! HIKMA	2MG/ML	N 018140	001		Mar CAHN
AP	+!	4MG/ML	N 018140	002		Mar CAHN

TABLET; ORAL
ATIVAN

AB	+ BAUSCH	0.5MG	N 017794	001		Feb CAHN
AB	+	1MG	N 017794	002		Feb CAHN
AB	+!	2MG	N 017794	003		Feb CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	MICRO LABS	25MG	A 091541	001	Sep 24, 2012	Mar CAHN
AB		50MG	A 091541	002	Sep 24, 2012	Mar CAHN
AB		100MG	A 091541	003	Sep 24, 2012	Mar CAHN
AB	STRIDES PHARMA	25MG	A 090382	001	Oct 06, 2010	Apr CAHN
AB		50MG	A 090382	002	Oct 06, 2010	Apr CAHN
AB		100MG	A 090382	003	Oct 06, 2010	Apr CAHN
	@ TEVA	25MG	A 076958	001	Apr 06, 2010	Jul DISC
	@	50MG	A 076958	002	Apr 06, 2010	Jul DISC
	@	100MG	A 076958	003	Apr 06, 2010	Jul DISC

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX SM

+! BAUSCH AND LOMB INC 0.38%

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

AB	+! BAUSCH AND LOMB	0.5%	N 020583	001	Mar 09, 1998	Apr CFTG
AB	LOTEPREDNOL ETABONATE					
AB	HI TECH	0.5%	A 207609	001	Apr 17, 2019	Apr NFTG

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	BEXIMCO PHARMS USA	10MG	A 075300	001	Dec 17, 2001	Feb CAHN
AB		20MG	A 075300	002	Dec 17, 2001	Feb CAHN
AB		40MG	A 075300	003	Dec 17, 2001	Feb CAHN
	@ MYLAN	10MG	A 075451	001	Dec 17, 2001	Feb DISC
	@	20MG	A 075451	002	Dec 17, 2001	Feb DISC
	@	40MG	A 075451	003	Dec 17, 2001	Feb DISC

LOXAPINE

POWDER; INHALATION

ADASUVE

+! ALEXZA PHARMS 10MG

N 022549	001	Dec 21, 2012	Aug CAHN
----------	-----	--------------	----------

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

@ TEVA BRANDED PHARM EQ 25MG BASE/ML

N 017658	001		Feb CAHN
----------	-----	--	----------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

+ @ TEVA BRANDED PHARM	EQ 5MG BASE
+ @	EQ 10MG BASE
+ @	EQ 25MG BASE
+ @	EQ 50MG BASE

N 017525	001		Feb CAHN
N 017525	002		Feb CAHN
N 017525	003		Feb CAHN
N 017525	004		Feb CAHN

TABLET; ORAL

LOXITANE

+ @ TEVA BRANDED PHARM	EQ 10MG BASE
+ @	EQ 25MG BASE
+ @	EQ 50MG BASE
+ @	EQ 50MG BASE

N 017525	006		Feb CAHN
N 017525	007		Feb CAHN
N 017525	008		Feb CAHN
N 017525	008		Feb CAHN

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

	@	AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Jun DISC
	@		40MG	A208002	002	Jan 03, 2019	Jun DISC
	@		60MG	A208002	003	Jan 03, 2019	Jun DISC
	@		80MG	A208002	004	Jan 03, 2019	Jun DISC
	@		120MG	A208002	005	Jan 03, 2019	Jun DISC
>D> AB		EMCURE PHARMS LTD	20MG	A208058	001	Sep 04, 2019	Sep DISC
>A>	@		20MG	A208058	001	Sep 04, 2019	Sep DISC
AB			20MG	A208058	001	Sep 04, 2019	Aug NEWA
>D> AB			40MG	A208058	002	Sep 04, 2019	Sep DISC
>A>	@		40MG	A208058	002	Sep 04, 2019	Sep DISC
AB			40MG	A208058	002	Sep 04, 2019	Aug NEWA
>D> AB			60MG	A208058	003	Sep 04, 2019	Sep DISC
>A>	@		60MG	A208058	003	Sep 04, 2019	Sep DISC
AB			60MG	A208058	003	Sep 04, 2019	Aug NEWA
>D> AB			80MG	A208058	004	Sep 04, 2019	Sep DISC
>A>	@		80MG	A208058	004	Sep 04, 2019	Sep DISC
AB			80MG	A208058	004	Sep 04, 2019	Aug NEWA
	@	INVAGEN PHARMS	20MG	A208028	001	Jan 03, 2019	Jul DISC
	@		40MG	A208028	002	Jan 03, 2019	Jul DISC
	@		60MG	A208028	003	Jan 03, 2019	Jul DISC
	@		80MG	A208028	004	Jan 03, 2019	Jul DISC
	@		120MG	A208028	005	Jan 03, 2019	Jul DISC
	@	LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Jul DISC
	@		40MG	A208031	002	Jan 03, 2019	Jul DISC
	@		60MG	A208031	003	Jan 03, 2019	Jul DISC
	@		80MG	A208031	004	Jan 03, 2019	Jul DISC
	@		120MG	A208031	005	Jan 03, 2019	Jul DISC
AB		TEVA PHARMS USA	20MG	A208060	001	May 17, 2019	May NEWA
AB			40MG	A208060	002	May 17, 2019	May NEWA
AB			60MG	A208060	003	May 17, 2019	May NEWA
AB			80MG	A208060	004	May 17, 2019	May NEWA
AB			120MG	A208060	005	May 17, 2019	May NEWA
	@	TORRENT	20MG	A208055	001	Jan 03, 2019	Feb DISC
	@		40MG	A208055	002	Jan 03, 2019	Feb DISC
	@		80MG	A208055	003	Jan 03, 2019	Feb DISC
	@		120MG	A208055	004	Jan 03, 2019	Feb DISC
	@	ZYDUS PHARMS	20MG	A208052	001	Mar 19, 2019	Aug DISC
AB			20MG	A208052	001	Mar 19, 2019	Mar NEWA
	@		40MG	A208052	002	Mar 19, 2019	Aug DISC
AB			40MG	A208052	002	Mar 19, 2019	Mar NEWA
	@		60MG	A208052	003	Mar 19, 2019	Aug DISC
AB			60MG	A208052	003	Mar 19, 2019	Mar NEWA
	@		80MG	A208052	004	Mar 19, 2019	Aug DISC
AB			80MG	A208052	004	Mar 19, 2019	Mar NEWA
	@		120MG	A208052	005	Mar 19, 2019	Aug DISC
AB			120MG	A208052	005	Mar 19, 2019	Mar NEWA

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan CTEC
AP		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Jan CTEC

MALATHION

LOTION; TOPICAL

MALATHION

!	SUVEN LIFE	0.5%	A091559	001	May 23, 2012	Aug CHRS
		0.5%	A091559	001	May 23, 2012	Aug CTEC
	OVIDE					
+	@ TARO PHARM INDS LTD	0.5%	N018613	001	Aug 02, 1982	Aug DISC

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

@	LUITPOLD	12.5GM/50ML	A087409	001	Jan 21, 1982	Mar DISC
---	----------	-------------	---------	-----	--------------	----------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

AA	+	CASPER PHARMA LLC	12.5MG	N010721	006		Feb	CMFD
	+	@	12.5MG	N010721	006		Jan	CRLD
AA	+		25MG	N010721	004		Feb	CMFD
	+	@	25MG	N010721	004		Jan	CRLD
AA	+		50MG	N010721	001	Jan 20, 1982	Feb	CMFD
	+	@	50MG	N010721	001	Jan 20, 1982	Jan	CRLD

MECLIZINE HYDROCHLORIDE

AA	!	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Jan	CHRS
AA	!		25MG	A201451	002	Feb 23, 2011	Jan	CHRS
>A>	@	ANI PHARMS INC	12.5MG	A084657	002		Sep	CMS1
	@		12.5MG	A088732	001	Dec 11, 1985	May	CAHN
AA		INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	Feb	NEWA
AA			25MG	A205136	002	Feb 22, 2019	Feb	NEWA
			50MG	A205136	003	Feb 22, 2019	Feb	NEWA

TABLET, CHEWABLE; ORAL

ANTIVERT

AA	+	CASPER PHARMA LLC	25MG	N010721	005		Feb	CMFD
	+	@	25MG	N010721	005		Jan	CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

	@	CIPLA	150MG/ML	A210335	001	Jan 25, 2019	Jul	DISC
AB			150MG/ML	A210335	001	Jan 25, 2019	Jan	NEWA
AB		SUN PHARM	150MG/ML	A210760	001	May 01, 2019	Apr	NEWA
AB			150MG/ML	A210761	001	Apr 24, 2019	Apr	NEWA

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

	@	UPSHER SMITH LABS	10MG	A088484	001	Jul 26, 1984	Jul	CAHN
--	---	-------------------	------	---------	-----	--------------	-----	------

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

	@	BRECKENRIDGE	250MG	A090359	001	Feb 05, 2013	Feb	DISC
--	---	--------------	-------	---------	-----	--------------	-----	------

MELOXICAM

CAPSULE; ORAL

VIVLODEX

	+	EGALET	5MG	N207233	001	Oct 22, 2015	Feb	CAHN
	+	!	10MG	N207233	002	Oct 22, 2015	Feb	CAHN
	+	ZYLA	5MG	N207233	001	Oct 22, 2015	Jul	CAHN
	+	!	10MG	N207233	002	Oct 22, 2015	Jul	CAHN

SUSPENSION; ORAL

MOBIC

	+	@	AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004	Jun	CAHN
--	---	---	-----------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

MELOXICAM

>D>	AB	HERITAGE PHARMA	7.5MG	A077936	001	Jul 19, 2006	Sep	DISC
>A>		@	7.5MG	A077936	001	Jul 19, 2006	Sep	DISC
	AB		7.5MG	A077936	001	Jul 19, 2006	Feb	CAHN
>D>	AB		15MG	A077936	002	Jul 19, 2006	Sep	DISC
>A>		@	15MG	A077936	002	Jul 19, 2006	Sep	DISC
	AB		15MG	A077936	002	Jul 19, 2006	Feb	CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

AP	+	APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Feb	CMFD
		MELPHALAN HYDROCHLORIDE						
AP		ALVOGEN INC	EQ 50MG BASE/VIAL	A204817	001	May 17, 2019	May	NEWA
AP		GLAND PHARMA LTD	EQ 50MG BASE/VIAL	A209826	001	May 28, 2019	May	NEWA
>A>	AP	NORATECH	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep	NEWA
AP		US WORLDMEDS LLC	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019	Apr	NEWA

POWDER; INTRAVENOUS

EVOMELA

	+	!	ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar	CAHN
--	---	---	----------	-------------------	---------	-----	--------------	-----	------

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL					
MEMANTINE HYDROCHLORIDE					
AA	! TORRENT	2MG/ML	A205446	001	Dec 07, 2015 Jan CAHN
TABLET; ORAL					
MEMANTINE HYDROCHLORIDE					
	@ APOTEX INC	5MG	A090244	001	Jul 11, 2018 Jan DISC
	@	10MG	A090244	002	Jul 11, 2018 Jan DISC
AB	CADILA	5MG	A090961	001	Jul 10, 2017 Feb CAHN
AB		10MG	A090961	002	Jul 10, 2017 Feb CAHN
AB	CELLTRION	5MG	A090073	001	Sep 04, 2015 Aug CAHN
AB		10MG	A090073	002	Sep 04, 2015 Aug CAHN

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL					
DEMEROL					
	+ @ US PHARM HOLDINGS	50MG	N005010	001	Aug DISC
	+ @	100MG	N005010	004	Aug DISC
MEPERIDINE HYDROCHLORIDE					
	@ SPECGX LLC	50MG	A040352	001	Jun 13, 2000 Aug DISC
	@	100MG	A040352	002	Jun 13, 2000 Aug DISC
AA	! WEST-WARD PHARMS INT	50MG	A040110	001	Mar 12, 1997 Aug CHRS
AA	!	100MG	A040110	002	Mar 12, 1997 Aug CHRS

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION					
MEPERGAN					
	@ HIKMA	25MG/ML; 25MG/ML	N011730	001	Jun CAHN

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL					
SOLAGE					
	@ ALMIRALL	2%; 0.01%	N020922	001	Dec 10, 1999 Feb CAHN

MEROPENEM

INJECTABLE; INJECTION					
MEROPENEM					
>D> AP	HOSPIRA INC	500MG/VIAL	A090940	001	Jun 22, 2010 Sep DISC
>A>	@	500MG/VIAL	A090940	001	Jun 22, 2010 Sep DISC
>D> AP		1GM/VIAL	A090940	002	Jun 22, 2010 Sep DISC
>A>	@	1GM/VIAL	A090940	002	Jun 22, 2010 Sep DISC
AP	HQ SPCLT PHARMA	500MG/VIAL	A210773	001	Aug 16, 2019 Aug NEWA
AP		1GM/VIAL	A210773	002	Aug 16, 2019 Aug NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL					
DELZICOL					
AB	+! APIL	400MG	N204412	001	Feb 01, 2013 Apr CFTG
MESALAMINE					
AB	TEVA PHARMS USA	400MG	A207873	001	May 09, 2019 Apr NFTG
SUPPOSITORY; RECTAL					
MESALAMINE					
AB	AMRING PHARMS	1GM	A208362	001	Jun 21, 2019 Jun NEWA
AB	PHARM SOURCING	1GM	A207448	001	Apr 19, 2019 Apr NEWA
AB	SANDOZ INC	1GM	A202065	001	Jun 12, 2019 May NEWA
TABLET, DELAYED RELEASE; ORAL					
MESALAMINE					
	@ SUN PHARM	1.2GM	A211858	001	Jan 25, 2019 Aug DISC
AB		1.2GM	A211858	001	Jan 25, 2019 Jan NEWA

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28					
NORINYL 1+50 28-DAY					
	+ @ ACTAVIS LABS UT INC	0.05MG; 1MG	N016659	001	Jul DISC

METAPROTERENOL SULFATE

TABLET;ORAL

METAPROTERENOL SULFATE

@ HERITAGE PHARMA 10MG
 @ 20MG
 @ PAR PHARM 10MG
 @ 20MG

A072519 001 Mar 30, 1990 May CAHN
 A072520 001 Mar 30, 1990 May CAHN
 A072024 001 Jun 28, 1988 Jul DISC
 A072025 001 Jun 28, 1988 Jul DISC

METAXALONE

TABLET;ORAL

METAXALONE

AB APPCO PHARMA LLC 800MG

A208774 001 Sep 24, 2018 Feb CAHN

METFORMIN HYDROCHLORIDE

FOR SUSPENSION, EXTENDED RELEASE;ORAL

RIOMET ER

+! SUN PHARM 500MG/5ML

N212595 001 Aug 29, 2019 Aug NEWA

TABLET;ORAL

GLUCOPHAGE

+ @ BRISTOL MYERS SQUIBB 500MG
 + @ 850MG
 + @ 1GM
 + @ EMD SERONO INC 500MG
 + @ 625MG
 + @ 750MG
 + @ 850MG
 + @ 1GM

N020357 001 Mar 03, 1995 Jun DISC
 N020357 002 Mar 03, 1995 Jun DISC
 N020357 005 Nov 05, 1998 Jun DISC
 N020357 001 Mar 03, 1995 Jul CAHN
 N020357 003 Nov 05, 1998 Jul CAHN
 N020357 004 Nov 05, 1998 Jul CAHN
 N020357 002 Mar 03, 1995 Jul CAHN
 N020357 005 Nov 05, 1998 Jul CAHN

METFORMIN HYDROCHLORIDE

AB ! GRANULES INDIA 1GM
 AB HERITAGE PHARMA 500MG
 AB 850MG
 AB 1GM
 @ SUNSHINE LAKE 500MG
 @ 850MG
 @ 1GM

A090564 003 Apr 22, 2010 Jun CHRS
 A075978 001 Jan 25, 2002 Feb CAHN
 A075978 002 Jan 25, 2002 Feb CAHN
 A075978 003 Nov 05, 2002 Feb CAHN
 A208999 001 Oct 12, 2018 Apr DISC
 A208999 002 Oct 12, 2018 Apr DISC
 A208999 003 Oct 12, 2018 Apr DISC

TABLET, EXTENDED RELEASE;ORAL

GLUCOPHAGE XR

+ @ BRISTOL MYERS SQUIBB 500MG
 + @ 750MG
 + @ EMD SERONO INC 500MG
 + @ 750MG

N021202 001 Oct 13, 2000 Jun DISC
 N021202 004 Apr 11, 2003 Jun DISC
 N021202 001 Oct 13, 2000 Jul CAHN
 N021202 004 Apr 11, 2003 Jul CAHN

METFORMIN HYDROCHLORIDE

AB ! AMNEAL PHARMS NY 750MG
 AB1 CADILA 500MG
 AB 750MG
 AB1 INVENTIA 500MG
 AB2 ! LUPIN LTD 1GM
 >D> AB1 ! SUN PHARM INDS (IN) 500MG
 >A> AB1 500MG
 AB1 ! 500MG
 @ YICHANG HUMANWELL 500MG
 @ 750MG

A078596 002 Jan 03, 2008 Jun CHRS
 A077060 001 Apr 20, 2005 Feb CAHN
 A077078 001 Apr 21, 2005 Feb CAHN
 A201991 001 Jan 18, 2012 Aug CAHN
 A090692 002 Jun 29, 2011 Apr CHRS
 A077336 001 Feb 09, 2006 Sep CHRS
 A077336 001 Feb 09, 2006 Sep CHRS
 A077336 001 Feb 09, 2006 Jun CHRS
 A211052 001 Sep 24, 2018 Mar DISC
 A211052 002 Sep 24, 2018 Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

@ MYLAN 500MG;EQ 15MG BASE
 @ 850MG;EQ 15MG BASE

A090406 001 Feb 25, 2011 Jul DISC
 A090406 002 Feb 25, 2011 Jul DISC

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+ @ TAKEDA PHARMS USA 1GM;EQ 15MG BASE
 + @ 1GM;EQ 30MG BASE

N022024 001 May 12, 2009 Mar DISC
 N022024 002 May 12, 2009 Mar DISC

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA PHARM ASSOC 10MG/ML

A207368 001 Aug 22, 2019 Aug NEWA

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

>A> AA PHARM ASSOC 5MG/5ML
 >A> AA 10MG/5ML

A207537 001 Oct 02, 2019 Sep NEWA
 A207537 002 Oct 01, 2019 Sep NEWA

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

@ MICRO LABS

25MG

A207438 001 Oct 05, 2018 Mar DISC

@

50MG

A207438 002 Oct 05, 2018 Mar DISC

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB MICRO LABS

1GM

A212172 001 Aug 01, 2019 Jul NEWA

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP SLATE

1GM/10ML (100MG/ML)

A208116 001 Jan 19, 2017 Feb CAHN

ROBAXIN

AP +! HIKMA

1GM/10ML (100MG/ML)

N011790 001 Feb CAHN

TABLET; ORAL

METHOCARBAMOL

>A> AA ANI PHARMS INC

500MG

A084277 001 Sep CAHN

AA ! GRANULES INDIA LTD

500MG

A209312 001 May 07, 2018 Jul CHRS

>D> AA WATSON LABS

500MG

A084277 001 Sep CAHN

ROBAXIN

+ @ AUXILIUM PHARMS LLC

500MG

N011011 004 Jul DISC

METHOTREXATE

SOLUTION; SUBCUTANEOUS

RASUVO

+! MEDEXUS

7.5MG/0.15ML (7.5MG/0.15ML)

N205776 001 Jul 10, 2014 Apr CAHN

+!

10MG/0.20ML (10MG/0.20ML)

N205776 002 Jul 10, 2014 Apr CAHN

+!

12.5MG/0.25ML (12.5MG/0.25ML)

N205776 003 Jul 10, 2014 Apr CAHN

+!

15MG/0.30ML (15MG/0.30ML)

N205776 004 Jul 10, 2014 Apr CAHN

+!

17.5MG/0.35ML (17.5MG/0.35ML)

N205776 005 Jul 10, 2014 Apr CAHN

+!

20MG/0.4ML (20MG/0.4ML)

N205776 006 Jul 10, 2014 Apr CAHN

+!

22.5MG/0.45ML (22.5MG/0.45ML)

N205776 007 Jul 10, 2014 Apr CAHN

+!

25MG/0.5ML (25MG/0.5ML)

N205776 008 Jul 10, 2014 Apr CAHN

+ @

27.5MG/0.55ML (27.5MG/0.55ML)

N205776 009 Jul 10, 2014 Apr CAHN

+!

30MG/0.6ML (30MG/0.6ML)

N205776 010 Jul 10, 2014 Apr CAHN

METHOXSALEN

CAPSULE; ORAL

OXSORALEN-ULTRA

AB +! BAUSCH

10MG

N019600 001 Oct 30, 1986 Aug CAHN

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

@ BRECKENRIDGE PHARM

2.5MG

A040642 001 Dec 06, 2011 Jun DISC

@

5MG

A040642 002 Dec 06, 2011 Jun DISC

METHYLDOPA

TABLET; ORAL

METHYLDOPA

AB HERITAGE PHARMA

250MG

A070098 001 Feb 20, 1986 Feb CAHN

AB

500MG

A070343 001 Feb 20, 1986 Feb CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ LUITPOLD

50MG/ML

A071279 001 Oct 02, 1987 Mar DISC

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHYLERGONOVINE MALEATE

AB TEVA PHARMS USA

0.2MG

A211455 001 Mar 20, 2019 Mar NEWA

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
ADHANSIA XR

+	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019	Mar	CRLD
		25MG	N212038	001	Feb 27, 2019	Feb	NEWA
+		35MG	N212038	002	Feb 27, 2019	Feb	NEWA
+		45MG	N212038	003	Feb 27, 2019	Feb	NEWA
+		55MG	N212038	004	Feb 27, 2019	Feb	NEWA
+		70MG	N212038	005	Feb 27, 2019	Feb	NEWA
+		85MG	N212038	006	Feb 27, 2019	Feb	NEWA

METHYLPHENIDATE HYDROCHLORIDE

AB1	GRANULES PHARMS	10MG	A211796	001	May 23, 2019	May	NEWA
AB1		20MG	A211796	002	May 23, 2019	May	NEWA
AB1		30MG	A211796	003	May 23, 2019	May	NEWA
AB1		40MG	A211796	004	May 23, 2019	May	NEWA
AB1		60MG	A211796	005	May 23, 2019	May	NEWA
AB1	! MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	May	CTEC

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018	Jan	DISC
	QUILLIVANT XR						
+	! NEXTWAVE	5MG/ML	N202100	001	Sep 27, 2012	Feb	CAHN
+	! NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012	Jan	CTEC

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AA	NOVELGENIX THERAPS	5MG/5ML	A210139	001	Oct 03, 2018	Sep	CAHN
>A>	AA		10MG/5ML	A210139	002	Oct 03, 2018	Sep	CAHN
>D>	AA	WES PHARMA INC	5MG/5ML	A210139	001	Oct 03, 2018	Sep	CAHN
>D>	AA		10MG/5ML	A210139	002	Oct 03, 2018	Sep	CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	ALKEM LABS LTD	5MG	A211779	001	Oct 04, 2019	Sep	NEWA
>A>	AB		10MG	A211779	002	Oct 04, 2019	Sep	NEWA
>A>	AB		20MG	A211779	003	Oct 04, 2019	Sep	NEWA
		@ AUROLIFE PHARMA LLC	5MG	A209276	001	Oct 25, 2018	Apr	DISC
		@	10MG	A209276	002	Oct 25, 2018	Apr	DISC
		@	20MG	A209276	003	Oct 25, 2018	Apr	DISC
		@ CEDIPROF INC	5MG	A208737	001	Feb 01, 2019	Aug	DISC
AB			5MG	A208737	001	Feb 01, 2019	Jan	NEWA
		@	10MG	A208737	002	Feb 01, 2019	Aug	DISC
AB			10MG	A208737	002	Feb 01, 2019	Jan	NEWA
		@	20MG	A208737	003	Feb 01, 2019	Aug	DISC
AB			20MG	A208737	003	Feb 01, 2019	Jan	NEWA
		@ LANNETT CO INC	5MG	A086429	001		Jan	DISC
		@	10MG	A085799	001		Jan	DISC
		@	20MG	A086428	001		Jan	DISC

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

@	LANNETT CO INC	20MG	A089601	001	Jun 01, 1988	Jan	DISC
	METHYLPHENIDATE HYDROCHLORIDE						
AB	! ABHAI LLC	20MG	A207488	002	Jun 09, 2015	Jan	NEWA
AB	ANDOR PHARMS	18MG	A211918	001	Apr 24, 2019	Apr	NEWA
AB		27MG	A211918	002	Apr 24, 2019	Apr	NEWA
AB		36MG	A211918	003	Apr 24, 2019	Apr	NEWA
AB		54MG	A211918	004	Apr 24, 2019	Apr	NEWA
AB	ASCENT PHARMS INC	18MG	A211009	001	Sep 03, 2019	Aug	NEWA
AB		27MG	A211009	002	Sep 03, 2019	Aug	NEWA
AB		36MG	A211009	003	Sep 03, 2019	Aug	NEWA
AB		54MG	A211009	004	Sep 03, 2019	Aug	NEWA
	@ HERITAGE PHARMA	20MG	A075450	001	Dec 21, 2001	May	CAHN
AB	PAR PHARM	36MG	A204659	001	Jul 15, 2019	Jul	NEWA
AB		54MG	A204659	002	Jul 15, 2019	Jul	NEWA

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB	+	PHARMACIA AND UPJOHN	2MG	N011153	002		Mar	CFTG
		METHYLPREDNISOLONE						
>D>	AB	LUPIN LTD	2MG	A209097	001	Feb 22, 2019	Sep	DISC
>A>		@	2MG	A209097	001	Feb 22, 2019	Sep	DISC
AB			2MG	A209097	001	Feb 22, 2019	Mar	NFTG

TABLET; ORAL

METHYLPREDNISOLONE

AB		2MG	A209097	001	Feb 22, 2019	Feb NEWA
>D>	AB	4MG	A209097	002	Feb 22, 2019	Sep DISC
>A>	@	4MG	A209097	002	Feb 22, 2019	Sep DISC
AB		4MG	A209097	002	Feb 22, 2019	Feb NEWA
>D>	AB	8MG	A209097	003	Feb 22, 2019	Sep DISC
>A>	@	8MG	A209097	003	Feb 22, 2019	Sep DISC
AB		8MG	A209097	003	Feb 22, 2019	Feb NEWA
>D>	AB	16MG	A209097	004	Feb 22, 2019	Sep DISC
>A>	@	16MG	A209097	004	Feb 22, 2019	Sep DISC
AB		16MG	A209097	004	Feb 22, 2019	Feb NEWA
>D>	AB	32MG	A209097	005	Feb 22, 2019	Sep DISC
>A>	@	32MG	A209097	005	Feb 22, 2019	Sep DISC
AB		32MG	A209097	005	Feb 22, 2019	Feb NEWA
>A>	AB	NOVAST LABS	A210985	001	Jan 09, 2019	Sep CAHN
>D>	AB	RICONPHARMA LLC	A210985	001	Jan 09, 2019	Sep CAHN
AB		SUNGEN PHARMA	A212262	001	Jun 27, 2019	Jun NEWA
AB		TIANJIN TIANYAO	A204072	001	May 14, 2018	Apr CMFD

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

	@	AMNEAL PHARMS CO	40MG/ML	A210043	001	May 20, 2019	Jul DISC
AB			40MG/ML	A210043	001	May 20, 2019	May NEWA
	@		80MG/ML	A210043	002	May 20, 2019	Jul DISC
AB			80MG/ML	A210043	002	May 20, 2019	May NEWA

METHYLTESTOSTERONE

CAPSULE; ORAL

VIRILON

@	CHARTWELL	10MG	A087750	001	Nov 24, 1982	Jun CAHN
---	-----------	------	---------	-----	--------------	----------

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

@	SANDOZ INC	0.3%	A075720	001	Aug 06, 2001	May DISC
	OPTIPRANOLOL					
+	@ BAUSCH AND LOMB	0.3%	N019907	001	Dec 29, 1989	Aug DISC
+	!	0.3%	N019907	001	Dec 29, 1989	May CTEC

METOLAZONE

TABLET; ORAL

METOLAZONE

>A>	@	ANI PHARMS INC	5MG	A076833	001	Mar 01, 2004	Sep CAHN
>A>	@		10MG	A075543	003	Dec 24, 2003	Sep CAHN
>D>	@	TEVA	5MG	A076833	001	Mar 01, 2004	Sep CAHN
>D>	@		10MG	A075543	003	Dec 24, 2003	Sep CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

TOPROL-XL

AB	+	TOPROL	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Mar CAHN
AB	+	!	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Mar CAHN
AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Mar CAHN
AB	+	!	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Mar CAHN

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

+	@	NOVARTIS	1MG/ML	N018704	001	Mar 30, 1984	Jun DISC
		METOPROLOL TARTRATE					
AP	!	HOSPIRA	1MG/ML	A078085	001	Apr 29, 2008	Jun CHRS
	@	LUITPOLD	1MG/ML	A090386	001	Sep 30, 2009	Mar DISC
	@		1MG/ML	A091307	001	Dec 29, 2010	Feb DISC

TABLET; ORAL

METOPROLOL TARTRATE

AB		HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995	Apr CAHN
AB			100MG	A074141	002	Jan 31, 1995	Apr CAHN

METRONIDAZOLE

GEL;VAGINAL							
METROGEL-VAGINAL							
AB	+! BAUSCH	0.75%	N020208	001	Aug 17, 1992	Mar	CAHN
METRONIDAZOLE							
AB	GAGE DEVELOPMENT	0.75%	A211786	001	Jul 02, 2019	Jun	NEWA
AB	PERRIGO UK FINCO	0.75%	A211786	001	Jul 02, 2019	Jul	CAHN
INJECTABLE;INJECTION							
METRONIDAZOLE IN PLASTIC CONTAINER							
AP	INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Feb	NEWA
TABLET;ORAL							
METRONIDAZOLE							
AB	CADILA	250MG	A206560	001	Nov 16, 2016	Mar	CAHN
AB		500MG	A206560	002	Nov 16, 2016	Mar	CAHN
AB	STRIDES PHARMA	250MG	A070040	001	Jan 29, 1985	Apr	CAHN
AB		500MG	A070039	001	Jan 29, 1985	Apr	CAHN

METYROSINE

CAPSULE;ORAL							
DEMSER							
	+! BAUSCH	250MG	N017871	001		Mar	CAHN

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS							
MICAFUNGIN SODIUM							
AP	FRESENIUS KABI USA	EQ 50MG BASE/VIAL	A207344	001	May 17, 2019	May	NFTG
AP		EQ 100MG BASE/VIAL	A207344	002	May 17, 2019	May	NFTG
MYCAMINE							
AP	+! ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	May	CFTG
AP	+!	EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May	CDFR

MIDAZOLAM

SPRAY;NASAL							
NAYZILAM							
	+! UCB INC	5MG/SPRAY	N211321	001	May 17, 2019	May	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION							
MIDOZALAM HYDROCHLORIDE							
>D> AP	MYLAN ASI	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Sep	DISC
>A>	@	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Sep	DISC
AP		EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr	CAHN
>D> AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Sep	DISC
>A>	@	EQ 5MG BASE/ML	A090316	002	May 04, 2011	Sep	DISC
AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr	CAHN

MIDODRINE HYDROCHLORIDE

TABLET;ORAL							
MIDODRINE HYDROCHLORIDE							
	@ CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	May	DISC
	@	5MG	A076514	002	Sep 11, 2003	May	DISC
	@	10MG	A076514	003	Jul 02, 2004	May	DISC
AB	MYLAN PHARMS INC	5MG	A076577	002	Sep 10, 2003	May	CHRS
AB	RUBICON	2.5MG	A212543	001	Aug 19, 2019	Aug	NEWA
AB		5MG	A212543	002	Aug 19, 2019	Aug	NEWA
AB		10MG	A212543	003	Aug 19, 2019	Aug	NEWA
ORVATEN							
AB	! UPSHER SMITH LABS	5MG	A076725	002	Nov 03, 2004	May	CHRS

MIFEPRISTONE

TABLET;ORAL							
MIFEPREX							
AB	+! DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000	Mar	CFTG
MIFEPRISTONE							
AB	GENBIOPRO	200MG	A091178	001	Apr 11, 2019	Mar	NFTG

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

MINOCIN

AB	+	BAUSCH	EQ 50MG BASE	N050649	001	May 31, 1990	May CAHN
	+	@	EQ 75MG BASE	N050649	003	Feb 12, 2001	May CAHN
AB	+		EQ 100MG BASE	N050649	002	May 31, 1990	May CAHN

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

@ SUN PHARM INDS INC

EQ 45MG BASE

N201922 001 Jul 11, 2012 Aug CAHN

@

EQ 67.5MG BASE

N201922 002 Jul 11, 2012 Aug CAHN

@

EQ 90MG BASE

N201922 003 Jul 11, 2012 Aug CAHN

@

EQ 112.5MG BASE

N201922 004 Jul 11, 2012 Aug CAHN

@ EQ 135MG BASE

N201922 005 Jul 11, 2012 Aug CAHN

SUSPENSION;ORAL

MINOCIN

@ BAUSCH

EQ 50MG BASE/5ML

N050445 001

May CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB AUROBINDO PHARMA LTD

EQ 55MG BASE

A202261 008 Aug 21, 2019 Aug NEWA

AB BARR LABS INC

EQ 80MG BASE

A065485 007 Apr 26, 2017 Jan CMFD

AB EQ 105MG BASE

A065485 008 Apr 26, 2017 Jan CMFD

@ MYLAN

EQ 55MG BASE

A203443 001 Aug 21, 2019 Aug NEWA

@ MYLAN LABS LTD

EQ 65MG BASE

A201467 001 Jul 30, 2019 Aug DISC

AB EQ 65MG BASE

A201467 001 Jul 30, 2019 Jul NEWA

@

EQ 115MG BASE

A201467 002 Jul 30, 2019 Aug DISC

AB EQ 115MG BASE

A201467 002 Jul 30, 2019 Jul NEWA

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

@ WATSON LABS

15MG

A076312 001 Jun 19, 2003 May DISC

@

30MG

A076312 002 Jun 19, 2003 May DISC

@

45MG

A076312 003 Jun 19, 2003 May DISC

MISOPROSTOL

TABLET;ORAL

MISOPROSTOL

AB ZYDUS PHARMS

0.1MG

A210201 001 Jul 02, 2019 Jun NEWA

AB 0.2MG

A210201 002 Jul 02, 2019 Jun NEWA

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

AP WEST-WARD PHARMS INT

20MG/VIAL

A064117 002 Apr 19, 1995 Jan CMFD

AP 40MG/VIAL

A064117 003 Jun 02, 1999 Jan CMFD

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION

MITOXANTRONE HYDROCHLORIDE

@ MYLAN INSTITUTIONAL EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A078980 001 Apr 13, 2009 Mar DISC

@ EQ 30MG BASE/15ML (EQ 2MG BASE/ML)

A078980 002 Apr 13, 2009 Mar DISC

>D> AP MYLAN LABS LTD EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A201014 001 Dec 11, 2012 Sep DISC

>A> @ EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A201014 001 Dec 11, 2012 Sep DISC

NOVANTRONE

>D> @ EMD SERONO EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

N019297 001 Dec 23, 1987 Sep CRLD

>A> + @ EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

N019297 001 Dec 23, 1987 Sep CRLD

MODAFINIL

TABLET;ORAL

MODAFINIL

AB CADILA

100MG

A209966 001 Sep 14, 2017 Aug CMFD

@

100MG

A209966 001 Sep 14, 2017 May CAHN

AB 200MG

A209966 002 Sep 14, 2017 Aug CMFD

@

200MG

A209966 002 Sep 14, 2017 May CAHN

@ HIKMA PHARMS

100MG

A090543 001 Sep 26, 2012 Aug DISC

@

200MG

A090543 002 Sep 26, 2012 Aug DISC

@ ZYDUS PHARMS

100MG

A209966 001 Sep 14, 2017 Apr DISC

@

200MG

A209966 002 Sep 14, 2017 Apr DISC

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION							
ASMANEX HFA							
	+ MERCK SHARP DOHME	0.05MG/INH	N205641	003	Aug 12, 2019	Aug	NEWA
CREAM; TOPICAL							
ELOCON							
	+ @ MERCK SHARP DOHME	0.1%	N019625	002	Apr 19, 2013	Aug	DISC
MOMETASONE FUROATE							
AB	! GLENMARK GENERICS	0.1%	A078541	001	May 28, 2008	Aug	CHRS
OINTMENT; TOPICAL							
ELOCON							
	+ @ MERCK SHARP DOHME	0.1%	N019543	001	Apr 30, 1987	Jul	DISC
MOMETASONE FUROATE							
AB	! GLENMARK GENERICS	0.1%	A078571	001	May 28, 2008	Jul	CHRS

MONTELUKAST SODIUM

GRANULE; ORAL							
MONTELUKAST SODIUM							
	@ MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012	Feb	DISC
AB	TORRENT	EQ 4MG BASE/PACKET	A210431	001	Jul 31, 2018	Mar	CAHN
TABLET; ORAL							
MONTELUKAST SODIUM							
AB	L PERRIGO CO	EQ 10MG BASE	A206112	001	Apr 26, 2017	May	CAHN
	@ MYLAN PHARMS INC	EQ 10MG BASE	A079103	001	Aug 03, 2012	Jul	DISC
	@ VINTAGE PHARMS LLC	EQ 10MG BASE	A091576	001	Aug 03, 2012	Feb	DISC
TABLET, CHEWABLE; ORAL							
MONTELUKAST SODIUM							
	@ MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012	Apr	DISC
	@	EQ 5MG BASE	A079142	002	Aug 03, 2012	Apr	DISC
	@ VINTAGE PHARMS LLC	EQ 4MG BASE	A091588	001	Aug 03, 2012	Feb	DISC
	@	EQ 5MG BASE	A091588	002	Aug 03, 2012	Feb	DISC

MORPHINE SULFATE

INJECTABLE; INJECTION							
ASTRAMORPH PF							
	@ FRESENIUS KABI USA	0.5MG/ML	A071050	001	Oct 07, 1986	Mar	DISC
MITIGO							
AP	PIRAMAL CRITICAL	10MG/ML	A204393	001	Jul 16, 2018	Aug	CAHN
AP		25MG/ML	A204393	002	Jul 16, 2018	Aug	CAHN
MORPHINE SULFATE							
>D>	+! ICU MEDICAL INC	5MG/ML	N019916	002	Oct 27, 2006	Sep	DISC
>A>	+ @	5MG/ML	N019916	002	Oct 27, 2006	Sep	DISC
SOLUTION; ORAL							
MORPHINE SULFATE							
	@ LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015	Feb	DISC
	@	20MG/5ML	A202310	001	Oct 30, 2015	Jan	DISC
	@	100MG/5ML	N201517	001	Jun 23, 2011	Jan	DISC
	@ VISTAPHARM	10MG/5ML	A201947	001	Jan 05, 2012	Jul	DISC
TABLET; ORAL							
MORPHINE SULFATE							
AB	+ HIKMA	15MG	N022207	001	Mar 17, 2008	Jul	CFTG
	+	15MG	N022207	001	Mar 17, 2008	Jun	CAHN
AB	+!	30MG	N022207	002	Mar 17, 2008	Jul	CFTG
	+!	30MG	N022207	002	Mar 17, 2008	Jun	CAHN
AB	UPSHER SMITH LABS	15MG	A210610	001	Jul 22, 2019	Jul	NFTG
AB		30MG	A210610	002	Jul 22, 2019	Jul	NFTG
TABLET, EXTENDED RELEASE; ORAL							
ARYMO ER							
	+ @ EGALET	15MG	N208603	001	Jan 09, 2017	Mar	CAHN
	+ @	30MG	N208603	002	Jan 09, 2017	Mar	CAHN
	+ @	60MG	N208603	003	Jan 09, 2017	Mar	CAHN
	+ @ ZYLA	15MG	N208603	001	Jan 09, 2017	Jul	CAHN
	+ @	30MG	N208603	002	Jan 09, 2017	Jul	CAHN
	+ @	60MG	N208603	003	Jan 09, 2017	Jul	CAHN
MORPHINE SULFATE							
	@ MYLAN PHARMS INC	15MG	A200824	001	Oct 18, 2011	Aug	DISC
	@	30MG	A200824	002	Oct 18, 2011	Aug	DISC
	@	60MG	A200824	003	Oct 18, 2011	Aug	DISC
	@	100MG	A200824	004	Oct 18, 2011	Aug	DISC
	@	200MG	A200824	005	Oct 18, 2011	Feb	DISC

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT1	ALEMBIC PHARMS LTD	EQ 0.5% BASE	A209469	001	Feb 13, 2019	Jan NEWA
	TABLET;ORAL					
	MOXIFLOXACIN HYDROCHLORIDE					
	@ SUNSHINE LAKE	EQ 400MG BASE	A206295	001	Sep 28, 2018	Mar DISC

MUPIROCINOINTMENT;TOPICAL
MUPIROCIN

AB	! PERRIGO ISRAEL	2%	A065123	001	Nov 07, 2003	May CAHN
----	------------------	----	---------	-----	--------------	----------

MYCOPHENOLATE MOFETILSUSPENSION;ORAL
MYCOPHENOLATE MOFETIL

AB	VISTAPHARM	200MG/ML	A210370	001	Feb 12, 2019	Jan NEWA
	TABLET;ORAL					
	MYCOPHENOLATE MOFETIL					
	@ OXFORD PHARMS	500MG	A090606	001	Jul 16, 2010	Aug DISC
>D> AB	TEVA PHARMS	500MG	A065457	001	May 04, 2009	Sep DISC
>A>	@	500MG	A065457	001	May 04, 2009	Sep DISC

NABUMETONETABLET;ORAL
NABUMETONE

AB	NEXGEN PHARMA INC	500MG	A203166	001	Aug 30, 2019	Aug NEWA
AB		750MG	A203166	002	Aug 30, 2019	Aug NEWA
		1GM	A203166	003	Aug 30, 2019	Aug NEWA
>D>	@ SCIEGEN PHARMS INC	500MG	A078420	001	Sep 24, 2008	Sep CMFD
>A> AB		500MG	A078420	001	Sep 24, 2008	Sep CMFD
>D>	@	750MG	A078420	002	Sep 24, 2008	Sep CMFD
>A> AB		750MG	A078420	002	Sep 24, 2008	Sep CMFD

NADOLOLTABLET;ORAL
NADOLOL

AB	HERITAGE PHARMA	20MG	A074229	001	Aug 30, 1996	Apr CAHN
AB		40MG	A074229	002	Aug 30, 1996	Apr CAHN
AB		80MG	A074255	001	Jan 24, 1996	Apr CAHN
	@	120MG	A074255	002	Jan 24, 1996	Apr CAHN
	@	160MG	A074255	003	Jan 24, 1996	Apr CAHN
>A> AB	VGYAAN	20MG	A212856	001	Sep 13, 2019	Sep NEWA
>A> AB		40MG	A212856	002	Sep 13, 2019	Sep NEWA
>A> AB		80MG	A212856	003	Sep 13, 2019	Sep NEWA

NAFCILLIN SODIUMINJECTABLE;INJECTION
NAFCILLIN SODIUM

>D> AP	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Sep DISC
>A>	@	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Sep DISC
>D> AP		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Sep DISC
>A>	@	EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Sep DISC

NAFTIFINE HYDROCHLORIDEGEL;TOPICAL
NAFTIFINE HYDROCHLORIDE

	@ TARO	2%	A208201	001	Apr 10, 2019	May DISC
AB		2%	A208201	001	Apr 10, 2019	Mar NFTG
AB	TOLMAR	1%	A206165	001	Mar 20, 2019	Mar NFTG
	NAFTIN					
AB	+! SEBELA IRELAND LTD	1%	N019356	001	Jun 18, 1990	Mar CFTG
AB	+!	2%	N204286	001	Jun 27, 2013	Mar CFTG

NALBUPHINE HYDROCHLORIDEINJECTABLE;INJECTION
NALBUPHINE HYDROCHLORIDE

	@ DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	May CAHN
	@	20MG/ML	A074471	002	Mar 19, 1998	May CAHN
AP	MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Jan NEWA
AP		20MG/ML	A206506	002	Feb 06, 2019	Jan NEWA

NALDEMEDINE TOSYLATETABLET; ORAL
SYMPROIC

+! BDSI EQ 0.2MG BASE N208854 001 Mar 23, 2017 Apr CAHN

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION
NALOXONE HYDROCHLORIDE>A> AP AUROBINDO PHARMA LTD 0.4MG/ML A212455 001 Oct 15, 2019 Sep NEWA
AP VIRTUS PHARMS 0.4MG/ML A207846 001 Dec 17, 2018 Jul CAHNSOLUTION; INTRAMUSCULAR, SUBCUTANEOUS
EVZIO (AUTOINJECTOR)

+! KALEO INC 2MG/0.4ML (2MG/0.4ML) N209862 001 Oct 19, 2016 Feb CTNA

SPRAY, METERED; NASAL
NALOXONE HYDROCHLORIDEAB @ TEVA PHARMS USA 4MG/SPRAY A209522 001 Apr 19, 2019 May DISC
4MG/SPRAY A209522 001 Apr 19, 2019 Apr NFTG

NARCAN

+! ADAPT 4MG/SPRAY N208411 001 Nov 18, 2015 May CTEC
AB +! 4MG/SPRAY N208411 001 Nov 18, 2015 Apr CFTGNALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

AB NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE
LUPIN EQ 0.5MG BASE; EQ 50MG BASE A075735 001 Jul 11, 2001 Feb CAHNNANDROLONE DECANOATEINJECTABLE; INJECTION
NANDROLONE DECANOATE

@ LUITPOLD 200MG/ML A091252 001 Aug 30, 2010 Feb DISC

NAPROXENSUSPENSION; ORAL
NAPROSYN

AB + ATNAHS PHARMA US 25MG/ML N018965 001 Mar 23, 1987 Jun CHRS

NAPROXEN

AB ! WEST-WARD PHARMS INT 25MG/ML A074190 001 Mar 30, 1994 Jun CHRS

TABLET; ORAL
NAPROXENAB PERRIGO PHARMS CO 250MG A077339 001 Apr 27, 2005 Apr CAHN
AB 375MG A077339 002 Apr 27, 2005 Apr CAHN
AB 500MG A077339 003 Apr 27, 2005 Apr CAHNNAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

+ @ CURRAX 60MG; EQ 10MG BASE N021926 002 May 14, 2015 Apr CAHN
AB +! 500MG; EQ 85MG BASE N021926 001 Apr 15, 2008 Apr CAHNNARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

>A> AB ANI PHARMS INC EQ 1MG BASE A078751 001 Jul 07, 2010 Sep CAHN
>A> AB EQ 2.5MG BASE A078751 002 Jul 07, 2010 Sep CAHN
@ CASI PHARMS INC EQ 1MG BASE A090288 001 Jul 07, 2010 Jun DISC
@ EQ 2.5MG BASE A090288 002 Jul 07, 2010 Jun DISC
>D> AB TEVA PHARMS EQ 1MG BASE A078751 001 Jul 07, 2010 Sep CAHN
>D> AB EQ 2.5MG BASE A078751 002 Jul 07, 2010 Sep CAHNNATEGLINIDE

TABLET; ORAL

NATEGLINIDE

AB CADILA PHARMS LTD 60MG A206432 001 Apr 19, 2019 Apr NEWA
AB 120MG A206432 002 Apr 19, 2019 Apr NEWA
AB ! ZYDUS PHARMS 120MG A205248 002 Jul 06, 2016 Jul CHRS
STARLIX
+ @ NOVARTIS 60MG N021204 001 Dec 22, 2000 Jul DISC
+ @ 120MG N021204 002 Dec 22, 2000 Jul DISC

>D> NEBIVOLOL HYDROCHLORIDE; VALSARTAN

>D> TABLET; ORAL

>D> BYVALSON

>D> +! ALLERGAN SALES LLC EQ 5MG BASE; 80MG N206302 001 Jun 03, 2016 Sep DISC

>A> + @ EQ 5MG BASE; 80MG N206302 001 Jun 03, 2016 Sep DISC

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

@ LANNETT CO INC 500MG A204435 001 Jun 10, 2016 Jun DISC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

@ WATSON LABS EQ 40MG BASE/ML; 200,000 UNITS/ML A062664 001 Apr 08, 1986 Jul DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP AMRING PHARMS 5MG/10ML (0.5MG/ML) A210989 001 Aug 22, 2018 Jan CAHN

AP 10MG/10ML (1MG/ML) A210989 002 Aug 22, 2018 Jan CAHN

AP BE PHARMS 5MG/10ML (0.5MG/ML) A212512 001 May 13, 2019 Apr NEWA

AP 10MG/10ML (1MG/ML) A212512 002 May 13, 2019 Apr NEWA

>A> AP GLAND PHARMA LTD 5MG/10ML (0.5MG/ML) A212968 001 Oct 16, 2019 Sep NEWA

>A> AP 10MG/10ML (1MG/ML) A212968 002 Oct 16, 2019 Sep NEWA

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

+ @ SCIOS LLC 1.5MG/VIAL N020920 001 Aug 10, 2001 Aug DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

>D> @ JUBILANT GENERICS 500MG A209156 001 May 14, 2018 Sep CMFD

>A> AB 500MG A209156 001 May 14, 2018 Sep CMFD

@ 500MG A209156 001 May 14, 2018 Apr DISC

>D> @ 750MG A209156 002 May 14, 2018 Sep CMFD

>A> AB 750MG A209156 002 May 14, 2018 Sep CMFD

@ 750MG A209156 002 May 14, 2018 Apr DISC

>D> @ 1GM A209156 003 May 14, 2018 Sep CMFD

>A> AB 1GM A209156 003 May 14, 2018 Sep CMFD

@ 1GM A209156 003 May 14, 2018 Apr DISC

AB MYLAN 500MG A203742 001 Feb 22, 2019 Feb NEWA

AB 750MG A203742 002 Feb 22, 2019 Feb NEWA

AB 1GM A203742 003 Feb 22, 2019 Feb NEWA

AB YICHANG HUMANWELL 500MG A212017 001 Jun 10, 2019 May NEWA

AB 750MG A212017 002 Jun 10, 2019 May NEWA

AB 1GM A212017 003 Jun 10, 2019 May NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

>A> @ ANI PHARMS INC 20MG A074670 001 Oct 28, 1996 Sep CAHN

>A> @ 30MG A074670 002 Oct 28, 1996 Sep CAHN

>D> @ WATSON LABS 20MG A074670 001 Oct 28, 1996 Sep CAHN

>D> @ 30MG A074670 002 Oct 28, 1996 Sep CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB2 NOVAST LABS 30MG A210614 001 Mar 12, 2019 Feb NEWA

AB2 60MG A210614 002 Mar 12, 2019 Feb NEWA

AB2 90MG A210614 003 Mar 12, 2019 Feb NEWA

AB2 OSMOTICA PHARM US 90MG A077127 003 Oct 03, 2007 Apr CMS1

AB2 SPIL 30MG A210838 001 Apr 16, 2019 Apr NEWA

AB2 60MG A210838 002 Apr 16, 2019 Apr NEWA

AB2 90MG A210838 003 Apr 16, 2019 Apr NEWA

NITISINONE

CAPSULE;ORAL						
NITISINONE						
AB	NOVITIUM PHARMA	2MG	A211041	001	Aug 26, 2019	Aug NFTG
AB		5MG	A211041	002	Aug 26, 2019	Aug NFTG
AB		10MG	A211041	003	Aug 26, 2019	Aug NFTG
ORFADIN						
AB	+ SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002	Aug CFTG
AB	+	5MG	N021232	002	Jan 18, 2002	Aug CFTG
AB	+	10MG	N021232	003	Jan 18, 2002	Aug CFTG

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL						
NITROFURANTOIN						
	@ MYLAN	50MG	A074967	001	Jul 09, 1997	Jul DISC
	@	100MG	A077025	001	Aug 18, 2004	Jul DISC

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL						
NITROMIST						
+!	EVUS	0.4MG/SPRAY	N021780	001	Nov 02, 2006	May CAHN
FILM, EXTENDED RELEASE;TRANSDERMAL						
MINITRAN						
	@ MEDICIS	0.4MG/HR	A089773	001	Aug 30, 1996	May DISC
	@ VALEANT PHARMS	0.1MG/HR	A089771	001	Aug 30, 1996	May DISC
	@	0.6MG/HR	A089774	001	Aug 30, 1996	Jun DISC
	@ VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May DISC
NITRO-DUR						
+!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	May CTEC
+!		0.2MG/HR	N020145	002	Apr 04, 1995	May CTEC
+!		0.4MG/HR	N020145	004	Apr 04, 1995	May CTEC
+!		0.6MG/HR	N020145	005	Apr 04, 1995	Jun CTEC
NITROGLYCERIN						
AB2	HERCON PHARM	0.1MG/HR	A089885	002	Oct 30, 2017	Feb NEWA
AB2	! MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	Feb CTEC
TABLET;SUBLINGUAL						
NITROGLYCERIN						
AB	ALVOGEN	0.3MG	A211604	001	Apr 30, 2019	Apr NEWA
AB		0.4MG	A211604	002	Apr 30, 2019	Apr NEWA
AB		0.6MG	A211604	003	Apr 30, 2019	Apr NEWA

NORETHINDRONE

TABLET;ORAL-28						
MICRONOR						
+	@ JANSSEN PHARMS	0.35MG	N016954	001		Mar DISC
NORETHINDRONE						
AB2	! MYLAN LABS LTD	0.35MG	A200980	001	Jun 12, 2013	Mar CHRS

NORETHINDRONE ACETATE

TABLET;ORAL									
NORETHINDRONE ACETATE									
>D>	AB	AUROBINDO PHARMA LTD	5MG	A204236	001	Jan 08, 2016	Sep	DISC	
>A>		@	5MG	A204236	001	Jan 08, 2016	Sep	DISC	
	AB	RISING	5MG	A206490	001	Nov 05, 2018	May	CAHN	

NYSTATIN

CREAM;TOPICAL						
NYSTATIN						
AT	TORRENT	100,000 UNITS/GM	A212557	001	Jul 24, 2019	Jul NEWA
OINTMENT;TOPICAL						
NYSTATIN						
AT	TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Jan NEWA
POWDER;TOPICAL						
NYSTATIN						
AT	LUPIN	100,000 UNITS/GM	A065138	001	Jul 23, 2004	Feb CAHN
TABLET;ORAL						
NYSTATIN						
	@ UPSHER SMITH LABS	500,000 UNITS	A062524	001	Nov 26, 1985	Jul CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>D>	AT	CROWN LABS INC	100,000 UNITS/GM;0.1%	A207731	001	Dec 26, 2017	Sep DISC
>A>		@	100,000 UNITS/GM;0.1%	A207731	001	Dec 26, 2017	Sep DISC
		@ ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar DISC

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP		HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Apr CAHN
AP			EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Apr CAHN
		@	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Mar DISC
AP			EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Jan CAHN
AP			EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Apr CAHN
		@	EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Mar DISC
AP			EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Jan CAHN
		@ SUN PHARM INDS	EQ 0.05MG BASE/ML	A077372	001	Aug 14, 2007	Jul DISC
		@	EQ 0.1MG BASE/ML	A077372	002	Aug 14, 2007	Jul DISC
		@	EQ 0.2MG BASE/ML	A077373	001	Aug 14, 2007	Jul DISC
		@	EQ 0.5MG BASE/ML	A077372	003	Aug 14, 2007	Jul DISC
		@	EQ 1MG BASE/ML	A077373	002	Aug 14, 2007	Jul DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT		APOTEX INC	0.3%	A076513	001	May 14, 2004	Feb CMFD
		@ SANDOZ INC	0.3%	A076231	001	May 14, 2004	Mar DISC

SOLUTION/DROPS; OTIC

OFLOXACIN

AT		AMNEAL PHARMS CO	0.3%	A211525	001	Aug 30, 2019	Aug NEWA
		@ SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Mar DISC

TABLET; ORAL

OFLOXACIN

>D>	AB	LARKEN LABS	400MG	A076093	003	Sep 02, 2003	Sep DISC
>A>		@	400MG	A076093	003	Sep 02, 2003	Sep DISC

OLANZAPINE

TABLET; ORAL

OLANZAPINE

		@ SUNSHINE LAKE	2.5MG	A206238	001	Nov 19, 2018	Apr DISC
		@	5MG	A206238	002	Nov 19, 2018	Apr DISC
		@	7.5MG	A206238	003	Nov 19, 2018	Apr DISC
		@	10MG	A206238	004	Nov 19, 2018	Apr DISC
		@	15MG	A206238	005	Nov 19, 2018	Apr DISC
		@	20MG	A206238	006	Nov 19, 2018	Apr DISC

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

		@ HEC PHARM	5MG	A208146	001	Jul 02, 2018	Feb DISC
		@	10MG	A208146	002	Jul 02, 2018	Feb DISC
		@	15MG	A208146	003	Jul 02, 2018	Feb DISC
		@	20MG	A208146	004	Jul 02, 2018	Feb DISC

OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

CLINOLIPID 20%

+	!	BAXTER HLTHCARE CORP	16% (160GM/1000ML) ; 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Aug CMFD
+		@	16% (160GM/1000ML) ; 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun CDFR

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

>A>	AB	MICRO LABS	5MG	A206372	001	Sep 17, 2019	Sep NEWA
>A>	AB		20MG	A206372	002	Sep 17, 2019	Sep NEWA
>A>	AB		40MG	A206372	003	Sep 17, 2019	Sep NEWA
	AB	SUNSHINE LAKE	5MG	A211049	001	Feb 22, 2019	Feb NEWA
	AB		20MG	A211049	002	Feb 22, 2019	Feb NEWA
	AB		40MG	A211049	003	Feb 22, 2019	Feb NEWA
	AB	UMEDICA LABS PVT LTD	5MG	A207135	001	Jul 18, 2019	Jul NEWA
	AB		20MG	A207135	002	Jul 18, 2019	Jul NEWA

TABLET;ORAL
OLMESARTAN MEDOXOMIL

AB		40MG		A207135	003	Jul 18, 2019	Jul NEWA
----	--	------	--	---------	-----	--------------	----------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 0.2% BASE		A209420	001	Apr 29, 2019	Apr NEWA
AT	AUROBINDO PHARMA LTD	EQ 0.2% BASE		A209995	001	Apr 04, 2019	Mar NEWA
>A> AT	FDC LTD	EQ 0.1% BASE		A209282	001	Sep 26, 2019	Sep NEWA
AT	GLAND PHARMA LTD	EQ 0.1% BASE		A209619	001	Aug 02, 2019	Jul NEWA
AT	USV	EQ 0.1% BASE		A203152	001	Dec 07, 2015	Jun CAHN

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL
TECHNIVIE

	+ @ ABBVIE INC	12.5MG;75MG;50MG		N207931	001	Jul 24, 2015	Apr DISC
--	----------------	------------------	--	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	ASCENT PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS		A207420	001	Feb 25, 2019	Feb NEWA
AB	BIONPHARMA INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS		A206455	001	Aug 07, 2019	Jul NEWA
	@ PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS		A091018	001	Jun 24, 2014	Jun DISC
AB	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS		A211355	001	Jul 10, 2019	Jun NEWA
AB	ZYDUS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS		A210107	001	Jun 14, 2019	Jun NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

>A> AB	HETERO LABS LTD III	10MG		A204012	001	Sep 26, 2019	Sep NEWA
>A> AB		20MG		A204012	002	Sep 26, 2019	Sep NEWA
	@ MYLAN	10MG		A075876	001	May 29, 2003	Jun DISC
>D> AB		40MG		A075876	003	Jan 21, 2009	Sep DISC
>A>	@	40MG		A075876	003	Jan 21, 2009	Sep DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
ZEGERID

>A> AB	+ SALIX	20MG;1.1GM		N021849	001	Feb 27, 2006	Sep CAHN
>A> AB	+	40MG;1.1GM		N021849	002	Feb 27, 2006	Sep CAHN
>D> AB	+ SANTARUS INC	20MG;1.1GM		N021849	001	Feb 27, 2006	Sep CAHN
>D> AB	+	40MG;1.1GM		N021849	002	Feb 27, 2006	Sep CAHN

FOR SUSPENSION;ORAL
ZEGERID

AB	+ SALIX	20MG/PACKET;1.68GM/PACKET		N021636	001	Jun 15, 2004	Apr CAHN
AB	+	40MG/PACKET;1.68GM/PACKET		N021636	002	Dec 21, 2004	Apr CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

	@ LUITPOLD	EQ 2MG BASE/ML		A079039	001	Nov 18, 2008	Feb DISC
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
	@ HIKMA FARMACEUTICA	EQ 2MG BASE/ML		A076780	001	Dec 26, 2006	Feb DISC
	@ LUITPOLD	EQ 2MG BASE/ML		A079032	001	Nov 18, 2008	Feb DISC
	@ TEVA	EQ 2MG BASE/ML		A076759	001	Nov 22, 2006	Aug DISC

TABLET;ORAL

		ONDANSETRON HYDROCHLORIDE					
	@ MYLAN	EQ 24MG BASE		A076930	004	Jun 25, 2007	Feb DISC

ORPHENADRINE CITRATEINJECTABLE;INJECTION
NORFLEX

+ @ TELIGENT 30MG/ML

N013055 001

Jan CRLD

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

AB LUPIN 100MG

A040284 001 Jun 19, 1998 Feb CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB ALEMBIC PHARMS LTD EQ 30MG BASE

A211823 001 Jun 24, 2019 Jun NEWA

AB EQ 45MG BASE

A211823 002 Jun 24, 2019 Jun NEWA

AB EQ 75MG BASE

A211823 003 Jun 24, 2019 Jun NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB TEVA PHARMS USA EQ 6MG BASE/ML

A211125 001 Feb 27, 2019 Feb NEWA

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

AP PIRAMAL CRITICAL EQ 1GM BASE/VIAL

A206681 001 Sep 11, 2017 Jul CAHN

AP EQ 2GM BASE/VIAL

A206681 002 Sep 11, 2017 Jul CAHN

AP EQ 10GM BASE/VIAL

A206760 001 Oct 26, 2017 Jul CAHN

OXALIPLATIN

INJECTABLE;INTRAVENOUS

ELOXATIN

+ @ SANOFI AVENTIS US 50MG/VIAL

N021492 001 Aug 09, 2002 Feb CDFF

AP +! 50MG/10ML (5MG/ML)

N021759 001 Jan 31, 2005 Feb CDFF

+ @ 100MG/VIAL

N021492 002 Aug 09, 2002 Feb CDFF

AP +! 100MG/20ML (5MG/ML)

N021759 002 Jan 31, 2005 Feb CDFF

+ @ 200MG/40ML (5MG/ML)

N021759 003 Nov 17, 2006 Feb CDFF

OXALIPLATIN

AP ACCORD HLTHCARE 50MG/10ML (5MG/ML)

A207474 001 Mar 21, 2017 Feb CDFF

AP 100MG/20ML (5MG/ML)

A207474 002 Mar 21, 2017 Feb CDFF

AP 200MG/40ML (5MG/ML)

A207474 003 Mar 21, 2017 Feb CDFF

AP ACTAVIS LLC 50MG/10ML (5MG/ML)

A204880 001 Mar 05, 2018 Feb CDFF

AP 100MG/20ML (5MG/ML)

A204880 002 Mar 05, 2018 Feb CDFF

AP ! ACTAVIS TOTOWA 50MG/VIAL

A078803 001 Aug 08, 2012 Jul CHRS

AP 50MG/VIAL

A078803 001 Aug 08, 2012 Feb CDFF

AP ! 100MG/VIAL

A078803 002 Aug 08, 2012 Jul CHRS

AP 100MG/VIAL

A078803 002 Aug 08, 2012 Feb CDFF

AP CIPLA 50MG/10ML (5MG/ML)

A208523 001 Feb 10, 2017 Feb CDFF

AP 100MG/20ML (5MG/ML)

A208523 002 Feb 10, 2017 Feb CDFF

AP EUGIA PHARMA 50MG/10ML (5MG/ML)

A205529 001 Sep 06, 2017 Feb CDFF

AP 100MG/20ML (5MG/ML)

A205529 002 Sep 06, 2017 Feb CDFF

AP FRESENIUS KABI USA 50MG/10ML (5MG/ML)

A078811 001 Jun 10, 2010 Feb CDFF

AP 100MG/20ML (5MG/ML)

A078811 002 Jun 10, 2010 Feb CDFF

AP 50MG/VIAL

A078819 001 Jun 02, 2010 Feb CDFF

AP 50MG/10ML (5MG/ML)

A090030 001 Jan 31, 2017 Feb CDFF

AP 100MG/VIAL

A078819 002 Jun 02, 2010 Feb CDFF

AP 100MG/20ML (5MG/ML)

A090030 002 Jan 31, 2017 Feb CDFF

AP 200MG/40ML (5MG/ML)

A090030 003 Jan 31, 2017 Feb CDFF

AP GLAND PHARMA LTD 50MG/10ML (5MG/ML)

A207325 001 Feb 10, 2017 Feb CDFF

AP 50MG/VIAL

A207385 001 May 23, 2017 Feb CDFF

AP 100MG/20ML (5MG/ML)

A207325 002 Feb 10, 2017 Feb CDFF

AP 100MG/VIAL

A207385 002 May 23, 2017 Feb CDFF

AP 200MG/40ML (5MG/ML)

A207325 003 Oct 18, 2017 Feb CDFF

AP HOSPIRA WORLDWIDE 50MG/10ML (5MG/ML)

A078813 001 Aug 07, 2009 Feb CDFF

AP 100MG/20ML (5MG/ML)

A078813 002 Aug 07, 2009 Feb CDFF

AP INGENUS PHARMS LLC 50MG/10ML (5MG/ML)

A207562 001 Oct 16, 2018 Feb CDFF

AP 100MG/20ML (5MG/ML)

A207562 002 Oct 16, 2018 Feb CDFF

AP JIANGSU HENGRUI MED 50MG/10ML (5MG/ML)

A203869 001 Jun 18, 2014 Feb CDFF

AP 100MG/20ML (5MG/ML)

A203869 002 Jun 18, 2014 Feb CDFF

AP MYLAN LABS LTD 50MG/10ML (5MG/ML)

A091358 001 Aug 07, 2012 Feb CDFF

AP 100MG/20ML (5MG/ML)

A091358 002 Aug 07, 2012 Feb CDFF

>D> AP 200MG/40ML (5MG/ML)

A091358 003 Nov 14, 2017 Sep DISC

>A> @ 200MG/40ML (5MG/ML)

A091358 003 Nov 14, 2017 Sep DISC

AP 200MG/40ML (5MG/ML)

A091358 003 Nov 14, 2017 Feb CDFF

AP QILU PHARM CO LTD 50MG/10ML (5MG/ML)

A204368 001 Jun 07, 2016 Feb CDFF

AP 50MG/VIAL

A204616 001 May 11, 2016 Feb CDFF

INJECTABLE; INTRAVENOUS
OXALIPLATIN

AP			100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	Feb CDFR
AP			100MG/VIAL	A204616	002	May 11, 2016	Feb CDFR
AP	!		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Feb CDFR
AP		SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Feb CDFR
	@		50MG/VIAL	A090849	001	Apr 28, 2011	Feb CDFR
AP			100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Feb CDFR
	@		100MG/VIAL	A090849	002	Apr 28, 2011	Feb CDFR
	@	SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Feb CDFR
	@		100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Feb CDFR
	@	SUN PHARM	50MG/VIAL	A078818	001	Aug 07, 2009	Jul DISC
	@		50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Jul DISC
	@		100MG/VIAL	A078818	002	Aug 07, 2009	Jul DISC
	@		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Jul DISC
	@		200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Jul DISC
AP			200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Apr CDFR
AP	!	SUN PHARMA GLOBAL	50MG/VIAL	A078818	001	Aug 07, 2009	Feb CDFR
AP			50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Feb CDFR
AP	!		100MG/VIAL	A078818	002	Aug 07, 2009	Feb CDFR
AP			100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Feb CDFR
AP	+!	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Feb CDFR
AP	+!		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Feb CDFR

INJECTABLE; IV (INFUSION)
OXALIPLATIN

AP	SUN PHARMA GLOBAL	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Feb NEWA
----	-------------------	---------------------	---------	-----	--------------	----------

OXAPROZIN

TABLET; ORAL
OXAPROZIN

@	BEXIMCO PHARMS USA	600MG	A075842	001	Apr 12, 2001	Mar CAHN
---	--------------------	-------	---------	-----	--------------	----------

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

>D> AA	LANNETT CO INC	5MG/5ML	A076682	001	Dec 28, 2004	Sep DISC
>A>	@	5MG/5ML	A076682	001	Dec 28, 2004	Sep DISC

TABLET; ORAL

OXYBUTYNIN CHLORIDE

>D> AB	APCO PHARMA LLC	5MG	A209025	001	Dec 21, 2017	Sep CAHN
>A> AB	ARISE	5MG	A209025	001	Dec 21, 2017	Sep CAHN
AB	EMCURE PHARMS LTD	5MG	A211682	001	May 10, 2019	Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB	!	ACCORD HLTHCARE	15MG	A207138	003	Feb 29, 2016	Aug CHRS
AB		AJANTA PHARMA LTD	5MG	A211655	001	Feb 28, 2019	Feb NEWA
AB			10MG	A211655	002	Feb 28, 2019	Feb NEWA
AB			15MG	A211655	003	Feb 28, 2019	Feb NEWA
AB		MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Aug CHRS

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA	ALKEM LABS LTD	5MG/5ML	A211748	001	Feb 07, 2019	Feb NEWA
AA		100MG/5ML	A211749	001	Feb 04, 2019	Jan NEWA
>A> AA	EYWA	5MG/5ML	A207511	001	Nov 23, 2016	Sep CAHN
>A> AA		100MG/5ML	A209897	001	Sep 06, 2017	Sep CAHN
	@ LANNETT CO INC	100MG/5ML	A204085	001	Sep 09, 2014	Jan DISC
AA	PHARM ASSOC	5MG/5ML	A206914	001	Feb 01, 2019	May CPOT
AA		5MG/ML	A206914	001	Feb 01, 2019	Jan NEWA
>D> AA	WES PHARMA INC	5MG/5ML	A207511	001	Nov 23, 2016	Sep CAHN
>D> AA		100MG/5ML	A209897	001	Sep 06, 2017	Sep CAHN

TABLET; ORAL

OXAYDO

ZYLA

		5MG	N202080	001	Jun 17, 2011	Jul CAHN
--	--	-----	---------	-----	--------------	----------

7.5MG

			N202080	002	Jun 17, 2011	Jul CAHN
--	--	--	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDE

@ VINTAGE PHARMS

		5MG	A077712	003	Mar 02, 2009	Apr DISC
--	--	-----	---------	-----	--------------	----------

@		10MG	A077712	004	Apr 13, 2015	Apr DISC
---	--	------	---------	-----	--------------	----------

@		15MG	A077712	001	Jan 31, 2007	Apr DISC
---	--	------	---------	-----	--------------	----------

@		20MG	A077712	005	Apr 13, 2015	Apr DISC
---	--	------	---------	-----	--------------	----------

@		30MG	A077712	002	Jan 31, 2007	Apr DISC
---	--	------	---------	-----	--------------	----------

TABLET; ORAL

ROXYBOND

>D>	@	DAIICHI SANKYO INC	5MG	N209777	001	Apr 20, 2017	Sep CAHN
>D>	@		15MG	N209777	002	Apr 20, 2017	Sep CAHN
>D>	@		30MG	N209777	003	Apr 20, 2017	Sep CAHN
>A>	@	INSPIRION DELIVERY	5MG	N209777	001	Apr 20, 2017	Sep CAHN
>A>	@		15MG	N209777	002	Apr 20, 2017	Sep CAHN
>A>	@		30MG	N209777	003	Apr 20, 2017	Sep CAHN

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@	DR REDDYS	10USP UNITS/ML (10USP UNITS/ML)	A077453	001	Jan 24, 2008	May CAHN
@		100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008	May CAHN

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

>D>	@	ACCORD HLTHCARE	6MG/ML	A205720	001	Aug 17, 2018	Mar DISC
>D>	AP	+ HQ SPCLT PHARMA	6MG/ML	N020262	001	Dec 29, 1992	Sep DISC
>A>		+ @	6MG/ML	N020262	001	Dec 29, 1992	Sep DISC

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

PALIPERIDONE

>A>	AB	AMNEAL PHARMS	1.5MG	A204707	001	Sep 23, 2019	Sep NEWA
>A>	AB		3MG	A204707	002	Sep 23, 2019	Sep NEWA
>A>	AB		6MG	A204707	003	Sep 23, 2019	Sep NEWA
>A>	AB		9MG	A204707	004	Sep 23, 2019	Sep NEWA
	AB	INVENTIA	1.5MG	A204452	001	Jun 12, 2019	Aug CAHN
	AB		3MG	A204452	002	Jun 12, 2019	Aug CAHN
	AB		6MG	A204452	003	Jun 12, 2019	Aug CAHN
	AB		9MG	A204452	004	Jun 12, 2019	Aug CAHN
	AB	INVENTIA HLTHCARE	1.5MG	A204452	001	Jun 12, 2019	May NEWA
	AB		3MG	A204452	002	Jun 12, 2019	May NEWA
	AB		6MG	A204452	003	Jun 12, 2019	May NEWA
	AB		9MG	A204452	004	Jun 12, 2019	May NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Mar DISC
---	--------------------	---	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

HIKMA		EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016	Jul CAHN
-------	--	---	---------	-----	--------------	----------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP		DR REDDYS	30MG/10ML (3MG/ML)	A078156	001	Aug 19, 2008	May CAHN
AP			60MG/10ML (6MG/ML)	A078156	002	Aug 19, 2008	May CAHN
AP			90MG/10ML (9MG/ML)	A078156	003	Aug 19, 2008	May CAHN
	@	LUITPOLD	30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008	Mar DISC
	@		90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008	Mar DISC

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

AP	!	DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990	May CAHN
	!		2MG/ML	A072760	001	Jul 31, 1990	May CAHN

PANOBIINOSTAT LACTATE

CAPSULE; ORAL

FARYDAK

+	SECURA	EQ 10MG BASE	N205353	001	Feb 23, 2015	Jun CAHN
+		EQ 15MG BASE	N205353	002	Feb 23, 2015	Jun CAHN
+	!	EQ 20MG BASE	N205353	003	Feb 23, 2015	Jun CAHN

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP SUN PHARM EQ 40MG BASE/VIAL

A077674 001 Aug 19, 2019 Aug NEWA

POWDER;IV (INFUSION)

PANTOPRAZOLE SODIUM

>D> HIKMA EQ 40MG BASE/VIAL

N209463 001 Jun 30, 2017 Sep CHRS

>A> +! EQ 40MG BASE/VIAL

N209463 001 Jun 30, 2017 Sep CRLD

>A> ! EQ 40MG BASE/VIAL

N209463 001 Jun 30, 2017 Sep CHRS

EQ 40MG BASE/VIAL

N209463 001 Jun 30, 2017 Jul CAHN

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB INGENUS PHARMS LLC EQ 40MG BASE

A211368 001 Mar 01, 2019 Feb NEWA

AB L PERRIGO CO EQ 20MG BASE

A203024 001 May 07, 2014 May CAHN

AB RUBICON EQ 20MG BASE

A090807 001 May 02, 2012 Aug CAHN

AB EQ 40MG BASE

A090807 002 May 02, 2012 Aug CAHN

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

AB @ VALEANT PHARMS INTL 125MG

N019853 002 Jan CAHN

+! 250MG

N019853 001 Apr CFTG

+! 250MG

N019853 001 Jan CAHN

PENICILLAMINE

AB AMERIGEN PHARMS LTD 250MG

A209921 001 May 07, 2019 Apr NFTG

AB WATSON LABS INC 250MG

A210976 001 Jun 24, 2019 Jun NEWA

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

NEBUPENT

AN +! FRESENIUS KABI USA 300MG/VIAL

N019887 001 Jun 15, 1989 Apr CFTG

PENTAMIDINE ISETHIONATE

AN SETON PHARMS 300MG/VIAL

A206667 001 Apr 24, 2019 Apr NFTG

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

PENTOBARBITAL SODIUM

>A> AP ATHENEX 50MG/ML

A206677 001 Nov 27, 2017 Sep CAHN

>D> AP RENAISSANCE SSA LLC 50MG/ML

A206677 001 Nov 27, 2017 Sep CAHN

PENTOSTATIN

INJECTABLE;INJECTION

PENTOSTATIN

@ MYLAN INSTITUTIONAL 10MG/VIAL

A203554 001 Sep 19, 2014 Mar DISC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

>A> @ ANI PHARMS INC 400MG

A074878 001 Jul 09, 1997 May CAHN

@ 400MG

A075107 001 Sep 04, 1998 Sep CAHN

@ MYLAN 400MG

A074425 001 Jul 08, 1997 Jun DISC

>D> @ WATSON LABS 400MG

A075107 001 Sep 04, 1998 Sep CAHN

PERMETHRIN

CREAM;TOPICAL

PERMETHRIN

AB ENCUBE ETHICALS 5%

A211303 001 Apr 03, 2019 Mar NEWA

AB PERRIGO ISRAEL 5%

A076369 001 Apr 21, 2003 May CAHN

PEXIDARTINIB HYDROCHLORIDE

CAPSULE;ORAL

TURALIO

+! DAIICHI SANKYO INC EQ 200MG BASE

N211810 001 Aug 02, 2019 Aug NEWA

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

@ UPSHER SMITH LABS 35MG

A084399 001 Jul CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1	AMNEAL PHARMS CO	10MG/ML (10MG/ML)	A211079	001	Jul 05, 2018	Aug CTEC
AP1		50MG/5ML (10MG/ML)	A211078	001	Jul 19, 2018	Aug CTEC
AP1		100MG/10ML (10MG/ML)	A211078	002	Jul 19, 2018	Aug CTEC
AP	FRESENIUS KABI USA	10MG/ML (10MG/ML)	A210665	001	Jan 29, 2019	Jan NEWA
AP1		50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019	Aug CTEC
AP		50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019	Jan NEWA
AP1		100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019	Aug CTEC
AP		100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019	Jan NEWA
AP2	MEITHEAL	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Aug CTEC
AP		10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Jun CAHN
AP1		50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Aug CTEC
AP		50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Jun CAHN
AP1		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Aug CTEC
AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Jun CAHN
AP1	PAR STERILE PRODUCTS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Aug CTEC
AP1		50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Aug CTEC
AP1		100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Aug CTEC
AP1	SANDOZ INC	10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Aug CTEC
AP		10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Jan NEWA
AP1		50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Aug CTEC
AP		50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Jan NEWA
AP1		100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Aug CTEC
AP		100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Jan NEWA
AP2	WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Aug CTEC
AP2	+	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Aug NEWA
AP2	+	100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Aug NEWA

VAZCULEP

AP	+	AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Aug CHRS
AP	+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Aug CHRS
AP1	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Aug CTEC

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	+	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan CTEC
AT	+		10%	N207926	002	Jan 15, 2015	Jan CTEC
AT	+	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Jan CTEC
AT	+		10%	N203510	002	Mar 21, 2013	Jan CTEC

PHENYTOIN SODIUM

CAPSULE; ORAL

EXTENDED PHENYTOIN SODIUM

>A>	AB	LUPIN LTD	100MG EXTENDED	A211633	001	Sep 30, 2019	Sep NEWA
		@ SUN PHARM INDS (IN)	100MG EXTENDED	A040621	001	Dec 11, 2006	Jul DISC

INJECTABLE; INJECTION

PHENYTOIN SODIUM

		@ LUITPOLD	50MG/ML	A040781	001	Dec 04, 2007	Feb DISC
--	--	------------	---------	---------	-----	--------------	----------

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

AB		DR REDDYS LABS LTD	10MG/ML	A207719	001	May 22, 2019	May NEWA
AB	!	HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983	May CTEC

TABLET; ORAL

MEPHYTON

AB	+	BAUSCH	5MG	N010104	003		Feb CAHN
AB	+	VALEANT PHARMS INTL	5MG	N010104	003		Jan CAHN
AB		PHYTONADIONE					
AB		ZYDUS	5MG	A210189	001	Feb 20, 2019	Feb NEWA

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	5MG	A212377	001	Aug 13, 2019	Jul NEWA
AB			7.5MG	A212377	002	Aug 13, 2019	Jul NEWA
		SALAGEN					
AB	+	CONCORDIA	5MG	N020237	001	Mar 22, 1994	Jul CAHN
AB	+		7.5MG	N020237	002	Apr 18, 2003	Jul CAHN

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

+ @ ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	Jan DISC
-----------------------	--------------	---------	-----	--------------	----------

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

AB	+! BAUSCH	1%	N021302	001	Dec 13, 2001	Aug CAHN
----	-----------	----	---------	-----	--------------	----------

PIMECROLIMUS

AB	GLENMARK PHARMS LTD	1%	A211769	001	Aug 29, 2019	Aug NEWA
----	---------------------	----	---------	-----	--------------	----------

PIMOZIDE

TABLET; ORAL

ORAP

>D>	AB	+ TEVA	1MG	N017473	003	Aug 27, 1997	Sep DISC
-----	----	--------	-----	---------	-----	--------------	----------

>A>		+ @	1MG	N017473	003	Aug 27, 1997	Sep DISC
-----	--	-----	-----	---------	-----	--------------	----------

>D>	AB	+!	2MG	N017473	001	Jul 31, 1984	Sep DISC
-----	----	----	-----	---------	-----	--------------	----------

>A>		+ @	2MG	N017473	001	Jul 31, 1984	Sep DISC
-----	--	-----	-----	---------	-----	--------------	----------

PIMOZIDE

>D>	AB	PAR PHARM	1MG	A204521	001	Sep 28, 2015	Sep CTEC
-----	----	-----------	-----	---------	-----	--------------	----------

>A>			1MG	A204521	001	Sep 28, 2015	Sep CTEC
-----	--	--	-----	---------	-----	--------------	----------

>D>	AB		2MG	A204521	002	Sep 28, 2015	Sep CTEC
-----	----	--	-----	---------	-----	--------------	----------

>A>		!	2MG	A204521	002	Sep 28, 2015	Sep CHRS
-----	--	---	-----	---------	-----	--------------	----------

>A>			2MG	A204521	002	Sep 28, 2015	Sep CTEC
-----	--	--	-----	---------	-----	--------------	----------

PINDOLOL

TABLET; ORAL

PINDOLOL

AB	BAYSHORE PHARMS LLC	5MG	A211712	001	Aug 01, 2019	Jul NEWA
----	---------------------	-----	---------	-----	--------------	----------

AB		10MG	A211712	002	Aug 01, 2019	Jul NEWA
----	--	------	---------	-----	--------------	----------

@ ZYDUS PHARMS	5MG	A209866	001	Aug 18, 2017	Jun DISC
----------------	-----	---------	-----	--------------	----------

@	10MG	A209866	002	Aug 18, 2017	Jun DISC
---	------	---------	-----	--------------	----------

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	ASTRAL	EQ 2GM BASE/VIAL; EQ 250MG	A212287	001	Jul 29, 2019	Jul NEWA
----	--------	----------------------------	---------	-----	--------------	----------

		BASE/VIAL				
--	--	-----------	--	--	--	--

AP		EQ 3GM BASE/VIAL; EQ 375MG	A212287	002	Jul 29, 2019	Jul NEWA
----	--	----------------------------	---------	-----	--------------	----------

		BASE/VIAL				
--	--	-----------	--	--	--	--

AP		EQ 4GM BASE/VIAL; EQ 500MG	A212287	003	Jul 29, 2019	Jul NEWA
----	--	----------------------------	---------	-----	--------------	----------

		BASE/VIAL				
--	--	-----------	--	--	--	--

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	BRECKENRIDGE	10MG	A206136	001	Jun 20, 2017	Aug CAHN
----	--------------	------	---------	-----	--------------	----------

AB		20MG	A206136	002	Jun 20, 2017	Aug CAHN
----	--	------	---------	-----	--------------	----------

AB	CADILA	10MG	A205585	001	Jul 17, 2018	Feb CAHN
----	--------	------	---------	-----	--------------	----------

AB		20MG	A205585	002	Jul 17, 2018	Feb CAHN
----	--	------	---------	-----	--------------	----------

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

@ MYLAN EQ 1MG BASE

A206070 001 Apr 04, 2019 Apr DISC

@ EQ 2MG BASE

A206070 002 Apr 04, 2019 Apr DISC

@ EQ 4MG BASE

A206070 003 Apr 04, 2019 Apr DISC

AB	MYLAN PHARMS INC	EQ 1MG BASE	A206070	001	Apr 04, 2019	Mar NEWA
----	------------------	-------------	---------	-----	--------------	----------

AB		EQ 2MG BASE	A206070	002	Apr 04, 2019	Mar NEWA
----	--	-------------	---------	-----	--------------	----------

AB		EQ 4MG BASE	A206070	003	Apr 04, 2019	Mar NEWA
----	--	-------------	---------	-----	--------------	----------

PITAVASTATIN MAGNESIUM

TABLET; ORAL

ZYPITAMAG

>A>		+ @ MEDICURE	EQ 1MG BASE	N208379	001	Jul 14, 2017	Sep DISC
-----	--	--------------	-------------	---------	-----	--------------	----------

>D>		+ ZYDUS PHARMS	EQ 1MG BASE	N208379	001	Jul 14, 2017	Sep DISC
-----	--	----------------	-------------	---------	-----	--------------	----------

PITOLISANT HYDROCHLORIDETABLET; ORAL
WAKIX

>D>	+	BIOPROJET PHARMA	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Sep CAHN
	+		EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Aug NEWA
>D>	+	!	EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Sep CAHN
	+	!	EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Aug NEWA
>A>	+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Sep CAHN
>A>	+	!	EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Sep CAHN

PLAZOMICIN SULFATESOLUTION; INTRAVENOUS
ZEMDRI

+	!	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	Jul CAHN
---	---	-----------	--------------------------------------	---------	-----	--------------	----------

PLECANATIDETABLET; ORAL
TRULANCE

+	!	BAUSCH	3MG	N208745	001	Jan 19, 2017	Mar CAHN
+	!	SALIX	3MG	N208745	001	Jan 19, 2017	Apr CAHN

POLYETHYLENE GLYCOL 3350FOR SOLUTION; ORAL
GLYCOLAX

@	LANNETT CO INC	17GM/SCOOPFUL	A076652	001	Jul 02, 2004	May DISC
@	NEXGEN PHARMA INC	17GM/SCOOPFUL	A077706	001	Sep 27, 2006	May DISC
@	PADDOCK LLC	17GM/SCOOPFUL	A077893	001	May 26, 2006	May DISC

POSACONAZOLETABLET, DELAYED RELEASE; ORAL
NOXAFIL

AB	+	!	MERCK SHARP DOHME	100MG	N205053	001	Nov 25, 2013	Aug CFTG
AB			POSACONAZOLE					
AB			SINOTHERAPEUTICS INC	100MG	A212411	001	Aug 21, 2019	Aug NFTG

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

AB		ANDA REPOSITORY	8MEQ	A205549	001	Dec 08, 2015	Aug CAHN
AB			10MEQ	A205549	002	Dec 08, 2015	Aug CAHN
AB		PRINSTON INC	8MEQ	A209026	001	Jun 11, 2019	May NEWA
AB			10MEQ	A209026	002	Jun 11, 2019	May NEWA
AB		ZYDUS PHARMS	8MEQ	A208445	001	Mar 11, 2019	Feb NEWA
AB			10MEQ	A208445	002	Mar 11, 2019	Feb NEWA

FOR SOLUTION; ORAL
POTASSIUM CHLORIDE

AA		AMNEAL PHARMS LLC	20MEQ	A210902	001	May 23, 2019	May NEWA
AA		BELCHER PHARMS LLC	20MEQ	A212183	001	May 06, 2019	Apr NEWA

SOLUTION; ORAL

POTASSIUM CHLORIDE

AA		PHARM ASSOC	20MEQ/15ML	A210766	001	Mar 29, 2019	Mar NEWA
AA			40MEQ/15ML	A210766	002	Mar 29, 2019	Mar NEWA

TABLET, EXTENDED RELEASE; ORAL
K-TAB

>D>	AB2	+	!	ABBVIE	20MEQ	N018279	003	Nov 25, 2013	Sep CTEC
>A>	AB3	+	!		20MEQ	N018279	003	Nov 25, 2013	Sep CTEC
				KLOR-CON M15					
	AB1			UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Mar CTEC
				POTASSIUM CHLORIDE					
	AB1			ADARE PHARMS INC	10MEQ	A076368	002	Jun 05, 2019	Jun NEWA
				@ ANDA REPOSITORY	8MEQ	A206881	001	Jan 22, 2019	Aug CAHN
				@	10MEQ	A206881	002	Jan 22, 2019	Aug CAHN
	AB1			BRECKENRIDGE	10MEQ	A206630	001	Mar 29, 2019	Aug CAHN
	AB3				10MEQ	A210097	001	Jun 17, 2019	Aug CAHN
	AB1				15MEQ	A206630	002	Mar 29, 2019	Aug CAHN
	AB1				20MEQ	A206630	003	Mar 29, 2019	Aug CAHN
>D>	AB2				20MEQ	A210098	001	Apr 26, 2019	Sep CTEC
>A>	AB3				20MEQ	A210098	001	Apr 26, 2019	Sep CTEC
	AB2				20MEQ	A210098	001	Apr 26, 2019	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

	@ PII	8MEQ	A206881	001	Jan 22, 2019	Jul DISC
AB2		8MEQ	A206881	001	Jan 22, 2019	Jan NEWA
AB1		10MEQ	A206630	001	Mar 29, 2019	Mar NEWA
	@	10MEQ	A206881	002	Jan 22, 2019	Jul DISC
AB2		10MEQ	A206881	002	Jan 22, 2019	Jan NEWA
AB3		10MEQ	A210097	001	Jun 17, 2019	Jun NEWA
AB1		15MEQ	A206630	002	Mar 29, 2019	Mar NEWA
AB1		20MEQ	A206630	003	Mar 29, 2019	Mar NEWA
AB2		20MEQ	A210098	001	Apr 26, 2019	Apr NEWA
AB1	PRINSTON INC	10MEQ	A209922	001	Apr 30, 2019	Apr NEWA
AB1		15MEQ	A209922	002	Apr 30, 2019	Apr NEWA
AB1		20MEQ	A209922	003	Apr 30, 2019	Apr NEWA
>D> AB2	VITRUVIAS THERAP	20MEQ	A209688	002	Jan 12, 2018	Sep CTEC
>A> AB3		20MEQ	A209688	002	Jan 12, 2018	Sep CTEC
>A> AB3	YICHANG HUMANWELL	10MEQ	A212561	001	Sep 30, 2019	Sep NEWA
>A> AB3		20MEQ	A212561	002	Sep 30, 2019	Sep NEWA

>A> POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

>A> SOLUTION;INTRAVENOUS

>A> POTASSIUM PHOSPHATES

>A>	+! CMP DEV LLC	4500MG/15ML (300MG/ML);2650MG/15ML (175MG/ML)	N212121	001	Sep 19, 2019	Sep NEWA
-----	----------------	---	---------	-----	--------------	----------

PRALATREXATE

SOLUTION;INTRAVENOUS
FOLOTYN

+	ACROTECH	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Mar CAHN
+	!	40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Mar CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	HERITAGE PHARMA	0.125MG	A077724	001	Feb 19, 2008	May CAHN
>A> AB		0.125MG	A090241	001	Oct 08, 2010	Sep CAHN
	@	0.125MG	A091254	001	Nov 30, 2010	May CAHN
AB		0.25MG	A077724	002	Feb 19, 2008	May CAHN
>A> AB		0.25MG	A090241	002	Oct 08, 2010	Sep CAHN
	@	0.25MG	A091254	002	Nov 30, 2010	May CAHN
AB		0.5MG	A077724	003	Feb 19, 2008	May CAHN
>A> AB		0.5MG	A090241	003	Oct 08, 2010	Sep CAHN
	@	0.5MG	A091254	003	Nov 30, 2010	May CAHN
>A> AB		0.75MG	A090241	004	Oct 08, 2010	Sep CAHN
	@	0.75MG	A091254	004	Nov 30, 2010	May CAHN
AB		1MG	A077724	004	Feb 19, 2008	May CAHN
>A> AB		1MG	A090241	005	Oct 08, 2010	Sep CAHN
	@	1MG	A091254	005	Nov 30, 2010	May CAHN
AB		1.5MG	A077724	005	Feb 19, 2008	May CAHN
>A> AB		1.5MG	A090241	006	Oct 08, 2010	Sep CAHN
	@	1.5MG	A091254	006	Nov 30, 2010	May CAHN
>D> AB	TEVA PHARMS	0.125MG	A090241	001	Oct 08, 2010	Sep CAHN
>D> AB		0.25MG	A090241	002	Oct 08, 2010	Sep CAHN
>D> AB		0.5MG	A090241	003	Oct 08, 2010	Sep CAHN
>D> AB		0.75MG	A090241	004	Oct 08, 2010	Sep CAHN
>D> AB		1MG	A090241	005	Oct 08, 2010	Sep CAHN
>D> AB		1.5MG	A090241	006	Oct 08, 2010	Sep CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	APNAR PHARMA LP	10MG	A076397	003	Oct 23, 2006	Jun CAHN
AB		20MG	A076397	002	Oct 23, 2006	Jun CAHN
AB		40MG	A076397	001	Oct 23, 2006	Jun CAHN
AB		80MG	A077491	001	Feb 11, 2008	Jun CAHN

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC
ECONOPRED

@	EYEVANCE	0.125%	N017468	001		May CAHN
---	----------	--------	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	May CTEC
@	SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	May DISC

PREDNISONE

TABLET;ORAL

PREDNISONE

AB	GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Jul CMFD
	@	1MG	A211496	001	Dec 28, 2018	May DISC
AB		2.5MG	A211495	001	Dec 07, 2018	Jul CMFD
	@	2.5MG	A211495	001	Dec 07, 2018	May DISC
AB		5MG	A211495	002	Dec 07, 2018	Jul CMFD
	@	5MG	A211495	002	Dec 07, 2018	May DISC
AB		10MG	A210525	001	Dec 04, 2018	Jul CMFD
	@	10MG	A210525	001	Dec 04, 2018	May DISC
AB		20MG	A210525	002	Dec 04, 2018	Jul CMFD
	@	20MG	A210525	002	Dec 04, 2018	May DISC
AB		50MG	A210525	003	Dec 04, 2018	Jul CMFD
	@	50MG	A210525	003	Dec 04, 2018	May DISC
AB	SUN PHARM INDUSTRIES	5MG	A089247	002	Dec 04, 1985	Jan CMS1
AB		10MG	A089247	003	Dec 04, 1985	Jan CMS1

PREGABALIN

CAPSULE;ORAL

LYRICA

AB	+	PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Jul CFTG
AB	+		50MG	N021446	002	Dec 30, 2004	Jul CFTG
AB	+		75MG	N021446	003	Dec 30, 2004	Jul CFTG
AB	+		100MG	N021446	004	Dec 30, 2004	Jul CFTG
AB	+		150MG	N021446	005	Dec 30, 2004	Jul CFTG
AB	+		200MG	N021446	006	Dec 30, 2004	Jul CFTG
AB	+		225MG	N021446	007	Dec 30, 2004	Jul CFTG
AB	+		300MG	N021446	008	Dec 30, 2004	Jul CFTG

PREGABALIN

AB	ALEMBIC PHARMS LTD	25MG	A203459	001	Jul 19, 2019	Jul NFTG	
AB		50MG	A203459	002	Jul 19, 2019	Jul NFTG	
AB		75MG	A203459	003	Jul 19, 2019	Jul NFTG	
AB		100MG	A203459	004	Jul 19, 2019	Jul NFTG	
AB		150MG	A203459	005	Jul 19, 2019	Jul NFTG	
AB		200MG	A203459	006	Jul 19, 2019	Jul NFTG	
AB		225MG	A203459	007	Jul 19, 2019	Jul NFTG	
AB		300MG	A203459	008	Jul 19, 2019	Jul NFTG	
>A>	AB	ALKEM LABS LTD	25MG	A211177	001	Sep 30, 2019	Sep NEWA
>A>	AB		50MG	A211177	002	Sep 30, 2019	Sep NEWA
AB		75MG	A207799	001	Jul 19, 2019	Jul NFTG	
AB		100MG	A207799	002	Jul 19, 2019	Jul NFTG	
AB		150MG	A207799	003	Jul 19, 2019	Jul NFTG	
AB		200MG	A207799	004	Jul 19, 2019	Jul NFTG	
AB		225MG	A207799	005	Jul 19, 2019	Jul NFTG	
AB		300MG	A207799	006	Jul 19, 2019	Jul NFTG	
AB	AMNEAL PHARMS CO	25MG	A209743	001	Jul 19, 2019	Jul NFTG	
AB		50MG	A209743	002	Jul 19, 2019	Jul NFTG	
AB		75MG	A209743	003	Jul 19, 2019	Jul NFTG	
AB		100MG	A209743	004	Jul 19, 2019	Jul NFTG	
AB		150MG	A209743	005	Jul 19, 2019	Jul NFTG	
AB		200MG	A209743	006	Jul 19, 2019	Jul NFTG	
AB		225MG	A209743	007	Jul 19, 2019	Jul NFTG	
AB		300MG	A209743	008	Jul 19, 2019	Jul NFTG	
AB	DR REDDYS	25MG	A209664	001	Jul 19, 2019	Jul NFTG	
AB		50MG	A209664	002	Jul 19, 2019	Jul NFTG	
AB		75MG	A209664	003	Jul 19, 2019	Jul NFTG	
AB		100MG	A209664	004	Jul 19, 2019	Jul NFTG	
AB		150MG	A209664	005	Jul 19, 2019	Jul NFTG	
AB		200MG	A209664	006	Jul 19, 2019	Jul NFTG	
AB		225MG	A209664	007	Jul 19, 2019	Jul NFTG	
AB		300MG	A209664	008	Jul 19, 2019	Jul NFTG	
>A>	AB	HAINAN	75MG	A210891	001	Sep 30, 2019	Sep NEWA
>A>	AB		300MG	A210891	002	Sep 30, 2019	Sep NEWA
>A>	AB	HETERO LABS LTD III	25MG	A206912	001	Oct 08, 2019	Sep NEWA
>A>	AB		50MG	A206912	002	Oct 08, 2019	Sep NEWA

CAPSULE;ORAL
PREGABALIN

>A>	AB	75MG	A206912	003	Oct 08, 2019	Sep NEWA
>A>	AB	100MG	A206912	004	Oct 08, 2019	Sep NEWA
>A>	AB	150MG	A206912	005	Oct 08, 2019	Sep NEWA
>A>	AB	200MG	A206912	006	Oct 08, 2019	Sep NEWA
>A>	AB	225MG	A206912	007	Oct 08, 2019	Sep NEWA
>A>	AB	300MG	A206912	008	Oct 08, 2019	Sep NEWA
	AB	25MG	A211384	001	Jul 19, 2019	Jul NFTG
	AB	50MG	A211384	002	Jul 19, 2019	Jul NFTG
	AB	75MG	A211384	003	Jul 19, 2019	Jul NFTG
	AB	100MG	A211384	004	Jul 19, 2019	Jul NFTG
	AB	150MG	A211384	005	Jul 19, 2019	Jul NFTG
	AB	200MG	A211384	006	Jul 19, 2019	Jul NFTG
	AB	225MG	A211384	007	Jul 19, 2019	Jul NFTG
	AB	300MG	A211384	008	Jul 19, 2019	Jul NFTG
	AB	25MG	A209357	001	Jul 19, 2019	Jul NFTG
	AB	50MG	A209357	002	Jul 19, 2019	Jul NFTG
	AB	75MG	A209357	003	Jul 19, 2019	Jul NFTG
	AB	100MG	A209357	004	Jul 19, 2019	Jul NFTG
	AB	150MG	A209357	005	Jul 19, 2019	Jul NFTG
	AB	200MG	A209357	006	Jul 19, 2019	Jul NFTG
	AB	225MG	A209357	007	Jul 19, 2019	Jul NFTG
	AB	300MG	A209357	008	Jul 19, 2019	Jul NFTG
>A>	AB	25MG	A091228	001	Sep 20, 2019	Sep NEWA
>A>	AB	50MG	A091228	002	Sep 20, 2019	Sep NEWA
>A>	AB	75MG	A091228	003	Sep 20, 2019	Sep NEWA
>A>	AB	100MG	A091228	004	Sep 20, 2019	Sep NEWA
>A>	AB	150MG	A091228	005	Sep 20, 2019	Sep NEWA
>A>	AB	200MG	A091228	006	Sep 20, 2019	Sep NEWA
>A>	AB	225MG	A091228	007	Sep 20, 2019	Sep NEWA
>A>	AB	300MG	A091228	008	Sep 20, 2019	Sep NEWA
	AB	25MG	A210432	001	Jul 19, 2019	Jul NFTG
	AB	50MG	A210432	002	Jul 19, 2019	Jul NFTG
	AB	75MG	A210432	003	Jul 19, 2019	Jul NFTG
	AB	100MG	A210432	004	Jul 19, 2019	Jul NFTG
	AB	150MG	A210432	005	Jul 19, 2019	Jul NFTG
	AB	200MG	A210432	006	Jul 19, 2019	Jul NFTG
	AB	225MG	A210432	007	Jul 19, 2019	Jul NFTG
	AB	300MG	A210432	008	Jul 19, 2019	Jul NFTG
	AB	25MG	A208677	001	Jul 19, 2019	Jul NFTG
	AB	50MG	A208677	002	Jul 19, 2019	Jul NFTG
	AB	75MG	A208677	003	Jul 19, 2019	Jul NFTG
	AB	100MG	A208677	004	Jul 19, 2019	Jul NFTG
	AB	150MG	A208677	005	Jul 19, 2019	Jul NFTG
	AB	200MG	A208677	006	Jul 19, 2019	Jul NFTG
	AB	225MG	A208677	007	Jul 19, 2019	Jul NFTG
	AB	300MG	A208677	008	Jul 19, 2019	Jul NFTG
	AB	25MG	A091219	001	Jul 19, 2019	Jul NFTG
	AB	50MG	A091219	002	Jul 19, 2019	Jul NFTG
	AB	75MG	A091224	001	Jul 19, 2019	Jul NFTG
	AB	100MG	A091224	002	Jul 19, 2019	Jul NFTG
	AB	150MG	A091224	003	Jul 19, 2019	Jul NFTG
	AB	200MG	A091224	004	Jul 19, 2019	Jul NFTG
	AB	225MG	A091224	005	Jul 19, 2019	Jul NFTG
	AB	300MG	A091224	006	Jul 19, 2019	Jul NFTG

SOLUTION;ORAL
LYRICA

AA	+! PF PRISM CV	20MG/ML	N022488	001	Jan 04, 2010	Jul CFTG
	PREGABALIN					
AA	ALKEM LABS LTD	20MG/ML	A207623	001	Jul 19, 2019	Jul NFTG

PRETOMANIDTABLET;ORAL
PRETOMANID

+!	TB ALLIANCE	200MG	N212862	001	Aug 14, 2019	Aug NEWA
----	-------------	-------	---------	-----	--------------	----------

PROBENECIDTABLET;ORAL
PROBENECID

>D>	AB	500MG	A084211	002		Sep CHRS
>A>	AB	500MG	A084211	002		Sep CHRS
>D>	AB	500MG	A084442	004	Mar 29, 1983	Sep CHRS

		TABLET;ORAL							
		PROBENECID							
>A>	!	500MG		A084442	004	Mar 29, 1983	Sep	CHRS	
		<u>PROCHLORPERAZINE EDISYLATE</u>							
		INJECTABLE;INJECTION							
		PROCHLORPERAZINE EDISYLATE							
AP	NEXUS PHARMS	EQ 5MG BASE/ML		A204860	001	Feb 15, 2019	Feb	NEWA	
		<u>PROCHLORPERAZINE MALEATE</u>							
		TABLET;ORAL							
		PROCHLORPERAZINE MALEATE							
	@ TEVA PHARMS	EQ 5MG BASE		A040120	001	Jul 11, 1996	Jul	DISC	
	@	EQ 10MG BASE		A040120	002	Jul 11, 1996	Jul	DISC	
		<u>PROGESTERONE</u>							
		INJECTABLE;INJECTION							
		PROGESTERONE							
	@ LUITPOLD	50MG/ML		A090845	001	Jun 22, 2009	Mar	DISC	
		<u>PROMETHAZINE HYDROCHLORIDE</u>							
		SUPPOSITORY;RECTAL							
		PROMETHAZINE HYDROCHLORIDE							
AB	PERRIGO ISRAEL	12.5MG		A040500	001	Jun 30, 2003	May	CAHN	
AB		25MG		A040500	002	Jun 30, 2003	May	CAHN	
		TABLET;ORAL							
		PROMETHAZINE HYDROCHLORIDE							
	@ IMPAX LABS	12.5MG		A040791	002	Feb 12, 2008	Mar	DISC	
	@	25MG		A040791	003	Feb 12, 2008	Mar	DISC	
		<u>PROPRANOLOL HYDROCHLORIDE</u>							
		CAPSULE, EXTENDED RELEASE;ORAL							
		INNOPRAN XL							
BX	+ ANI PHARMS INC	80MG		N021438	001	Mar 12, 2003	Jul	CRLD	
BX	+!	120MG		N021438	002	Mar 12, 2003	Jul	CHRS	
BX	+	120MG		N021438	002	Mar 12, 2003	Jul	CRLD	
		PROPRANOLOL HYDROCHLORIDE							
>A>	AB	ADARE PHARMS INC	60MG	A078703	001	Jul 15, 2011	Sep	CAHN	
>A>	AB		80MG	A078703	002	Jul 15, 2011	Sep	CAHN	
>A>	AB		120MG	A078703	003	Jul 15, 2011	Sep	CAHN	
>A>	AB		160MG	A078703	004	Jul 15, 2011	Sep	CAHN	
>D>	AB	RP SCHERER	60MG	A078703	001	Jul 15, 2011	Sep	CAHN	
>D>	AB		80MG	A078703	002	Jul 15, 2011	Sep	CAHN	
>D>	AB		120MG	A078703	003	Jul 15, 2011	Sep	CAHN	
>D>	AB		160MG	A078703	004	Jul 15, 2011	Sep	CAHN	
		TABLET;ORAL							
		PROPRANOLOL HYDROCHLORIDE							
>A>	@ ANI PHARMS INC	60MG		A071791	001	Jul 15, 1987	Sep	CAHN	
	@ INNOGENIX	10MG		A070322	002	Oct 22, 1985	May	CMS1	
	@	20MG		A070322	003	Oct 22, 1985	May	CMS1	
	@	40MG		A070322	004	Oct 22, 1985	May	CMS1	
	@	60MG		A070322	005	Sep 24, 1986	May	CMS1	
	@	80MG		A070322	001	Aug 04, 1986	Mar	CAHN	
>D>	@ WATSON LABS	60MG		A071791	001	Jul 15, 1987	Sep	CAHN	
		<u>PROTRIPTYLINE HYDROCHLORIDE</u>							
		TABLET;ORAL							
		VIVACTIL							
AB	HERITAGE PHARMA	5MG		A073644	001	Aug 24, 1995	May	CAHN	
AB	!	10MG		A073645	001	Aug 24, 1995	May	CAHN	
		<u>PYRIDOSTIGMINE BROMIDE</u>							
		INJECTABLE;INJECTION							
		MESTINON							
AP	+! BAUSCH	5MG/ML		N009830	001		Feb	CAHN	
		SYRUP;ORAL							
		MESTINON							
AA	+! BAUSCH	60MG/5ML		N015193	001		Feb	CFTG	
	+!	60MG/5ML		N015193	001		Feb	CAHN	
		PYRIDOSTIGMINE BROMIDE							
AA	NOVITIUM PHARMA	60MG/5ML		A211694	001	Mar 08, 2019	Feb	NFTG	

TABLET;ORAL									
MESTINON									
AB	+	!	BAUSCH	60MG	N009829	002			Feb CAHN
PYRIDOSTIGMINE BROMIDE									
>D>			APNAR PHARMA LP	30MG	A211181	002	May 14, 2019		Sep CAHN
				30MG	A211181	002	May 14, 2019		May NEWA
>D>	AB			60MG	A211181	001	Jul 20, 2018		Sep CAHN
>A>			ELYSIUM	30MG	A211181	002	May 14, 2019		Sep CAHN
>A>	AB			60MG	A211181	001	Jul 20, 2018		Sep CAHN
TABLET, EXTENDED RELEASE;ORAL									
MESTINON									
AB	+	!	BAUSCH	180MG	N011665	001			Feb CAHN
<u>PYRIDOXINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
PYRIDOXINE HYDROCHLORIDE									
			@ DR REDDYS	100MG/ML	A080572	001			May CAHN
<u>QUETIAPINE FUMARATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
QUETIAPINE FUMARATE									
			@ AMNEAL PHARMS	EQ 400MG BASE	A211405	001	Oct 26, 2018		Apr DISC
<u>QUINIDINE GLUCONATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
QUINAGLUTE									
>D>			@ BAYER HLTHCARE	324MG	N016647	001			Sep CRLD
>A>			+ @	324MG	N016647	001			Sep CRLD
QUINIDINE GLUCONATE									
>D>	BX	!	SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987		Sep CTEC
>A>		!		324MG	A089338	001	Feb 11, 1987		Sep CTEC
<u>QUININE SULFATE</u>									
CAPSULE;ORAL									
QUININE SULFATE									
			@ MYLAN PHARMS INC	324MG	A202581	001	Dec 14, 2012		Mar DISC
<u>RABEPRAZOLE SODIUM</u>									
TABLET, DELAYED RELEASE;ORAL									
RABEPRAZOLE SODIUM									
			@ MYLAN	20MG	A076885	001	Nov 08, 2013		Jul DISC
AB			RUBICON	20MG	A204237	001	Nov 18, 2015		Feb CAHN
<u>RAMELTEON</u>									
TABLET;ORAL									
RAMELTEON									
AB			ZYDUS PHARMS	8MG	A211567	001	Jul 22, 2019		Jul NEWA
<u>RANITIDINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
RANITIDINE HYDROCHLORIDE									
AB			APPCO PHARMA LLC	EQ 150MG BASE	A211893	001	Apr 05, 2019		Mar NEWA
AB				EQ 300MG BASE	A211893	002	Apr 05, 2019		Mar NEWA
SYRUP;ORAL									
RANITIDINE HYDROCHLORIDE									
			@ TORRENT	EQ 15MG BASE/ML	A090102	001	May 26, 2009		Jul DISC
AA				EQ 15MG BASE/ML	A090102	001	May 26, 2009		Jan CAHN
TABLET;ORAL									
RANITIDINE HYDROCHLORIDE									
AB			HERITAGE PHARMA	EQ 150MG BASE	A075165	001	Sep 30, 1998		Feb CAHN
AB				EQ 300MG BASE	A075165	002	Sep 30, 1998		Feb CAHN
AB			STRIDES PHARMA	EQ 150MG BASE	A210010	001	Aug 01, 2018		Apr CAHN
AB				EQ 300MG BASE	A210010	002	Aug 01, 2018		Apr CAHN
AB			VKT PHARMA PVT LTD	EQ 150MG BASE	A211289	001	Jan 31, 2019		Jan NEWA
AB				EQ 300MG BASE	A211289	002	Jan 31, 2019		Jan NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL
RANEXA

AB	+	GILEAD	500MG	N021526	002	Jan 27, 2006	Feb CTEC
AB	+	!	1GM	N021526	001	Feb 12, 2007	Feb CTEC

RANOLAZINE

AB		ACTAVIS ELIZABETH	500MG	A208862	001	May 28, 2019	May NEWA
AB			1GM	A208862	002	May 28, 2019	May NEWA
AB		AJANTA PHARMA LTD	500MG	A210054	001	May 28, 2019	May NEWA
AB			1GM	A210054	002	May 28, 2019	May NEWA
AB		CADILA	500MG	A210188	001	Aug 19, 2019	Aug NEWA
AB			1GM	A210188	002	Aug 19, 2019	Aug NEWA
AB		CIPLA	500MG	A211291	001	May 28, 2019	May NEWA
AB			1GM	A211291	002	May 28, 2019	May NEWA
AB		GLENMARK PHARMS LTD	500MG	A211082	001	Jul 05, 2019	Jun NEWA
AB			1GM	A211082	002	Jul 05, 2019	Jun NEWA
AB		LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb CMFD
AB			1GM	A201046	002	Jul 29, 2013	Feb CMFD
AB		SCIEGEN PHARMS INC	500MG	A211829	001	Jun 04, 2019	May NEWA
AB			1GM	A211829	002	Jun 04, 2019	May NEWA
AB		SUN PHARM	500MG	A211707	001	May 28, 2019	May NEWA
AB			1GM	A211707	002	May 28, 2019	May NEWA

RASAGILINE

TABLET;ORAL

RASAGILINE

>A>	AB	INDOCO REMEDIES	EQ 0.5MG BASE	A206153	001	Oct 04, 2019	Sep NEWA
>A>	AB		EQ 1MG BASE	A206153	002	Oct 04, 2019	Sep NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB		MICRO LABS	EQ 0.5MG BASE	A207004	001	Mar 29, 2019	Mar NEWA
AB			EQ 1MG BASE	A207004	002	Mar 29, 2019	Mar NEWA

REPAGLINIDE

TABLET;ORAL

PRANDIN

+	@	GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Mar DISC
+	@		1MG	N020741	002	Dec 22, 1997	Mar DISC
+	@		2MG	N020741	003	Dec 22, 1997	Mar DISC

REPAGLINIDE

AB	!	AUROBINDO PHARMA LTD	2MG	A203820	003	Jan 22, 2014	Mar CHRS
	@	MYLAN	0.5MG	A090252	001	Aug 23, 2013	Feb DISC
	@		1MG	A090252	002	Jan 22, 2014	Jul DISC
	@		2MG	A090252	003	Jan 22, 2014	Jul DISC

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

+	!	ALMIRALL	1%	N022055	001	Apr 12, 2007	Mar CAHN
---	---	----------	----	---------	-----	--------------	----------

RIBAVIRIN

CAPSULE;ORAL

RIBAVIRIN

	@	CASI PHARMS INC	200MG	A076192	001	Apr 06, 2004	Jun DISC
--	---	-----------------	-------	---------	-----	--------------	----------

SOLUTION;ORAL

REBETOL

+	@	SCHERING	40MG/ML	N021546	001	Jul 29, 2003	Jun DISC
---	---	----------	---------	---------	-----	--------------	----------

TABLET;ORAL

RIBAVIRIN

AB		BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb CAHN
AB			400MG	A202546	002	Aug 12, 2014	Feb CAHN
AB			500MG	A202546	003	Aug 12, 2014	Feb CAHN
AB			600MG	A202546	004	Aug 12, 2014	Feb CAHN
AB		HERITAGE PHARMA	200MG	A077053	001	Dec 05, 2005	May CAHN

RILUZOLE

TABLET;ORAL

RILUZOLE

@ DAITO PHARMS CO LTD	50MG	A204430	001	Oct 16, 2018	Mar DISC
-----------------------	------	---------	-----	--------------	----------

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

@ HERITAGE PHARMA	100MG	A076375	001	Jan 14, 2003	May CAHN
-------------------	-------	---------	-----	--------------	----------

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

@ EYEVANCE	1%	N020474	001	Dec 30, 1994	May CAHN
------------	----	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM

@ HANGZHOU BINJIANG	35MG	A207516	001	Feb 15, 2019	Aug DISC	
AB	35MG	A207516	001	Feb 15, 2019	Feb NEWA	
@ MYLAN	5MG	A200477	001	Nov 30, 2015	May DISC	
@	30MG	A200477	002	Nov 30, 2015	May DISC	
@	35MG	A200477	003	Nov 30, 2015	May DISC	
@	75MG	A200477	004	Jun 10, 2014	May DISC	
@	150MG	A200477	005	Jun 10, 2014	May DISC	
AB	ORCHID HLTHCARE	30MG	A205280	001	May 13, 2019	Apr NEWA
AB		35MG	A205280	002	May 13, 2019	Apr NEWA

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

AB	SUN PHARM	35MG	A203925	001	Jul 09, 2019	Jun NEWA
@ ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018	Feb DISC	

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

AA	TORRENT	1MG/ML	A078909	001	Jul 29, 2009	Jan CAHN
----	---------	--------	---------	-----	--------------	----------

TABLET;ORAL

RISPERIDONE

AB	CELLTRION	0.25MG	A078871	001	Oct 09, 2008	Aug CAHN
AB		0.5MG	A078871	002	Oct 09, 2008	Aug CAHN
AB		1MG	A078871	003	Oct 09, 2008	Aug CAHN
AB		2MG	A078871	004	Oct 09, 2008	Aug CAHN
AB		3MG	A078871	005	Oct 09, 2008	Aug CAHN
AB		4MG	A078871	006	Oct 09, 2008	Aug CAHN
>D> AB	CEYONE	0.25MG	A078269	001	Oct 08, 2008	Sep CAHN
>D> AB		0.5MG	A078269	002	Oct 08, 2008	Sep CAHN
>D> AB		1MG	A078269	003	Oct 08, 2008	Sep CAHN
>D> AB		2MG	A078269	004	Oct 08, 2008	Sep CAHN
>D> AB		3MG	A078269	005	Oct 08, 2008	Sep CAHN
>D> AB		4MG	A078269	006	Oct 08, 2008	Sep CAHN
	@ HERITAGE PHARMA	0.25MG	A076228	001	Jun 30, 2008	Aug DISC
AB		0.25MG	A076228	001	Jun 30, 2008	May CAHN
AB		0.25MG	A077769	001	Oct 16, 2008	May CAHN
	@	0.5MG	A076228	002	Jun 30, 2008	Aug DISC
AB		0.5MG	A076228	002	Jun 30, 2008	May CAHN
AB		0.5MG	A077769	002	Oct 16, 2008	May CAHN
	@	1MG	A076228	003	Jun 30, 2008	Aug DISC
AB		1MG	A076228	003	Jun 30, 2008	May CAHN
AB		1MG	A077769	003	Oct 16, 2008	May CAHN
	@	2MG	A076228	004	Jun 30, 2008	Aug DISC
AB		2MG	A076228	004	Jun 30, 2008	May CAHN
AB		2MG	A077769	004	Oct 16, 2008	May CAHN
	@	3MG	A076228	005	Jun 30, 2008	Aug DISC
AB		3MG	A076228	005	Jun 30, 2008	May CAHN
AB		3MG	A077769	005	Oct 16, 2008	May CAHN
	@	4MG	A076228	006	Jun 30, 2008	Aug DISC
AB		4MG	A076228	006	Jun 30, 2008	May CAHN
AB		4MG	A077769	006	Oct 16, 2008	May CAHN
>A> AB	RISING	0.25MG	A078269	001	Oct 08, 2008	Sep CAHN
>A> AB		0.5MG	A078269	002	Oct 08, 2008	Sep CAHN
>A> AB		1MG	A078269	003	Oct 08, 2008	Sep CAHN
>A> AB		2MG	A078269	004	Oct 08, 2008	Sep CAHN

TABLET;ORAL
RISPERIDONE

>A>	AB	3MG	A078269	005	Oct 08, 2008	Sep CAHN
>A>	AB	4MG	A078269	006	Oct 08, 2008	Sep CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB	HERITAGE PHARMA	0.5MG	A076908	001	Mar 12, 2012	May CAHN
AB		1MG	A076908	002	Mar 12, 2012	May CAHN
AB		2MG	A076908	003	Mar 12, 2012	May CAHN

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

AB	ZYDUS NOVELTECH INC	4.6MG/24HR	A206318	001	Mar 04, 2019	Feb NEWA
AB		9.5MG/24HR	A206318	002	Mar 04, 2019	Feb NEWA
AB		13.3MG/24HR	A206318	003	Mar 04, 2019	Feb NEWA

RIVASTIGMINE TARTRATE

CAPSULE;ORAL
EXELON

+	@ NOVARTIS	EQ 1.5MG BASE	N020823	003	Apr 21, 2000	Aug DISC
+	@	EQ 3MG BASE	N020823	004	Apr 21, 2000	Aug DISC
+	@	EQ 4.5MG BASE	N020823	005	Apr 21, 2000	Aug DISC
+	@	EQ 6MG BASE	N020823	006	Apr 21, 2000	Aug DISC

RIVASTIGMINE TARTRATE

AB	! DR REDDYS LABS INC	EQ 1.5MG BASE	A077130	001	Oct 31, 2007	Aug CHRS
AB	!	EQ 6MG BASE	A077130	004	Oct 31, 2007	Aug CHRS

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP	CAMARGO PHARM	50MG/5ML (10MG/ML)	A210437	001	Aug 13, 2019	Jul NEWA
AP		100MG/10ML (10MG/ML)	A210437	002	Aug 13, 2019	Jul NEWA
AP	SANOVEL ILAC	50MG/5ML (10MG/ML)	A210437	001	Aug 13, 2019	Aug CAHN
AP		100MG/10ML (10MG/ML)	A210437	002	Aug 13, 2019	Aug CAHN

ROFLUMILAST

TABLET;ORAL
ROFLUMILAST

AB	MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Mar NEWA
----	------------	--------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

AB	CADILA	EQ 0.25MG BASE	A090411	001	Jun 01, 2009	Feb CAHN	
AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009	Feb CAHN	
AB		EQ 1MG BASE	A090411	003	Jun 01, 2009	Feb CAHN	
AB		EQ 2MG BASE	A090411	004	Jun 01, 2009	Feb CAHN	
AB		EQ 3MG BASE	A090411	005	Jun 01, 2009	Feb CAHN	
AB		EQ 4MG BASE	A090411	006	Jun 01, 2009	Feb CAHN	
AB		EQ 5MG BASE	A090411	007	Jun 01, 2009	Feb CAHN	
AB	CELLTRION	EQ 0.25MG BASE	A079050	001	May 29, 2008	Jul CAHN	
AB		EQ 0.5MG BASE	A079050	002	May 29, 2008	Jul CAHN	
AB		EQ 1MG BASE	A079050	003	May 29, 2008	Jul CAHN	
AB		EQ 2MG BASE	A079050	004	May 29, 2008	Jul CAHN	
AB		EQ 3MG BASE	A079050	005	May 29, 2008	Jul CAHN	
AB		EQ 4MG BASE	A079050	006	May 29, 2008	Jul CAHN	
AB		EQ 5MG BASE	A079050	007	May 29, 2008	Jul CAHN	
>D>	AB	LAX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Sep CAHN
	AB		EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Mar CAHN
>D>	AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Sep CAHN
	AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Mar CAHN
>D>	AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Sep CAHN
	AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Mar CAHN
>D>	AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Sep CAHN
	AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Mar CAHN
>D>	AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Sep CAHN
	AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Mar CAHN
>D>	AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Sep CAHN
	AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Mar CAHN
>D>	AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Sep CAHN
	AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Mar CAHN
>A>	AB	MLV	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Sep CAHN

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

>A>	AB	EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Sep CAHN
>A>	AB	EQ 1MG BASE	A079165	003	Feb 07, 2012	Sep CAHN
>A>	AB	EQ 2MG BASE	A079165	004	Feb 07, 2012	Sep CAHN
>A>	AB	EQ 3MG BASE	A079165	005	Feb 07, 2012	Sep CAHN
>A>	AB	EQ 4MG BASE	A079165	006	Feb 07, 2012	Sep CAHN
>A>	AB	EQ 5MG BASE	A079165	007	Feb 07, 2012	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB	CELLTRION	EQ 2MG BASE	A091395	001	Aug 27, 2012	Aug CAHN
AB		EQ 4MG BASE	A091395	002	Aug 27, 2012	Aug CAHN
AB		EQ 6MG BASE	A091395	003	Aug 27, 2012	Aug CAHN
AB		EQ 8MG BASE	A091395	004	Aug 27, 2012	Aug CAHN
AB		EQ 12MG BASE	A091395	005	Aug 27, 2012	Aug CAHN

ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE

>A>	@ ANI PHARMS INC	EQ 2MG BASE	A076747	001	Jan 25, 2013	Sep CAHN
>A>	@	EQ 4MG BASE	A076747	002	Jan 25, 2013	Sep CAHN
>A>	@	EQ 8MG BASE	A076747	003	Jan 25, 2013	Sep CAHN
>D>	@ TEVA	EQ 2MG BASE	A076747	001	Jan 25, 2013	Sep CAHN
>D>	@	EQ 4MG BASE	A076747	002	Jan 25, 2013	Sep CAHN
>D>	@	EQ 8MG BASE	A076747	003	Jan 25, 2013	Sep CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

	@ AMNEAL PHARMS CO	5MG	A208850	001	Oct 16, 2018	Apr DISC
	@	10MG	A208850	002	Oct 16, 2018	Apr DISC
	@	20MG	A208850	003	Oct 16, 2018	Apr DISC
	@	40MG	A208850	004	Oct 16, 2018	Apr DISC
	@ MYLAN	5MG	A079161	001	Jul 19, 2016	Jul DISC
	@	10MG	A079161	002	Jul 19, 2016	Jul DISC
	@	20MG	A079161	003	Jul 19, 2016	Jul DISC
	@	40MG	A079161	004	Jul 19, 2016	Jul DISC
AB	SCIEGEN PHARMS INC	5MG	A206381	001	Apr 24, 2019	Apr NEWA
AB		10MG	A206381	002	Apr 24, 2019	Apr NEWA
AB		20MG	A206381	003	Apr 24, 2019	Apr NEWA
AB		40MG	A206381	004	Apr 24, 2019	Apr NEWA
AB	SHANDONG	5MG	A207375	001	May 07, 2019	Apr NEWA
AB		10MG	A207375	002	May 07, 2019	Apr NEWA
AB		20MG	A207375	003	May 07, 2019	Apr NEWA
AB		40MG	A207375	004	May 07, 2019	Apr NEWA
	@ TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul DISC
	@	10MG	A079166	002	Jul 19, 2016	Jul DISC
	@	20MG	A079166	003	Jul 19, 2016	Jul DISC
	@	40MG	A079166	004	Jul 19, 2016	Jul DISC
	@ ZYDUS PHARMS	5MG	A206513	001	Mar 01, 2019	Aug DISC
AB		5MG	A206513	001	Mar 01, 2019	Feb NEWA
	@	10MG	A206513	002	Mar 01, 2019	Aug DISC
AB		10MG	A206513	002	Mar 01, 2019	Feb NEWA
	@	20MG	A206513	003	Mar 01, 2019	Aug DISC
AB		20MG	A206513	003	Mar 01, 2019	Feb NEWA
	@	40MG	A206513	004	Mar 01, 2019	Aug DISC
AB		40MG	A206513	004	Mar 01, 2019	Feb NEWA

RUFINAMIDE

SUSPENSION;ORAL

BANZEL

AB	+! EISAI INC	40MG/ML	N201367	001	Mar 03, 2011	Apr CFTG
AB	BIONPHARMA INC	40MG/ML	A211388	001	Apr 23, 2019	Apr NFTG
AB	HIKMA	40MG/ML	A207363	001	Apr 23, 2019	Apr NFTG

TABLET;ORAL

RUFINAMIDE

	@ MYLAN	200MG	A205095	001	May 16, 2016	Feb DISC
	@	400MG	A205095	002	May 16, 2016	Feb DISC

SAPROPTERIN DIHYDROCHLORIDEPOWDER; ORAL
KUVAN

AB	+	BIOMARIN PHARM	100MG/PACKET	N205065	001	Dec 19, 2013	Aug CFTG
>D>	AB	+	500MG/PACKET	N205065	002	Oct 27, 2015	Sep CTEC
>A>		+	500MG/PACKET	N205065	002	Oct 27, 2015	Sep CTEC
AB	+		500MG/PACKET	N205065	002	Oct 27, 2015	Aug CFTG

SAPROPTERIN DIHYDROCHLORIDE

AB		PAR PHARM INC	100MG/PACKET	A207207	001	Aug 20, 2019	Aug NFTG
>D>	AB		500MG/PACKET	A210027	001	Aug 20, 2019	Sep DISC
>A>		@	500MG/PACKET	A210027	001	Aug 20, 2019	Sep DISC
AB			500MG/PACKET	A210027	001	Aug 20, 2019	Aug NFTG

TABLET; ORAL
KUVAN

	+	BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007	May CTEC
AB	+		100MG	N022181	001	Dec 13, 2007	Apr CFTG
		SAPROPTERIN DIHYDROCHLORIDE					
		@ PAR PHARM INC	100MG	A207200	001	May 10, 2019	May DISC
AB			100MG	A207200	001	May 10, 2019	Apr NFTG

SCOPOLAMINEFILM, EXTENDED RELEASE; TRANSDERMAL
SCOPOLAMINE

AB		MYLAN TECHNOLOGIES	1MG/72HR	A203753	001	Jun 19, 2019	Jun NEWA
----	--	--------------------	----------	---------	-----	--------------	----------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

AB		BOSCOGEN	5MG	A074912	001	Apr 30, 1998	Jun CAHN
AB		KENTON	5MG	A074912	001	Apr 30, 1998	Mar CAHN
		@ MYLAN	5MG	A074866	001	Nov 26, 1997	Aug DISC

TABLET, ORALLY DISINTEGRATING; ORAL
ZELAPAR

	+	BAUSCH	1.25MG	N021479	001	Jun 14, 2006	Mar CAHN
--	---	--------	--------	---------	-----	--------------	----------

SELENIOUS ACIDSOLUTION; INTRAVENOUS
SELENIOUS ACID

	+	AM REGENT	EQ 600MCG BASE/10ML (EQ 60MCG BASE/ML)	N209379	001	Apr 30, 2019	Apr NEWA
--	---	-----------	--	---------	-----	--------------	----------

SELINEXORTABLET; ORAL
XPOVIO

	+	KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019	Jul NEWA
--	---	--------------------	------	---------	-----	--------------	----------

SEMAGLUTIDE

TABLET; ORAL

RYBELSUS

>A>		+	NOVO	3MG	N213051	001	Sep 20, 2019	Sep NEWA
>A>		+		7MG	N213051	002	Sep 20, 2019	Sep NEWA
>A>		+		14MG	N213051	003	Sep 20, 2019	Sep NEWA

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

	+	BAUSCH	2%	N021385	001	Dec 10, 2003	Jun CAHN
--	---	--------	----	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

		@ CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007	Jun DISC
AB			EQ 25MG BASE	A077106	001	Feb 06, 2007	Feb CAHN
		@	EQ 50MG BASE	A077106	002	Feb 06, 2007	Jun DISC
AB			EQ 50MG BASE	A077106	002	Feb 06, 2007	Feb CAHN
		@	EQ 100MG BASE	A077106	003	Feb 06, 2007	Jun DISC
AB			EQ 100MG BASE	A077106	003	Feb 06, 2007	Feb CAHN
		@ HERITAGE PHARMA	EQ 25MG BASE	A077299	001	Feb 06, 2007	May CAHN
		@	EQ 25MG BASE	A077345	001	Feb 06, 2007	May CAHN
		@	EQ 50MG BASE	A077299	002	Feb 06, 2007	May CAHN
		@	EQ 50MG BASE	A077345	002	Feb 06, 2007	May CAHN

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	EQ 100MG BASE	A077299	003	Feb 06, 2007	May CAHN
@	EQ 100MG BASE	A077345	003	Feb 06, 2007	May CAHN
@ MYLAN PHARMS INC	EQ 25MG BASE	A078626	001	Jan 31, 2008	May DISC
@	EQ 50MG BASE	A078626	002	Jan 31, 2008	May DISC

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

AB	+ GENZYME	400MG	N021179	001	Jul 12, 2000	Feb CFTG
AB	+!	800MG	N021179	002	Jul 12, 2000	Feb CFTG
	SEVELAMER HYDROCHLORIDE					
AB	GLENMARK PHARMS LTD	400MG	A204724	001	Feb 08, 2019	Feb NFTG
AB		800MG	A204724	002	Feb 08, 2019	Feb NFTG

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

REVATIO

AB	+! PFIZER	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	May CFTG
	SILDENAFIL CITRATE					
AB	NOVITIUM PHARMA	EQ 10MG BASE/ML	A212260	001	May 31, 2019	May NFTG

TABLET;ORAL

SILDENAFIL CITRATE

AB	LUPIN LTD	EQ 25MG BASE	A212051	001	Mar 22, 2019	Mar NEWA
AB		EQ 50MG BASE	A212051	002	Mar 22, 2019	Mar NEWA
AB		EQ 100MG BASE	A212051	003	Mar 22, 2019	Mar NEWA
AB	MYLAN	EQ 25MG BASE	A201171	001	Mar 25, 2019	Mar NEWA
AB		EQ 50MG BASE	A201171	002	Mar 25, 2019	Mar NEWA
AB		EQ 100MG BASE	A201171	003	Mar 25, 2019	Mar NEWA

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

AB	MICRO LABS	5MG	A090383	001	Sep 16, 2011	Mar CAHN
AB		10MG	A090383	002	Sep 16, 2011	Mar CAHN
AB		20MG	A090383	003	Sep 16, 2011	Mar CAHN
AB		40MG	A090383	004	Sep 16, 2011	Mar CAHN
AB		80MG	A090383	005	Sep 16, 2011	Mar CAHN

SIPONIMOD

TABLET;ORAL

MAYZENT

+	NOVARTIS PHARMS CORP	0.25MG	N209884	001	Mar 26, 2019	Mar NEWA
+	!	2MG	N209884	002	Mar 26, 2019	Mar NEWA

SIPONIMOD FUMARIC ACID

TABLET;ORAL

MAYZENT

+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr CAIN
+	!	EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr CAIN

SIROLIMUS

SOLUTION;ORAL

RAPAMUNE

AA	+! PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999	Jan CFTG
	SIROLIMUS					
AA	NOVITIUM PHARMA	1MG/ML	A211040	001	Jan 28, 2019	Jan NFTG

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

	EXELA PHARMA SCS LLC	0.5MEQ/ML	A211091	001	Jun 20, 2019	Jun NEWA
AP		0.9MEQ/ML	A211091	002	Jun 20, 2019	Jun NEWA
AP		1MEQ/ML	A211091	003	Jun 20, 2019	Jun NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>A>	AP	JUBILANT CADISTA	9MG/ML	A203352	001	May 18, 2016	Sep CAHN
>D>	AP	JUBILANT HOLLISTRSTR	9MG/ML	A203352	001	May 18, 2016	Sep CAHN
		+ @ LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Aug DISC
		SODIUM CHLORIDE 3% IN PLASTIC CONTAINER					
	AP	FRESENIUS KABI USA	3GM/100ML	A209476	001	Mar 13, 2019	Feb NEWA

SODIUM CHROMATE CR-51

INJECTABLE;INJECTION

SODIUM CHROMATE CR 51

@	CURIUM	100uCi/ML	N016708	001		Jan CAHN
---	--------	-----------	---------	-----	--	----------

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP	DECATUR	10-200mCi/ML	A204464	001	Oct 21, 2014	Apr CAHN
----	---------	--------------	---------	-----	--------------	----------

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

@	CURIUM	0.8-100mCi	N016515	002		Jan CAHN
+ @		0.8-100mCi	N016517	001		Jan CAHN
@		15-100uCi	N016517	002		Jan CAHN

SOLUTION;ORAL

SODIUM IODIDE I 131

+ @	CURIUM	3.5-150mCi/VIAL	N016515	001		Jan CAHN
-----	--------	-----------------	---------	-----	--	----------

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

AP	DR REDDYS LABS LTD	25MG/ML	A210114	001	Apr 10, 2019	Mar NEWA	
>D>	AP	NAMIGEN LLC	25MG/ML	A207426	001	Dec 08, 2016	Sep CAHN
>A>	AP	SAGENT PHARMS INC	25MG/ML	A207426	001	Dec 08, 2016	Sep CAHN
		@ SUN PHARM	25MG/ML	A210467	001	Nov 26, 2018	Jul DISC
AP	VIRTUS PHARM	25MG/ML	A209834	001	Jun 26, 2018	Jul CAHN	

SOLUTION;INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+ @	EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017	Jul DISC
-----	----------------------	----------------------	---------	-----	--------------	----------

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

AB	+! HORIZON THERAP	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Feb CAHN
----	-------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

BUPHENYL

AB	+! HORIZON THERAP	500MG	N020572	001	May 13, 1996	Feb CAHN
----	-------------------	-------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>D>	AA	AILEX PHARMS LLC	454GM/BOT	A206815	001	Feb 18, 2016	Sep CAHN
>A>	AA	NOVELGENIX THERAPS	454GM/BOT	A206815	001	Feb 18, 2016	Sep CAHN

SOFOSBUVIR

PELLETS;ORAL

SOVALDI

+	GILEAD SCIENCES INC	150MG/PACKET	N212480	001	Aug 28, 2019	Aug NEWA
+		200MG/PACKET	N212480	002	Aug 28, 2019	Aug NEWA

TABLET;ORAL

SOVALDI

+	GILEAD SCIENCES INC	200MG	N204671	002	Aug 28, 2019	Aug NEWA
---	---------------------	-------	---------	-----	--------------	----------

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019	May NEWA
AB		10MG	A205483	002	May 20, 2019	May NEWA
AB	ALEMBIC PHARMS LTD	5MG	A205575	001	May 20, 2019	May NEWA

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB		10MG	A205575	002	May 20, 2019	May NEWA
AB	ALKEM LABS LTD	5MG	A210224	001	May 20, 2019	May NEWA
AB		10MG	A210224	002	May 20, 2019	May NEWA
AB	AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019	May NEWA
AB		10MG	A209719	002	May 20, 2019	May NEWA
AB	BRECKENRIDGE	5MG	A209818	001	May 20, 2019	May NEWA
AB		10MG	A209818	002	May 20, 2019	May NEWA
AB	CELLTRION	5MG	A210582	001	May 20, 2019	May NEWA
AB		10MG	A210582	002	May 20, 2019	May NEWA
AB	CIPLA	5MG	A209839	001	May 20, 2019	May NEWA
AB		10MG	A209839	002	May 20, 2019	May NEWA
AB	GLENMARK PHARMS INC	5MG	A209239	001	May 20, 2019	May NEWA
AB		10MG	A209239	002	May 20, 2019	May NEWA
AB	JIANGXI BOYA SEEHOT	5MG	A210281	001	May 20, 2019	May NEWA
AB		10MG	A210281	002	May 20, 2019	May NEWA
AB	MSN LABS PVT LTD	5MG	A210688	001	May 20, 2019	May NEWA
AB		10MG	A210688	002	May 20, 2019	May NEWA
AB	QILU PHARM CO LTD	5MG	A209333	001	May 20, 2019	May NEWA
AB		10MG	A209333	002	May 20, 2019	May NEWA
AB	SCIEGEN PHARMS INC	5MG	A211657	001	May 20, 2019	May NEWA
AB		10MG	A211657	002	May 20, 2019	May NEWA
>A> AB	STRIDES PHARMA	5MG	A212214	001	Sep 26, 2019	Sep NEWA
>A> AB		10MG	A212214	002	Sep 26, 2019	Sep NEWA
AB	UNICHEM LABS LTD	5MG	A211701	001	Aug 27, 2019	Aug NEWA
AB		10MG	A211701	002	Aug 27, 2019	Aug NEWA
AB	WATSON LABS INC	5MG	A202551	001	May 20, 2019	May NEWA
AB		10MG	A202551	002	May 20, 2019	May NEWA

SOLRIAMFETOL

TABLET;ORAL

SUNOSI

+	JAZZ	75MG	N211230	001	Jun 17, 2019	Jun NEWA
+		150MG	N211230	002	Jun 17, 2019	Jun NEWA

SOMATROPIN

INJECTABLE;INJECTION

GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280	006	Aug 24, 1995	Aug CAIN
	+		13.8MG/VIAL	N020280	007	Oct 23, 1996	Aug CAIN
		GENOTROPIN PRESERVATIVE FREE					
	+	PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998	Aug CAIN
	+		0.4MG/VIAL	N020280	002	Jan 27, 1998	Aug CAIN
	+		0.6MG/VIAL	N020280	003	Jan 27, 1998	Aug CAIN
	+		0.8MG/VIAL	N020280	005	Jan 27, 1998	Aug CAIN
	+		1MG/VIAL	N020280	008	Jan 27, 1998	Aug CAIN
	+		1.2MG/VIAL	N020280	009	Jan 27, 1998	Aug CAIN
	+		1.4MG/VIAL	N020280	010	Jan 27, 1998	Aug CAIN
	+	@	1.5MG/VIAL	N020280	004	Aug 24, 1995	Aug CAIN
	+		1.6MG/VIAL	N020280	011	Jan 27, 1998	Aug CAIN
	+		1.8MG/VIAL	N020280	012	Jan 27, 1998	Aug CAIN
	+		2MG/VIAL	N020280	013	Jan 27, 1998	Aug CAIN

NORDITROPIN

	@	NOVO NORDISK INC	5MG/1.5ML	N021148	001	Jun 20, 2000	Aug CAIN
	@		10MG/1.5ML	N021148	002	Jun 20, 2000	Aug CAIN
	@		15MG/1.5ML	N021148	003	Jun 20, 2000	Aug CAIN

NORDITROPIN FLEXPRO

BX		NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010	Aug CAIN
BX			10MG/1.5ML	N021148	009	Mar 01, 2010	Aug CAIN
			15MG/1.5ML	N021148	010	Mar 01, 2010	Aug CAIN
			30MG/3ML	N021148	011	Jan 23, 2015	Aug CAIN

NORDITROPIN NORDIFLEX

	@	NOVO NORDISK INC	5MG/1.5ML	N021148	004	Oct 01, 2004	Aug CAIN
	@		10MG/1.5ML	N021148	005	Oct 01, 2004	Aug CAIN
	@		15MG/1.5ML	N021148	006	Oct 01, 2004	Aug CAIN
	@		30MG/3ML	N021148	007	Mar 10, 2009	Aug CAIN

NUTROPIN

	@	GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Aug CAIN
	@		10MG/VIAL	N020168	002	Nov 17, 1993	Aug CAIN
		NUTROPIN AQ					
	@	GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Aug CAIN

INJECTABLE; INJECTION							
NUTROPIN AQ NUSPIN							
	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Aug CAIN
	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Aug CAIN
	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Aug CAIN
NUTROPIN AQ PEN							
	+	@ GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002	Aug CAIN
	+	@	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Aug CAIN
OMNITROPE							
BX		SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006	Aug CAIN
BX			5MG/1.5ML	N021426	003	Jan 16, 2008	Aug CAIN
BX			5.8MG/VIAL	N021426	001	May 30, 2006	Aug CAIN
BX			10MG/1.5ML	N021426	004	Aug 25, 2008	Aug CAIN
SAIZEN							
	@	EMD SERONO	4MG/VIAL	N019764	005	Jan 16, 2007	Aug CAIN
BX	+		5MG/VIAL	N019764	002	Oct 08, 1996	Aug CAIN
	@		6MG/VIAL	N019764	001	Oct 08, 1996	Aug CAIN
	+		8.8MG/VIAL	N019764	003	Aug 29, 2000	Aug CAIN
SEROSTIM							
		EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997	Aug CAIN
BX			5MG/VIAL	N020604	002	Aug 23, 1996	Aug CAIN
BX			6MG/VIAL	N020604	001	Aug 23, 1996	Aug CAIN
	@		8.8MG/VIAL	N020604	004	Sep 06, 2001	Aug CAIN
INJECTABLE; SUBCUTANEOUS							
SEROSTIM LQ							
	@	EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604	005	Feb 11, 2005	Aug CAIN
<u>SOTALOL HYDROCHLORIDE</u>							
TABLET; ORAL							
BETAPACE							
AB	+	COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May CTEC
AB	+		120MG	N019865	005	Apr 20, 1994	May CTEC
AB	+		160MG	N019865	002	Oct 30, 1992	May CTEC
AB	+		240MG	N019865	003	Oct 30, 1992	May CTEC
BETAPACE AF							
AB	+	COVIS PHARMA BV	80MG	N021151	001	Feb 22, 2000	May CTEC
AB	+		120MG	N021151	002	Feb 22, 2000	May CTEC
AB	+		160MG	N021151	003	Feb 22, 2000	May CTEC
SORINE							
AB		UPSHER SMITH LABS	80MG	A075500	001	Apr 27, 2001	May CTEC
AB			120MG	A075500	004	Apr 27, 2001	May CTEC
AB			160MG	A075500	002	Apr 27, 2001	May CTEC
AB			240MG	A075500	003	Apr 27, 2001	May CTEC
SOTALOL HYDROCHLORIDE							
AB		APOTEX	80MG	A076214	001	Aug 27, 2003	May CTEC
AB			120MG	A076214	002	Aug 27, 2003	May CTEC
AB			160MG	A076214	003	Aug 27, 2003	May CTEC
AB		APOTEX INC	80MG	A076140	001	Sep 26, 2002	May CTEC
AB			120MG	A076140	002	Sep 26, 2002	May CTEC
AB			160MG	A076140	003	Sep 26, 2002	May CTEC
AB			240MG	A076140	004	Sep 26, 2002	May CTEC
AB		BEXIMCO PHARMS USA	80MG	A207428	001	Oct 21, 2016	May CTEC
AB			80MG	A207429	001	Nov 02, 2018	May CTEC
AB			120MG	A207428	002	Oct 21, 2016	May CTEC
AB			120MG	A207429	002	Nov 02, 2018	May CTEC
AB			160MG	A207428	003	Oct 21, 2016	May CTEC
AB			160MG	A207429	003	Nov 02, 2018	May CTEC
AB		EPIC PHARMA INC	80MG	A077070	001	Nov 04, 2005	May CTEC
AB			120MG	A077070	002	Nov 04, 2005	May CTEC
AB			160MG	A077070	003	Nov 04, 2005	May CTEC
AB		MYLAN	80MG	A077616	001	Feb 07, 2007	May CTEC
AB			120MG	A077616	002	Feb 07, 2007	May CTEC
AB			160MG	A077616	003	Feb 07, 2007	May CTEC
AB		OXFORD PHARMS	80MG	A075563	001	Nov 07, 2003	May CTEC
AB			120MG	A075563	002	Nov 07, 2003	May CTEC
AB			160MG	A075563	003	Nov 07, 2003	May CTEC
AB			240MG	A075563	004	Nov 07, 2003	May CTEC
AB		TEVA	80MG	A075429	001	May 01, 2000	May CTEC
AB			120MG	A075429	002	May 01, 2000	May CTEC
AB			160MG	A075429	003	May 01, 2000	May CTEC
AB			240MG	A075429	004	May 01, 2000	May CTEC
	@	UPSHER SMITH LABS	80MG	A075366	001	May 01, 2000	Jun DISC
AB			80MG	A075366	001	May 01, 2000	May CTEC

TABLET;ORAL

SOTALOL HYDROCHLORIDE							
	@	120MG	A075366	002	May 01, 2000	Jun	DISC
AB		120MG	A075366	002	May 01, 2000	May	CTEC
	@	160MG	A075366	003	May 01, 2000	Jun	DISC
AB		160MG	A075366	003	May 01, 2000	May	CTEC
	@	240MG	A075366	004	May 01, 2000	Jun	DISC
AB		240MG	A075366	004	May 01, 2000	May	CTEC

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

@	ACTAVIS ELIZABETH	25MG	A040353	003	Mar 15, 2006	Jun	DISC
@		50MG	A040353	001	Jul 29, 1999	Jun	DISC
@		100MG	A040353	002	Jul 29, 1999	Jun	DISC
@	CASI PHARMS INC	25MG	A086809	001		Jun	DISC

STAVUDINE

FOR SOLUTION;ORAL

ZERIT

+	@	BRISTOL-MYERS SQUIBB	1MG/ML	N020413	001	Sep 06, 1996	Mar	DISC
---	---	----------------------	--------	---------	-----	--------------	-----	------

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION

METASTRON

AP	+	Q BIOMED	1mCi/ML	N020134	001	Jun 18, 1993	Jan	CAHN
----	---	----------	---------	---------	-----	--------------	-----	------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

AP		AMRING PHARMS	20MG/ML	A210231	001	Jun 04, 2018	Jan	CAHN
AP		DR REDDYS	20MG/ML	A210698	001	Aug 02, 2019	Jul	NEWA
>A>	AP	GPP	20MG/ML	A212638	001	Oct 09, 2019	Sep	NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE;INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>A>	AP	ANDA REPOSITORY	80MG/ML;16MG/ML	A212231	001	Jun 26, 2019	Sep	CAHN
AP	!	MYLAN LABS LTD	80MG/ML;16MG/ML	A206607	001	Aug 30, 2017	Aug	CHRS
>D>	AP	SOMERSET THERAPS LLC	80MG/ML;16MG/ML	A212231	001	Jun 26, 2019	Sep	CAHN
AP			80MG/ML;16MG/ML	A212231	001	Jun 26, 2019	Jun	NEWA
	@	TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991	Aug	DISC

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

AB		HERITAGE PHARMA	800MG;160MG	A070037	001	Jun 02, 1987	May	CAHN
----	--	-----------------	-------------	---------	-----	--------------	-----	------

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH

AB		HERITAGE PHARMA	400MG;80MG	A070030	001	Jun 02, 1987	May	CAHN
----	--	-----------------	------------	---------	-----	--------------	-----	------

SUMATRIPTAN

SPRAY;NASAL

TOSYMRA

	+	DR REDDYS LABS LTD	10MG/SPRAY	N210884	001	Jan 25, 2019	Jan	NEWA
>D>	+	UPSHER SMITH LABS	10MG/SPRAY	N210884	001	Jan 25, 2019	Sep	CAHN
>A>	+		10MG/SPRAY	N210884	001	Jan 25, 2019	Sep	CAHN
	+		10MG/SPRAY	N210884	001	Jan 25, 2019	Jul	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

>D>	AP	MYLAN LABS LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014	Sep	DISC
>A>	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014	Sep	DISC
	@	PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	Apr	DISC
	@	ZYDUS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Apr	CAHN

POWDER;INHALATION

ONZETRA XSAIL

>D>	+	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Sep	CDFR
-----	---	---------------	--------------	---------	-----	--------------	-----	------

>A>	POWDER;NASAL						
>A>	ONZETRA XSAIL						
>A>	+! AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Sep	CDFR
>A>	+! CURRAX	EQ 11MG BASE	N206099	001	Jan 27, 2016	Sep	CAHN
	SOLUTION;SUBCUTANEOUS						
	ZEMBRACE SYMTOUCH						
	+ UPSHER SMITH LABS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jul	CAHN
<u>TACROLIMUS</u>							
	OINTMENT;TOPICAL						
	TACROLIMUS						
AB	ACCORD HLTHCARE	0.03%	A211688	001	Jan 31, 2019	Jan	NEWA
AB		0.1%	A211688	002	Jan 31, 2019	Jan	NEWA
<u>TADALAFIL</u>							
	TABLET;ORAL						
	ALYQ						
AB2	TEVA PHARMS USA	20MG	A209942	001	Feb 05, 2019	Jan	NEWA
	TADALAFIL						
AB	ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209167	002	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209167	004	Mar 26, 2019	Mar	NEWA
AB	AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209654	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209654	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209654	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210392	001	Feb 05, 2019	Jan	NEWA
AB	ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A204809	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A204809	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A204809	004	Mar 26, 2019	Mar	NEWA
AB	AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209744	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209744	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209744	004	Mar 26, 2019	Mar	NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A206285	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A206285	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A206285	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A206286	001	Feb 05, 2019	Jan	NEWA
AB	CIPLA	2.5MG	A209539	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209539	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209539	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209539	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210255	001	Feb 05, 2019	Jan	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A210069	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A210069	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A210069	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210145	001	Feb 05, 2019	Jan	NEWA
AB	HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209908	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209908	003	Mar 26, 2019	Mar	NEWA
AB2		20MG	A209907	001	Feb 05, 2019	Jan	NEWA
AB1		20MG	A209908	004	Mar 26, 2019	Mar	NEWA
AB	LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A210567	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A210567	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A210567	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210572	001	Feb 05, 2019	Jan	NEWA
>A> AB	MACLEODS PHARMS LTD	2.5MG	A207244	001	Oct 07, 2019	Sep	NEWA
>A> AB		5MG	A207244	002	Oct 07, 2019	Sep	NEWA
>A> AB		10MG	A207244	003	Oct 07, 2019	Sep	NEWA
>A> AB1		20MG	A207244	004	Oct 07, 2019	Sep	NEWA
>A> AB2		20MG	A207290	001	Oct 16, 2019	Sep	NEWA
AB	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Apr	NEWA
AB		5MG	A206957	001	Apr 29, 2019	Apr	NEWA
AB		10MG	A206956	002	Apr 29, 2019	Apr	NEWA
AB1		20MG	A206956	003	Apr 29, 2019	Apr	NEWA
AB	QILU PHARM CO LTD	2.5MG	A210420	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A210420	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A210420	003	Mar 26, 2019	Mar	NEWA

TABLET;ORAL
TADALAFIL

AB1		20MG	A210420	004	Mar 26, 2019	Mar NEWA
AB	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Mar NEWA
AB		5MG	A208934	002	Mar 26, 2019	Mar NEWA
AB		10MG	A208934	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A208934	004	Mar 26, 2019	Mar NEWA
AB	SUNSHINE LAKE	2.5MG	A211335	001	Mar 26, 2019	Mar NEWA
AB		5MG	A211335	002	Mar 26, 2019	Mar NEWA
AB		10MG	A211335	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A211335	004	Mar 26, 2019	Mar NEWA
AB	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Mar NEWA
AB		5MG	A211839	002	Mar 26, 2019	Mar NEWA
AB		10MG	A211839	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A211839	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A212062	001	Mar 26, 2019	Mar NEWA
AB	UNICHEM LABS LTD	2.5MG	A209250	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209250	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209250	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209250	004	Mar 26, 2019	Mar NEWA
>D> AB	WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019	Sep DISC
>A> @		2.5MG	A205885	001	Mar 29, 2019	Sep DISC
AB		2.5MG	A205885	001	Mar 29, 2019	Mar NEWA
>D> AB		5MG	A205885	002	Mar 29, 2019	Sep DISC
>A> @		5MG	A205885	002	Mar 29, 2019	Sep DISC
AB		5MG	A205885	002	Mar 29, 2019	Mar NEWA
>D> AB		10MG	A205885	003	Mar 29, 2019	Sep DISC
>A> @		10MG	A205885	003	Mar 29, 2019	Sep DISC
AB		10MG	A205885	003	Mar 29, 2019	Mar NEWA
>D> AB1		20MG	A205885	004	Mar 29, 2019	Sep DISC
>A> @		20MG	A205885	004	Mar 29, 2019	Sep DISC
AB1		20MG	A205885	004	Mar 29, 2019	Mar NEWA
AB	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Mar NEWA
AB		5MG	A206693	002	Mar 26, 2019	Mar NEWA
AB		10MG	A206693	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A206693	004	Mar 26, 2019	Mar NEWA

TAFAMIDIS

CAPSULE;ORAL
VYNDAMAX

+!	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019	May NEWA
----	---------------	------	---------	-----	--------------	----------

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL
VYNDAQEL

+!	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	May NEWA
----	---------------	------	---------	-----	--------------	----------

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC
TAFLUPROST

AT	MICRO LABS	0.0015%	A209051	001	Aug 19, 2019	Aug NFTG
AT	ZIOPTAN					
AT	+! OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012	Aug CFTG

TAMOXIFEN CITRATE

SOLUTION;ORAL
SOLTAMOX

	FORTOVIA	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Aug CAHN
--	----------	-------------------	---------	-----	--------------	----------

TAZAROTENE

CREAM;TOPICAL
TAZAROTENE

	@ FOUGERA PHARMS INC	0.1%	A211175	001	Jan 28, 2019	Aug DISC
AB		0.1%	A211175	001	Jan 28, 2019	May CPOT
AB		1%	A211175	001	Jan 28, 2019	Jan NEWA

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE;INJECTION
HEPATOLITE

@	PHARMALUCENCE	N/A	N018467	001	Mar 16, 1982	Aug DISC
---	---------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION
TECHNISCAN MAG3

AP	+	!	CURIUM	N/A	N019882	001	Jun 15, 1990	Jul CFTG
	+	!		N/A	N019882	001	Jun 15, 1990	Jan CAHN
TECHNETIUM TC99M MERTIATIDE KIT								
AP			PHARMALUCENCE	N/A	A208994	001	Jul 12, 2019	Jul NFTG

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION
TECHNISCAN

+	!	CURIUM	N/A	N018321	001			Jan CAHN
---	---	--------	-----	---------	-----	--	--	----------

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
DRAXIMAGE DTPA

>A>								
>A>	+	!	JUBILANT DRAXIMAGE	N/A	N018511	001	Dec 29, 1989	Sep CTNA
>D>			DTPA					
>D>	+	!	JUBILANT DRAXIMAGE	N/A	N018511	001	Dec 29, 1989	Sep CTNA

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION
TECHNISCAN PYP KIT

AP			CURIUM	N/A	N017538	001		Jan CAHN
----	--	--	--------	-----	---------	-----	--	----------

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION
ULTRATAG

+	!	CURIUM	N/A	N019981	001	Jun 10, 1991	Jan CAHN
---	---	--------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS
ULTRA-TECHNEKOW FM

+	!	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan CAHN
@			0.25-3 CI/GENERATOR	N017243	002		Jan CAHN

SOLUTION; INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

+	@	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	Feb DISC
---	---	---------------	----------------------	---------	-----	--------------	----------

TEGASEROD MALEATE

TABLET; ORAL
ZELNORM

	+	@	ALFASIGMA	EQ 2MG BASE	N021200	001	Jul 24, 2002	Aug CAHN
>D>	+	@		EQ 6MG BASE	N021200	002	Jul 24, 2002	Sep CMFD
>A>	+	!		EQ 6MG BASE	N021200	002	Jul 24, 2002	Sep CMFD
	+	@		EQ 6MG BASE	N021200	002	Jul 24, 2002	Aug CAHN
	+	@	US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002	Jul CRLD
	+	@		EQ 6MG BASE	N021200	002	Jul 24, 2002	Jul CRLD

TELMISARTAN

TABLET; ORAL
TELMISARTAN

	@	CIPLA	20MG	A078710	001	Jan 08, 2014	Jun DISC
AB			20MG	A078710	001	Jan 08, 2014	Feb CAHN
	@		40MG	A078710	002	Jan 08, 2014	Feb CAHN
	@		80MG	A078710	003	Jan 08, 2014	Feb CAHN
	@	HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019	Aug DISC
AB			20MG	A207843	001	Feb 19, 2019	Feb NEWA
	@		40MG	A207843	002	Feb 19, 2019	Aug DISC
AB			40MG	A207843	002	Feb 19, 2019	Feb NEWA
	@		80MG	A207843	003	Feb 19, 2019	Aug DISC
AB			80MG	A207843	003	Feb 19, 2019	Feb NEWA
AB		INVENTIA	20MG	A205150	001	Oct 30, 2015	Aug CAHN
			40MG	A205150	002	Oct 30, 2015	Aug CAHN
AB			80MG	A205150	003	Oct 30, 2015	Aug CAHN
	@	MICRO LABS	20MG	A207016	001	Oct 03, 2017	Mar DISC
	@		40MG	A207016	002	Oct 03, 2017	Mar DISC
	@		80MG	A207016	003	Oct 03, 2017	Mar DISC
	@	WATSON LABS	80MG	A078710	003	Jan 08, 2014	Feb DISC

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

@ APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jan DISC
@	20MG	A204159	002	Jul 05, 2018	Jan DISC
@	100MG	A204159	003	Jul 05, 2018	Jan DISC
@	140MG	A204159	004	Jul 05, 2018	Jan DISC
@	180MG	A204159	005	Jul 05, 2018	Jan DISC
@	250MG	A204159	006	Jul 05, 2018	Jan DISC

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TEMSIROLIMUS

AP	GLAND PHARMA LTD	25MG/ML (25MG/ML)	A207383	001	Aug 16, 2019	Aug NEWA
----	------------------	-------------------	---------	-----	--------------	----------

>A> TENAPANOR HYDROCHLORIDE

>A> TABLET; ORAL

>A> IBSRELA

>A>	+	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Sep NEWA
-----	---	-------------	--------------	---------	-----	--------------	----------

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

@ APOTEX INC	300MG	A206481	001	Jul 26, 2018	Jan DISC
--------------	-------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	APNAR PHARMA LP	EQ 1MG BASE	A074823	001	Mar 30, 1998	Jun CAHN
AB	!	EQ 2MG BASE	A074823	002	Mar 30, 1998	Jun CAHN
AB		EQ 5MG BASE	A074823	003	Mar 30, 1998	Jun CAHN
AB		EQ 10MG BASE	A074823	004	Mar 30, 1998	Jun CAHN
	@ BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Feb CAHN
	@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Feb CAHN
	@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Feb CAHN
	@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Feb CAHN
AB	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Mar CAHN
AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	Mar CAHN
AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	Mar CAHN
AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	Mar CAHN
AB	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun CAHN
AB		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun CAHN
AB		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun CAHN
AB		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 250MG BASE	A076377	001	Jul 02, 2007	May CAHN
----	-----------------	---------------	---------	-----	--------------	----------

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@ DR REDDYS	1MG/ML	A076853	001	Jul 20, 2004	May CAHN
-------------	--------	---------	-----	--------------	----------

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

BX	+	FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004	May CAHN
----	---	--------------------	------	---------	-----	--------------	----------

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB	!	PERRIGO ISRAEL	80MG	A077149	001	Mar 17, 2006	May CAHN
----	---	----------------	------	---------	-----	--------------	----------

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

AB	ALEMBIC PHARMS LTD	7MG	A209572	001	Apr 19, 2019	Apr NEWA
AB		14MG	A209572	002	Apr 19, 2019	Apr NEWA
	@ AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb DISC
	@	14MG	A209613	002	Sep 28, 2018	Feb DISC
	@ APOTEX INC	7MG	A209601	001	Nov 02, 2018	Jan DISC

TABLET;ORAL

TERIFLUNOMIDE

	@		14MG	A209601	002	Nov 02, 2018	Jan DISC
	@	AUROBINDO PHARMA LTD	7MG	A209638	001	Oct 26, 2018	Feb DISC
	@		14MG	A209638	002	Oct 26, 2018	Feb DISC
AB		MSN LABS PVT LTD	7MG	A209623	001	Apr 24, 2019	Apr NEWA
AB			14MG	A209623	002	Apr 24, 2019	Apr NEWA
	@	TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Mar DISC
	@		14MG	A209700	002	Sep 04, 2018	Mar DISC
	@	WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018	Feb DISC
	@		14MG	A209549	002	Jul 27, 2018	Feb DISC
	@	ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	May DISC
	@		14MG	A209668	002	Nov 30, 2018	May DISC

TESTOSTERONE

GEL;TRANSDERMAL

TESTOSTERONE

	@	PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Mar DISC
--	---	-----------	-------------------	---------	-----	--------------	----------

GEL, METERED;TRANSDERMAL

TESTOSTERONE

AB		ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM ACTUATION)	A204570	001	Apr 10, 2019	Mar NEWA
AB		AMNEAL PHARMS LLC	1.62% (20.25MG/1.25GM ACTUATION)	A207373	001	Apr 10, 2019	Mar NEWA
AB		DR REDDYS	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Mar NEWA
AB		LUPIN ATLANTIS	1.62% (20.25MG/1.25GM ACTUATION)	A208560	001	Apr 10, 2019	Mar NEWA
>A> AB		TWI PHARMS	1.62% (20.25MG/1.25GM ACTUATION)	A209390	001	Sep 23, 2019	Sep NEWA

TABLET, EXTENDED RELEASE;BUCCAL

STRIANT

	+	@	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	Jul DISC
--	---	---	---------------------	------	---------	-----	--------------	----------

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

	@	MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006	Mar DISC
AO		WILSHIRE PHARMS INC	200MG/ML	A206368	001	Apr 24, 2019	Apr NEWA

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL

JATENZO

	+	CLARUS	158MG	N206089	001	Mar 27, 2019	Mar NEWA
	+		198MG	N206089	002	Mar 27, 2019	Mar NEWA
	+	!	237MG	N206089	003	Mar 27, 2019	Mar NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

	@	LUPIN LTD	12.5MG	A210544	001	Apr 20, 2018	Feb DISC
	@		25MG	A210544	002	Apr 20, 2018	Feb DISC
AB		MYLAN	12.5MG	A207682	001	Jan 31, 2017	Jul CAHN
AB			25MG	A207682	002	Jan 31, 2017	Jul CAHN
AB		WEST-WARD PHARMS INT	12.5MG	A209739	001	Apr 08, 2019	Mar NEWA
AB			25MG	A209739	002	Apr 08, 2019	Mar NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

TETRACAINE HYDROCHLORIDE

		BAUSCH	0.5%	N210821	001	Mar 12, 2019	Apr CAHN
		VALEANT PHARMS	0.5%	N210821	001	Mar 12, 2019	Mar NEWA

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION

THALLOUS CHLORIDE TL 201

AP	+	!	CURIUM	1mCi/ML	N018150	001	Jan CAHN
----	---	---	--------	---------	---------	-----	----------

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB	!	HERITAGE PHARMA	100MG	A089807	001	Apr 30, 1990	Feb CAHN
AB	!		200MG	A089808	001	Apr 30, 1990	Feb CAHN
AB			300MG	A089763	001	Apr 30, 1990	Feb CAHN
	@		450MG	A081236	001	Nov 09, 1992	Feb CAHN

THIOTHIXENECAPSULE;ORAL
THIOTHIXENE

AB	MYLAN	1MG	A071093	002	Jun 23, 1987	Mar CTEC
AB		2MG	A071093	003	Jun 23, 1987	Mar CTEC
AB		5MG	A071093	004	Jun 23, 1987	Jul CHRS
AB	!	5MG	A071093	004	Jun 23, 1987	Mar CTEC
AB		10MG	A071093	001	Jun 23, 1987	Mar CTEC
AB	NOVITIUM PHARMA	1MG	A211642	001	Apr 05, 2019	Mar NEWA
AB		2MG	A211642	002	Apr 05, 2019	Mar NEWA
AB	!	5MG	A211642	003	Apr 05, 2019	Jul CHRS
AB		5MG	A211642	003	Apr 05, 2019	Mar NEWA
AB		10MG	A211642	004	Apr 05, 2019	Mar NEWA

THIOTHIXENE HYDROCHLORIDECONCENTRATE;ORAL
THIOTHIXENE HYDROCHLORIDE INTENSOL

>D>	@ CYCLE PHARMS LTD	EQ 5MG BASE/ML	A073494	001	Jun 30, 1992	Sep CAHN
>A>	@ HIKMA	EQ 5MG BASE/ML	A073494	001	Jun 30, 1992	Sep CAHN

TICAGRELORTABLET;ORAL
BRILINTA

	+ ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jun CTEC
	TICAGRELOR					
	@ AMNEAL PHARMS CO	90MG	A208531	001	Jan 23, 2019	Jun DISC
AB		90MG	A208531	001	Jan 23, 2019	Jan NEWA
AB	HISUN PHARM HANGZHOU	90MG	A208575	001	Jan 23, 2019	Jan NEWA
	@ WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Feb DISC
	@	90MG	A208390	002	Sep 04, 2018	Feb DISC

TIGECYCLINEPOWDER;INTRAVENOUS
TIGECYCLINE

AP	AMNEAL PHARMS LLC	50MG/VIAL	N211158	001	Aug 02, 2018	Jul CMFD
	@	50MG/VIAL	N211158	001	Aug 02, 2018	Feb DISC
AP	AUROBINDO PHARMA LTD	50MG/VIAL	A206335	001	Jun 11, 2019	May NEWA

TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC
TIMOPTIC

AT	+ VALEANT PHARMS INTL	EQ 0.25% BASE	N018086	001		Jan CAHN
AT1	+	EQ 0.5% BASE	N018086	002		Jan CAHN
	TIMOPTIC IN OCUDOSE					
	+! VALEANT PHARMS INTL	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Jan CAHN
	+!	EQ 0.5% BASE	N019463	002	Nov 05, 1986	Jan CAHN

TABLET;ORAL
BLOCADREN

	+ @ MERCK	5MG	N018017	001		Apr CRLD
	+ @	10MG	N018017	002		Apr CRLD
	+ @	20MG	N018017	004		Apr CRLD

TIMOLOL MALEATE

>A>	@ ANI PHARMS INC	5MG	A072917	001	Jul 31, 1991	Sep CAHN
>A>	@	10MG	A072918	001	Jul 31, 1991	Sep CAHN
>A>	@	20MG	A072919	001	Jul 31, 1991	Sep CAHN
>A> AB	ELYSIUM	5MG	A207556	001	May 02, 2019	Sep CAHN
>A> AB		10MG	A207556	002	May 02, 2019	Sep CAHN
>A> AB		20MG	A207556	003	May 02, 2019	Sep CAHN
>D> AB	INVATECH PHARMA	5MG	A207556	001	May 02, 2019	Sep CAHN
		5MG	A207556	001	May 02, 2019	Apr NEWA
>D> AB		10MG	A207556	002	May 02, 2019	Sep CAHN
AB		10MG	A207556	002	May 02, 2019	Apr NEWA
>D> AB		20MG	A207556	003	May 02, 2019	Sep CAHN
AB		20MG	A207556	003	May 02, 2019	Apr NEWA
AB	MYLAN	5MG	A072668	002	Jun 08, 1990	Apr CTEC
AB		10MG	A072668	003	Jun 08, 1990	Apr CTEC
AB	!	20MG	A072668	001	Jun 08, 1990	Apr CTEC
>D>	@ WATSON LABS	5MG	A072917	001	Jul 31, 1991	Sep CAHN
>D>	@	10MG	A072918	001	Jul 31, 1991	Sep CAHN
>D>	@	20MG	A072919	001	Jul 31, 1991	Sep CAHN

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL
THIOLA EC

+	MISSION PHARMACAL CO	100MG	N211843	001	Jun 28, 2019	Jun NEWA
+	!	300MG	N211843	002	Jun 28, 2019	Jun NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL
TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A212196	001	Mar 27, 2019	Mar NEWA
AB		EQ 4MG BASE	A212196	002	Mar 27, 2019	Mar NEWA
AB		EQ 6MG BASE	A212196	003	Mar 27, 2019	Mar NEWA
AB	CADILA PHARMS LTD	EQ 2MG BASE	A210021	001	Mar 26, 2019	Mar NEWA
AB		EQ 4MG BASE	A210021	002	Mar 26, 2019	Mar NEWA
AB		EQ 6MG BASE	A210021	003	Mar 26, 2019	Mar NEWA
>A> AB	NOVAST LABS	EQ 2MG BASE	A210267	001	Mar 12, 2019	Sep CAHN
>A> AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Sep CAHN
>A> AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Sep CAHN
>D> AB	RICONPHARMA LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Sep CAHN
AB		EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb NEWA
>D> AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Sep CAHN
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb NEWA
>D> AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Sep CAHN
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb NEWA

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A211798	001	Jan 25, 2019	Jan NEWA
AB		EQ 4MG BASE	A211798	002	Jan 25, 2019	Jan NEWA
	@ ANI PHARMS INC	EQ 2MG BASE	A076283	001	Jul 12, 2002	May CAHN
>A> AB		EQ 2MG BASE	A076284	001	Jul 03, 2002	Sep CAHN
	@	EQ 2MG BASE	A076371	001	Apr 09, 2003	May CAHN
	@	EQ 4MG BASE	A076283	002	Jul 12, 2002	May CAHN
>A> AB		EQ 4MG BASE	A076284	002	Jul 03, 2002	Sep CAHN
	@	EQ 4MG BASE	A076371	002	Apr 09, 2003	May CAHN
	@ PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Mar DISC
	@	EQ 4MG BASE	A207170	002	Jan 26, 2017	Mar DISC
>D> AB	TEVA	EQ 2MG BASE	A076284	001	Jul 03, 2002	Sep CAHN
>D> AB		EQ 4MG BASE	A076284	002	Jul 03, 2002	Sep CAHN

TOBRAMYCIN

SOLUTION;INHALATION
BETHKIS

+	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Jul CTEC
AN	+	300MG/4ML	N201820	001	Oct 12, 2012	Jun CFTG

TOBRAMYCIN

AN	DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Mar CMFD
	@	300MG/5ML	A207080	001	Jul 09, 2018	Jan DISC
	@ TEVA PHARMS USA	300MG/4ML	A210915	001	Jun 26, 2019	Jul DISC
AN		300MG/4ML	A210915	001	Jun 26, 2019	Jun NFTG

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	ALEMBIC PHARMS LTD	0.3%	A211847	001	Apr 19, 2019	Apr NEWA
----	--------------------	------	---------	-----	--------------	----------

TOFACITINIB CITRATE

TABLET;ORAL

XELJANZ

+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	May CHRS
---	-------------	-------------	---------	-----	--------------	----------

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@	COSETTE	100MG	N018894	001	Nov 02, 1984	Jun CAHN
@		250MG	N018894	002	Nov 02, 1984	Jun CAHN
@		500MG	N018894	003	Nov 02, 1984	Jun CAHN

TOLCAPONE

TABLET;ORAL

TASMAR

AB	+	BAUSCH	100MG	N020697	001	Jan 29, 1998	Mar CAHN
	@		200MG	N020697	002	Jan 29, 1998	Mar CAHN

TABLET;ORAL

TOLCAPONE

>D>	AB	INGENUS PHARMS LLC	100MG	A208937	001	Aug 07, 2018	Sep CAHN
>D>	AB	KINEDEXE UK	100MG	A210095	001	Aug 01, 2019	Sep CAHN
	AB		100MG	A210095	001	Aug 01, 2019	Jul NEWA
>A>	AB	MAYNE PHARMA	100MG	A210095	001	Aug 01, 2019	Sep CAHN
>A>	AB	NOVAST LABS	100MG	A208937	001	Aug 07, 2018	Sep CAHN

TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM

	@	ANI PHARMS INC	EQ 400MG BASE	A073308	001	Jan 24, 1992	May CAHN
>A>	@		EQ 400MG BASE	A073519	001	May 29, 1992	Sep CAHN
>D>	@	TEVA	EQ 400MG BASE	A073519	001	May 29, 1992	Sep CAHN

TABLET;ORAL

TOLMETIN SODIUM

@ ANI PHARMS INC EQ 600MG BASE

A073527 001 Jun 30, 1992 May CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AB		INVENTIA HLTHCARE	2MG	A204562	001	Aug 19, 2019	Aug NEWA
AB			4MG	A204562	002	Aug 19, 2019	Aug NEWA

TOLVAPTAN

TABLET;ORAL

JYNARQUE

+	!	OTSUKA PHARM CO LTD	45MG	N204441	003	Apr 23, 2018	Jun CHRS
+			90MG	N204441	005	Apr 23, 2018	Jun CHRS

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

QUDEXY XR

BC	+	UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014	Feb CTEC
BC	+		50MG	N205122	002	Mar 11, 2014	Feb CTEC
BC	+		100MG	N205122	003	Mar 11, 2014	Feb CTEC
BC	+	!	200MG	N205122	005	Mar 11, 2014	Feb CTEC

TROKENDI XR

BC	+	!	SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Apr CTEC
----	---	---	-----------------	-------	---------	-----	--------------	----------

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB		POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Jun NEWA
AB		RUBICON	50MG	A208708	001	Jun 28, 2019	Jun NEWA
AB			100MG	A208708	002	Jun 28, 2019	Jun NEWA
AB		UNICHEM LABS LTD	50MG	A211825	001	Aug 09, 2019	Jul NEWA

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

>D>	AB1	AUROBINDO PHARMA LTD	100MG	A204421	001	Oct 20, 2015	Sep DISC
>A>	@		100MG	A204421	001	Oct 20, 2015	Sep DISC
>D>	AB1		200MG	A204421	002	Oct 20, 2015	Sep DISC
>A>	@		200MG	A204421	002	Oct 20, 2015	Sep DISC
>D>	AB1		300MG	A204421	003	Oct 20, 2015	Sep DISC
>A>	@		300MG	A204421	003	Oct 20, 2015	Sep DISC

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARKA

+	@	ABBVIE	1MG;240MG	N020591	003	Oct 22, 1996	Aug DISC
		TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE					
		GLENMARK GENERICS	1MG;240MG	A079135	004	Aug 30, 2010	Aug CTEC

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP		APOLLO PHARMS INC	100MG/ML	A212676	001	Jul 17, 2019	Jul NEWA	
AP		CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jul NEWA	
	+	!	EXELA PHARMA SCS LLC	10MG/ML	N212020	001	Apr 15, 2019	Apr NEWA
AP		MICRO LABS	100MG/ML	A206713	001	Jun 27, 2017	Mar CAHN	

SOLUTION;INTRAVENOUS
TRANEXAMIC ACID

+! EXELA PHARMA SCS LLC 1GM/100ML (10MG/ML)

N212020 001 Apr 15, 2019 May CPOT

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS
TREPROSTINIL

>A>	AP	PAR STERILE PRODUCTS	1MG/ML	A209382	001	Sep 24, 2019	Sep NEWA
>A>	AP		2.5MG/ML	A209382	002	Sep 24, 2019	Sep NEWA
>A>	AP		5MG/ML	A209382	003	Sep 24, 2019	Sep NEWA
>A>	AP		10MG/ML	A209382	004	Sep 24, 2019	Sep NEWA
>A>	AP	TEVA PHARMS USA	1MG/ML	A206648	001	Sep 26, 2019	Sep NEWA
>A>	AP		2.5MG/ML	A206648	002	Sep 26, 2019	Sep NEWA
>A>	AP		5MG/ML	A206648	003	Sep 26, 2019	Sep NEWA
>A>	AP		10MG/ML	A206648	004	Sep 26, 2019	Sep NEWA

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL
ORENITRAM

+! UNITED THERAP EQ 1MG BASE
+ EQ 2.5MG BASE

N203496 003 Dec 20, 2013 Feb CHRS
N203496 004 Dec 20, 2013 Feb CHRS

TRETINOIN

CREAM;TOPICAL
TRETINOIN

AB1	TARO PHARMS	0.05%	A211644	001	Jan 25, 2019	Jan NEWA
AB		0.1%	A211645	001	Jan 22, 2019	Jan NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
TRIAMCINOLONE ACETONIDE

>A>	AT	MLV	0.025%	A040671	001	Jun 09, 2006	Sep CAHN
>A>	AT		0.1%	A040671	002	Jun 09, 2006	Sep CAHN
>D>	AT	SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	Sep CAHN
	AT		0.025%	A040671	001	Jun 09, 2006	May CAHN
>D>	AT		0.1%	A040671	002	Jun 09, 2006	Sep CAHN
	AT		0.1%	A040671	002	Jun 09, 2006	May CAHN
	AT	STRIDES PHARMA	0.025%	A210346	001	Feb 11, 2019	Jan NEWA
	AT		0.1%	A210346	002	Feb 11, 2019	Jan NEWA
	AT		0.5%	A210346	003	Feb 11, 2019	Jan NEWA

INJECTABLE;INJECTION
KENALOG-80

+! APOTHECON 80MG/ML

N014901 002 Apr 12, 2019 Apr NEWA

TRIAMCINOLONE ACETONIDE

AB	TEVA PHARMS USA	40MG/ML	A209852	001	Oct 05, 2018	Jul CMFD
@		40MG/ML	A209852	001	Oct 05, 2018	Mar DISC

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT	ALLIED	0.1%	A040672	002	Dec 13, 2006	Sep CAHN
>D>	AT	SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006	Sep CAHN
	AT		0.1%	A040672	002	Dec 13, 2006	May CAHN

TRIAMTERENE

CAPSULE;ORAL
DYRENIUM

AB	+ CONCORDIA	50MG	N013174	001		Aug CFTG
AB	+!	100MG	N013174	002		Aug CFTG

TRIAMTERENE

AB	AGNITIO	50MG	A211581	001	Aug 19, 2019	Aug NFTG
AB		100MG	A211581	002	Aug 19, 2019	Aug NFTG

TRICLABENDAZOLE

TABLET;ORAL
EGATEN

+! NOVARTIS 250MG

N208711 001 Feb 13, 2019 Feb NEWA

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL
SYPRINE

>D>	AB	+! ATON	250MG	N019194	001	Nov 08, 1985	Sep CAHN
>A>	AB	+! BAUSCH	250MG	N019194	001	Nov 08, 1985	Sep CAHN

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	250MG	A210619	001	Feb 08, 2019	Feb NEWA
AB	DR REDDYS LABS LTD	250MG	A211076	001	Jul 03, 2019	Jun NEWA
>A> AB	KADMON PHARMS LLC	250MG	A209415	001	Sep 16, 2019	Sep NEWA
AB	MSN LABS PVT LTD	250MG	A211134	001	May 22, 2019	May NEWA
>A> AB	PAR PHARM INC	250MG	A210096	001	Sep 25, 2019	Sep NEWA
AB	ZYDUS PHARMS	250MG	A211554	001	Apr 26, 2019	Apr NEWA

TRIMETHADIONE

TABLET;ORAL

TRIDIONE

+ @ ABBVIE	150MG	N005856	009		Jul DISC
------------	-------	---------	-----	--	----------

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	LUPIN	300MG	A076546	001	Aug 20, 2003	Feb CAHN
INJECTABLE;INJECTION						
TIGAN						
+! PAR STERILE PRODUCTS	100MG/ML	N017530	001		May CTEC	

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

SURMONTIL

+ @ ODYSSEY PHARMS	EQ 25MG BASE	N016792	001		Jul DISC	
+ @	EQ 50MG BASE	N016792	002		Jul DISC	
+ @	EQ 100MG BASE	N016792	003	Sep 15, 1982	Jul DISC	
TRIMIPRAMINE MALEATE						
AB	! CROSSMEDIKA SA	EQ 50MG BASE	A208127	002	Apr 15, 2016	Jul CHRS

UPADACITINIB

TABLET, EXTENDED RELEASE;ORAL

RINVOQ

+! ABBVIE INC	EQ 15MG BASE	N211675	001	Aug 16, 2019	Aug NEWA
---------------	--------------	---------	-----	--------------	----------

URSODIOL

CAPSULE;ORAL

URSODIOL

AB	AMNEAL PHARMS CO	300MG	A211301	001	Oct 16, 2018	Jun CMFD
	@	300MG	A211301	001	Oct 16, 2018	Apr DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

@ WATSON LABS INC	EQ 500MG BASE	A090370	001	Mar 16, 2011	Apr DISC
@	EQ 1GM BASE	A090370	002	Mar 16, 2011	Apr DISC

VALPROATE SODIUM

INJECTABLE;INJECTION

DEPACON

+ @ ABBVIE	EQ 100MG BASE/ML	N020593	001	Dec 30, 1996	Apr DISC	
VALPROATE SODIUM						
AP	! HIKMA FARMACEUTICA	EQ 100MG BASE/ML	A078523	001	Feb 17, 2010	Apr CHRS

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	NOVELGENIX THERAPS	250MG	A207611	001	Aug 05, 2019	Jul NEWA
	@ UPSHER SMITH LABS	250MG	A070631	001	Jun 11, 1987	Jul CAHN
SYRUP;ORAL						
DEPAKENE						
+ @ ABBVIE	250MG/5ML	N018082	001		Aug DISC	
VALPROIC ACID						
AA	! PHARM ASSOC	250MG/5ML	A075379	001	Dec 15, 2000	Aug CHRS

VALRUBICINSOLUTION; INTRAVESICAL
VALRUBICIN

AO	CUSTOPHARM INC	40MG/ML	A206430	001	Apr 19, 2019	Apr NFTG
	VALSTAR PRESERVATIVE FREE					
AO	+! ENDO PHARM	40MG/ML	N020892	001	Sep 25, 1998	Apr CFTG

VALSARTANTABLET; ORAL
VALSARTAN

AB	ALKEM LABS LTD	40MG	A205536	001	Mar 12, 2019	Feb NEWA
AB		80MG	A205536	002	Mar 12, 2019	Feb NEWA
AB		160MG	A205536	003	Mar 12, 2019	Feb NEWA
AB		320MG	A205536	004	Mar 12, 2019	Feb NEWA

VANCOMYCIN HYDROCHLORIDECAPSULE; ORAL
VANCOMYCIN HYDROCHLORIDE

AB	ORIENT PHARMA CO LTD	EQ 125MG BASE	A210729	001	Apr 29, 2019	Apr NEWA
AB		EQ 250MG BASE	A210729	002	Apr 29, 2019	Apr NEWA

FOR SOLUTION; ORAL
VANCOCIN HYDROCHLORIDE

ANI PHARMS INC EQ 250MG BASE/5ML

A061667 002 Jul 13, 1983 Jul CMFD

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

AP	HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	May NEWA
AP		EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	May NEWA

SOLUTION; INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

+! XELLIA PHARMS APS EQ 500MG BASE/100ML
 +! EQ 1GM BASE/200ML
 +! EQ 1.5GM BASE/300ML
 +! EQ 2GM BASE/400ML

N211962 001 Feb 15, 2019 Feb NEWA
 N211962 002 Feb 15, 2019 Feb NEWA
 N211962 003 Feb 15, 2019 Feb NEWA
 N211962 004 Feb 15, 2019 Feb NEWA

VARDENAFIL HYDROCHLORIDETABLET; ORAL
VARDENAFIL HYDROCHLORIDE

@ AMNEAL PHARMS CO 5MG
 @ 10MG
 @ 20MG

A210738 001 Oct 31, 2018 Apr DISC
 A210738 002 Oct 31, 2018 Apr DISC
 A210738 003 Oct 31, 2018 Apr DISC

VASOPRESSINSOLUTION; INTRAVENOUS
VASOSTRICT

+! PAR STERILE PRODUCTS 20UNITS/ML (20UNITS/ML)
 +! 200UNITS/10ML (20UNITS/ML)

N204485 001 Apr 17, 2014 Mar CDFR
 N204485 002 Dec 17, 2016 Mar CDFR

VECURONIUM BROMIDEINJECTABLE; INJECTION
VECURONIUM BROMIDE

AP	HIKMA	10MG/VIAL	A203725	001	Jul 30, 2019	Jul NEWA
AP		20MG/VIAL	A203725	002	Jul 30, 2019	Jul NEWA

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

AB	ANNORA PHARMA	EQ 37.5MG BASE	A212277	001	Jul 08, 2019	Jun NEWA
AB		EQ 75MG BASE	A212277	002	Jul 08, 2019	Jun NEWA
AB		EQ 150MG BASE	A212277	003	Jul 08, 2019	Jun NEWA

TABLET, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

AB	CADILA PHARMS LTD	EQ 75MG BASE	A211323	001	Aug 29, 2019	Aug NEWA
AB		EQ 150MG BASE	A211323	002	Aug 29, 2019	Aug NEWA
AB		EQ 225MG BASE	A211323	003	Aug 29, 2019	Aug NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

@ MYLAN

300MG

A078306 003 Aug 09, 2007 May DISC

VERELAN PM

+! RECRO GAINESVILLE

300MG

N020943 003 Nov 25, 1998 May CTEC

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

>A> AP ANDA REPOSITORY 5MG/2ML (2.5MG/ML)

>A> AP 10MG/4ML (2.5MG/ML)

>D> AP SOMERSET THERAPS LLC 5MG/2ML (2.5MG/ML)

>D> AP 10MG/4ML (2.5MG/ML)

A211035 001 Jun 18, 2018 Sep CAHN

A211035 002 Jun 18, 2018 Sep CAHN

A211035 001 Jun 18, 2018 Sep CAHN

A211035 002 Jun 18, 2018 Sep CAHN

TABLET;ORAL

CALAN

+ @ GD SEARLE LLC

80MG

N018817 001 Sep 10, 1984 May DISC

AB

+

120MG

N018817 002 Sep 10, 1984 May CHRS

VERAPAMIL HYDROCHLORIDE

AB

!

HERITAGE PHARMS INC

120MG

A071881 001 Apr 05, 1988 May CHRS

VIGABATRIN

FOR SOLUTION;ORAL

VIGADRONE

AA

AUCTA

500MG/PACKET

A210196 001 Jun 21, 2018 Jun CAHN

AA

SHANGHAI

500MG/PACKET

A210196 001 Jun 21, 2018 Mar CAHN

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

>D> +! ALLERGAN SALES LLC 10MG

>A> AB +! 10MG

>D> + 20MG

>A> AB + 20MG

>D> + 40MG

>A> AB + 40MG

N022567 001 Jan 21, 2011 Sep CFTG

N022567 001 Jan 21, 2011 Sep CFTG

N022567 002 Jan 21, 2011 Sep CFTG

N022567 002 Jan 21, 2011 Sep CFTG

N022567 003 Jan 21, 2011 Sep CFTG

N022567 003 Jan 21, 2011 Sep CFTG

>A> VILAZODONE HYDROCHLORIDE

>A> AB TEVA PHARMS USA 10MG

>A> AB 20MG

>A> AB 40MG

A208212 001 Sep 30, 2019 Sep NFTG

A208212 002 Sep 30, 2019 Sep NFTG

A208212 003 Sep 30, 2019 Sep NFTG

VINCRIStINE SULFATE

INJECTABLE, LIPOSOMAL;INTRAVENOUS

MARQIBO KIT

+! ACROTECH

5MG/5ML (1MG/ML)

N202497 001 Aug 09, 2012 Mar CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION

NAVELBINE

+ @ PIERRE FABRE

EQ 10MG BASE/ML

N020388 001 Dec 23, 1994 Jun DISC

VINORELBINE TARTRATE

>D> AP INGENUS PHARMS LLC EQ 10MG BASE/ML

AP EQ 10MG BASE/ML

>A> AP NOVAST LABS EQ 10MG BASE/ML

A208997 001 Aug 05, 2019 Sep CAHN

A208997 001 Aug 05, 2019 Jul NEWA

A208997 001 Aug 05, 2019 Sep CAHN

VORAPAXAR SULFATE

TABLET;ORAL

ZONTIVITY

+! TOPROL

EQ 2.08MG BASE

N204886 001 May 08, 2014 May CAHN

VORICONAZOLE

INJECTABLE;INTRAVENOUS

VFEND

AP

+!

PF PRISM CV

200MG/VIAL

N021267 001 May 24, 2002 May CDFR

VORICONAZOLE

>A> AP ALVOGEN 200MG/VIAL

>D> AP ALVOGEN INC 200MG/VIAL

AP 200MG/VIAL

AP HAINAN POLY PHARM 200MG/VIAL

AP SANDOZ INC 200MG/VIAL

AP ZYDUS PHARMS 200MG/VIAL

A206398 001 Mar 23, 2016 Sep CAHN

A206398 001 Mar 23, 2016 Sep CAHN

A206398 001 Mar 23, 2016 May CDFR

A211661 001 Nov 30, 2018 May CDFR

A090862 001 May 30, 2012 May CDFR

A208983 001 Jul 16, 2018 May CDFR

POWDER; INTRAVENOUS							
VORICONAZOLE							
AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	May	CDFR
POWDER; IV (INFUSION)							
VORICONAZOLE							
AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Feb	CTEC
TABLET; ORAL							
VORICONAZOLE							
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	Feb	CAHN
AB		200MG	A206762	002	May 24, 2016	Feb	CAHN
AB	CADILA	50MG	A206747	001	May 24, 2016	Apr	CAHN
AB		200MG	A206747	002	May 24, 2016	Apr	CAHN

WARFARIN SODIUM

TABLET; ORAL							
JANTOVEN							
AB	UPSHER SMITH LABS	1MG	A040416	001	Oct 02, 2003	Jul	CAHN
AB		2MG	A040416	002	Oct 02, 2003	Jul	CAHN
AB		2.5MG	A040416	003	Oct 02, 2003	Jul	CAHN
AB		3MG	A040416	004	Oct 02, 2003	Jul	CAHN
AB		4MG	A040416	005	Oct 02, 2003	Jul	CAHN
AB		5MG	A040416	006	Oct 02, 2003	Jul	CAHN
AB		6MG	A040416	007	Oct 02, 2003	Jul	CAHN
AB		7.5MG	A040416	008	Oct 02, 2003	Jul	CAHN
AB		10MG	A040416	009	Oct 02, 2003	Jul	CAHN

XENON XE-133

GAS; INHALATION							
XENON XE 133							
	CURIUM	10mCi/VIAL	N018327	001	Mar 09, 1982	May	CAHN
		20mCi/VIAL	N018327	002	Mar 09, 1982	May	CAHN

ZIDOVUDINE

INJECTABLE; INJECTION							
ZIDOVUDINE							
	@ LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	DISC

ZINC SULFATE

SOLUTION; INTRAVENOUS							
ZINC SULFATE							
+	AM REGENT	EQ 25MG BASE/5ML (EQ 5 BASE/ML)	N209377	002	Jul 18, 2019	Jul	NEWA
+		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019	Jul	NEWA

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL							
ZIPRASIDONE HYDROCHLORIDE							
	@ CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Jun	DISC
AB		EQ 20MG BASE	A208988	001	Aug 22, 2017	Feb	CAHN
	@	EQ 40MG BASE	A208988	002	Aug 22, 2017	Jun	DISC
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Feb	CAHN
	@	EQ 60MG BASE	A208988	003	Aug 22, 2017	Jun	DISC
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Feb	CAHN
	@	EQ 80MG BASE	A208988	004	Aug 22, 2017	Jun	DISC
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Feb	CAHN

ZOLEDRONIC ACID

	INJECTABLE; INTRAVENOUS						
	RECLAST						
AP	+!	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar CDFR
		ZOLEDRONIC					
AP		GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Mar CDFR
		ZOLEDRONIC ACID					
AP		ACCORD HLTHCARE	EQ 4MG BASE/5ML	A205279	001	Nov 28, 2016	Mar CDFR
	@	ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Jul DISC
AP			EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Mar CDFR
AP		AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Mar CDFR
AP		AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	Mar CDFR
AP		APOTEX INC	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar CDFR
AP		AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Mar CDFR
AP			EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Mar CDFR
AP		BPI LABS LLC	EQ 4MG BASE/5ML	A207341	001	Dec 29, 2017	Mar CDFR
AP		BRECKENRIDGE	EO 4MG BASE/5ML	A091170	001	Mar 04, 2013	Mar CDFR

INJECTABLE; INTRAVENOUS
ZOLEDRONIC ACID

AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Mar CDFR
AP	CIPLA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Mar CDFR
AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	May CDFR
AP		EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar CDFR
AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar CDFR
AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Mar CDFR
AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Mar CDFR
AP		EQ 5MG BASE/100ML	A209578	001	Aug 08, 2019	Jul NEWA
AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	Mar CDFR
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar CDFR
AP		EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar CDFR
AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Mar CDFR
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Mar CDFR
AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Mar CDFR
AP	SAGENT PHARMS INC	EQ 4MG BASE/5ML	A091493	001	Nov 24, 2014	Mar CDFR
AP	SHILPA MEDICARE LTD	EQ 4MG BASE/5ML	A208513	001	May 15, 2019	Apr NEWA
	@ SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Mar CDFR
	@	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Mar CDFR
AP	USV	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Jun CAHN
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar CDFR
	ZOMETA					
	+ @ NOVARTIS	EQ 4MG BASE/VIAL	N021223	001	Aug 20, 2001	Mar CDFR
AP	+	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Mar CDFR
AP	+	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Mar CDFR

INJECTABLE; IV (INFUSION)
ZOLEDRONIC ACID

AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Mar CDFR
	SOLUTION; INTRAVENOUS ZOLEDRONIC ACID					
	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Mar CDFR

ZOLMITRIPTANTABLET, ORALLY DISINTEGRATING; ORAL
ZOLMITRIPTAN

>A>	AB	MYLAN	2.5MG	A202855	001	Sep 20, 2019	Sep NEWA
>A>	AB		5MG	A202855	002	Sep 20, 2019	Sep NEWA

ZOLPIDEM TARTRATESPRAY, METERED; ORAL
ZOLPIMIST

+	!	AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008	Feb CAHN
---	---	------	-----------	---------	-----	--------------	----------

TABLET; ORAL

ZOLPIDEM TARTRATE

@	STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007	Apr CAHN
@		10MG	A076062	002	Apr 23, 2007	Apr CAHN
@	WOCKHARDT	5MG	A078426	001	May 15, 2007	Aug DISC
@		10MG	A078426	002	May 15, 2007	Aug DISC

TABLET; SUBLINGUAL

ZOLPIDEM TARTRATE

AB	!	NOVEL LABS INC	3.5MG	A204299	002	Jun 03, 2015	Mar CHRS
----	---	----------------	-------	---------	-----	--------------	----------

ZONISAMIDECAPSULE; ORAL
ZONISAMIDE

AB		BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Apr CAHN
AB			50MG	A077813	002	Aug 16, 2006	Apr CAHN
AB			100MG	A077813	003	Aug 16, 2006	Apr CAHN
AB		CELLTRION	25MG	A077636	003	Jul 27, 2006	Aug CAHN
AB			50MG	A077636	002	Jul 27, 2006	Aug CAHN
AB			100MG	A077636	001	Dec 22, 2005	Aug CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

ACP NIMBLE 120MG

N018060 001

Feb CAHN

@ 325MG

N018060 003 Dec 18, 1986

Feb CAHN

@ 650MG

N018060 002

Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

GRANULES INDIA LTD 650MG

A211544 001 Apr 16, 2019

Apr NEWA

>D> @ HERITAGE PHARMA 650MG

A207035 001 May 31, 2018

Sep CMFD

>A> 650MG

A207035 001 May 31, 2018

Sep CMFD

@ 650MG

A207035 001 May 31, 2018

Mar DISC

ADAPALENE

GEL;TOPICAL

ADAPALENE

GLENMARK GENERICS 0.1%

A091314 002 Jul 09, 2019

Jul NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

QUAGEN 5MG/5ML

A212266 001 May 16, 2019

May NEWA

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D> APNAR PHARMA LP 5MG/5ML

A091327 001 Oct 17, 2011

Sep CAHN

>A> ATHEM 5MG/5ML

A091327 001 Oct 17, 2011

Sep CAHN

HETERO LABS LTD III 5MG/5ML

A210622 001 Mar 13, 2019

Feb NEWA

TORRENT 5MG/5ML

A090474 002 Mar 30, 2009

Jan CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D> APNAR PHARMA LP 5MG/5ML

A091327 002 Oct 17, 2011

Sep CAHN

>A> ATHEM 5MG/5ML

A091327 002 Oct 17, 2011

Sep CAHN

TORRENT 5MG/5ML

A090474 001 Mar 30, 2009

Jan CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ HERITAGE PHARMA 5MG

A078615 003 Dec 28, 2007

May CAHN

@ 10MG

A078615 004 Dec 28, 2007

May CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ PERRIGO R AND D 5MG;120MG

A210719 001 Nov 16, 2018

May DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

CHLORHEXIDINE GLUCONATE

BAJAJ 0.75%

N020111 001 Sep 11, 1997

Apr CTNA

0.75%

N020111 001 Sep 11, 1997

Jan CMFD

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

! AVANTHI INC 12MG

A040829 001 May 13, 2009

Jan CHRS

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

! P AND L 1%

A074165 001 Jul 16, 1993

Aug CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 25MG;EQ 200MG FREE ACID AND
POTASSIUM SALT

A210676 001 Feb 14, 2019

Jan NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

@ ACTAVIS ELIZABETH	25MG;220MG	A207597	001	Jan 25, 2019	Jul DISC
	25MG;220MG	A207597	001	Jan 25, 2019	Jan NEWA
APOTEX INC	25MG;220MG	A211830	001	Aug 22, 2019	Aug NEWA
@ P AND L	25MG;220MG	A207597	001	Jan 25, 2019	Aug CAHN
PERRIGO R AND D	25MG;220MG	A208499	001	May 10, 2019	Apr NEWA

DOCOSANOL

CREAM; TOPICAL

DOCOSANOL

P AND L	10%	A208754	001	Nov 19, 2018	Aug CAHN
---------	-----	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	AMNEAL PHARMS NY	EQ 20MG BASE	A209716	001	Jun 05, 2019	May NEWA
	MYLAN	EQ 20MG BASE	A212376	001	Oct 16, 2019	Sep NEWA

TABLET, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

@ ACTAVIS ELIZABETH	EQ 20MG BASE	A209202	001	Mar 05, 2019	Apr DISC
	EQ 20MG BASE	A209202	001	Mar 05, 2019	Feb NEWA
@ P AND L	EQ 20MG BASE	A209202	001	Mar 05, 2019	Aug CAHN

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

P AND L	10MG	A075512	001	Jul 26, 2001	Aug CAHN
---------	------	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

P AND L	30MG/5ML	A203330	001	Nov 18, 2014	Aug CAHN
---------	----------	---------	-----	--------------	----------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

! P AND L	30MG/5ML	A203330	002	Nov 18, 2014	Aug CAHN
-----------	----------	---------	-----	--------------	----------

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

@ MYLAN	30MG	A077081	004	Jul 21, 2011	Jul DISC
---------	------	---------	-----	--------------	----------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

@ MYLAN	30MG	A077081	005	Jul 21, 2011	Jul DISC
---------	------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

HI TECH	0.05MG/SPRAY	A208024	001	Apr 17, 2019	Apr NEWA
---------	--------------	---------	-----	--------------	----------

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

@ OHM LABS INC	600MG	A209254	001	Jul 16, 2018	Mar DISC
@	1.2GM	A209254	002	Jul 16, 2018	Mar DISC

IBUPROFEN

SUSPENSION; ORAL

>D>	CHILDREN'S ELIXSURE				
>D>	MOBERG PHARMA NORTH	100MG/5ML	N021604	001	Jan 07, 2004
>A>	@	100MG/5ML	N021604	001	Jan 07, 2004

IBUPROFEN

@ GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018	Feb DISC
P AND L	100MG/5ML	A074916	001	Apr 30, 1999	Aug CAHN

SUSPENSION/DROPS; ORAL

INFANT'S ADVIL

+! PFIZER	50MG/1.25ML	N020812	002	Jan 12, 2000	Aug NEWA
PEDIATRIC ADVIL					

+ @ PFIZER	100MG/2.5ML	N020812	001	Jan 30, 1998	Aug DISC
------------	-------------	---------	-----	--------------	----------

TABLET; ORAL

IBUPROFEN

! PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005	Jun CHRS
-------------------	-------	---------	-----	--------------	----------

TABLET;ORAL
MOTRIN IB

+ J AND J CONSUMER INC 200MG N019012 003 Dec 17, 1990 May CHRS

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL
ZURAGARD

>D> +! ZUREX PHARMA 70% (10.5ML) N210872 001 Apr 26, 2019 Sep DISC
>D> + @ 70% (10.5ML) N210872 001 Apr 26, 2019 Sep DISC
>A> +! 70% (10.5ML) N210872 001 Apr 26, 2019 May CMS2

KETOCONAZOLE

SHAMPOO;TOPICAL
NIZORAL A-D

+! KRAMER 1% N020310 001 Oct 10, 1997 Jan CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC
ZADITOR

! ALCON PHARMS LTD EQ 0.025% BASE A077200 001 Sep 02, 2008 Feb CTNA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE
PERRIGO R AND D 5MG
5MG

A211983 001 Mar 28, 2019 Jul CMS1
A211983 001 Mar 26, 2019 Mar NEWA

LEVONORGESTREL

TABLET;ORAL
LEVONORGESTREL

ACCORD HLTHCARE 1.5MG A207660 001 May 02, 2019 Apr NEWA
ALVOGEN 1.5MG A202246 001 Jun 05, 2015 Jul CAHN
@ APOTEX INC 1.5MG A205329 001 Sep 18, 2018 Jan DISC
@ FDN CONSUMER 1.5MG A200670 001 Jul 12, 2012 Jun DISC
! L PERRIGO CO 0.75MG A090740 001 Dec 30, 2010 May CAHN
>A> NAARI PTE LTD 1.5MG A202380 001 May 29, 2015 Sep CAHN
>D> OC PHARMA 1.5MG A202380 001 May 29, 2015 Sep CAHN

LORATADINE

CAPSULE;ORAL
LORATADINE

@ BIONPHARMA INC 10MG A202538 001 Dec 21, 2018 Mar DISC

TABLET;ORAL
LORATADINE

GUARDIAN DRUG 10MG A207569 001 Mar 12, 2019 Mar CAHN
NEWGEN PHARMS LLC 10MG A207569 001 Mar 12, 2019 Feb NEWA

TABLET, CHEWABLE;ORAL
LORATADINE

PERRIGO PHARMA INTL 5MG A210033 001 Jun 12, 2019 May NEWA
SUN PHARM 5MG A210088 001 Apr 16, 2018 Mar CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
LORATADINE AND PSEUDOEPHEDRINE SULFATE

@ HERITAGE PHARMA 5MG;120MG A076208 001 Jan 28, 2004 May CAHN
P AND L 10MG;240MG A075706 001 Feb 21, 2003 Aug CAHN

MICONAZOLE NITRATE

CREAM;VAGINAL
MICONAZOLE 7

P AND L 2% A074164 001 Mar 29, 1996 Aug CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL
M-ZOLE 3 COMBINATION PACK

P AND L 2%,200MG A074926 001 Apr 16, 1999 Aug CAHN

SUPPOSITORY;VAGINAL
MICONAZOLE NITRATE

P AND L 100MG A073507 001 Nov 19, 1993 Aug CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

P AND L 5%

A208092 001 Feb 17, 2017 Aug CAHN

MINOXIDIL (FOR WOMEN)

P AND L 5%

A208092 002 Jul 27, 2017 Aug CAHN

TARO 5%

A209074 002 Apr 22, 2019 Apr NEWA

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

P AND L 2%

A074588 001 Apr 05, 1996 Aug CAHN

MINOXIDIL EXTRA STRENGTH (FOR MEN)

P AND L 5%

A075518 001 Nov 17, 2000 Aug CAHN

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

@ CATALENT EQ 200MG BASE

A202807 001 Jan 04, 2019 Jul DISC

TABLET;ORAL

ALEVE

>D> +! BAYER EQ 200MG BASE

N020204 002 Jan 11, 1994 Sep CPOT

>A> +! 220MG

N020204 002 Jan 11, 1994 Sep CPOT

NAPROXEN SODIUM

>D> AMNEAL PHARMS NY EQ 200MG BASE

A079096 001 Dec 16, 2008 Sep CPOT

>A> 220MG

A079096 001 Dec 16, 2008 Sep CPOT

>D> AUROBINDO PHARMA LTD EQ 200MG BASE

A205497 001 Mar 18, 2016 Sep CPOT

>A> 220MG

A205497 001 Mar 18, 2016 Sep CPOT

>D> CONTRACT PHARMACAL EQ 200MG BASE

A074635 001 Jan 13, 1997 Sep CPOT

>D> @ EQ 200MG BASE

A074789 001 Feb 27, 1997 Sep CPOT

>A> 220MG

A074635 001 Jan 13, 1997 Sep CPOT

>A> @ 220MG

A074789 001 Feb 27, 1997 Sep CPOT

>D> DR REDDYS LABS INC EQ 200MG BASE

A075168 001 Jul 28, 1998 Sep CPOT

>A> 220MG

A075168 001 Jul 28, 1998 Sep CPOT

>D> GRANULES INDIA EQ 200MG BASE

A091353 001 Sep 20, 2011 Sep CPOT

>A> 220MG

A091353 001 Sep 20, 2011 Sep CPOT

>D> LNK INTL INC EQ 200MG BASE

A204872 001 Jan 23, 2017 Sep CPOT

>A> 220MG

A204872 001 Jan 23, 2017 Sep CPOT

>D> MARKSANS PHARMA EQ 200MG BASE

A090545 001 Mar 16, 2011 Sep CPOT

>A> 220MG

A090545 001 Mar 16, 2011 Sep CPOT

>D> NOVELGENIX THERAPS EQ 200MG BASE

A207612 001 Nov 16, 2018 Sep CPOT

>A> 220MG

A207612 001 Nov 16, 2018 Sep CPOT

>D> PERRIGO EQ 200MG BASE

A074661 001 Jan 13, 1997 Sep CPOT

>A> 220MG

A074661 001 Jan 13, 1997 Sep CPOT

>D> @ PLD ACQUISITIONS LLC EQ 200MG BASE

A074646 001 Jan 13, 1997 Sep CPOT

>A> @ 220MG

A074646 001 Jan 13, 1997 Sep CPOT

>D> SUN PHARM INDS LTD EQ 200MG BASE

A091183 001 May 20, 2011 Sep CPOT

>A> 220MG

A091183 001 May 20, 2011 Sep CPOT

>D> YICHANG HUMANWELL EQ 200MG BASE

A212033 001 Aug 30, 2019 Sep CPOT

>A> EQ 200MG BASE

A212033 001 Aug 30, 2019 Aug NEWA

>A> 220MG

A212033 001 Aug 30, 2019 Sep CPOT

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

>D> +! BAYER EQ 200MG BASE;120MG

N021076 001 Nov 29, 1999 Sep CPOT

>D> +! EQ 200MG BASE;120MG

N021076 001 Nov 29, 1999 Mar CPOT

>A> +! 220MG;120MG

N021076 001 Nov 29, 1999 Sep CPOT

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D> DR REDDYS LABS INC EQ 220MG BASE;120MG

A077381 001 Sep 27, 2006 Sep CPOT

>A> 220MG;120MG

A077381 001 Sep 27, 2006 Sep CPOT

>D> PERRIGO EQ 200MG BASE;120MG

A076518 001 Mar 17, 2004 Sep CPOT

>A> 220MG;120MG

A076518 001 Mar 17, 2004 Sep CPOT

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

P AND L EQ 2MG BASE

A074507 001 Mar 15, 1999 Aug CAHN

EQ 2MG BASE

A076569 001 Jul 29, 2004 Aug CAHN

EQ 2MG BASE

A078699 001 Dec 29, 2008 Aug CAHN

EQ 2MG BASE

A079044 001 Jul 08, 2009 Aug CAHN

EQ 2MG BASE

A079216 001 Jul 08, 2009 Aug CAHN

EQ 2MG BASE

A204794 001 May 10, 2016 Aug CAHN

GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX

EQ 4MG BASE	A074707	001	Mar 19, 1999	Aug CAHN
EQ 4MG BASE	A076568	002	Jul 29, 2004	Aug CAHN
EQ 4MG BASE	A078697	001	Dec 29, 2008	Aug CAHN
EQ 4MG BASE	A079038	001	Jul 08, 2009	Aug CAHN
EQ 4MG BASE	A079219	001	Jul 08, 2009	Aug CAHN
EQ 4MG BASE	A204833	001	Feb 26, 2016	Aug CAHN

TROCHE/LOZENGE;ORAL
NICOTINE POLACRILEX@ P AND L
@

EQ 2MG BASE	A209206	001	Jun 26, 2018	Aug CAHN
EQ 2MG BASE	A209519	001	Jul 02, 2018	Aug CAHN
EQ 2MG BASE	A210712	001	Sep 06, 2019	Aug NEWA
EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul CAHN
EQ 4MG BASE	A209206	002	Jun 26, 2018	Aug CAHN
EQ 4MG BASE	A209519	002	Jul 02, 2018	Aug CAHN
EQ 4MG BASE	A210712	002	Sep 06, 2019	Aug NEWA
EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul CAHN

PLD ACQUISITIONS

EQ 2MG BASE	A207868	001	Feb 07, 2019	Feb NEWA
EQ 4MG BASE	A207868	002	Feb 07, 2019	Feb NEWA

TEVA PHARMS USA INC

EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul NEWA
EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul NEWA

@ WATSON LABS INC

EQ 2MG BASE	A209206	001	Jun 26, 2018	Feb DISC
-------------	---------	-----	--------------	----------

@

EQ 4MG BASE	A209206	002	Jun 26, 2018	Feb DISC
-------------	---------	-----	--------------	----------

@ WATSON LABS TEVA

EQ 2MG BASE	A209519	001	Jul 02, 2018	Feb DISC
-------------	---------	-----	--------------	----------

@

EQ 4MG BASE	A209519	002	Jul 02, 2018	Feb DISC
-------------	---------	-----	--------------	----------

OMEPRAZOLETABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE

@ APOTEX INC

20MG
20MG

A210070	001	Feb 11, 2019	Aug DISC
A210070	001	Feb 11, 2019	Apr CTEC

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL
GLYCOLAX

@ LANNETT CO INC

17GM/PACKET

A090600	001	Oct 06, 2009	Jun DISC
---------	-----	--------------	----------

@

17GM/SCOOPFUL

A090600	002	Oct 06, 2009	Jun DISC
---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350

>D>

APNAR PHARMA LP

17GM/SCOOPFUL

A202071	001	Dec 28, 2012	Sep CAHN
---------	-----	--------------	----------

>A>

NOVELGENIX THERAPS

17GM/SCOOPFUL

A202071	001	Dec 28, 2012	Sep CAHN
---------	-----	--------------	----------

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

STRIDES PHARMA

EQ 75MG BASE
EQ 150MG BASE

A209160	001	Mar 05, 2018	Apr CAHN
A209161	001	Feb 22, 2018	Apr CAHN

UNIQUE PHARM LABS

EQ 75MG BASE
EQ 150MG BASE

A210250	001	Aug 30, 2019	Aug NEWA
A210228	001	Aug 30, 2019	Aug NEWA

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL

COLGATE TOTAL

+ @ COLGATE PALMOLIVE

0.24%;0.3%

N020231	001	Jul 11, 1997	Mar DISC
---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 09 SEPTEMBER 2019

NO SEPTEMBER 2019 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2019 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ABIRATERONE ACETATE</u>						
A 208327	001				PC	Apr 29, 2019
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379	002	>A> 8822438	Aug 24, 2027	U-1579	Y	
		>A> 8822438	Aug 24, 2027	U-1580	Y	
		>A> 8822438	Aug 24, 2027	U-2235	Y	
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308	001	10292990	May 20, 2034	U-2535		
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259	001	10167291	Jul 01, 2036	DP U-2145		
		10272083	Jan 21, 2035	U-2519		
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450	001	>A> 10383834	Nov 13, 2028	U-2262		
		>A> 10383834	Nov 13, 2028	U-2621		
<u>ACETAMINOPHEN - ACETAMINOPHEN</u>						
N 204767	001	>A> 8741959	Apr 19, 2030	DP		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	002	8461137	Feb 22, 2031	DS DP		
		8748413	Jul 10, 2030	DS DP		
		8828978	Jul 01, 2030	DP		
		9132125	Jul 01, 2030	DS DP	U-2249	
		9549923	Jul 01, 2030	DS DP		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	003	8461137	Feb 22, 2031	DS DP		
		8748413	Jul 10, 2030	DS DP		
		8828978	Jul 01, 2030	DP		
		9132125	Jul 01, 2030	DS DP	U-2249	
		9549923	Jul 01, 2030	DS DP		
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	10034867	Jul 07, 2020	DP U-2513		
		10034867	Jul 07, 2020	DP U-2514		
		10085974	Mar 13, 2029	DP U-2513		
		7078412	Jul 07, 2020	DS DP	U-2513	
		9056100	Jul 07, 2020	DP U-2513		
		9333195	Jul 07, 2020	DP U-2513		
		RE46417	Feb 10, 2025	DS DP	U-2513	
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595	001	10034867	Jul 07, 2020	DP U-2513	NC	Mar 29, 2022
		10034867	Jul 07, 2020	DP U-2514		
		10085974	Mar 13, 2029	DP U-2513		
		6681768	Aug 07, 2022	DP		
		7078412	Jul 07, 2020	DS DP	U-2513	
		7750023	Jul 07, 2020	DP U-2513		
		8051851	Apr 22, 2027	DP		
		8129405	Jul 07, 2020	DP U-2513		
		9056100	Jul 07, 2020	DP U-2513		
		9333195	Jul 07, 2020	DP U-2513		
		RE46417	Feb 10, 2025	DS DP	U-2513	
<u>ACYCLOVIR - AVACLYR</u>						
N 202408	001				ODE-235	Mar 29, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 001					ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 002					ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003					ODE-230	Jan 12, 2025
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10124131	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	10183012	Nov 26, 2028	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	10183012	Nov 26, 2028	U-2104			
<u>ALPELISIB - PIQRAY</u>						
N 212526 001	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIQRAY</u>						
N 212526 002	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIQRAY</u>						
N 212526 003	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMIFAMPRIDINE - RUZURGI</u>						
N 209321 001					ODE-244	May 06, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	10251900	May 15, 2035	U-2414		ODE-214 GAIN	Sep 28, 2025 Sep 28, 2030
<u>AMINOCAPROIC ACID - AMINOCAPROIC ACID</u>						
A 212780 001					CGT	Feb 26, 2020
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	10357567	Jan 12, 2038	U-804			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	10350171 9662315	Jun 14, 2038 May 22, 2029	DP DP U-2410			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	10350171 9662315	Jun 14, 2038 May 22, 2029	DP DP U-2410			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	10350171 9662315	Jun 14, 2038 May 22, 2029	DP DP U-2410			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	10130580 >A> 10441554	Apr 19, 2024 Mar 10, 2037	DP DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	10130580 >A> 10441554	Apr 19, 2024 Mar 10, 2037	DP DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	10130580 >A> 10441554	Apr 19, 2024 Mar 10, 2037	DP DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	10130580 >A> 10441554	Apr 19, 2024 Mar 10, 2037	DP DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10335451 9572856	Dec 16, 2029 Nov 20, 2030	U-2581 U-2221			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10335451 9572856	Dec 16, 2029 Nov 20, 2030	U-2581 U-2221			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	>A> 8445507 >A> 8445507 >A> 8802689 >A> 8802689 >A> 9481663 >A> 9481663	Sep 15, 2030 Sep 15, 2030 Mar 27, 2027 Mar 27, 2027 Jun 04, 2033 Jun 04, 2033	DS DP U-2237 DS DP U-2624 U-2237 U-2624 DS DP U-2237 DS DP U-2624		>A> I-808	Sep 17, 2022
<u>APREMILAST - OTEZLA</u>						
N 205437 001					I-803 ODE-248	Jul 19, 2022 Jul 19, 2026
<u>APREMILAST - OTEZLA</u>						
N 205437 002					I-803 ODE-248	Jul 19, 2022 Jul 19, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437	003				I-803 ODE-248	Jul 19, 2022 Jul 19, 2026
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	001 >A> 8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	002 >A> 8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	003 >A> 8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	004 >A> 8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	005 >A> 8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	006 >A> 8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	001 >A> 10226458 10238651	Mar 19, 2032 Mar 19, 2035	U-543 U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	002 >A> 10226458 10238651	Mar 19, 2032 Mar 19, 2035	U-543 U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	003 >A> 10226458 10238651	Mar 19, 2032 Mar 19, 2035	U-543 U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	004 >A> 10226458 10238651	Mar 19, 2032 Mar 19, 2035	U-543 U-2402			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238	001 8338429 8765764 8765764	Jun 30, 2023 Jan 15, 2023 Jan 15, 2023	U-2577 U-2314 U-2578		I-802 ODE-246	Jun 26, 2022 Jun 26, 2026
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001 7112592 7112592 7112592 8178554 8178554 8178554	Feb 24, 2022 Feb 24, 2022 Feb 24, 2022 Jul 24, 2021 Jul 24, 2021 Jul 24, 2021	DS DP U-2244 DS DP U-2508 DS DP U-282 DS DP U-2245 DS DP U-2509 DS DP U-282			
<u>AZELAIC ACID - FINACEA</u>						
N 207071	001 10322085	Oct 24, 2023	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	001 9387249	Jul 01, 2031	U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	002 9387249	Jul 01, 2031	U-3			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001 >A>	10392406	Apr 27, 2036	DS		NCE	Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002 >A>	10392406	Apr 27, 2036	DS		NCE	Oct 24, 2023
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	6479535	May 06, 2024	DP U-594			
	6479535	May 06, 2024	DP U-904			
<u>BECLOMETHASONE DIPROPIONATE - ONASL</u>						
N 202813 001	10188811	Oct 21, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - ONASL</u>						
N 202813 002	10188811	Oct 21, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					NPP	Aug 09, 2022
					>A> ODE-251	Aug 09, 2026
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 205128 001					PC	Aug 18, 2019
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10220049	Jun 03, 2029	DP U-916			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	10220049	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	10179137	Aug 31, 2030	DP U-1858			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX</u>						
N 022185 001	6753013	Jan 27, 2020	DP U-1761		NPP	Jul 25, 2022
	6753013	Jan 27, 2020	DP U-193		PED	Jan 25, 2023
	6753013	Jan 27, 2020	DP U-88			
	6787529	Jan 27, 2020	DP U-1761			
	6787529	Jan 27, 2020	DP U-193			
	6787529	Jan 27, 2020	DP U-88			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10130640	Jun 10, 2031	DP		NPP	Jul 30, 2022
	10130640*PED	Dec 10, 2031			PED	Jan 30, 2023
	>A> 6753013	Jan 27, 2020	DP U-1761			
	>A> 6753013	Jan 27, 2020	DP U-2627			
	>A> 9119781	Jun 10, 2031	DP U-1761			
	>A> 9119781	Jun 10, 2031	DP U-2627			
	>A> 9119781*PED	Dec 10, 2031				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10385067	Jun 19, 2035	U-257		NPP	Jun 18, 2022
					>A> ODE-256	Jun 18, 2026
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	7417148	Dec 11, 2025	U-1283			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	10286034	Nov 05, 2033	U-2568		NCE	Jun 21, 2024
	6579968	Jun 28, 2020	DS DP			
	6794489	Jun 28, 2020	DS DP			
	9352013	Nov 05, 2033	U-2568			
	9700592	Nov 05, 2033	U-2568			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	10286034	Nov 05, 2033	U-2568		NCE	Jun 21, 2024
	6579968	Jun 28, 2020	DS DP			
	6794489	Jun 28, 2020	DS DP			
	9352013	Nov 05, 2033	U-2568			
	9700592	Nov 05, 2033	U-2568			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10117951	Mar 13, 2029	DP		NCE	Jun 17, 2024
	10251894	Nov 27, 2033	U-2552			
	10322139	Jan 23, 2033	DP			
	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9750822	Mar 13, 2029	DP			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	10307368	Jul 10, 2021	DP			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	10201517	Jun 13, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	10307375	Sep 07, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 001	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 002	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	10166247	Jan 29, 2023	DP U-2001			
	10166247	Jan 29, 2023	DP U-2002			
	10166247	Jan 29, 2023	DP U-2122			
	10166247*PED	Jul 29, 2023				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	10166247	Jan 29, 2023	DP U-2001			
	10166247	Jan 29, 2023	DP U-2002			
	10166247	Jan 29, 2023	DP U-2122			
	10166247*PED	Jul 29, 2023				
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	10285910	Oct 11, 2022	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	10231964	Jul 02, 2034	U-1583			
	10307376	Nov 08, 2027	U-1585			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	8497284	Sep 24, 2024	U-2488			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	10213442	Feb 02, 2027	DP			
	10300078	Mar 14, 2034	DP			
	10357502	Mar 14, 2034	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 001	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 002	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					>A> I-809	Sep 27, 2022
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					>A> I-809	Sep 27, 2022
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10195159	May 07, 2022	DS			
<u>CARBOPROST TROMETHAMINE - CARBOPROST TROMETHAMINE</u>						
A 211941 001					CGT	Dec 29, 2019
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
	7737142	Mar 27, 2027	DS DP U-2545			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
	7737142	Mar 27, 2027	DS DP U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10028963	Sep 07, 2032	U-2565			
	10028963	Sep 07, 2032	U-2566			
	10376496	Sep 09, 2034	U-2610			
	10376496	Sep 09, 2034	U-2611			
	9724353	Sep 07, 2032	U-2565			
	9724353	Sep 07, 2032	U-2566			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CERITINIB - ZYKADIA</u>						
N 211225 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP			
	7964592	Jan 13, 2027	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8188276	Jan 31, 2023	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8399450	Nov 20, 2027	DS DP			
	8703787	Feb 02, 2032	U-1179			
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9309229	Jan 18, 2032	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001	8969412	Sep 05, 2026	DP U-2609			
	9504666	Dec 11, 2033	DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS</u>						
N 021587 001	10238640	May 25, 2024	DP			
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Nov 19, 2029	DS DP U-2586			
	8487093	Nov 19, 2029	DS DP U-2587			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	9827231	Jun 26, 2034	DP U-2162			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	7713947	Oct 16, 2026	U-2520		NP	Mar 29, 2022
	7888328	Apr 11, 2024	DP U-2521			
	8377903	May 31, 2026	U-2522			
	8785415	Apr 11, 2024	DP U-2523			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10231961	Feb 07, 2037	DP			
	>A> 10413505	Feb 07, 2037	U-2479			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10226423	Dec 20, 2037	DP			
	9907751	Nov 22, 2036	DP			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 210895 001	7229613	Apr 17, 2022	U-2516			
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOPA</u>						
N 209936 001	>A> 10383876	Mar 29, 2032	DS DP			
<u>CROFELEMER - MYTESI</u>						
N 202292 001	7341744	Jun 02, 2022	DP U-1319			
	9585868	Oct 31, 2031	U-1319			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10328037	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10328037	Aug 16, 2036	U-1399			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10166184	Oct 15, 2032	DP U-2341			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DALFAMPRIDINE - DALFAMPRIDINE</u>						
A 206863	001				PC	Mar 09, 2019
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	001				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	002				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	003				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	004				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	005				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	006				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	007				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	008				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	009				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	010				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	011				NPP	May 16, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	001				M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	002				M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	001	6414126	Oct 04, 2020	DS DP U-493	NP	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		9616028	Nov 12, 2030	DP		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	002	6414126	Oct 04, 2020	DS DP U-493	NP	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 002	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 003	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 004	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-493		I-804	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	6936590	Oct 04, 2020	U-493			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 002	6414126	Oct 04, 2020	DS DP U-493		NS	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
A 212667 001					CGT	Jan 12, 2020
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	10010530	Jan 28, 2036	DS		NCE	Jul 30, 2024
	10383853	Jan 28, 2036	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	8975254	Oct 27, 2030	DS DP U-2605			
	9657003	Oct 27, 2030	DS DP U-2605			
<u>DARUNAVIR - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	10201542	Oct 18, 2033	DP U-1753			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	10201541	May 17, 2032	DP			
	10201584	May 17, 2032	U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 001					PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 002					PC	Apr 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	003				PC	Apr 05, 2019
<u>DEFERASIROX - EXJADE</u>						
N 021882	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - EXJADE</u>						
N 021882	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - EXJADE</u>						
N 021882	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	002	7049328 8703156	Jun 28, 2021 Oct 29, 2029	U-735 DP U-735		
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	001				>A> ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	002				>A> ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	003				>A> ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	004				>A> ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685	001				>A> ODE-252	Jun 07, 2026
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517	001	10307459	May 07, 2023	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	10307459	May 07, 2023	DP			
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Aug 13, 2027	DP U-1412			
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001	8409606	May 14, 2030	DP		I-800	Jun 20, 2022
	8563027	Feb 12, 2030	U-2487		NP	Nov 30, 2021
	9254267	Sep 11, 2024	DP			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10159683	May 23, 2034	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 208129 001					PC	Nov 30, 2019
<u>DIGOXIN - DIGOXIN</u>						
A 213000 001					>A> CGT	Apr 01, 2020
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	8129385	Oct 05, 2027	DS DP		NC	Apr 08, 2022
	9242986	Dec 08, 2029	DS DP			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	>A> 8486975	Oct 07, 2031	DS DP U-2395		>A> I-806	Sep 19, 2022
	>A> 8486975	Oct 07, 2031	DS DP U-2629			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10238620	May 18, 2027	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10238620	May 18, 2027	U-620			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	10058564	Apr 05, 2022	U-1063			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	10265293	Aug 06, 2028	DS DP			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10179140	Jun 28, 2031	U-2553		NP	May 23, 2022
	9603860	Jun 28, 2031	U-2553			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001 >A>	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002 >A>	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003 >A>	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004 >A>	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-243	Aug 09, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-243	Aug 09, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-243	Aug 09, 2022
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>							
N 022291 003	8828430	Aug 01, 2027	DP U-2451				
	8828430*PED	Feb 01, 2028					
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>							
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306				
	7160870	Nov 20, 2022	DS DP U-2451				
	7160870*PED	May 20, 2023					
	7332481	May 24, 2021	U-1306				
	7332481	May 24, 2021	U-2451				
	7332481*PED	Nov 24, 2021					
	7452874	May 24, 2021	DS DP				
	7452874*PED	Nov 24, 2021					
	7473686	May 24, 2021	DS DP U-1306				
	7473686	May 24, 2021	DS DP U-2451				
	7473686*PED	Nov 24, 2021					
	7547719	Jul 13, 2025	DS DP U-1306				
	7547719	Jul 13, 2025	DS DP U-1575				
	7547719	Jul 13, 2025	DS DP U-2451				
	7547719	Jul 13, 2025	DS DP U-2452				
	7547719*PED	Jan 13, 2026					
	7790704	May 24, 2021	U-1306				
	7790704	May 24, 2021	U-2451				
	7790704*PED	Nov 24, 2021					
	7795293	May 21, 2023	U-1306				
	7795293	May 21, 2023	U-2451				
	7795293*PED	Nov 21, 2023					
	8071129	Aug 01, 2027	DP U-1306				
	8071129	Aug 01, 2027	DP U-2451				
	8071129	Aug 01, 2027	DP U-930				
	8071129*PED	Feb 01, 2028					
	8828430	Aug 01, 2027	DP U-1306				
	8828430	Aug 01, 2027	DP U-2451				
	8828430*PED	Feb 01, 2028					
	<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
	N 207027 001	7160870	Nov 20, 2022	DS DP U-1306			
		7160870	Nov 20, 2022	DS DP U-1736			
7160870*PED		May 20, 2023					
7332481		May 24, 2021	U-1306				
7332481		May 24, 2021	U-1736				
7332481*PED		Nov 24, 2021					
7473686		May 24, 2021	DS DP U-1306				
7473686		May 24, 2021	DS DP U-1736				
7473686*PED		Nov 24, 2021					
7547719		Jul 13, 2025	DS DP U-1306				
7547719		Jul 13, 2025	DS DP U-1575				
7547719		Jul 13, 2025	DS DP U-1736				
7547719		Jul 13, 2025	DS DP U-2452				
7547719*PED		Jan 13, 2026					
7790704		May 24, 2021	U-1306				
7790704		May 24, 2021	U-1736				
7790704*PED		Nov 24, 2021					
7795293		May 21, 2023	U-1306				
7795293		May 21, 2023	U-1736				
7795293*PED		Nov 24, 2023					
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>							
N 207027 002	7160870	Nov 20, 2022	DS DP U-1306				
	7160870	Nov 20, 2022	DS DP U-1736				
	7160870*PED	May 20, 2023					
	7332481	May 24, 2021	U-1306				
	7332481	May 24, 2021	U-1736				
	7332481*PED	Nov 24, 2021					
	7452874	May 24, 2021	DS DP				
	7452874*PED	Nov 24, 2021					

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	10258637	Apr 03, 2034	U-2290			
	>A> 10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	10258637	Apr 03, 2034	U-2290			
	>A> 10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034	U-2290			
	>A> 10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	10258637	Apr 03, 2034	U-2290			
	>A> 10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10258637	Apr 03, 2034	U-2290			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034	U-2290			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10294215	Jan 07, 2033	DP U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10294215	Jan 07, 2033	DP U-2087			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	>A> 10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	>A> 10231965	Feb 17, 2035	U-2618			
	>A> 10398693	Jul 18, 2038	DP			
	>A> 8299057	Mar 01, 2029	DS DP			
	>A> 8673893	Jul 08, 2028	U-2617			
	>A> 8673893	Jul 08, 2028	U-2618			
	>A> 9029356	Jul 08, 2028	DS DP			
	>A> 9085558	Jul 08, 2028	DP			
	>A> 9085565	May 22, 2033	DS DP			
	>A> 9255087	Jul 08, 2028	U-2617			
	>A> 9255087	Jul 08, 2028	U-2618			
	>A> 9616059	Jul 08, 2028	U-2618			
	>A> 9649306	May 22, 2033	U-2617			
	>A> 9649306	May 22, 2033	U-2618			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	>A> 10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	>A> 10231965	Feb 17, 2035	U-2618			
	>A> 10398693	Jul 18, 2038	DP			
	>A> 8299057	Mar 01, 2029	DS DP			
	>A> 8673893	Jul 08, 2028	U-2617			
	>A> 8673893	Jul 08, 2028	U-2618			
	>A> 9029356	Jul 08, 2028	DS DP			
	>A> 9085558	Jul 08, 2028	DP			
	>A> 9085565	May 22, 2033	DS DP			
	>A> 9255087	Jul 08, 2028	U-2617			
	>A> 9255087	Jul 08, 2028	U-2618			
	>A> 9616059	Jul 08, 2028	U-2618			
	>A> 9649306	May 22, 2033	U-2617			
	>A> 9649306	May 22, 2033	U-2618			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	8796245	Aug 07, 2029	U-2380			
	8906887	Dec 28, 2030	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 001					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 002					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 003					PC	Nov 05, 2019
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	8785500	Jul 09, 2031	U-2502		NCE*	Mar 05, 2024
	9592207	Mar 20, 2027	U-2502			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10206932	Nov 21, 2032	U-2439			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	10344765	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	10344765	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	10344765	Jun 27, 2034	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10337003	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1919			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10337003	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1919			
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	6414126	Oct 04, 2020	U-2588			
	6515117	Oct 04, 2020	U-2588			
	>A> 6872700	Jan 14, 2020	U-2589	Y		
	>A> 6872700	Jan 14, 2020	U-2590	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	>A> 6872700	Jan 14, 2020	U-2591	Y		
	6936590	Oct 04, 2020	U-2588			
	>A> 7456254	Jun 30, 2025	DP U-2588	Y		
	>A> 7456254	Jun 30, 2025	DP U-2589	Y		
	>A> 7456254	Jun 30, 2025	DP U-2590	Y		
	>A> 7456254	Jun 30, 2025	DP U-2592	Y		
	>A> 7612176	Apr 13, 2025	DP U-2589	Y		
	>A> 7612176	Apr 13, 2025	DP U-2590	Y		
	>A> 7612176	Apr 13, 2025	DP U-2592	Y		
	>A> 8329648	Aug 18, 2026	U-2588	Y		
	>A> 8329648	Aug 18, 2026	U-2589	Y		
	>A> 8329648	Aug 18, 2026	U-2590	Y		
	>A> 8329648	Aug 18, 2026	U-2593	Y		
	>A> 8329648	Aug 18, 2026	U-2594	Y		
	>A> 8329648	Aug 18, 2026	U-2595	Y		
	>A> 8329648	Aug 18, 2026	U-2596	Y		
	8361972	Mar 21, 2028	U-2588			
	>A> 8431685	Apr 13, 2025	DP U-2589	Y		
	>A> 8431685	Apr 13, 2025	DP U-2590	Y		
	>A> 8431685	Apr 13, 2025	DP U-2597	Y		
	>A> 8431685	Apr 13, 2025	DP U-2598	Y		
	>A> 8461105	Apr 13, 2025	DP U-2589	Y		
	>A> 8461105	Apr 13, 2025	DP U-2590	Y		
	>A> 8461105	Apr 13, 2025	DP U-2597	Y		
	>A> 8461105	Apr 13, 2025	DP U-2598	Y		
	8501698	Jun 20, 2027	U-2588			
	>A> 8895033	Oct 04, 2030	DP U-2589	Y		
	>A> 8895033	Oct 04, 2030	DP U-2590	Y		
	>A> 8895033	Oct 04, 2030	DP U-2597	Y		
	>A> 8895033	Oct 04, 2030	DP U-2600	Y		
	>A> 8895033	Oct 04, 2030	DP U-2601	Y		
	>A> 8895033	Oct 04, 2030	DP U-2602	Y		
	>A> 8906851	Aug 18, 2026	U-2589	Y		
	>A> 8906851	Aug 18, 2026	U-2590	Y		
	>A> 8906851	Aug 18, 2026	U-2593	Y		
	>A> 8906851	Aug 18, 2026	U-2597	Y		
	9198925	Oct 04, 2020	U-2588			
	>A> 9238076	Apr 15, 2024	DP U-2589	Y		
	>A> 9238076	Apr 15, 2024	DP U-2590	Y		
	>A> 9238076	Apr 15, 2024	DP U-2597	Y		
	>A> 9238076	Apr 15, 2024	DP U-2599	Y		
	>A> 9884092	Aug 18, 2026	U-2589	Y		
	>A> 9884092	Aug 18, 2026	U-2590	Y		
	>A> 9884092	Aug 18, 2026	U-2593	Y		
	>A> 9884092	Aug 18, 2026	U-2594	Y		
	>A> 9884092	Aug 18, 2026	U-2595	Y		
	>A> 9884092	Aug 18, 2026	U-2596	Y		
	>A> 9884092	Aug 18, 2026	U-2597	Y		
<u>FEBUXOSTAT - FEBUXOSTAT</u>						
A 205385 001					>A> PC	Dec 28, 2019
<u>FEBUXOSTAT - FEBUXOSTAT</u>						
A 205385 002					>A> PC	Dec 28, 2019
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327 001	10391094	May 29, 2032	DP U-2607		NCE	Aug 16, 2024
	7528143	Dec 16, 2026	DS			
	7825246	Dec 16, 2026	DS			
	8138199	Jun 30, 2028	U-2607			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	DP U-1432			
	7754702	Feb 15, 2028	DP U-2555			
	7754702	Feb 15, 2028	DP U-2556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	DP U-2557			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	10300039	Jul 21, 2030	U-2549		I-790	Nov 06, 2020
	5753706	Feb 03, 2020	DP U-1577			
<u>FERRIC MALTOL - ACCRUFER</u>						
N 212320 001	10179120	Jan 06, 2035	U-2603		NCE	Jul 25, 2024
	9248148	Mar 29, 2031	U-2603			
	9802973	Oct 23, 2035	DS DP U-2603			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 02, 2030	DP			
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	>A> 9187405	Jun 25, 2027	U-2613			
	>A> 9187405*PED	Dec 25, 2027				
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 001	10350186	Nov 05, 2024	U-2585			
	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 002	10350186	Nov 05, 2024	U-2585			
	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10179216	Jul 08, 2033	DP U-2133			
	10252010	Feb 07, 2031	DP			
	10300229	Jul 07, 2035	DP U-2133			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-2546			
	8703806	May 28, 2030	U-2546			
	8808713	May 28, 2030	DP U-2546			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8815258	Mar 17, 2031	U-2546			
	9415009	May 28, 2030	U-2546			
	9463161	May 28, 2030	DP U-2546			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
	7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
	7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10208073	May 23, 2032	U-2301			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-1826			
	6774122	Jan 09, 2021	U-2108			
	6774122	Jan 09, 2021	U-2163			
	6774122	Jan 09, 2021	U-2504			
	6774122	Jan 09, 2021	U-596			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-1826			
	7456160	Jan 09, 2021	U-2108			
	7456160	Jan 09, 2021	U-2163			
	7456160	Jan 09, 2021	U-2504			
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-1826			
	8329680	Jan 09, 2021	U-2108			
	8329680	Jan 09, 2021	U-2163			
	8329680	Jan 09, 2021	U-2504			
	8329680	Jan 09, 2021	U-596			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-1826			
	8466139	Jan 09, 2021	U-2108			
	8466139	Jan 09, 2021	U-2163			
	8466139	Jan 09, 2021	U-2504			
	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>FULVESTRANT - FULVESTRANT</u>						
N 210326 001	10188663	Feb 14, 2034	DP U-2540			
	9271990	May 17, 2034	DP U-2540			
	9833459	Feb 14, 2034	DP U-2540			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	6818787	Apr 06, 2025	DS DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	6818787	Apr 06, 2025	DS DP			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-801	Jul 12, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBUTROL - GADAVIST</u>						
N 201277	003				I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277	004				I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277	005				I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277	006				I-801	Jul 12, 2022
<u>GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68</u>						
N 210828	001				NCE W	Aug 21, 2024 Aug 21, 2024
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349	001				NCE	Nov 28, 2023
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656	001 >A>	10414748	Apr 13, 2036	DS DP		
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656	002 >A>	10414748	Apr 13, 2036	DS DP		
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394	001	10028937	Jun 10, 2030	U-2141	>A> D-175	Sep 26, 2022
		10028937	Jun 10, 2030	U-2532	NPP	Apr 30, 2022
		10039754	Jun 10, 2030	U-2141	ODE-232	Apr 30, 2026
		10039754	Jun 10, 2030	U-2532	ODE-233	Apr 30, 2026
		10286029	Mar 14, 2034	U-2532		
		8648037	Jan 19, 2032	DS DP U-2141		
		8648037	Jan 19, 2032	DS DP U-2532		
		9586978	Jun 10, 2030	U-2141		
		9586978	Jun 10, 2030	U-2532		
<u>GLUCAGON - BAQSIMI</u>						
N 210134	001	10213487	Feb 16, 2036	DP U-2604	NP	Jul 24, 2022
		6938798	Jan 03, 2022	DP		
<u>GLUCAGON - GVOKE PFS</u>						
N 212097	001				>A> NP	Sep 10, 2022
<u>GLUCAGON - GVOKE PFS</u>						
N 212097	002				>A> NP	Sep 10, 2022
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097	003				>A> NP	Sep 10, 2022
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097	004				>A> NP	Sep 10, 2022
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284	001	10183002	Sep 22, 2030	U-1816		
		10183003	Sep 22, 2030	U-1816		
		10183004	Sep 22, 2030	U-1816		
		10183005	Sep 22, 2030	U-1816		
		10183006	Sep 22, 2030	U-1816		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10376661	Sep 14, 2035	DP			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	10357570	Sep 28, 2024	U-2253			
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	10251895	Jun 06, 2036	DP		NP	Apr 25, 2022
	>A> 10426787	Jun 06, 2036	U-2625			
	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	10369109	Jun 16, 2023	DP			
<u>HYDROCORTISONE VALERATE - HYDROCORTISONE VALERATE</u>						
A 211750 001					CGT	Jul 16, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10294231	Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10294231	Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBUPROFEN - CHILDREN'S ADVIL-FLAVORED</u>						
N 020589 002	10238640	May 25, 2024	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003	9072661	Mar 16, 2032		U-2264		
	9072710	Mar 16, 2032		U-2266		
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10238644	Dec 11, 2029		U-68		
	10238645	Aug 18, 2029		U-1455		
	10238645	Aug 18, 2029		U-172		
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
>A>	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
>A>	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001 >A>	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
>A>	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
>A>	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 003 >A>	10376652	Jan 20, 2026	DP			
	7615532	Jun 28, 2029	DS DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	10220155	Jul 17, 2026	DP		M-242	Aug 08, 2022
	10357616	Jan 20, 2026	DP			
>A>	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
>A>	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	10029011	Nov 11, 2030	DP			
	9011391	Mar 26, 2024		U-1923		
	9011391	Mar 26, 2024		U-2496		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001					NP	Apr 26, 2022
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075 001	>A> 7541363	Nov 13, 2024	DS DP		>A> NCE	Aug 27, 2024
	>A> 7727993	Jan 28, 2023		U-2623		
	>A> 7727994	Jan 18, 2023		U-2623		
	>A> 8318201	Sep 05, 2027	DP			
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075 002	>A> 7541363	Nov 13, 2024	DS DP		>A> NCE	Aug 27, 2024
	>A> 7727993	Jan 28, 2023		U-2623		
	>A> 7727994	Jan 18, 2023		U-2623		
	>A> 8318201	Sep 05, 2027	DP			
<u>IVABRADINE - CORLANOR</u>						
N 209964 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694		NP	Apr 22, 2022
	7867996	Feb 22, 2026	DS DP U-1694		ODE-234	Apr 22, 2026
	7879842	Feb 22, 2026	DS DP U-1694		PED	Oct 15, 2020
					PED	Oct 22, 2022
					PED	Oct 22, 2026
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVACAFITOR - KALYDECO</u>						
N 203188 002					NPP	Jul 31, 2020
					ODE-186	Feb 21, 2021
					ODE-187	Dec 29, 2021
					ODE-189	Jul 31, 2024
					ODE-190	May 17, 2024
					ODE-199	Aug 15, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	10272046	Feb 27, 2033	DP U-2531		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	10272046	Feb 27, 2033	DP U-2531		NPP	Jul 31, 2020
	7495103	May 20, 2027	DS DP		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8324242	Aug 05, 2027	U-2527		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1311		ODE-199	Aug 15, 2025
	8354427	Jul 06, 2026	U-1905		ODE-236	Apr 29, 2026
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NPP	Jun 21, 2022
	10022352	Apr 09, 2027	DP U-2573		ODE-247	Jun 21, 2026
	10058546	Jul 15, 2033	U-2399			
	10058546	Jul 15, 2033	U-2572			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	10022352	Apr 09, 2027	DP U-2573		NPP	Jun 21, 2022
	10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
	10058546	Jul 15, 2033	U-2572		ODE-247	Jun 21, 2026
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2248			
	9670163	Dec 28, 2026	DP U-2246			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	10206939	Mar 13, 2034	U-1631			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	9474779	Aug 19, 2033	DS DP U-2350		ODE-242	May 02, 2026
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9968595	Mar 13, 2035	DP U-2351			
	9968595	Mar 13, 2035	DP U-2533			
	9968595	Mar 13, 2035	DP U-2534			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001 >A>	7442830	Nov 20, 2029	DS DP U-2434			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002 >A>	7442830	Nov 20, 2029	DS DP U-2434			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003 >A>	7442830	Nov 20, 2029	DS DP U-2434			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035	U-2470			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035	U-2470			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10172861	Nov 16, 2035	DS		NCE	Nov 26, 2023
<u>LATANOPROST - XELPROS</u>						
N 206185 001	9539262	Oct 15, 2028	U-2400			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10174017	Jan 27, 2030	DS DP U-1524		NC	Mar 12, 2022
	8394826	Nov 10, 2030	DS DP U-1524		NCE	Dec 18, 2022
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
	9993470	Mar 14, 2034	DS DP U-1524			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369		ODE-136	Apr 07, 2024
	10039779	Jan 30, 2034	DS DP U-2370		PED	Oct 07, 2024
	10039779*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	DP U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002	>A> 10039779	Jan 30, 2034	DS DP U-1470			
	>A> 10039779*PED	Jul 30, 2034				
	>A> 7964580	Mar 26, 2029	DS DP U-1470			
	>A> 7964580*PED	Sep 26, 2029				
	>A> 8088368	May 12, 2030	DS DP			
	>A> 8088368*PED	Nov 12, 2030				
	>A> 8273341	May 12, 2030	U-1470			
	>A> 8273341*PED	Nov 12, 2030				
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8334270*PED	Sep 21, 2028				
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8580765*PED	Sep 21, 2028				
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8618076*PED	Jun 11, 2031				
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8633309*PED	Sep 26, 2029				
	>A> 8735372	Mar 21, 2028	U-1470			
	>A> 8735372*PED	Sep 21, 2028				
	>A> 8822430	May 12, 2030	DS DP U-1470			
	>A> 8822430*PED	Nov 12, 2030				
	>A> 8841278	May 12, 2030	DP U-1470			
	>A> 8841278*PED	Nov 12, 2030				
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8889159*PED	Sep 26, 2029				
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9085573*PED	Sep 21, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002	>A> 9284342	Sep 13, 2030	DS DP U-1470			
	>A> 9284342*PED	Mar 13, 2031				
	>A> 9393256	Sep 14, 2032	U-1470			
	>A> 9393256*PED	Mar 14, 2033				
	>A> 9511056	May 12, 2030	U-1470			
	>A> 9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 001	>A> 7964580	Mar 26, 2029	DS DP U-1470			
	>A> 7964580*PED	Sep 26, 2029				
	>A> 8088368	May 12, 2030	DS DP			
	>A> 8088368*PED	Nov 12, 2030				
	>A> 8273341	May 12, 2030	U-1470			
	>A> 8273341*PED	Nov 12, 2030				
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8334270*PED	Sep 21, 2028				
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8580765*PED	Sep 21, 2028				
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8618076*PED	Jun 11, 2031				
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8633309*PED	Sep 26, 2029				
	>A> 8735372	Mar 21, 2028	U-1470			
	>A> 8735372*PED	Sep 21, 2028				
	>A> 8822430	May 12, 2030	DS DP U-1470			
	>A> 8822430*PED	Nov 12, 2030				
	>A> 8841278	May 12, 2030	DP U-1470			
	>A> 8841278*PED	Nov 12, 2030				
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8889159*PED	Sep 26, 2029				
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9085573*PED	Sep 21, 2028				
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
	>A> 9284342*PED	Mar 13, 2031				
	>A> 9393256	Sep 14, 2032	U-1470			
	>A> 9393256*PED	Mar 14, 2033				
	>A> 9511056	May 12, 2030	U-1470			
	>A> 9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 002	>A> 7964580	Mar 26, 2029	DS DP U-1470			
	>A> 7964580*PED	Sep 26, 2029				
	>A> 8088368	May 12, 2030	DS DP			
	>A> 8088368*PED	Nov 12, 2030				
	>A> 8273341	May 12, 2030	U-1470			
	>A> 8273341*PED	Nov 12, 2030				
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8334270*PED	Sep 21, 2028				
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8580765*PED	Sep 21, 2028				
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8618076*PED	Jun 11, 2031				
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8633309*PED	Sep 26, 2029				
	>A> 8735372	Mar 21, 2028	U-1470			
	>A> 8735372*PED	Sep 21, 2028				
	>A> 8822430	May 12, 2030	DS DP U-1470			
	>A> 8822430*PED	Nov 12, 2030				
	>A> 8841278	May 12, 2030	DP U-1470			
	>A> 8841278*PED	Nov 12, 2030				
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8889159*PED	Sep 26, 2029				
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9085573*PED	Sep 21, 2028				
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
	>A> 9284342*PED	Mar 13, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 002	>A> 9393256	Sep 14, 2032	U-1470			
	>A> 9393256*PED	Mar 14, 2033				
	>A> 9511056	May 12, 2030	U-1470			
	>A> 9511056*PED	Nov 12, 2030				
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001	>A> 6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	>A> 8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	>A> 8153689	Mar 19, 2028	DS DP			
	>A> 9120727	May 23, 2031	DS DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673 001	>A> 6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	>A> 8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	>A> 8153689	Mar 19, 2028	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		>A> I-807	Sep 17, 2022
	>A> 10407393	Aug 26, 2035	DS			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		>A> I-807	Sep 17, 2022
	>A> 10407393	Aug 26, 2035	DS			
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	10183012	Nov 26, 2028	U-2311			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8962630	Dec 09, 2029	U-2505			
	9416136	Aug 20, 2029	U-2505			
	9868739	Nov 09, 2031	U-2505			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8470367	Oct 31, 2027	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8470367	Oct 31, 2027	DP			
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	6514482	Sep 19, 2020	DP U-2484		NP	Dec 21, 2021
	6613308	Sep 19, 2020	U-2484			
	6858199	Nov 04, 2021	U-2485			
	6921528	Jun 19, 2020	U-2485			
	6979437	Sep 19, 2020	U-2484			
	7146978	Apr 16, 2021	U-2486			
	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	7556798	Nov 04, 2021	U-2485			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			
	8628754	Jun 19, 2020	U-2485			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001 >A>	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002 >A>	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 003 >A>	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8802628	Oct 30, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8802628	Oct 30, 2031	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6268343	Aug 22, 2022	DS DP U-968		NPP	Jun 17, 2022
	6268343*PED	Feb 22, 2023			PED	Dec 17, 2022
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	9265893	Sep 23, 2032	DP			
	9265893*PED	Mar 23, 2033				
	9968659	Jan 09, 2037	U-2313			
	9968659*PED	Jul 09, 2037				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	RE41956	Jan 21, 2021	DP			
	RE41956*PED	Jul 21, 2021				
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	10220155	Jul 17, 2026	DP			
	10220155*PED	Jan 17, 2027				
	10357616	Jan 20, 2026	DP			
>A>	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP U-1255			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 01, 2022	DP			
	6899699*PED	Jul 01, 2022				
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8672898*PED	Jul 02, 2022				
	8684969	Oct 20, 2025	DP			
	8684969*PED	Apr 20, 2026				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8920383*PED	Jan 17, 2027				
	9108002	Jan 26, 2026	DP			
	9108002*PED	Jul 26, 2026				
	9132239	Feb 01, 2032	DP			
	9132239*PED	Aug 01, 2032				
	9457154	Sep 27, 2027	DP			
	9457154*PED	Mar 27, 2028				
	9486588	Jan 02, 2022	DP			
	9486588*PED	Jul 02, 2022				
	9616180	Jan 20, 2026	DP			
	9616180*PED	Jul 20, 2026				
	9687611	Feb 27, 2027	DP			
	9687611*PED	Aug 27, 2027				
	9775953	Jul 17, 2026	DP			
	9775953*PED	Jan 17, 2027				
	9861757	Jan 20, 2026	DP			
	9861757*PED	Jul 20, 2026				
	9968659	Jan 09, 2037	U-2438			
	9968659*PED	Jul 09, 2037				
	RE46363	Aug 03, 2026	DP			
	RE46363*PED	Feb 03, 2027				
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	10265370	Nov 06, 2035	DP			
>A>	10406199	Nov 06, 2035	U-1723			
>A>	10406199	Nov 06, 2035	U-185			
>A>	10406199	Nov 06, 2035	U-1864			
>A>	10406199	Nov 06, 2035	U-1991			
>A>	10406199	Nov 06, 2035	U-3			
>A>	10406199	Nov 06, 2035	U-71			
>A>	10406199	Nov 06, 2035	U-8			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	10201663	Mar 10, 2034	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	10201663	Mar 10, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	10226471	Aug 31, 2031	DP			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001					NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10058511	May 03, 2033	DP U-2492			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			
	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2493			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8779187	Jan 23, 2027	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10172874	Aug 08, 2031	DP			
	10183034	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591 001	6890957	Aug 07, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET ER</u>						
N 212595 001	9962336	May 01, 2035	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	8628799	Jul 13, 2025	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	8628799	Jul 13, 2025	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10231927	Jan 02, 2033	U-1349			
	10231927	Jan 02, 2033	U-1699			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	10307417	Mar 10, 2031	DP			
	10376505	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP		Y	
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10238634	Jun 28, 2032	DP			
<u>MIDAZOLAM - NAYZILAM</u>						
N 211321 001	8217033	Jan 18, 2028	DP U-2526		NP	May 21, 2022
	8809322	Jan 18, 2028	DP		ODE-243	May 17, 2026
	9289432	Jan 18, 2028	DP U-2526			
	9687495	Jan 18, 2028	DP U-2526			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10195214	Jun 19, 2037	U-1643			
	10231983	Aug 22, 2038	U-1643			
	10314850	Aug 22, 2038	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10251873	May 30, 2038	U-2371			
	10383864	May 16, 2027	U-2371			
>A>	10406143	May 16, 2027	U-2371			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - MINOCYCLINE HYDROCHLORIDE</u>						
A 091424	002				PC	Aug 21, 2019
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544	001	10314788	Aug 12, 2028	DP		
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544	002	10314788	Aug 12, 2028	DP		
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544	003	10314788	Aug 12, 2028	DP		
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544	004	10314788	Aug 12, 2028	DP		
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286	001	10166205	Jan 31, 2033	DP		
		10166206	Jan 31, 2033	DP		
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787	001	10220158	Mar 20, 2035	DP U-2500		
		10314977	Nov 23, 2024	DP		
		10322239	Feb 28, 2031	U-1907		
		10335549	Apr 30, 2025	DP		
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862	001	10143792	May 24, 2031	U-2476		
		10220158	Mar 20, 2035	DP U-2500		
		10314977	Nov 23, 2024	DP		
		10322239	Feb 28, 2031	U-1907		
		10335549	Apr 30, 2025	DP		
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254	001	10174017	Jan 27, 2030	DS DP U-1524		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718	001	10233154	Sep 25, 2035	DS		
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
A 207868	001				PC	Oct 01, 2019
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
A 207868	002				PC	Oct 01, 2019
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	001	>A> 10154990	Dec 20, 2025	U-2620	>A> I-805	Sep 06, 2022
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	002	>A> 10154990	Dec 20, 2025	U-2620	>A> I-805	Sep 06, 2022
<u>NITISINONE - NITYR</u>						
N 209449	001	10328029	Jan 05, 2035	DP U-1836		
<u>NITISINONE - NITYR</u>						
N 209449	002	10328029	Jan 05, 2035	DP U-1836		
<u>NITISINONE - NITYR</u>						
N 209449	003	10328029	Jan 05, 2035	DP U-1836		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	10266822	Dec 05, 2025	DP U-1942			
	10266822	Dec 05, 2025	DP U-1943			
	10266822	Dec 05, 2025	DP U-1944			
	>A> 10436802	Sep 11, 2035	U-1941			
	>A> 10436802	Sep 11, 2035	U-1942			
	>A> 10436802	Sep 11, 2035	U-1943			
	>A> 10436802	Sep 11, 2035	U-1944			
	>A> 10436802	Sep 11, 2035	U-2093			
	>A> 10436802	Sep 11, 2035	U-2094			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	>A> 10383884	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	8383610	Sep 23, 2030	DS			
	9265740	Mar 05, 2029	U-1569			
	9314475	Mar 18, 2031	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	>A> 10383884	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	9265740	Mar 05, 2029	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001 >A>	10383884	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	9265740	Mar 05, 2029	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2020	DP			
	5948818	May 13, 2020	DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370		I-793	Jan 25, 2022
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			
	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	10272061	Apr 26, 2020	U-2525			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10188644	Sep 02, 2036	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	10369109	Jun 16, 2023	DP			
	>A> 10407434	Mar 30, 2025	DS			
	9060976	Aug 06, 2022	DP	Y		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	10369109	Jun 16, 2023	DP			
	>A> 10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	10369109	Jun 16, 2023	DP			
	>A> 10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	10369109	Jun 16, 2023	DP			
	>A> 10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	10369109	Jun 16, 2023	DP			
	>A> 10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	10369109	Jun 16, 2023	DP			
	>A> 10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	10369109	Jun 16, 2023	DP			
	>A> 10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	10314788	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001	10335391	Jun 11, 2035	U-2567			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2020	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 004	7473761	Dec 14, 2026	DS DP			
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 005	7473761	Dec 14, 2026	DS DP			
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
<u>PENICILLAMINE - PENICILLAMINE</u>						
A 210976 001					CGT	Dec 22, 2019
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	>A> 10391075	Feb 12, 2027	U-2622			
	>A> 8778997	May 07, 2027	U-1627			
	>A> 8778997	May 07, 2027	U-2622			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10189833	May 05, 2036	U-2606		NCE	Aug 02, 2024
	7893075	Oct 13, 2028	DS		>A> ODE-250	Aug 02, 2026
	8404700	Nov 21, 2027	DS			
	8461169	Apr 19, 2028	U-2606			
	8722702	Nov 21, 2027	DS			
	9169250	Nov 21, 2027	DS			
	9358235	Jun 08, 2033	U-2606			
	9802932	May 05, 2036	DS			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002					NCE	Apr 29, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	>A> 8383150	Sep 22, 2026	DP U-1607			
	>A> 8383150	Sep 22, 2026	DP U-2361			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	10188637	Mar 28, 2037	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	>A> 7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
	>A> 7910605	Sep 23, 2022	U-1101		>A> ODE-255	Aug 14, 2026
	>A> 8207197	Feb 25, 2029	DS DP			
	>A> 8354430	Feb 26, 2026	U-1101			
	>A> 8486947	Sep 26, 2029	U-1101			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	>A> 7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
	>A> 7910605	Sep 23, 2022	U-1101		>A> ODE-255	Aug 14, 2026
	>A> 8207197	Feb 25, 2029	DS DP			
	>A> 8354430	Feb 26, 2026	U-1101			
	>A> 8486947	Sep 26, 2029	U-1101			
<u>PREGABALIN - LYRICA</u>						
N 021446 001					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 002					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 003					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 004					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 005					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 006					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 007					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 008					NPP	May 23, 2022
					PED	Nov 23, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 022488 001					NPP PED	May 23, 2022 Nov 23, 2022
<u>PRETOMANID - PRETOMANID</u>						
N 212862 001					NCE >A> ODE-253 GAIN	Aug 14, 2024 Aug 14, 2026 Aug 14, 2029
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8987262	Oct 16, 2028	U-1988			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
A 211694 001					CGT	Sep 04, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 001					PC	May 27, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 002					PC	May 27, 2019
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	RE47301	Feb 02, 2027	DP			
	RE47351	Jun 22, 2019	DS DP U-869			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10343995	Mar 10, 2025	U-2440			
	8541451	Aug 25, 2031	DS			
	9765028	Jul 14, 2030	DS			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	10314828	Oct 02, 2029	U-1481			
	10335397	Oct 02, 2029	U-2579			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	10376590	Feb 13, 2028	U-2608			
	>A> 10406160	Jun 26, 2026	DP U-2608			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	10376590	Feb 13, 2028	U-2608			
	>A> 10406160	Jun 26, 2026	DP U-2608			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 001	>A> 10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 002	>A> 10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 003	>A> 10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 004	>A> 10413543	Feb 12, 2036	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	10350174	Dec 22, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	10350174	Dec 22, 2030	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10278974	Feb 10, 2031	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	10278974	Feb 10, 2031	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	10278974	Feb 10, 2031	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	>A> 7468390	Nov 27, 2023	DP		>A> NCE	Jul 07, 2020
	>A> 7468390*PED	May 27, 2024			>A> NPP	Oct 01, 2022
	>A> 8101659	Jan 14, 2023	DP		>A> PED	Jan 07, 2021
	>A> 8101659*PED	Jul 14, 2023			>A> PED	Apr 01, 2023
	>A> 8404744	Jan 14, 2023	DP			
	>A> 8404744*PED	Jul 14, 2023				
	>A> 8796331	Jan 14, 2023	U-1723			
	>A> 8796331*PED	Jul 14, 2023				
	>A> 8877938	May 27, 2027	DS DP			
	>A> 8877938*PED	Nov 27, 2027				
	>A> 9388134	Nov 08, 2026	U-1723			
	>A> 9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	>A> 7468390	Nov 27, 2023	DP		>A> NCE	Jul 07, 2020
	>A> 7468390*PED	May 27, 2024			>A> NPP	Oct 01, 2022
	>A> 8101659	Jan 14, 2023	DP		>A> PED	Jan 07, 2021
	>A> 8101659*PED	Jul 14, 2023			>A> PED	Apr 01, 2023
	>A> 8404744	Jan 14, 2023	DP			
	>A> 8404744*PED	Jul 14, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	>A> 8796331	Jan 14, 2023	U-1723			
	>A> 8796331*PED	Jul 14, 2023				
	>A> 8877938	May 27, 2027	DS DP			
	>A> 8877938*PED	Nov 27, 2027				
	>A> 9388134	Nov 08, 2026	U-1723			
	>A> 9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	>A> 7468390	Nov 27, 2023	DP		>A> NCE	Jul 07, 2020
	>A> 7468390*PED	May 27, 2024			>A> NPP	Oct 01, 2022
	>A> 8101659	Jan 14, 2023	DP		>A> PED	Jan 07, 2021
	>A> 8101659*PED	Jul 14, 2023			>A> PED	Apr 01, 2023
	>A> 8404744	Jan 14, 2023	DP			
	>A> 8404744*PED	Jul 14, 2023				
	>A> 8796331	Jan 14, 2023	U-1723			
	>A> 8796331*PED	Jul 14, 2023				
	>A> 8877938	May 27, 2027	DS DP			
	>A> 8877938*PED	Nov 27, 2027				
	>A> 9388134	Nov 08, 2026	U-1723			
	>A> 9388134*PED	May 08, 2027				
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10335390	Sep 04, 2035	U-2583			
<u>SELENIOUS ACID - SELENIOUS ACID</u>						
N 209379 001					NCE	Apr 30, 2024
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	8999996	Sep 15, 2032	DS DP		NCE	Jul 03, 2024
	9079865	Jul 26, 2032	U-2584		>A> ODE-257	Jul 03, 2026
	9714226	Jul 26, 2032	DS DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	10220155	Jul 17, 2026	DP			
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP			
	>A> 10376652	Jan 20, 2026	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	>A> 10086047	Dec 16, 2031	DP		>A> NCE	Dec 05, 2022
	>A> 10278923	May 02, 2034	U-2628		>A> NP	Sep 20, 2022
	>A> 8129343	Jan 29, 2029	DS DP U-2628			
	>A> 8536122	Mar 20, 2026	DS DP U-2628			
	>A> 9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	>A> 10086047	Dec 16, 2031	DP		>A> NCE	Dec 05, 2022
	>A> 10278923	May 02, 2034	U-2628		>A> NP	Sep 20, 2022
	>A> 8129343	Jan 29, 2029	DS DP U-2628			
	>A> 8536122	Mar 20, 2026	DS DP U-2628			
	>A> 9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	>A> 10086047	Dec 16, 2031	DP		>A> NCE	Dec 05, 2022
	>A> 10278923	May 02, 2034	U-2628		>A> NP	Sep 20, 2022
	>A> 8129343	Jan 29, 2029	DS DP U-2628			
	>A> 8536122	Mar 20, 2026	DS DP U-2628			
	>A> 9278123	Dec 16, 2031	DP U-2628			
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 212260 001					CGT	Nov 27, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 001	10300041	Apr 26, 2030	DP			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 002	10300041	Apr 26, 2030	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001 >A>	10434059	Nov 18, 2022	DP U-172			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-244	Aug 12, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					M-244	Aug 12, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					M-244	Aug 12, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10213400	Mar 15, 2033	U-2499		ODE-231	Oct 26, 2025
	>A> 7668730	Jun 16, 2024	U-1110	Y		
	>A> 7668730*PED	Dec 16, 2024				
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	10300087	Oct 14, 2035	DS	U-2312		
	10335432	Feb 10, 2032		U-2312		
	>A> 10398730	Feb 10, 2032		U-2312		
	>A> 10413569	Feb 10, 2032	DS			
	9913860	Oct 22, 2033	DS	U-2312		
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	10300087	Oct 14, 2035	DS	U-2312		
	>A> 10398730	Feb 10, 2032		U-2312		
	>A> 10413569	Feb 10, 2032	DS			
	9913860	Oct 22, 2033	DS	U-2312		
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	7964580	Mar 26, 2029	DS DP U-1470		NPP	Apr 07, 2020
	7964580*PED	Sep 26, 2029			ODE-135	Apr 07, 2024
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9549941	Mar 26, 2029	U-1958			
	9549941*PED	Sep 26, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	7964580	Mar 26, 2029	DS DP U-1470		NPP	Apr 07, 2020
	7964580*PED	Sep 26, 2029			ODE-135	Apr 07, 2024
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9549941	Mar 26, 2029	U-1958			
	9549941*PED	Sep 26, 2029				
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 002	>A> 7964580	Mar 26, 2029	DS DP U-1470			
	>A> 7964580*PED	Sep 26, 2029				
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8334270*PED	Sep 21, 2028				
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8580765*PED	Sep 21, 2028				
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8618076*PED	Jun 11, 2031				
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8633309*PED	Sep 26, 2029				
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8889159*PED	Sep 26, 2029				
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9085573*PED	Sep 21, 2028				
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
	>A> 9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 001	>A> 7964580	Mar 26, 2029	DS DP U-1470			
	>A> 7964580*PED	Sep 26, 2029				
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8334270*PED	Sep 21, 2028				
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8580765*PED	Sep 21, 2028				
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8618076*PED	Jun 11, 2031				
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8633309*PED	Sep 26, 2029				
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8889159*PED	Sep 26, 2029				
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9085573*PED	Sep 21, 2028				
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
	>A> 9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 002	>A> 7964580	Mar 26, 2029	DS DP U-1470			
	>A> 7964580*PED	Sep 26, 2029				
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8334270*PED	Sep 21, 2028				
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8580765*PED	Sep 21, 2028				
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8618076*PED	Jun 11, 2031				
	>A> 8633309	Mar 26, 2029	DS DP U-1470			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 002	>A> 8633309*PED	Sep 26, 2029				
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8889159*PED	Sep 26, 2029				
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9085573*PED	Sep 21, 2028				
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
	>A> 9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP U-2039			
	7964580	Mar 26, 2029	DS DP U-2040			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-2039			
	8334270	Mar 21, 2028	DS DP U-2040			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9284342*PED	Mar 13, 2031				
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 001	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		>A> ODE-254	Jun 17, 2026
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 002	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		>A> ODE-254	Jun 17, 2026
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 002	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		>A> ODE-254	Jun 17, 2026
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 008	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
>A>	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 009	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
>A>	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 010	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
>A>	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 011	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
>A>	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10245228	Jan 05, 2027	DP U-1351			
	10342762	Jan 05, 2027	DP			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	10232061	Jul 06, 2038	DP			
	10335502	Jul 06, 2038	DP			
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	Jul 01, 2025	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001 >A>	10398859	Dec 19, 2027	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	10166190	May 30, 2028	DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 003	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	9770441	Aug 31, 2035	DS DP U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	8168663	Dec 19, 2023	DS DP			
	8653119	Jan 28, 2024	U-2524			
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10342791	Dec 02, 2035	U-2582			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10376487	Jul 27, 2035	U-2615			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001					NCE PED	Jul 07, 2019 Jan 07, 2020
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	10065947	Feb 03, 2030	DP			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	10065947	Feb 03, 2030	DP			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320		ODE-240	May 16, 2026
	5789379*PED	Oct 14, 2020			ODE-37	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320		PED	Jun 21, 2020
	7056886*PED	Mar 18, 2023				
	7847061	Nov 01, 2025	U-1320			
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320			
	9060992*PED	May 01, 2026				
	9539310	Nov 01, 2025	U-1320			
	9539310*PED	May 01, 2026				
	9545434	Nov 01, 2025	U-1320			
	9545434*PED	May 01, 2026				
	9545435	Nov 01, 2025	U-1320			
	9545435*PED	May 01, 2026				
	9555079	Nov 01, 2025	U-1320			
	9555079*PED	May 01, 2026				
	9572867	Nov 01, 2025	U-1320			
	9572867*PED	May 01, 2026				
	9592273	Nov 01, 2025	U-1320			
	9592273*PED	May 01, 2026				
	9592274	Nov 01, 2025	U-1320			
	9592274*PED	May 01, 2026				
	9968655	Nov 01, 2025	U-2308			
	9968655*PED	May 01, 2026				
	9968656	Nov 01, 2025	U-2308			
	9968656*PED	May 01, 2026				
	9968658	Nov 01, 2025	U-1320			
	9968658*PED	May 01, 2026				
	9974835	Nov 01, 2025	U-1320			
	9974835*PED	May 01, 2026				
	9974837	Nov 01, 2025	U-1320			
	9974837*PED	May 01, 2026				
	9981014	Nov 01, 2025	U-1320			
	9981014*PED	May 01, 2026				
	9981016	Nov 01, 2025	U-1320			
	9981016*PED	May 01, 2026				
	9987334	Nov 01, 2025	U-1320			
	9987334*PED	May 01, 2026				
	9987335	Nov 01, 2025	U-1320			
	9987335*PED	May 01, 2026				
	9993528	Nov 01, 2025	U-1320			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9993528*PED	May 01, 2026				
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	>A> 8541448	Dec 30, 2029	DS DP		>A> NCE	Sep 12, 2024
	>A> 8969377	Dec 30, 2029	DS DP			
	>A> 9006281	May 02, 2030		U-2626		
	>A> 9408840	Dec 30, 2029		U-2626		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 001					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 002					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 003					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 004					CGT	Oct 02, 2019
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	RE46284	Dec 16, 2026	U-1751		I-794	Feb 22, 2022
	RE46284	Dec 16, 2026	U-2503		ODE-229	Feb 22, 2026
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	RE46284	Dec 16, 2026	U-1751		I-794	Feb 22, 2022
	RE46284	Dec 16, 2026	U-2503		ODE-229	Feb 22, 2026
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	10207066	Nov 04, 2030	DP U-909			
	8664187	Jun 20, 2025	U-909			
	8869794	Sep 12, 2028	DP U-909			
	9421166	Dec 19, 2022	DP U-909			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	10363224	Mar 19, 2033	U-766			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 001					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 002					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 003					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 004					PC	Sep 21, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	6517847	Aug 03, 2020	DP U-2368			
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711 001					NCE ODE-228	Feb 13, 2024 Feb 13, 2026
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Feb 10, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Feb 10, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	10159681	Apr 13, 2030	U-2510			
	9844510	Dec 08, 2028	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001					M-245	Jun 09, 2022
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	>A> 8962629	Jan 15, 2031	DS U-2616		NCE	Aug 16, 2024
	>A> 9951080	Oct 17, 2036	DS DP			
	>A> 9963459	Oct 17, 2036	DP			
	>A> RE47221	Dec 01, 2030	DS			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2023	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2023	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VORICONAZOLE - VFEND</u>						
N 021266 001					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021266 002					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021267 001					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021630 001					NPP	Jan 29, 2022

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 39th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm